Ciclesonide    B-Hormone105407119
,    O
cortisone    O
acetate    O
,    O
hydrocortisone    B-Hormone105407119
aceponate    I-Hormone105407119
,    O
hydrocortisone    O
acetate    O
,    O
hydrocortisone    B-Hormone105407119
buteprate    I-Hormone105407119
,    O
hydrocortisone    B-Hormone105407119
butyrate    I-Hormone105407119
,    O
hydrocortisone    O
valerate    O
,    O
prednicarbate    B-Hormone105407119
,    O
and    O
tixocortol    B-Hormone105407119
pivalate    I-Hormone105407119
.    O

Beclometasone    O
,    O
betamethasone    B-Hormone105407119
,    O
dexamethasone    O
,    O
fluocortolone    B-Hormone105407119
,    O
halometasone    B-Hormone105407119
,    O
and    O
mometasone    O
.    O

An    O
antileukotriene    O
is    O
a    O
drug    O
which    O
functions    O
as    O
a    O
leukotriene    B-Hormone105407119
-    O
related    O
enzyme    O
inhibitor    O
(    O
arachidonate    O
5-lipoxygenase    O
)    O
or    O
leukotriene    O
receptor    O
antagonist    O
(    O
cysteinyl    O
leukotriene    O
receptors    O
)    O
and    O
consequently    O
opposes    O
the    O
function    O
of    O
these    O
inflammatory    O
mediators    O
;    O
leukotrienes    O
are    O
produced    O
by    O
the    O
immune    O
system    O
and    O
serve    O
to    O
promote    O
bronchoconstriction    O
,    O
inflammation    O
,    O
microvascular    O
permeability    O
,    O
and    O
mucus    O
secretion    O
in    O
asthma    O
and    O
COPD    O
.    O

Leukotriene    O
E4    O
(    O
LTE4    O
)    O
is    O
a    O
cysteinyl    O
leukotriene    B-Hormone105407119
involved    O
in    O
inflammation    O
.    O

Activated    O
mast    O
cells    O
also    O
synthesize    O
and    O
secrete    O
lipid    O
-    O
derived    O
mediators    O
(    O
such    O
as    O
prostaglandins    O
,    O
leukotriene    B-Hormone105407119
,    O
and    O
platelet    O
-    O
activating    O
factor    O
)    O
and    O
cytokines    O
(    O
such    O
as    O
interleukin    O
1    O
,    O
interleukin    O
3    O
,    O
interleukin    O
4    O
,    O
interleukin    O
5    O
,    O
interleukin    O
6    O
,    O
interleukin    O
13    O
,    O
tumor    O
necrosis    O
factor    O
-    O
alpha    O
,    O
GM    O
-    O
CSF    O
,    O
and    O
several    O
chemokines    O
.    O

These    O
mediators    O
include    O
histamine    O
;    O
leukotriene    B-Hormone105407119
C4    O
,    O
D4    O
,    O
and    O
E4    O
;    O
and    O
a    O
host    O
of    O
cytokines    O
.    O

Eicosanoids    O
include    O
prostaglandins    O
that    O
produce    O
fever    O
and    O
the    O
dilation    O
of    O
blood    O
vessels    O
associated    O
with    O
inflammation    O
,    O
and    O
leukotriene    B-Hormone105407119
that    O
attract    O
certain    O
white    O
blood    O
cells    O
(    O
leukocytes    O
)    O
.    O

During    O
an    O
episode    O
of    O
this    O
type    O
of    O
bronchoconstriction    O
,    O
the    O
levels    O
of    O
inflammatory    O
mediators    O
,    O
particularly    O
leukotrienes    B-Hormone105407119
,    O
histamine    O
,    O
and    O
interleukin    O
,    O
increase    O
.    O

Non    O
-    O
surgical    O
methods    O
of    O
treating    O
capsules    O
include    O
massage    O
,    O
external    O
ultrasound    O
,    O
treatment    O
with    O
leukotriene    B-Hormone105407119
pathway    O
inhibitors    O
(    O
e.g.    O
Accolate    O
,    O
Singulair    O
)    O
,    O
and    O
pulsed    O
electromagnetic    O
field    O
therapy    O
.    O

It    O
dilates    O
airways    O
(    O
bronchodilation    O
)    O
contracted    O
by    O
the    O
allergic    O
mediator    O
,    O
histamine    O
;    O
inhibits    O
Immunoglobulin    O
E    O
-    O
activated    O
mast    O
cells    O
from    O
releasing    O
histamine    O
and    O
leukotriene    B-Hormone105407119
(    O
viz    O
.    O

The    O
release    O
of    O
membrane    O
phospholipids    O
leads    O
to    O
increased    O
production    O
of    O
arachidonic    O
acid    O
which    O
in    O
turn    O
results    O
in    O
elevated    O
leukotriene    B-Hormone105407119
,    O
prostaglandin    O
and    O
thromboxane    O
production    O
.    O

The    O
ingredients    O
in    O
Azerizin    O
are    O
known    O
to    O
inhibit    O
each    O
of    O
these    O
three    O
major    O
paths    O
of    O
inflammation    O
by    O
blocking    O
or    O
down    O
-    O
regulating    O
pro    O
-    O
inflammatory    O
catalysts    O
at    O
multiple    O
points    O
in    O
the    O
inflammatory    O
cascade    O
,    O
e.g.    O
,    O
inhibition    O
of    O
phospholipase    O
,    O
lipooxygenase    O
,    O
COX-2    O
,    O
leukotrienes    B-Hormone105407119
,    O
thromboxane    O
,    O
prostaglandins    O
,    O
nitric    O
oxide    O
,    O
monocyte    O
chemoattractant    O
protein-1    O
(    O
MCP-1    O
)    O
,    O
tumor    O
necrosis    O
factor    O
(    O
TNF    O
)    O
and    O
interleukin-12    O
.    O

In    O
other    O
words    O
,    O
glucocorticoids    O
not    O
only    O
suppress    O
immune    O
response    O
,    O
but    O
also    O
inhibit    O
the    O
two    O
main    O
products    O
of    O
inflammation    O
,    O
prostaglandins    O
and    O
leukotrienes    B-Hormone105407119
.    O

Zafirlukast    O
blocks    O
the    O
action    O
of    O
the    O
cysteinyl    O
leukotriene    B-Hormone105407119
on    O
the    O
CysLT1    O
receptors    O
,    O
thus    O
reducing    O
constriction    O
of    O
the    O
airways    O
,    O
build    O
-    O
up    O
of    O
mucus    O
in    O
the    O
lungs    O
and    O
inflammation    O
of    O
the    O
breathing    O
passages    O
.    O

Zileuton    O
(    O
trade    O
name    O
ZYFLO    O
)    O
is    O
an    O
orally    O
active    O
inhibitor    O
of    O
5-lipoxygenase    O
,    O
and    O
thus    O
inhibits    O
leukotrienes    B-Hormone105407119
(    O
LTB4    O
,    O
LTC4    O
,    O
LTD4    O
,    O
and    O
LTE4    O
)    O
formation    O
,    O
used    O
for    O
the    O
maintenance    O
treatment    O
of    O
asthma    O
.    O

Zileuton    O
is    O
an    O
active    O
oral    O
inhibitor    O
of    O
the    O
enzyme    O
5-lipoxygenase    O
,    O
which    O
forms    O
leukotrienes    B-Hormone105407119
,    O
5-hydroxyeicosatetraenoic    O
acid    O
,    O
and    O
5-oxo    O
-    O
eicosatetraenoic    O
acid    O
from    O
arachidonic    O
acid    O
.    O

The    O
first    O
has    O
long    O
been    O
identified    O
with    O
the    O
Mayo    O
Clinic    O
,    O
and    O
it    O
recommended    O
treatment    O
with    O
beta    O
agonists    O
such    O
as    O
terbutaline    O
,    O
phosphodiesterase    O
-    O
inhibitor    O
theophylline    O
,    O
and    O
leukotriene    B-Hormone105407119
-    O
receptor    O
antagonists    O
montelukast    O
sodium    O
.    O

The    O
resulting    O
substances    O
,    O
called    O
"    O
eicosanoid    B-Hormone105407119
"    O
:    O
prostaglandins    O
(    O
PG    O
)    O
,    O
leukotriene    B-Hormone105407119
(    O
LT    O
)    O
,    O
lipoxins    O
and    O
thromboxane    O
(    O
TX    O
)    O
;    O
and    O
docosanoids    O
:    O
resolvins    O
,    O
protectins    O
,    O
and    O
maresins    O
,    O
are    O
powerful    O
lipid    O
mediators    O
that    O
produce    O
specific    O
actions    O
in    O
the    O
organism    O
;    O
they    O
organize    O
inflammation    O
,    O
hemodynamic    O
,    O
immune    O
response    O
and    O
the    O
repair    O
of    O
tissue    O
.    O

Ultraspiracle    B-Hormone105407119
protein    I-Hormone105407119
,    O
a    O
part    O
of    O
the    O
ecdysone    O
receptor    O

Proligestone    B-Hormone105407119

Progestogen    O
esters    O
of    O
other    O
groups    O
of    O
progestins    O
have    O
also    O
been    O
introduced    O
,    O
including    O
the    O
19-norprogesterone    B-Hormone105407119
derivatives    O
gestonorone    B-Hormone105407119
caproate    I-Hormone105407119
,    O
segesterone    O
acetate    O
(    O
nestorone    O
)    O
,    O
nomegestrol    B-Hormone105407119
acetate    I-Hormone105407119
,    O
and    O
norgestomet    O
(    O
11β-methyl-17α-acetoxy-19-norprogesterone    O
)    O
,    O
and    O
the    O
19-nortestosterone    O
derivatives    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
norethisterone    O
enanthate    O
,    O
and    O
quingestanol    B-Hormone105407119
acetate    I-Hormone105407119
.    O

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-Hormone105407119
)    O
,    O
desogestrel    B-Hormone105407119
,    O
ethylestrenol    B-Hormone105407119
,    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
ethinylestradiol    O
,    O
gestrinone    B-Hormone105407119
,    O
levonorgestrel    B-Hormone105407119
,    O
norethisterone    B-Hormone105407119
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    B-Hormone105407119
)    O
,    O
quinestrol    B-Hormone105407119
,    O
19-norprogesterone    B-Hormone105407119
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-Hormone105407119
acetate    I-Hormone105407119
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
.    O

Nomegestrol    B-Hormone105407119
acetate    I-Hormone105407119
,    O
abbreviated    O
as    O
NOMAC    B-Hormone105407119
,    O
is    O
a    O
progestin    O
,    O
or    O
a    O
synthetic    O
progestogen    O
,    O
which    O
was    O
first    O
introduced    O
in    O
the    O
mid-1980s    O
and    O
is    O
used    O
in    O
the    O
treatment    O
of    O
gynecological    O
disorders    O
,    O
in    O
hormone    O
replacement    O
therapy    O
(    O
HRT    O
)    O
for    O
menopausal    O
symptoms    O
,    O
and    O
in    O
hormonal    O
contraceptives    O
.    O

It    O
is    O
marketed    O
alone    O
under    O
the    O
brand    O
name    O
Lutenyl    B-Hormone105407119
and    O
in    O
combination    O
with    O
estradiol    O
under    O
the    O
brand    O
names    O
Naemis    B-Hormone105407119
and    O
Zoely    B-Hormone105407119
.    O

#    O
Dipivefrine    B-Hormone105407119

Estrogen    O
insensitivity    O
syndrome    O
(    O
EIS    O
)    O
,    O
or    O
estrogen    O
resistance    O
,    O
is    O
a    O
form    O
of    O
congenital    O
estrogen    O
deficiency    O
or    O
hypoestrogenism    B-Hormone105407119
which    O
is    O
caused    O
by    O
a    O
defective    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
ER    O
)    O
–    O
specifically    O
,    O
the    O
estrogen    O
receptor    O
alpha    O
(    O
ERα    O
)    O
–    O
that    O
results    O
in    O
an    O
inability    O
of    O
estrogen    O
to    O
mediate    O
its    O
biological    O
effects    O
in    O
the    O
body    O
.    O
Congenital    O
estrogen    O
deficiency    O
can    O
alternatively    O
be    O
caused    O
by    O
a    O
defect    O
in    O
aromatase    O
,    O
the    O
enzyme    O
responsible    O
for    O
the    O
biosynthesis    O
of    O
estrogens    O
,    O
a    O
condition    O
which    O
is    O
referred    O
to    O
as    O
aromatase    B-Hormone105407119
deficiency    I-Hormone105407119
and    O
is    O
similar    O
in    O
symptomatology    O
to    O
EIS    O
.    O

Aromatase    B-Hormone105407119
deficiency    I-Hormone105407119
,    O
a    O
condition    O
in    O
which    O
aromatase    O
is    O
absent    O
and    O
androgens    O
can    O
not    O
be    O
converted    O
into    O
estrogens    O
.    O

17α-Dihydroequilenin    O
,    O
or    O
α-dihydroequilenin    O
,    O
also    O
known    O
as    O
6,8-didehydro-17α-estradiol    O
,    O
as    O
well    O
as    O
estra-1,3,5(10),6,8-pentaen-3,17α-diol    O
,    O
is    O
a    O
naturally    O
occurring    O
steroidal    O
estrogen    O
found    O
in    O
horses    O
that    O
is    O
closely    O
related    O
to    O
equilin    B-Hormone105407119
,    O
equilenin    B-Hormone105407119
,    O
and    O
17α-estradiol    O
,    O
and    O
,    O
as    O
the    O
3-sulfate    O
ester    O
sodium    O
salt    O
,    O
is    O
a    O
minor    O
constituent    O
(    O
1.2%    O
)    O
of    O
conjugated    O
equine    O
estrogens    O
(    O
Premarin    B-Hormone105407119
)    O
.    O

17β-Dihydroequilenin    O
,    O
or    O
β-dihydroequilenin    O
,    O
also    O
known    O
as    O
6,8-didehydro-17β-estradiol    O
,    O
as    O
well    O
as    O
estra-1,3,5(10),6,8-pentaen-3,17β-diol    O
,    O
is    O
a    O
naturally    O
occurring    O
steroidal    O
estrogen    O
found    O
in    O
horses    O
that    O
is    O
closely    O
related    O
to    O
equilin    B-Hormone105407119
,    O
equilenin    B-Hormone105407119
,    O
and    O
estradiol    O
,    O
and    O
,    O
as    O
the    O
3-sulfate    O
ester    O
sodium    O
salt    O
,    O
is    O
a    O
minor    O
constituent    O
(    O
0.5%    O
)    O
of    O
conjugated    O
equine    O
estrogens    O
(    O
Premarin    B-Hormone105407119
)    O
.    O

8,9-Dehydroestrone    O
,    O
or    O
Δ8-estrone    O
,    O
also    O
known    O
as    O
estra-1,3,5(10),8-tetraen-3-ol-17-one    O
,    O
is    O
a    O
naturally    O
occurring    O
steroidal    O
estrogen    O
found    O
in    O
horses    O
that    O
is    O
closely    O
related    O
to    O
equilin    B-Hormone105407119
,    O
equilenin    B-Hormone105407119
,    O
and    O
estrone    O
,    O
and    O
,    O
as    O
the    O
3-sulfate    O
ester    O
sodium    O
salt    O
,    O
is    O
a    O
minor    O
constituent    O
(    O
3.5%    O
)    O
of    O
conjugated    O
equine    O
estrogens    O
(    O
Premarin    B-Hormone105407119
)    O
.    O

Intermediate    O
molecules    O
mediating    O
these    O
effects    O
include    O
VEGF    O
,    O
BDNF    B-Hormone105407119
,    O
and    O
GDNF    O
.    O

Mutations    O
in    O
this    O
gene    O
have    O
been    O
linked    O
to    O
a    O
decreased    O
expression    O
of    O
the    O
gene    O
that    O
codes    O
for    O
BDNF    B-Hormone105407119
(    O
brain    O
-    O
derived    O
neurotrophic    O
factor    O
)    O
,    O
which    O
is    O
a    O
common    O
gene    O
used    O
in    O
neurodevelopment    O
.    O

The    O
evidence    O
for    O
brain-derived    B-Hormone105407119
neurotrophic    I-Hormone105407119
factor    I-Hormone105407119
(    O
BDNF    O
)    O
in    O
mediating    O
some    O
of    O
the    O
neurobiological    O
effects    O
of    O
physical    O
exercise    O
was    O
noted    O
in    O
one    O
review    O
which    O
hypothesized    O
that    O
increased    O
BDNF    O
signaling    O
is    O
responsible    O
for    O
the    O
antidepressant    O
effect    O
.    O

Bromantane    O
has    O
been    O
found    O
to    O
increase    O
the    O
expression    O
of    O
neurotrophin    B-Hormone105407119
including    O
brain-derived    B-Hormone105407119
neurotrophic    I-Hormone105407119
factor    I-Hormone105407119
and    O
nerve    O
growth    O
factor    O
in    O
certain    O
rat    O
brain    O
areas    O
.    O

It    O
comprises    O
Gq/11    O
coupling    O
,    O
phospholipase    O
C    O
activation    O
,    O
intracellular    O
calcium    O
release    O
from    O
inositol    O
trisphosphate    O
receptor    O
-    O
sensitive    O
stores    O
,    O
CaMKII    O
activation    O
and    O
BDNF    B-Hormone105407119
production    O
.    O

In    O
neuronal    O
cells    O
BDNF    B-Hormone105407119
(    O
brain    O
derived    O
neurotrophic    O
factor    O
)    O
is    O
known    O
to    O
induce    O
the    O
transcription    O
of    O
this    O
cluster    O
;    O
the    O
pathway    O
is    O
thought    O
to    O
involve    O
the    O
BDNF    O
-    O
mediated    O
activation    O
of    O
ERK1/2    O
,    O
which    O
in    O
turn    O
activates    O
MSK    O
,    O
another    O
kinase    O
enzyme    O
.    O

Increased    O
brain-derived    B-Hormone105407119
neurotrophic    I-Hormone105407119
factor    I-Hormone105407119
(    O
BDNF    O
)    O
signaling    O
in    O
the    O
ventral    O
tegmental    O
area    O
(    O
VTA    O
)    O
has    O
been    O
shown    O
to    O
mediate    O
opiate    O
-    O
induced    O
withdrawal    O
symptoms    O
via    O
downregulation    O
of    O
insulin    O
receptor    O
substrate    O
2    O
(    O
IRS2    O
)    O
,    O
protein    O
kinase    O
B    O
(    O
AKT    O
)    O
,    O
and    O
mechanistic    O
target    O
of    O
rapamycin    O
complex    O
2    O
(    O
mTORC2    O
)    O
.    O

R7    O
is    O
a    O
prodrug    O
of    O
7,8-dihydroxyflavone    O
,    O
an    O
agonist    O
of    O
TrkB    O
,    O
the    O
main    O
receptor    O
of    O
brain-derived    B-Hormone105407119
neurotrophic    I-Hormone105407119
factor    I-Hormone105407119
(    O
BDNF    O
)    O
.    O

Brain-derived    B-Hormone105407119
neurotrophic    I-Hormone105407119
factor    I-Hormone105407119
(    O
"    O
BDNF    O
"    O
)    O
,    O
another    O
important    O
gene    O
in    O
neural    O
plasticity    O
,    O
has    O
also    O
been    O
shown    O
to    O
have    O
reduced    O
methylation    O
and    O
increased    O
transcription    O
in    O
animals    O
that    O
have    O
undergone    O
learning    O
.    O

The    O
change    O
in    O
methylation    O
state    O
of    O
histones    O
at    O
the    O
location    O
of    O
specific    O
gene    O
promoters    O
,    O
as    O
opposed    O
to    O
just    O
genome    O
-    O
wide    O
,    O
is    O
also    O
involved    O
in    O
memory    O
formation    O
.    O
Zif268    O
and    O
BDNF    B-Hormone105407119
genes    O
are    O
critical    O
for    O
memory    O
consolidation    O
.    O

HDAC2    O
interacted    O
more    O
than    O
HDAC1    O
with    O
specific    O
memory    O
-    O
forming    O
promoters    O
such    O
as    O
Bdnf    B-Hormone105407119
,    O
Egr1    O
,    O
Fos    O
,    O
and    O
GLUR1    O
.    O

The    O
genes    O
that    O
are    O
unsilenced    O
via    O
acetylation    O
of    O
the    O
heterochromatin    O
abnormally    O
express    O
the    O
genes    O
involved    O
in    O
BDNF    B-Hormone105407119
-    O
TrkB    O
-    O
CREB    O
signaling    O
pathway    O
.    O

To    O
study    O
the    O
molecular    O
actions    O
of    O
cocaine    O
in    O
this    O
region    O
,    O
researchers    O
studied    O
the    O
histone    O
modifications    O
of    O
three    O
different    O
promoters    O
:    O
"    O
cFos    O
"    O
,    O
"    O
BDNF    B-Hormone105407119
"    O
,    O
and    O
"    O
Cdk5    O
"    O
.    O

BDNF    B-Hormone105407119
polymorphisms    O
have    O
also    O
been    O
hypothesized    O
to    O
have    O
a    O
genetic    O
influence    O
,    O
but    O
replication    O
results    O
have    O
been    O
mixed    O
and    O
,    O
as    O
of    O
2005    O
,    O
were    O
insufficient    O
for    O
a    O
meta    O
-    O
analysis    O
.    O

This    O
signal    O
transduction    O
pathway    O
then    O
uses    O
downstream    O
molecules    O
such    O
as    O
TrkB    O
,    O
BDNF    B-Hormone105407119
,    O
and    O
PKA    O
to    O
increase    O
the    O
synaptic    O
output    O
of    O
the    O
involved    O
motor    O
neuron    O
which    O
in    O
turn    O
increases    O
the    O
motor    O
output    O
of    O
the    O
involved    O
muscles    O
and    O
,    O
thus    O
,    O
decreases    O
functional    O
impairment    O
.    O

Theanine    O
increases    O
serotonin    O
,    O
dopamine    O
,    O
GABA    B-Hormone105407119
,    O
and    O
glycine    O
levels    O
in    O
various    O
areas    O
of    O
the    O
brain    O
,    O
as    O
well    O
as    O
BDNF    B-Hormone105407119
and    O
NGF    O
levels    O
in    O
certain    O
brain    O
areas    O
.    O

The    O
neurotrophine    O
,    O
brain-derived    B-Hormone105407119
neurotrophic    I-Hormone105407119
factor    I-Hormone105407119
(    O
BDNF    O
)    O
is    O
thought    O
to    O
play    O
a    O
key    O
role    O
in    O
exercise    O
-    O
induced    O
cognitive    O
improvements    O
.    O

Its    O
mechanism    O
of    O
action    O
remains    O
poorly    O
defined    O
however    O
,    O
with    O
GABAergic    O
,    O
NGF-    O
and    O
BDNF    B-Hormone105407119
-    O
release    O
-    O
promoting    O
,    O
MT1    O
receptor    O
agonism    O
,    O
MT3    O
receptor    O
antagonism    O
,    O
and    O
sigma    O
agonism    O
suggested    O
as    O
potential    O
mechanisms    O
.    O

On    O
the    O
other    O
hand    O
,    O
activation    O
of    O
synaptic    O
NMDA    O
receptors    O
activated    O
only    O
the    O
CREB    O
pathway    O
,    O
which    O
activates    O
BDNF    B-Hormone105407119
(    O
brain    O
-    O
derived    O
neurotrophic    O
factor    O
)    O
,    O
not    O
activating    O
apoptosis    O
.    O

According    O
to    O
the    O
United    O
States    O
National    O
Library    O
of    O
Medicine    O
's    O
medical    O
subject    O
headings    O
,    O
the    O
term    O
"    O
neurotrophin    O
"    O
may    O
be    O
used    O
as    O
a    O
synonym    O
for    O
"    O
neurotrophic    O
factor    O
"    O
,    O
but    O
the    O
term    O
"    O
neurotrophin    O
"    O
is    O
more    O
generally    O
reserved    O
for    O
four    O
structurally    O
related    O
factors    O
:    O
nerve    O
growth    O
factor    O
(    O
NGF    O
)    O
,    O
brain-derived    B-Hormone105407119
neurotrophic    I-Hormone105407119
factor    I-Hormone105407119
(    O
BDNF    O
)    O
,    O
neurotrophin-3    B-Hormone105407119
(    O
NT-3    O
)    O
,    O
and    O
neurotrophin-4    B-Hormone105407119
(    O
NT-4    O
)    O
.    O

However    O
,    O
in    O
the    O
CNS    O
(    O
where    O
BDNF    B-Hormone105407119
is    O
mainly    O
secreted    O
in    O
the    O
spinal    O
cord    O
,    O
substantia    O
nigra    O
,    O
amygdala    O
,    O
hypothalamus    O
,    O
cerebellum    O
,    O
hippocampus    O
and    O
cortex    O
)    O
more    O
factors    O
determine    O
cell    O
fate    O
,    O
including    O
neural    O
activity    O
and    O
neurotransmitter    O
input    O
.    O

Of    O
additional    O
interest    O
is    O
the    O
potential    O
for    O
δ    O
agonists    O
to    O
be    O
developed    O
for    O
use    O
as    O
a    O
novel    O
class    O
of    O
antidepressant    O
drugs    O
,    O
following    O
robust    O
evidence    O
of    O
both    O
antidepressant    O
effects    O
and    O
also    O
upregulation    O
of    O
BDNF    B-Hormone105407119
production    O
in    O
the    O
brain    O
in    O
animal    O
models    O
of    O
depression    O
.    O

Somatrem    B-Hormone105407119

The    O
lateral    O
hypothalamus    O
,    O
also    O
called    O
the    O
lateral    O
hypothalamic    O
area    O
,    O
contains    O
the    O
primary    O
orexinergic    B-Hormone105407119
nucleus    O
within    O
the    O
hypothalamus    O
that    O
widely    O
projects    O
throughout    O
the    O
nervous    O
system    O
;    O
this    O
system    O
of    O
neurons    O
mediates    O
an    O
array    O
of    O
cognitive    O
and    O
physical    O
processes    O
,    O
such    O
as    O
promoting    O
feeding    O
behavior    O
and    O
arousal    O
,    O
reducing    O
pain    O
perception    O
,    O
and    O
regulating    O
body    O
temperature    O
,    O
digestive    O
functions    O
,    O
and    O
blood    O
pressure    O
,    O
among    O
many    O
others    O
.    O

The    O
neurotransmitter    O
glutamate    O
and    O
the    O
endocannabinoids    O
(    O
e.g.    O
,    O
anandamide    O
)    O
and    O
the    O
orexin    B-Hormone105407119
neuropeptides    O
orexin    O
-    O
A    O
and    O
orexin-B    B-Hormone105407119
are    O
the    O
primary    O
signaling    O
neurochemicals    O
in    O
orexin    O
neurons    O
;    O
pathway    O
-    O
specific    O
neurochemicals    O
include    O
GABA    B-Hormone105407119
,    O
melanin    O
-    O
concentrating    O
hormone    O
,    O
nociceptin    O
,    O
glucose    O
,    O
the    O
dynorphin    O
peptides    O
,    O
and    O
the    O
appetite    O
-    O
regulating    O
peptide    O
hormones    O
leptin    B-Hormone105407119
and    O
ghrelin    O
,    O
among    O
others    O
.    O

Tsunematsu    O
and    O
colleagues    O
created    O
transgenic    O
mice    O
that    O
expressed    O
melanopsin    O
in    O
hypothalamic    O
orexin    B-Hormone105407119
neurons    O
.    O

After    O
switching    O
off    O
the    O
blue    O
light    O
,    O
the    O
hypothalamic    O
orexin    B-Hormone105407119
neurons    O
showed    O
activity    O
for    O
several    O
tens    O
of    O
seconds    O
.    O

Almorexant    O
(    O
INN    O
,    O
codenamed    O
ACT-078573    O
)    O
is    O
an    O
orexin    O
antagonist    O
,    O
functioning    O
as    O
a    O
competitive    O
receptor    O
antagonist    O
of    O
the    O
OX1    O
and    O
OX2    O
orexin    B-Hormone105407119
receptors    O
,    O
which    O
was    O
being    O
developed    O
by    O
the    O
pharmaceutical    O
companies    O
Actelion    O
and    O
GSK    O
for    O
the    O
treatment    O
of    O
insomnia    O
.    O

Therefore    O
,    O
it    O
is    O
possible    O
that    O
stimulation    O
of    O
the    O
peripheral    O
trigeminal    O
nerve    O
activates    O
the    O
hypothalamus    O
and    O
the    O
hypothalamus    O
in    O
turn    O
communicates    O
with    O
the    O
trigeminal    O
nucleus    O
caudalis    O
via    O
neurotransmitters    O
such    O
as    O
orexin    B-Hormone105407119
.    O

In    O
recent    O
decades    O
,    O
many    O
more    O
hormones    O
with    O
at    O
least    O
some    O
catabolic    O
effects    O
have    O
been    O
discovered    O
,    O
including    O
cytokines    O
,    O
orexin    B-Hormone105407119
(    O
also    O
known    O
as    O
hypocretin    B-Hormone105407119
)    O
,    O
and    O
melatonin    O
.    O

The    O
lateral    O
hypothalamus    O
contains    O
two    O
sets    O
of    O
neurons    O
that    O
increase    O
eating    O
and    O
decrease    O
metabolic    O
rate    O
by    O
secreting    O
the    O
peptides    O
orexin    B-Hormone105407119
and    O
melanin    O
concentrating    O
hormone    O
(    O
MCH    O
)    O
.    O

Oxabolone    B-Hormone105407119
cipionate    I-Hormone105407119
(    O
Steranabol    O
Depo    O
,    O
Steranabol    O
Ritardo    O
)    O

Examples    O
include    O
testosterone    O
cypionate    O
,    O
estradiol    B-Hormone105407119
cypionate    I-Hormone105407119
,    O
hydrocortisone    O
cypionate    O
,    O
and    O
oxabolone    B-Hormone105407119
cypionate    I-Hormone105407119
.    O

NOMAC    O
is    O
the    O
C17α    O
acetate    O
ester    O
of    O
nomegestrol    B-Hormone105407119
and    O
the    O
19-demethylated    O
(    O
or    O
19-nor    O
)    O
analogue    O
of    O
megestrol    O
acetate    O
,    O
and    O
can    O
also    O
be    O
referred    O
to    O
as    O
19-normegestrol    O
acetate    O
.    O

"    O
gastrin-17    B-Hormone105407119
"    O
(    O
"    O
little    B-Hormone105407119
gastrin    I-Hormone105407119
"    O
)    O

Sacubitrilat    O
inhibits    O
the    O
enzyme    O
neprilysin    O
,    O
a    O
neutral    O
endopeptidase    O
that    O
degrades    O
vasoactive    O
peptides    O
,    O
including    O
natriuretic    O
peptides    O
,    O
bradykinin    B-Hormone105407119
,    O
and    O
adrenomedullin    B-Hormone105407119
.    O

Adrenomedullin    B-Hormone105407119
(    O
ADM    B-Hormone105407119
or    O
AM    B-Hormone105407119
)    O
is    O
a    O
vasodilator    O
peptide    B-Hormone105407119
hormone    I-Hormone105407119
of    O
uncertain    O
significance    O
in    O
human    O
health    O
and    O
disease    O
.    O

Calico    O
has    O
licensed    O
experimental    O
drug    O
compounds    O
P7C3    O
analogues    O
involved    O
in    O
enhancing    O
the    O
activity    O
of    O
the    O
enzyme    O
nicotinamide    B-Hormone105407119
phosphoribosyltransferase    I-Hormone105407119
,    O
which    O
plays    O
a    O
role    O
in    O
nicotinamide    O
adenine    O
dinucleotide    O
biosynthesis    O
.    O

:    O
V09IX05    O
Fluorodopa    B-Hormone105407119
(18F)    I-Hormone105407119

Fluorodopa    B-Hormone105407119

1950    O
Nordisk    O
markets    O
NPH    B-Hormone105407119
insulin    I-Hormone105407119

The    O
long    O
-    O
acting    O
insulin    O
class    O
,    O
which    O
includes    O
insulin    O
glargine    O
,    O
do    O
not    O
appear    O
much    O
better    O
than    O
neutral    O
protamine    O
Hagedorn    O
(NPH)    B-Hormone105407119
insulin    I-Hormone105407119
but    O
have    O
a    O
significantly    O
greater    O
cost    O
making    O
them    O
,    O
as    O
of    O
2010    O
,    O
not    O
cost    O
effective    O
.    O

NPH    B-Hormone105407119
insulin    I-Hormone105407119
,    O
also    O
known    O
as    O
isophane    B-Hormone105407119
insulin    I-Hormone105407119
,    O
is    O
an    O
intermediate    O
–    O
acting    O
insulin    O
given    O
to    O
help    O
control    O
blood    O
sugar    O
levels    O
in    O
people    O
with    O
diabetes    O
.    O

i.e.    O
,    O
prostate    O
cancer    O
not    O
responding    O
to    O
androgen    B-Hormone105407119
deprivation    I-Hormone105407119
or    O
treatment    O
with    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
antagonists    O
.    O

Androgen    B-Hormone105407119
deprivation    I-Hormone105407119
therapy    I-Hormone105407119

As    O
an    O
example    O
,    O
one    O
condition    O
in    O
which    O
spironolactone    O
is    O
contraindicated    O
is    O
prostate    O
cancer    O
in    O
men    O
being    O
treated    O
with    O
androgen    B-Hormone105407119
deprivation    I-Hormone105407119
therapy    I-Hormone105407119
,    O
as    O
spironolactone    O
has    O
been    O
shown    O
"    O
in    O
vitro    O
"    O
to    O
significantly    O
accelerate    O
carcinoma    O
growth    O
in    O
the    O
absence    O
of    O
any    O
other    O
androgens    O
.    O

Growth    O
hormone    O
is    O
a    O
peptide    B-Hormone105407119
hormone    I-Hormone105407119
secreted    O
by    O
the    O
pituitary    O
gland    O
that    O
stimulates    O
growth    O
and    O
cell    O
reproduction    O
.    O

Ghrelin    O
(    O
pronounced    O
)    O
,    O
the    O
"    O
hunger    O
hormone    O
"    O
,    O
also    O
known    O
as    O
lenomorelin    O
(    O
INN    O
)    O
,    O
is    O
a    O
peptide    B-Hormone105407119
hormone    I-Hormone105407119
produced    O
by    O
ghrelinergic    O
cells    O
in    O
the    O
gastrointestinal    O
tract    O
which    O
functions    O
as    O
a    O
neuropeptide    O
in    O
the    O
central    O
nervous    O
system    O
.    O

It    O
is    O
shown    O
to    O
help    O
slow    O
this    O
process    O
,    O
and    O
increase    O
adult    O
height    O
prediction    O
in    O
adolescent    O
males    O
treated    O
with    O
protein    O
-    O
based    O
peptide    B-Hormone105407119
hormones    I-Hormone105407119
for    O
the    O
treatment    O
of    O
growth    O
hormone    O
deficiency    O
.    O

Insulin    O
"    O
(    O
from    O
the    O
Latin    O
,    O
insula    O
meaning    O
island    O
)    O
"    O
is    O
a    O
peptide    B-Hormone105407119
hormone    I-Hormone105407119
produced    O
by    O
beta    O
cells    O
of    O
the    O
pancreatic    O
islets    O
,    O
and    O
it    O
is    O
considered    O
to    O
be    O
the    O
main    O
anabolic    O
hormone    O
of    O
the    O
body    O
.    O

These    O
cells    O
share    O
the    O
common    O
function    O
of    O
secreting    O
a    O
low    O
molecular    O
weight    O
polypeptide    B-Hormone105407119
hormone    I-Hormone105407119
.    O

#    O
Oxytocinergic    O
system    O
–    O
Oxytocin    O
is    O
a    O
peptide    B-Hormone105407119
hormone    I-Hormone105407119
produced    O
in    O
the    O
hypothalamus    O
that    O
is    O
passed    O
through    O
the    O
posterior    O
pituitary    O
gland    O
into    O
the    O
bloodstream    O
.    O

Because    O
neprilysin    O
is    O
thought    O
to    O
be    O
the    O
rate    O
-    O
limiting    O
step    O
in    O
amyloid    O
beta    O
degradation    O
,    O
it    O
has    O
been    O
considered    O
a    O
potential    O
therapeutic    O
target    O
;    O
compounds    O
such    O
as    O
the    O
peptide    B-Hormone105407119
hormone    I-Hormone105407119
somatostatin    B-Hormone105407119
have    O
been    O
identified    O
that    O
increase    O
the    O
enzyme    O
's    O
activity    O
level    O
.    O

The    O
2014    O
-    O
15    O
list    O
of    O
NCAA    O
banned    O
drugs    O
includes    O
the    O
following    O
classes    O
:    O
stimulants    O
(    O
except    O
for    O
phenylephrine    O
and    O
pseudoephedrine    O
,    O
which    O
are    O
permitted    O
)    O
;    O
anabolic    B-Hormone105407119
agent    I-Hormone105407119
;    O
diuretics    O
and    O
other    O
masking    O
agents    O
;    O
"    O
street    O
drugs    O
"    O
(    O
the    O
NCAA    O
gives    O
as    O
examples    O
heroin    O
,    O
marijuana    O
,    O
tetrahydrocannabinol    O
(    O
THC    O
)    O
,    O
and    O
synthetic    O
cannabinoids    O
)    O
;    O
peptide    B-Hormone105407119
hormone    I-Hormone105407119
and    O
analogues    O
;    O
anti    O
-    O
estrogens    O
,    O
and    O
beta-2    O
agonists    O
.    O

Discovered    O
in    O
non    O
-    O
human    O
animals    O
around    O
1930    O
by    O
Oscar    O
Riddle    O
and    O
confirmed    O
in    O
humans    O
in    O
1970    O
by    O
Henry    O
Friesen    O
prolactin    O
is    O
a    O
peptide    B-Hormone105407119
hormone    I-Hormone105407119
,    O
encoded    O
by    O
the    O
"    O
PRL    O
"    O
gene    O
.    O

Phytosulfokines    B-Hormone105407119
are    O
plant    O
hormones    O
that    O
belong    O
to    O
the    O
growing    O
class    O
of    O
plant    O
peptide    B-Hormone105407119
hormone    I-Hormone105407119
.    O

CPE    O
is    O
involved    O
in    O
the    O
biosynthesis    O
of    O
most    O
neuropeptides    O
and    O
peptide    B-Hormone105407119
hormone    I-Hormone105407119
.    O

Progesterone    B-Hormone105407119
Only    I-Hormone105407119
Pill    I-Hormone105407119

Dobson    O
and    O
Cutrer    O
view    O
progesterone-only    B-Hormone105407119
birth    I-Hormone105407119
control    I-Hormone105407119
pills    I-Hormone105407119
as    O
potentially    O
problematic    O
,    O
since    O
they    O
may    O
be    O
potentially    O
abortive    O
contraceptives    O
because    O
of    O
the    O
theoretical    O
possibility    O
that    O
they    O
may    O
have    O
a    O
slight    O
secondary    O
action    O
of    O
preventing    O
a    O
fertilized    O
embryo    O
from    O
implanting    O
within    O
the    O
uterine    O
wall    O
,    O
while    O
Alcorn    O
implicates    O
all    O
hormonal    O
contraceptives    O
as    O
problematic    O
in    O
these    O
regards    O
.    O

At    O
very    O
low    O
daily    O
dose    O
of    O
30    O
µg    O
,    O
levonorgestrel    O
is    O
used    O
in    O
some    O
progestogen    B-Hormone105407119
only    I-Hormone105407119
pill    I-Hormone105407119

Examples    O
of    O
endogenous    O
compounds    O
that    O
have    O
been    O
implicated    O
in    O
stress    O
and    O
depression    O
include    O
corticotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
(    O
CRH    O
)    O
,    O
cytokines    O
(    O
e.g.    O
,    O
interferon-α    O
,    O
interleukin-2    O
)    O
,    O
tachykinins    O
(    O
e.g.    O
,    O
substance    O
P    O
)    O
,    O
glucocorticoids    O
(    O
e.g.    O
,    O
cortisol    B-Hormone105407119
,    O
cortisone    O
)    O
,    O
and    O
dynorphin    O
.    O

Changes    O
in    O
the    O
expression    O
of    O
neuropeptides    O
such    O
as    O
corticotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
and    O
neuropeptide    B-Hormone105407119
Y    I-Hormone105407119
may    O
play    O
a    O
role    O
in    O
benzodiazepine    O
dependence    O
.    O

The    O
HPA    O
axis    O
involves    O
three    O
structure    O
,    O
the    O
hypothalamus    O
which    O
release    O
CRH    B-Hormone105407119
that    O
stimulates    O
the    O
pituitary    O
gland    O
to    O
release    O
ACTH    O
which    O
stimulates    O
the    O
adrenal    O
glands    O
to    O
release    O
cortisol    O
.    O

Under    O
certain    O
conditions    O
stress    O
hormones    O
may    O
facilitate    O
inflammation    O
through    O
induction    O
of    O
signaling    O
pathways    O
and    O
through    O
activation    O
of    O
the    O
Corticotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
.    O

Release    O
of    O
corticotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
(    O
CRH    O
)    O
from    O
the    O
hypothalamus    O
is    O
influenced    O
by    O
stress    O
.    O

Glucocorticoids    O
act    O
to    O
inhibit    O
feedback    O
of    O
both    O
the    O
hypothalamus    O
,    O
decreasing    O
corticotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
[    O
CRH    O
]    O
,    O
and    O
corticotrophs    O
in    O
the    O
anterior    O
pituitary    O
gland    O
,    O
decreasing    O
the    O
amount    O
of    O
adrenocorticotropic    O
hormone    O
[    O
ACTH    O
]    O
.    O

In    O
addition    O
to    O
the    O
effects    O
listed    O
above    O
,    O
use    O
of    O
high    O
-    O
dose    O
steroids    O
for    O
more    O
than    O
a    O
week    O
begins    O
to    O
produce    O
suppression    O
of    O
the    O
patient    O
's    O
adrenal    O
glands    O
because    O
the    O
exogenous    O
glucocorticoids    O
suppress    O
hypothalamic    O
corticotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
and    O
pituitary    O
adrenocorticotropic    O
hormone    O
.    O

Corticotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
released    O
from    O
the    O
hypothalamus    O
stimulates    O
corticotrophs    O
in    O
the    O
anterior    O
pituitary    O
to    O
release    O
ACTH    O
,    O
which    O
relays    O
the    O
signal    O
to    O
the    O
adrenal    O
cortex    O
.    O

In    O
turn    O
,    O
production    O
of    O
ACTH    O
is    O
stimulated    O
by    O
the    O
presence    O
of    O
corticotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
(    O
CRH    O
)    O
,    O
which    O
is    O
released    O
by    O
neurons    O
of    O
the    O
hypothalamus    O
.    O

In    O
the    O
HPA    O
axis    O
,    O
cortisol    O
(    O
a    O
glucocorticoid    O
)    O
inhibits    O
the    O
release    O
of    O
CRH    B-Hormone105407119
and    O
ACTH    O
,    O
hormones    O
that    O
in    O
turn    O
stimulate    O
corticosteroid    O
synthesis    O
.    O

Corticotropin    O
-    O
releasing    O
hormone    O
(    O
CRH    B-Hormone105407119
)    O
:    O
regulates    O
the    O
release    O
of    O
adrenocorticotropic    O
hormone    O
from    O
the    O
anterior    O
pituitary    O
;    O
this    O
cascade    O
is    O
primarily    O
responsible    O
for    O
stress    O
responses    O

Endocrine    O
systems    O
controlled    O
by    O
the    O
hypothalamus    O
are    O
regulated    O
by    O
anti    O
-    O
diuretic    O
hormone    O
(    O
ADH    O
)    O
,    O
corticotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
,    O
gonadotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
,    O
growth    B-Hormone105407119
hormone-releasing    I-Hormone105407119
hormone    I-Hormone105407119
,    O
oxytocin    O
,    O
all    O
of    O
which    O
are    O
secreted    O
by    O
the    O
hypothalamus    O
.    O

Corticotropin    O
-    O
releasing    O
hormone    O
receptors    O
(    O
CRHRs    O
)    O
,    O
also    O
known    O
as    O
corticotropin    O
-    O
releasing    O
factor    O
receptors    O
(    O
CRFRs    O
)    O
are    O
a    O
G    O
protein    O
-    O
coupled    O
receptor    O
family    O
that    O
binds    O
corticotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
(CRH)    I-Hormone105407119
.    O

This    O
binding    O
of    O
Corticotropin    B-Hormone105407119
Releasing-Hormone    I-Hormone105407119
(CRH)    I-Hormone105407119
activates    O
the    O
hypothalamic    O
-    O
pituitary    O
-    O
adrenal    O
(    O
HPA    O
)    O
axis    O
,    O
one    O
of    O
the    O
two    O
parts    O
of    O
the    O
fight    O
-    O
or    O
-    O
flight    O
response    O
to    O
stress    O
.    O

Epitiostanol    B-Hormone105407119

Steroid    O
sulfatase    O
(    O
STS    O
)    O
inhibitors    O
such    O
as    O
estradiol    O
sulfamate    O
,    O
estrone    O
sulfamate    O
,    O
irosustat    O
,    O
and    O
danazol    B-Hormone105407119
inhibit    O
the    O
conversion    O
of    O
steroid    O
sulfates    O
such    O
as    O
estrone    B-Hormone105407119
sulfate    I-Hormone105407119
and    O
DHEA    O
sulfate    O
into    O
their    O
hormonally    O
active    O
forms    O
.    O

Estrone    B-Hormone105407119
sulfate    I-Hormone105407119

E2S    O
can    O
also    O
be    O
metabolized    O
into    O
estrone    B-Hormone105407119
sulfate    I-Hormone105407119
(    O
E1S    O
)    O
,    O
which    O
in    O
turn    O
can    O
be    O
converted    O
into    O
estrone    O
and    O
estradiol    O
.    O

Like    O
many    O
other    O
progestogens    O
,    O
NOMAC    O
has    O
been    O
assessed    O
and    O
found    O
"    O
in    O
vitro    O
"    O
to    O
inhibit    O
the    O
conversion    O
of    O
estrone    B-Hormone105407119
sulfate    I-Hormone105407119
to    O
estrone    O
(    O
via    O
inhibition    O
of    O
steroid    O
sulfatase    O
)    O
and    O
estrone    O
to    O
estradiol    O
(    O
via    O
inhibition    O
of    O
)    O
at    O
high    O
concentrations    O
(    O
0.5–50    O
μM    O
)    O
and    O
to    O
stimulate    O
the    O
conversion    O
of    O
estrone    O
into    O
estrone    O
sulfate    O
(    O
via    O
activation    O
of    O
estrogen    O
sulfotransferase    O
activity    O
)    O
at    O
low    O
concentrations    O
(    O
0.05–0.5    O
μM    O
)    O
,    O
whilst    O
not    O
affecting    O
aromatase    O
activity    O
at    O
any    O
tested    O
concentration    O
(    O
up    O
to    O
10    O
μM    O
)    O
.    O

It    O
produces    O
8,9-dehydroestradiol    O
as    O
an    O
important    O
active    O
metabolite    O
,    O
analogously    O
to    O
conversion    O
of    O
estrone    O
or    O
estrone    B-Hormone105407119
sulfate    I-Hormone105407119
into    O
estradiol    O
.    O

However    O
,    O
Park    O
Jong    O
-    O
sei    O
of    O
the    O
Olympic    O
Doping    O
Control    O
Center    O
found    O
that    O
Johnson    O
's    O
blood    O
and    O
urine    O
samples    O
contained    O
stanozolol    B-Hormone105407119
,    O
and    O
he    O
was    O
disqualified    O
three    O
days    O
later    O
.    O

In    O
July    O
2006    O
,    O
Zakari    O
was    O
reported    O
to    O
have    O
failed    O
a    O
drugs    O
test    O
for    O
the    O
banned    O
substance    O
stanozolol    B-Hormone105407119
.    O

Jenrry    O
Mejia    O
,    O
formerly    O
of    O
the    O
New    O
York    O
Mets    O
,    O
was    O
suspended    O
in    O
July    O
2015    O
when    O
he    O
tested    O
positive    O
for    O
boldenone    O
and    O
stanozolol    B-Hormone105407119
,    O
and    O
in    O
February    O
2016    O
he    O
again    O
tested    O
positive    O
for    O
boldenone    O
;    O
this    O
marked    O
Mejia    O
's    O
third    O
positive    O
test    O
for    O
a    O
performance    O
-    O
enhancing    O
drug    O
,    O
for    O
which    O
he    O
received    O
the    O
first    O
PED    O
-    O
related    O
lifetime    O
ban    O
in    O
MLB    O
history    O
.    O

Following    O
the    O
Strikeforce    O
card    O
on    O
June    O
22    O
,    O
2007    O
former    O
PRIDE    O
and    O
UFC    O
fighter    O
Phil    O
Baroni    O
tested    O
positive    O
for    O
boldenone    O
,    O
as    O
well    O
as    O
stanozolol    B-Hormone105407119
.    O

Liliya    O
Nurutdinova    O
(    O
Russia    O
)    O
was    O
disqualified    O
after    O
testing    O
positive    O
for    O
the    O
anabolic    O
steroid    O
stanozolol    B-Hormone105407119
.    O

The    O
original    O
bronze    O
medalist    O
Dmitriy    O
Polyunin    O
(    O
Uzbekistan    O
)    O
was    O
disqualifed    O
for    O
doping    O
after    O
his    O
sample    O
was    O
found    O
positive    O
for    O
the    O
anabolic    O
steroid    O
stanozolol    B-Hormone105407119
,    O
and    O
the    O
medal    O
was    O
instead    O
awarded    O
Mick    O
Hill    O
(    O
Great    O
Britain    O
)    O
.    O

Burkman    O
was    O
originally    O
chosen    O
to    O
be    O
on    O
the    O
inaugural    O
season    O
of    O
"    O
The    O
Ultimate    O
Fighter    O
"    O
,    O
but    O
he    O
failed    O
pre    O
-    O
show    O
drug    O
test    O
failure    O
and    O
admitted    O
to    O
taking    O
Winstrol    B-Hormone105407119
.    O

The    O
management    O
of    O
lipodermatosclerosis    O
may    O
include    O
treating    O
venous    O
insufficiency    O
with    O
leg    O
elevation    O
and    O
elastic    O
compression    O
stockings    O
;    O
in    O
some    O
difficult    O
cases    O
,    O
the    O
condition    O
may    O
be    O
improved    O
with    O
the    O
additional    O
use    O
of    O
the    O
fibrinolytic    O
agent    O
,    O
stanozol    B-Hormone105407119
.    O

Copeland    O
was    O
said    O
to    O
have    O
received    O
somatropin    O
,    O
genotropin    O
,    O
and    O
stanozolol    B-Hormone105407119
between    O
September    O
2004    O
and    O
February    O
2007    O
.    O

This    O
article    O
mentioned    O
several    O
current    O
and    O
former    O
WWE    O
wrestlers    O
,    O
including    O
Guerrero    O
,    O
who    O
was    O
alleged    O
to    O
have    O
obtained    O
hCG    O
and    O
the    O
steroid    O
stanozolol    B-Hormone105407119
in    O
early    O
2005    O
.    O

On    O
August    O
23    O
,    O
2004    O
,    O
Russian    O
shot    O
putter    O
Irina    O
Korzhanenko    O
was    O
stripped    O
of    O
her    O
gold    O
medal    O
and    O
thereby    O
received    O
a    O
lifetime    O
ban    O
by    O
the    O
International    O
Olympic    O
Committee    O
after    O
she    O
tested    O
positive    O
for    O
the    O
steroid    O
stanozolol    B-Hormone105407119
.    O

She    O
competed    O
at    O
the    O
2013    O
World    O
Championships    O
in    O
the    O
Women    O
's    O
+    O
75    O
kg    O
,    O
winning    O
the    O
Bronze    O
medal    O
but    O
later    O
lost    O
medal    O
and    O
was    O
banned    O
from    O
international    O
competition    O
by    O
the    O
International    O
Weightlifting    O
Federation    O
for    O
use    O
of    O
anabolic    O
steroid    O
Stanozolol    B-Hormone105407119
.    O

He    O
tested    O
positive    O
for    O
banned    O
substance    O
stanozolol    B-Hormone105407119
,    O
an    O
anabolic    O
steroid    O
.    O

One    O
positive    O
test    O
for    O
the    O
anabolic    O
steroid    O
stanozolol    B-Hormone105407119
at    O
the    O
GP    O
Carnevale    O
Europa    O
and    O
twice    O
for    O
the    O
hormone    O
testosterone    O
at    O
the    O
Giro    O
di    O
San    O
Marino    O
and    O
Sparkassen    O
Giro    O
Bochum    O
.    O

However    O
,    O
the    O
validity    O
of    O
her    O
record    O
and    O
title    O
was    O
called    O
into    O
question    O
by    O
a    O
positive    O
blood    O
test    O
result    O
for    O
the    O
banned    O
steroids    O
oxandrolone    B-Hormone105407119
and    O
stanozolol    B-Hormone105407119
,    O
and    O
she    O
was    O
"    O
provisionally    O
suspended    O
"    O
by    O
the    O
International    O
Weightlifting    O
Federation    O
.    O

In    O
June    O
2016    O
,    O
IWF    O
announced    O
that    O
retests    O
of    O
the    O
samples    O
taken    O
from    O
the    O
2012    O
Olympics    O
indicated    O
that    O
Zulfiya    O
Chinshanlo    O
had    O
tested    O
positive    O
for    O
prohibited    O
substances    O
,    O
namely    O
Oxandrolone    B-Hormone105407119
and    O
Stanazolol    B-Hormone105407119
.    O

Already    O
in    O
retirement    O
,    O
Antonova    O
was    O
suspended    O
from    O
competition    O
for    O
two    O
years    O
in    O
July    O
2013    O
,    O
after    O
a    O
re    O
-    O
tested    O
doping    O
sample    O
from    O
the    O
2009    O
world    O
championships    O
proved    O
positive    O
for    O
stanozolol    B-Hormone105407119
.    O

The    O
IAAF    O
reported    O
in    O
December    O
2015    O
that    O
Andrianova    O
would    O
be    O
retroactively    O
suspended    O
for    O
testing    O
positive    O
for    O
the    O
performance    O
-    O
enhancing    O
drug    O
stanozolol    B-Hormone105407119
.    O

On    O
April    O
3    O
,    O
MLB    O
announced    O
that    O
Santana    O
would    O
be    O
suspended    O
for    O
80    O
games    O
after    O
testing    O
positive    O
for    O
Stanozolol    B-Hormone105407119
,    O
a    O
performance    O
-    O
enhancing    O
drug    O
.    O

Stanozolol    B-Hormone105407119

He    O
was    O
due    O
to    O
compete    O
at    O
the    O
2012    O
Olympic    O
Games    O
but    O
was    O
withdrawn    O
after    O
his    O
A    O
-    O
sample    O
tested    O
positive    O
for    O
hydroxystanozolol    B-Hormone105407119
during    O
a    O
drug    O
test    O
.    O

He    O
was    O
due    O
to    O
compete    O
at    O
the    O
2012    O
Olympic    O
Games    O
but    O
was    O
withdrawn    O
after    O
his    O
A    O
-    O
sample    O
tested    O
positive    O
for    O
hydroxystanozolol    B-Hormone105407119
during    O
a    O
drug    O
test    O
.    O

He    O
was    O
due    O
to    O
compete    O
at    O
the    O
2012    O
Olympic    O
Games    O
but    O
was    O
withdrawn    O
after    O
his    O
A    O
-    O
sample    O
tested    O
positive    O
for    O
hydroxystanozolol    B-Hormone105407119
during    O
a    O
drug    O
test    O
.    O

Stanozolol    B-Hormone105407119
,    O
an    O
anabolic    O
steroid    O
.    O

After    O
the    O
fight    O
he    O
tested    O
positive    O
for    O
the    O
banned    O
substance    O
stanozolol    B-Hormone105407119
.    O

In    O
the    O
report    O
,    O
Kirk    O
Radomski    O
claimed    O
he    O
sold    O
Deca    O
-    O
Durabolin    O
and    O
Winstrol    B-Hormone105407119
to    O
Zaun    O
in    O
2001    O
,    O
after    O
a    O
referral    O
from    O
Jason    O
Grimsley    O
.    O

Stanozolol    B-Hormone105407119

In    O
September    O
2005    O
Baggaley    O
tested    O
positive    O
for    O
banned    O
steroids    O
(    O
stanozolol    B-Hormone105407119
and    O
methandienone    B-Hormone105407119
)    O
.    O

He    O
received    O
a    O
doping    O
ban    O
for    O
two    O
years    O
in    O
2001    O
,    O
after    O
testing    O
positive    O
for    O
stanozolol    B-Hormone105407119
at    O
the    O
Jamaican    O
Championships    O
.    O

He    O
finished    O
second    O
at    O
the    O
Jamaican    O
National    O
Championships    O
that    O
year    O
but    O
his    O
doping    O
test    O
from    O
the    O
competition    O
was    O
positive    O
for    O
the    O
banned    O
steroid    O
stanozolol    B-Hormone105407119
.    O

The    O
use    O
of    O
growth    O
hormone    O
and    O
insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
1    I-Hormone105407119
to    O
increase    O
height    O
and    O
body    O
size    O
in    O
short    O
stature    O
,    O
growth    B-Hormone105407119
hormone    I-Hormone105407119
deficiency    I-Hormone105407119
,    O
and    O
Laron    B-Hormone105407119
syndrome    I-Hormone105407119

Insensitivity    O
to    O
GH    O
is    O
traditionally    O
termed    O
Laron    B-Hormone105407119
dwarfism    I-Hormone105407119
,    O
but    O
over    O
the    O
last    O
15    O
years    O
many    O
different    O
types    O
of    O
GH    O
resistance    O
have    O
been    O
identified    O
,    O
primarily    O
involving    O
mutations    O
of    O
the    O
GH    O
binding    O
protein    O
or    O
receptors    O
.    O

The    O
anatomist    O
Gary    O
D.    O
Richards    O
introduced    O
a    O
new    O
skeptical    O
hypothesis    O
in    O
June    O
2006    O
:    O
that    O
the    O
skeletons    O
from    O
Flores    O
might    O
be    O
the    O
remains    O
of    O
people    O
who    O
suffered    O
from    O
Laron    B-Hormone105407119
syndrome    I-Hormone105407119
,    O
a    O
genetic    O
disorder    O
first    O
reported    O
in    O
1966    O
.    O

Laron-type    B-Hormone105407119

Insect    B-Hormone105407119
diuretic    I-Hormone105407119
hormones    I-Hormone105407119
are    O
hormones    O
that    O
regulate    O
water    O
balance    O
through    O
diuretic    O
action    O
.    O

They    O
also    O
contain    O
neurons    O
with    O
receptors    O
for    O
angiotensin    O
,    O
atrial    B-Hormone105407119
natriuretic    I-Hormone105407119
factor    I-Hormone105407119
,    O
endothelin    B-Hormone105407119
and    O
relaxin    O
,    O
each    O
of    O
which    O
important    O
in    O
the    O
regulation    O
of    O
fluid    O
and    O
electrolyte    O
balance    O
.    O

The    O
kidney    O
mechanisms    O
used    O
to    O
restore    O
EABV    O
include    O
,    O
(    O
1    O
)    O
sympathetic    O
nerve    O
activity    O
;    O
(    O
2    O
)    O
Atriopeptin    B-Hormone105407119
(    O
ANP    O
)    O
secretion    O
from    O
the    O
atria    O
;    O
(    O
3    O
)    O
Starling    O
forces    O
;    O
(    O
4    O
)    O
Renin–angiotensin–aldosterone    B-Hormone105407119
system    I-Hormone105407119

It    O
is    O
associated    O
with    O
accumulation    O
of    O
atrial    B-Hormone105407119
natriuretic    I-Hormone105407119
factor    I-Hormone105407119
.    O

Inhibitors    O
have    O
been    O
designed    O
with    O
the    O
aim    O
of    O
developing    O
analgesic    O
and    O
antihypertensive    O
agents    O
that    O
act    O
by    O
preventing    O
neprilysin    O
's    O
activity    O
against    O
signaling    O
peptides    O
such    O
as    O
enkephalins    O
,    O
substance    O
P    O
,    O
endothelin    B-Hormone105407119
,    O
and    O
atrial    B-Hormone105407119
natriuretic    I-Hormone105407119
factor    I-Hormone105407119
.    O

Inhibitors    O
have    O
been    O
designed    O
with    O
the    O
aim    O
of    O
developing    O
analgesic    O
and    O
antihypertensive    O
agents    O
that    O
act    O
by    O
preventing    O
neprilysin    O
's    O
activity    O
against    O
signaling    O
peptides    O
such    O
as    O
enkephalins    O
,    O
substance    O
P    O
,    O
endothelin    B-Hormone105407119
,    O
and    O
atrial    B-Hormone105407119
natriuretic    I-Hormone105407119
factor    I-Hormone105407119
.    O

The    O
kidney    O
is    O
directed    O
to    O
excrete    O
or    O
retain    O
sodium    O
via    O
the    O
action    O
of    O
aldosterone    O
,    O
antidiuretic    O
hormone    O
(    O
ADH    O
,    O
or    O
vasopressin    O
)    O
,    O
atrial    B-Hormone105407119
natriuretic    I-Hormone105407119
peptide    I-Hormone105407119
(    O
ANP    O
)    O
,    O
and    O
other    O
hormones    O
.    O

Glucocorticoids    O
could    O
act    O
centrally    O
,    O
as    O
well    O
as    O
peripherally    O
,    O
to    O
assist    O
in    O
the    O
normalization    O
of    O
extracellular    O
fluid    O
volume    O
by    O
regulating    O
body    O
’s    O
action    O
to    O
atrial    B-Hormone105407119
natriuretic    I-Hormone105407119
peptide    I-Hormone105407119
(    O
ANP    O
)    O
.    O

Atrial    B-Hormone105407119
natriuretic    I-Hormone105407119
peptide    I-Hormone105407119
causes    O
the    O
distal    O
convoluted    O
tubule    O
to    O
secrete    O
more    O
sodium    O
.    O

Atrial    B-Hormone105407119
natriuretic    I-Hormone105407119
peptide    I-Hormone105407119
,    O
a    O
peptide    O
hormone    O
.    O

Disruption    O
of    O
caveolin-3    O
disturbs    O
the    O
structure    O
of    O
cardiac    O
caveolae    O
and    O
blocks    O
atrial    B-Hormone105407119
natriuretic    I-Hormone105407119
peptide    I-Hormone105407119
(    O
ANP    O
)    O
expression    O
,    O
a    O
cardiac    O
-    O
related    O
hormone    O
involved    O
in    O
many    O
functions    O
including    O
maintaining    O
cellular    O
homeostasis    O
.    O

Sacubitrilat    O
inhibits    O
the    O
enzyme    O
neprilysin    O
,    O
which    O
is    O
responsible    O
for    O
the    O
degradation    O
of    O
atrial    B-Hormone105407119
and    O
brain    O
natriuretic    O
peptide    O
,    O
two    O
blood    O
pressure    O
-    O
lowering    O
peptides    O
that    O
work    O
mainly    O
by    O
reducing    O
blood    O
volume    O
.    O

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-Hormone105407119
)    O
,    O
desogestrel    B-Hormone105407119
,    O
ethylestrenol    B-Hormone105407119
,    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
ethinylestradiol    O
,    O
gestrinone    B-Hormone105407119
,    O
levonorgestrel    B-Hormone105407119
,    O
norethisterone    B-Hormone105407119
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    B-Hormone105407119
)    O
,    O
quinestrol    B-Hormone105407119
,    O
19-norprogesterone    B-Hormone105407119
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-Hormone105407119
acetate    I-Hormone105407119
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
.    O

The    O
estranes    O
include    O
norethisterone    B-Hormone105407119
(    O
norethindrone    O
)    O
,    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
norethisterone    O
enanthate    O
,    O
lynestrenol    B-Hormone105407119
,    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-Hormone105407119
,    O
desogestrel    B-Hormone105407119
,    O
etonogestrel    B-Hormone105407119
,    O
gestodene    B-Hormone105407119
,    O
norgestimate    B-Hormone105407119
,    O
dienogest    B-Hormone105407119
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    B-Hormone105407119
.    O

No    O
statistically    O
significant    O
increase    O
in    O
risk    O
was    O
associated    O
with    O
the    O
other    O
formulations    O
of    O
oral    O
contraceptive    O
(    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
norgestrel    O
and    O
norgestimate    B-Hormone105407119
)    O
.    O

Prednylidene    B-Hormone105407119
=    O
11β,17α,21-trihydroxy-16-methylenepregna-1,4-diene-3,20-dione    O

Genentech    O
justified    O
it    O
by    O
the    O
prolonged    O
research    O
and    O
development    O
investment    O
,    O
orphan    O
drug    O
status    O
,    O
and    O
a    O
pioneering    O
post    O
-    O
marketing    O
surveillance    O
registry    O
for    O
tracking    O
safety    O
and    O
effectiveness    O
(    O
National    B-Hormone105407119
Cooperative    I-Hormone105407119
Growth    I-Hormone105407119
Study    I-Hormone105407119
)    O
.    O

Chlormadinone    B-Hormone105407119
acetate    O
was    O
the    O
first    O
oral    O
contraceptive    O
produced    O
by    O
Jenapharm    O
.    O

The    O
only    O
approved    O
medicine    O
to    O
treat    O
EPP    O
is    O
afamelanotide    B-Hormone105407119
,    O
developed    O
by    O
Australian    O
-    O
based    O
Clinuvel    O
Pharmaceuticals    O
and    O
approved    O
by    O
the    O
European    O
Commission    O
in    O
December    O
2014    O
for    O
treatment    O
or    O
prevention    O
of    O
phototoxicity    O
in    O
adult    O
patients    O
with    O
EPP    O
.    O

In    O
December    O
2014    O
,    O
afamelanotide    B-Hormone105407119
received    O
authorization    O
from    O
the    O
European    O
Commission    O
as    O
a    O
treatment    O
for    O
the    O
prevention    O
of    O
phototoxicity    O
in    O
adult    O
patients    O
with    O
EPP    O
.    O

Afamelanotide    B-Hormone105407119

Two    O
known    O
endogenous    O
inverse    O
agonists    O
are    O
the    O
Agouti    O
-    O
related    O
peptide    O
(    O
AgRP    O
)    O
and    O
its    O
associated    O
peptide    O
Agouti    B-Hormone105407119
signalling    I-Hormone105407119
peptide    I-Hormone105407119
(    O
ASIP    O
)    O
.    O

The    O
mammalian    O
proteins    O
Agouti    B-Hormone105407119
signalling    I-Hormone105407119
peptide    I-Hormone105407119
and    O
Agouti    O
related    O
peptide    O
are    O
the    O
only    O
known    O
mammalian    O
examples    O
of    O
this    O
motif    O
.    O

Agouti    B-Hormone105407119
signalling    I-Hormone105407119
peptide    I-Hormone105407119

In    O
horses    O
,    O
point    O
coloration    O
is    O
produced    O
by    O
the    O
action    O
of    O
the    O
Agouti    B-Hormone105407119
gene    O
,    O
which    O
acts    O
on    O
the    O
extension    O
gene    O
,    O
when    O
present    O
,    O
to    O
suppress    O
black    O
color    O
to    O
all    O
but    O
the    O
extremities    O
of    O
the    O
horse    O
;    O
the    O
legs    O
,    O
mane    O
,    O
tail    O
and    O
tips    O
of    O
the    O
ears    O
.    O

N-terminal    B-Hormone105407119
pro-B-type    I-Hormone105407119
natriuretic    I-Hormone105407119
peptide    I-Hormone105407119
(    O
NT    O
-    O
pro    O
BNP    O
)    O

"The    B-Hormone105407119
cream"    I-Hormone105407119
is    O
a    O
testosterone    O
-    O
based    O
ointment    O
that    O
is    O
used    O
in    O
conjunction    O
with    O
anabolic    B-Hormone105407119
steroids    I-Hormone105407119
such    O
as    O
tetrahydrogestrinone    B-Hormone105407119
(    O
THG    O
,    O
also    O
known    O
as    O
"    O
the    O
clear    O
"    O
)    O
in    O
order    O
to    O
mask    O
doping    O
in    O
professional    O
athletes    O
.    O

Records    O
seized    O
by    O
the    O
government    O
belonging    O
to    O
the    O
Bay    O
Area    O
Laboratory    O
Co    O
-    O
operative    O
,    O
later    O
discovered    O
to    O
be    O
the    O
source    O
of    O
a    O
designer    O
steroid    O
,    O
indicate    O
that    O
he    O
had    O
used    O
the    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
"    O
The    B-Hormone105407119
Clear    I-Hormone105407119
"    O
and    O
synthetic    O
testosterone    O
ointment    O
"    O
The    B-Hormone105407119
Cream    I-Hormone105407119
"    O
provided    O
by    O
BALCO    O
since    O
2003    O
.    O

FS    B-Hormone105407119
Shampoo    I-Hormone105407119

This    O
term    O
has    O
traditionally    O
been    O
applied    O
to    O
semisolids    O
that    O
possess    O
a    O
relatively    O
fluid    O
consistency    O
formulated    O
as    O
either    O
water    O
-    O
in    O
-    O
oil    O
(    O
e.g.    O
,    O
cold    O
cream    O
)    O
or    O
oil    O
-    O
in    O
-    O
water    O
(    O
e.g.    O
,    O
fluocinolone    B-Hormone105407119
acetonide    I-Hormone105407119
cream    O
)    O
emulsions    O
.    O

Amcinonide    B-Hormone105407119
,    O
budesonide    B-Hormone105407119
,    O
desonide    B-Hormone105407119
,    O
fluocinolone    B-Hormone105407119
acetonide    I-Hormone105407119
,    O
fluocinonide    B-Hormone105407119
,    O
halcinonide    B-Hormone105407119
,    O
and    O
triamcinolone    B-Hormone105407119
acetonide    I-Hormone105407119
.    O

Estrogen    O
insensitivity    O
syndrome    O
(    O
EIS    O
)    O
,    O
or    O
estrogen    O
resistance    O
,    O
is    O
a    O
form    O
of    O
congenital    O
estrogen    O
deficiency    O
or    O
hypoestrogenism    B-Hormone105407119
which    O
is    O
caused    O
by    O
a    O
defective    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
ER    O
)    O
–    O
specifically    O
,    O
the    O
estrogen    O
receptor    O
alpha    O
(    O
ERα    O
)    O
–    O
that    O
results    O
in    O
an    O
inability    O
of    O
estrogen    O
to    O
mediate    O
its    O
biological    O
effects    O
in    O
the    O
body    O
.    O
Congenital    O
estrogen    O
deficiency    O
can    O
alternatively    O
be    O
caused    O
by    O
a    O
defect    O
in    O
aromatase    O
,    O
the    O
enzyme    O
responsible    O
for    O
the    O
biosynthesis    O
of    O
estrogens    O
,    O
a    O
condition    O
which    O
is    O
referred    O
to    O
as    O
aromatase    B-Hormone105407119
deficiency    I-Hormone105407119
and    O
is    O
similar    O
in    O
symptomatology    O
to    O
EIS    O
.    O

Treatment    O
with    O
up    O
to    O
extremely    O
high    O
doses    O
of    O
ethinylestradiol    O
(    O
fourteen    O
100-µg    O
patches    O
per    O
week    O
)    O
had    O
no    O
effect    O
on    O
any    O
of    O
his    O
symptoms    O
of    O
hypoestrogenism    B-Hormone105407119
,    O
did    O
not    O
produce    O
any    O
estrogenic    O
effects    O
such    O
as    O
gynecomastia    O
,    O
and    O
had    O
no    O
effect    O
on    O
any    O
of    O
his    O
physiological    O
parameters    O
(    O
e.g.    O
,    O
hormone    O
levels    O
or    O
bone    O
parameters    O
)    O
,    O
suggesting    O
a    O
profile    O
of    O
complete    O
estrogen    O
insensitivity    O
syndrome    O
.    O

Congenital    O
estrogen    O
deficiency    O
is    O
a    O
congenital    O
form    O
of    O
hypoestrogenism    B-Hormone105407119
in    O
which    O
the    O
body    O
is    O
unable    O
to    O
produce    O
or    O
use    O
estrogens    O
.    O

Hyperprolactinaemia    O
,    O
or    O
excess    O
serum    O
prolactin    O
,    O
is    O
associated    O
with    O
hypoestrogenism    B-Hormone105407119
,    O
anovulatory    O
infertility    O
,    O
oligomenorrhoea    O
,    O
amenorrhoea    O
,    O
unexpected    O
lactation    O
and    O
loss    O
of    O
libido    O
in    O
women    O
and    O
erectile    O
dysfunction    O
and    O
loss    O
of    O
libido    O
in    O
men    O
.    O

Generally    O
,    O
side    O
effects    O
include    O
signs    O
and    O
symptoms    O
of    O
hypoestrogenism    B-Hormone105407119
.    O

Sex    B-Hormone105407119
hormone-binding    I-Hormone105407119
globulin    I-Hormone105407119
,    O
corticosteroid    O
-    O
binding    O
globulin    O
,    O
thyroxine-binding    B-Hormone105407119
globulin    I-Hormone105407119
,    O
prolactin    O
,    O
and    O
triglycerides    O
,    O
which    O
are    O
known    O
to    O
be    O
elevated    O
by    O
estrogen    O
,    O
were    O
all    O
within    O
normal    O
ranges    O
in    O
spite    O
of    O
the    O
extremely    O
high    O
levels    O
of    O
estrogen    O
,    O
and    O
inhibin    O
B    O
levels    O
were    O
also    O
normal    O
.    O

Thyroxine-binding    B-Hormone105407119
globulin    I-Hormone105407119

In    O
atypical    O
cases    O
,    O
this    O
last    O
approach    O
can    O
benefit    O
from    O
measurements    O
of    O
TBG    B-Hormone105407119
,    O
but    O
usually    O
only    O
requires    O
measurement    O
of    O
TSH    O
,    O
fT3    O
and    O
fT4    O
,    O
and    O
as    O
such    O
has    O
no    O
added    O
laboratory    O
requirements    O
besides    O
the    O
measurement    O
of    O
the    O
same    O
.    O

|    O
Thyroxine-binding    B-Hormone105407119
globulin    I-Hormone105407119
(    O
TBG    O
)    O

any    O
compound    O
(    O
not    O
being    O
Trilostane    B-Hormone105407119
or    O
a    O
compound    O
for    O
the    O
time    O
being    O
specified    O
in    O
sub    O
-    O
paragraph    O
(    O
b    O
)    O
above    O
)    O
structurally    O
derived    O
from    O
17-hydroxyandrostan-3-one    O
or    O
from    O
17-hydroxyestran-3-one    O
by    O
modification    O
in    O
any    O
of    O
the    O
following    O
ways    O
,    O
that    O
is    O
to    O
say    O
,    O

3β-HSD    O
is    O
potently    O
inhibited    O
by    O
azastene    O
,    O
cyanoketone    O
,    O
epostane    O
,    O
and    O
trilostane    B-Hormone105407119
.    O

Extension    O
of    O
the    O
C17α    O
alkyl    O
chain    O
longer    O
than    O
an    O
ethyl    O
group    O
abolishes    O
androgenic    O
activity    O
and    O
converts    O
the    O
drug    O
into    O
an    O
antiandrogen    B-Hormone105407119
,    O
as    O
in    O
topterone    O
(    O
17α-propyltestosterone    O
)    O
and    O
allylestrenol    B-Hormone105407119
(    O
17α-allyl-3-deketo-19-nortestosterone    O
)    O
(    O
an    O
extended    O
-    O
chain    O
variant    O
of    O
ethylestrenol    B-Hormone105407119
)    O
.    O

Ethylestrenol    B-Hormone105407119
(ethylnandrol)    I-Hormone105407119

Derivatives    O
of    O
ethyltestosterone    O
include    O
norethandrolone    O
(    O
ethylnandrolone    O
,    O
ethylestrenolone    O
)    O
,    O
ethylestrenol    B-Hormone105407119
(    O
ethylnandrol    O
)    O
,    O
norboletone    B-Hormone105407119
,    O
ethyldienolone    O
,    O
tetrahydrogestrinone    B-Hormone105407119
,    O
bolenol    B-Hormone105407119
(    O
ethylnorandrostenol    O
)    O
,    O
and    O
propetandrol    B-Hormone105407119
.    O

Quingestanol    B-Hormone105407119
acetate    I-Hormone105407119

Progestogen    O
esters    O
of    O
other    O
groups    O
of    O
progestins    O
have    O
also    O
been    O
introduced    O
,    O
including    O
the    O
19-norprogesterone    B-Hormone105407119
derivatives    O
gestonorone    B-Hormone105407119
caproate    I-Hormone105407119
,    O
segesterone    O
acetate    O
(    O
nestorone    O
)    O
,    O
nomegestrol    B-Hormone105407119
acetate    I-Hormone105407119
,    O
and    O
norgestomet    O
(    O
11β-methyl-17α-acetoxy-19-norprogesterone    O
)    O
,    O
and    O
the    O
19-nortestosterone    O
derivatives    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
norethisterone    O
enanthate    O
,    O
and    O
quingestanol    B-Hormone105407119
acetate    I-Hormone105407119
.    O

A    O
free    B-Hormone105407119
androgen    I-Hormone105407119
index    I-Hormone105407119
expresses    O
the    O
ratio    O
of    O
testosterone    O
to    O
SHBG    O
and    O
can    O
be    O
used    O
to    O
summarize    O
the    O
activity    O
of    O
free    O
testosterone    O
.    O

Proellex    O
is    O
a    O
very    O
similar    O
drug    O
to    O
asoprisnil    B-Hormone105407119
.    O

In    O
men    O
,    O
due    O
to    O
androgen    B-Hormone105407119
deprivation    I-Hormone105407119
,    O
a    O
variety    O
of    O
side    O
effects    O
of    O
varying    O
severity    O
may    O
occur    O
during    O
bicalutamide    O
treatment    O
,    O
with    O
breast    O
pain    O
/    O
tenderness    O
and    O
gynecomastia    O
(    O
breast    O
development    O
/    O
enlargement    O
)    O
being    O
the    O
most    O
common    O
.    O

Depressed    O
mood    O
can    O
be    O
the    O
result    O
of    O
a    O
number    O
of    O
infectious    O
diseases    O
,    O
nutritional    O
deficiencies    O
,    O
neurological    O
conditions    O
and    O
physiological    O
problems    O
,    O
including    O
hypoandrogenism    B-Hormone105407119
(    O
in    O
men    O
)    O
,    O
Addison    O
's    O
disease    O
,    O
Cushing    O
's    O
syndrome    O
,    O
hypothyroidism    O
,    O
Lyme    O
disease    O
,    O
multiple    O
sclerosis    O
,    O
Parkinson    O
's    O
disease    O
,    O
chronic    O
pain    O
,    O
stroke    O
,    O
diabetes    O
,    O
and    O
cancer    O
.    O

Hypoprolactinemia    O
,    O
or    O
serum    O
prolactin    O
deficiency    O
,    O
is    O
associated    O
with    O
ovarian    O
dysfunction    O
in    O
women    O
,    O
and    O
arteriogenic    O
erectile    O
dysfunction    O
,    O
premature    O
ejaculation    O
,    O
oligozoospermia    O
,    O
asthenospermia    O
,    O
hypofunction    O
of    O
seminal    O
vesicles    O
and    O
hypoandrogenism    B-Hormone105407119
in    O
men    O
.    O

Recombinant    O
growth    O
hormone    O
available    O
in    O
the    O
U.S.    O
(    O
and    O
their    O
manufacturers    O
)    O
included    O
"    O
Nutropin    O
"    O
(    O
Genentech    O
)    O
,    O
"    O
Humatrope    O
"    O
(    O
Eli    O
Lilly    O
and    O
Company    O
)    O
,    O
"    O
Genotropin    O
"    O
(    O
Pfizer    O
)    O
,    O
"    O
Norditropin    O
"    O
(    O
Novo    O
Nordisk    O
)    O
,    O
"    O
Tev    O
-    O
Tropin    O
"    O
(    O
Teva    O
)    O
and    O
"    O
Saizen    B-Hormone105407119
"    O
(    O
Merck    O
Serono    O
)    O
.    O

Screening    O
is    O
done    O
by    O
use    O
of    O
"    O
in    O
vitro    O
"    O
test    O
systems    O
(    O
by    O
examining    O
,    O
for    O
instance    O
,    O
if    O
an    O
agent    O
interacts    O
with    O
the    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
or    O
the    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
)    O
and    O
via    O
the    O
use    O
of    O
in    O
animal    O
models    O
,    O
such    O
as    O
development    O
of    O
tadpoles    O
and    O
uterine    O
growth    O
in    O
prepubertal    O
rodents    O
.    O

This    O
is    O
because    O
nandrolone    O
is    O
metabolized    O
by    O
5α-reductase    O
to    O
the    O
much    O
weaker    O
androgen    O
5α-dihydronandrolone    O
(    O
DHN    O
)    O
,    O
which    O
has    O
both    O
reduced    O
affinity    O
for    O
the    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
AR    O
)    O
relative    O
to    O
nandrolone    O
"    O
in    O
vitro    O
"    O
and    O
weaker    O
androgenic    O
activity    O
"    O
in    O
vivo    O
"    O
.    O

Androgen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
AR    O
)    O
antagonist    O
/    O
very    O
weak    O
partial    O
agonist    O

It    O
was    O
a    O
successor    O
of    O
EPI-001    O
and    O
targets    O
the    O
N    O
-    O
terminal    O
domain    O
(    O
NTD    O
)    O
of    O
the    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
AR    O
)    O
.    O

Unlike    O
other    O
steroidal    O
antiandrogens    O
such    O
as    O
cyproterone    B-Hormone105407119
acetate    I-Hormone105407119
(    O
CPA    O
)    O
,    O
it    O
is    O
not    O
also    O
a    O
progestogen    O
,    O
instead    O
acting    O
as    O
a    O
selective    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
antagonist    O
similarly    O
to    O
nonsteroidal    O
antiandrogens    O
such    O
as    O
bicalutamide    O
.    O

It    O
is    O
reported    O
to    O
possess    O
an    O
IC50    O
of    O
700    O
nM    O
for    O
the    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
AR    O
)    O
,    O
about    O
4-fold    O
less    O
than    O
that    O
of    O
bicalutamide    O
.    O

It    O
binds    O
to    O
the    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
AR    O
)    O
(    O
Ki    O
=    O
320    O
nM    O
)    O
and    O
progesterone    B-Hormone105407119
receptor    I-Hormone105407119
(    O
Ki    O
=    O
20    O
nM    O
)    O
and    O
acts    O
as    O
a    O
weak    O
but    O
clinically    O
relevant    O
inhibitor    O
of    O
5α-reductase    O
(    O
IC50    O
=    O
1.4    O
μM    O
)    O
.    O

It    O
is    O
an    O
antagonist    O
of    O
the    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
Ki    O
=    O
2.2    O
μM    O
)    O
,    O
and    O
with    O
the    O
exception    O
of    O
antiprogestogen    O
activity    O
in    O
rat    O
and    O
rabbit    O
models    O
,    O
is    O
devoid    O
of    O
other    O
hormonal    O
activities    O
.    O

In    O
addition    O
to    O
the    O
mineralocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
,    O
prorenone    O
also    O
binds    O
to    O
the    O
glucocorticoid    B-Hormone105407119
,    O
androgen    B-Hormone105407119
,    O
and    O
progesterone    B-Hormone105407119
receptor    I-Hormone105407119
.    O

In    O
addition    O
to    O
the    O
mineralocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
,    O
mexrenone    O
also    O
binds    O
to    O
the    O
glucocorticoid    B-Hormone105407119
,    O
androgen    B-Hormone105407119
,    O
and    O
progesterone    B-Hormone105407119
receptor    I-Hormone105407119
.    O

Androgen    B-Hormone105407119
receptor    I-Hormone105407119
antagonist    O
(    O
Ki    O
=    O
240    O
nM    O
)    O

Androgen    B-Hormone105407119
receptor    I-Hormone105407119
,    O

EIS    O
is    O
analogous    O
to    O
androgen    O
insensitivity    O
syndrome    O
(    O
AIS    O
)    O
,    O
a    O
condition    O
in    O
which    O
the    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
AR    O
)    O
is    O
defective    O
and    O
insensitive    O
to    O
androgens    O
,    O
such    O
as    O
testosterone    O
and    O
dihydrotestosterone    B-Hormone105407119
(    O
DHT    O
)    O
.    O

This    O
is    O
a    O
critical    O
residue    O
that    O
is    O
completely    O
conserved    O
among    O
species    O
and    O
in    O
the    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
AR    O
)    O
and    O
mineralocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
(    O
MR    O
)    O
.    O

In    O
contrast    O
to    O
EIS    O
,    O
androgen    O
insensitivity    O
syndrome    O
(    O
AIS    O
)    O
,    O
a    O
condition    O
in    O
which    O
the    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
AR    O
)    O
is    O
defective    O
,    O
is    O
relatively    O
common    O
.    O

Valproic    O
acid    O
has    O
been    O
found    O
to    O
be    O
an    O
antagonist    O
of    O
the    O
androgen    B-Hormone105407119
and    O
progesterone    B-Hormone105407119
receptor    I-Hormone105407119
,    O
and    O
hence    O
as    O
a    O
nonsteroidal    O
antiandrogen    B-Hormone105407119
and    O
antiprogestogen    O
,    O
at    O
concentrations    O
much    O
lower    O
than    O
therapeutic    O
serum    O
levels    O
.    O

Spinal    O
and    O
bulbar    O
muscular    O
atrophy    O
(    O
SBMA    O
)    O
,    O
also    O
known    O
as    O
Kennedy    O
's    O
disease    O
,    O
is    O
a    O
severe    O
neurodegenerative    O
syndrome    O
that    O
is    O
associated    O
with    O
a    O
particular    O
mutation    O
of    O
the    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
's    O
polyglutamine    O
tract    O
called    O
a    O
trinucleotide    O
repeat    O
expansion    O
.    O

The    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
gene    O
contains    O
two    O
polymorphic    O
trinucleotide    O
microsatellites    O
in    O
exon    O
1    O
.    O

MAIS    O
has    O
a    O
mild    O
presentation    O
that    O
often    O
goes    O
unnoticed    O
and    O
untreated    O
;    O
even    O
with    O
semenological    O
,    O
clinical    O
and    O
laboratory    O
data    O
,    O
it    O
can    O
be    O
difficult    O
to    O
distinguish    O
between    O
men    O
with    O
and    O
without    O
MAIS    O
,    O
and    O
thus    O
a    O
diagnosis    O
of    O
MAIS    O
is    O
not    O
usually    O
made    O
without    O
confirmation    O
of    O
an    O
AR    B-Hormone105407119
gene    I-Hormone105407119
mutation    O
.    O

Management    O
of    O
MAIS    O
is    O
currently    O
limited    O
to    O
symptomatic    O
management    O
;    O
methods    O
to    O
correct    O
a    O
malfunctioning    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
protein    O
that    O
result    O
from    O
an    O
AR    O
gene    O
mutation    O
are    O
not    O
currently    O
available    O
.    O

It    O
is    O
a    O
known    O
endocrine    O
disruptor    O
(    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
antagonist    O
)    O
and    O
to    O
interfere    O
with    O
the    O
sexual    O
differention    O
of    O
male    O
rats    O
.    O

NOMAC    O
has    O
weak    O
or    O
moderate    O
antiandrogen    B-Hormone105407119
activity    O
(    O
5    O
to    O
20    O
times    O
less    O
than    O
that    O
of    O
cyproterone    B-Hormone105407119
acetate    I-Hormone105407119
(    O
a    O
strong    O
antiandrogen    O
)    O
,    O
with    O
approximately    O
12–31%    O
of    O
the    O
of    O
testosterone    O
for    O
the    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
)    O
.    O

Androgen    B-Hormone105407119
receptor    I-Hormone105407119
,    O

At    O
high    O
concentrations    O
,    O
BPA    O
also    O
binds    O
to    O
and    O
acts    O
as    O
an    O
antagonist    O
of    O
the    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
AR    O
)    O
.    O

AR    B-Hormone105407119
,    O

Digit    O
ratio    O
in    O
men    O
correlates    O
with    O
genetic    O
variation    O
in    O
the    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
gene    O
.    O

The    O
condition    O
is    O
associated    O
with    O
mutation    O
of    O
the    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
"    O
AR    O
"    O
)    O
gene    O
and    O
is    O
inherited    O
in    O
an    O
X    O
-    O
linked    O
recessive    O
manner    O
.    O

The    O
genetics    O
of    O
spinal    O
and    O
bulbar    O
muscular    O
atrophy    O
have    O
to    O
do    O
with    O
the    O
mutated    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
gene    O
located    O
on    O
the    O
X    O
chromosome    O
.    O

It    O
also    O
binds    O
to    O
the    O
glucocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
,    O
but    O
is    O
only    O
a    O
weak    O
antiglucocorticoid    O
relative    O
to    O
mifepristone    O
,    O
and    O
has    O
no    O
relevant    O
affinity    O
to    O
the    O
estrogen    B-Hormone105407119
,    O
androgen    B-Hormone105407119
and    O
mineralocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
.    O

Metandienone    O
binds    O
to    O
and    O
activates    O
the    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
AR    O
)    O
in    O
order    O
to    O
exert    O
its    O
effects    O
.    O

M    O
,    O
C4    O
,    O
C5    O
and    O
C4    O
-    O
2    O
also    O
expressed    O
reduced    O
human    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
mRNA    O
as    O
expected    O
in    O
AI    O
cells    O
.    O

LN95    O
cells    O
differ    O
from    O
parental    O
LNCaP    O
cells    O
morphologically    O
,    O
with    O
pronounced    O
dendritic    O
extensions    O
,    O
and    O
molecularly    O
,    O
with    O
Androgen    B-Hormone105407119
receptor    I-Hormone105407119
variant    O
expression    O
similar    O
to    O
that    O
of    O
AR    O
-    O
V7High    O
VCaP    O
cells    O
.    O

While    O
LNCaP    O
-    O
AI    O
are    O
wholly    O
androgen    O
independent    O
,    O
they    O
retain    O
high    O
expression    O
of    O
Androgen    B-Hormone105407119
receptor    I-Hormone105407119
,    O
low    O
expression    O
of    O
AR    O
-    O
V7    O
,    O
and    O
remain    O
androgen    O
responsive    O
..    O

It    O
has    O
been    O
found    O
to    O
possess    O
slightly    O
lower    O
affinity    O
for    O
the    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
AR    O
)    O
and    O
progesterone    B-Hormone105407119
receptor    I-Hormone105407119
(    O
PR    O
)    O
relative    O
to    O
nandrolone    O
in    O
rat    O
and    O
rabbit    O
tissue    O
bioassays    O
,    O
whereas    O
trenbolone    O
was    O
found    O
to    O
possess    O
the    O
same    O
affinity    O
for    O
the    O
AR    O
as    O
dienolone    O
but    O
several    O
-    O
fold    O
increased    O
affinity    O
for    O
the    O
PR    O
.    O

Mutations    O
in    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
genes    O
are    O
highly    O
implicated    O
,    O
as    O
these    O
are    O
involved    O
in    O
penile    O
development    O
,    O
testes    O
descent    O
,    O
and    O
testes    O
development    O
.    O

It    O
contains    O
10    O
NR    O
-    O
interacting    O
boxes    O
(    O
LXXLL    O
motifs    O
)    O
and    O
functions    O
as    O
a    O
coregulator    O
of    O
several    O
nuclear    O
receptors    O
via    O
its    O
LXXLL    O
motifs    O
including    O
ESR1    O
,    O
ESR2    O
,    O
ERR    O
-    O
alpha    O
,    O
PR    B-Hormone105407119
,    O
GR    B-Hormone105407119
,    O
AR    B-Hormone105407119
,    O
and    O
RXR    O
.    O

It    O
acts    O
as    O
a    O
partial    O
agonist    O
for    O
the    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
with    O
a    O
Ki    O
of    O
5nM    O
,    O
and    O
no    O
significant    O
affinity    O
for    O
any    O
other    O
receptors    O
tested    O
.    O

It    O
binds    O
to    O
the    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
more    O
strongly    O
than    O
older    O
drugs    O
such    O
as    O
andarine    O
with    O
a    O
Ki    O
of    O
1.7    O
nM    O
,    O
and    O
in    O
animal    O
studies    O
it    O
showed    O
both    O
a    O
good    O
ratio    O
of    O
anabolic    O
to    O
androgenic    O
effects    O
,    O
and    O
dose    O
-    O
dependent    O
suppression    O
of    O
spermatogenesis    O
with    O
spontaneous    O
recovery    O
after    O
cessation    O
of    O
treatment    O
.    O

Other    O
receptors    O
also    O
show    O
this    O
functional    O
profile    O
,    O
including    O
p75NTR    O
,    O
the    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
,    O
RET    O
,    O
several    O
integrins    O
and    O
Patched    O
.    O

Androgen    B-Hormone105407119
receptor    I-Hormone105407119
,    O

Octreotide    B-Hormone105407119
,    O
which    O
is    O
a    O
human    O
-    O
made    O
form    O
of    O
the    O
natural    O
hormone    O
somatostatin    O
,    O
blocks    O
the    O
action    O
of    O
VIP    O
.    O

Octreotate    O
or    O
octreotide    O
acid    O
is    O
a    O
somatostatin    B-Hormone105407119
analogue    O
that    O
is    O
closely    O
related    O
to    O
octreotide    B-Hormone105407119
.    O

For    O
functioning    O
tumors    O
,    O
the    O
somatostatin    O
analog    O
class    O
of    O
medications    O
,    O
such    O
as    O
octreotide    B-Hormone105407119
,    O
can    O
reduce    O
the    O
excessive    O
production    O
of    O
hormones    O
.    O

Octreotide    B-Hormone105407119
(    O
trade    O
name    O
Sandostatin    B-Hormone105407119
,    O
among    O
others    O
)    O
is    O
an    O
octapeptide    O
that    O
mimics    O
natural    O
somatostatin    B-Hormone105407119
pharmacologically    O
,    O
though    O
it    O
is    O
a    O
more    O
potent    O
inhibitor    O
of    O
growth    O
hormone    O
,    O
glucagon    O
,    O
and    O
insulin    O
than    O
the    O
natural    O
hormone    O
.    O

The    O
primary    O
current    O
medical    O
treatment    O
of    O
acromegaly    O
is    O
to    O
use    O
somatostatin    O
analogues    O
–    O
octreotide    B-Hormone105407119
(    O
Sandostatin    O
)    O
or    O
lanreotide    O
(    O
Somatuline    O
)    O
.    O

Octreotide    B-Hormone105407119
or    O
Lanreotide    O
(    O
somatostatin    B-Hormone105407119
analogues    O
)    O
may    O
decrease    O
the    O
secretory    O
activity    O
of    O
the    O
carcinoid    O
,    O
and    O
may    O
also    O
have    O
an    O
anti    O
-    O
proliferative    O
effect    O
.    O

Indium-111    O
is    O
used    O
medically    O
in    O
nuclear    O
imaging    O
,    O
as    O
a    O
radiotracer    O
nuclide    O
tag    O
for    O
gamma    O
camera    O
localization    O
of    O
protein    O
radiopharmaceuticals    O
,    O
such    O
as    O
In-111-labeled    O
octreotide    B-Hormone105407119
,    O
which    O
binds    O
to    O
receptors    O
on    O
certain    O
endocrine    O
tumors    O
(    O
Octreoscan    O
)    O
.    O

Vasoactive    B-Hormone105407119
intestinal    I-Hormone105407119
peptide    I-Hormone105407119
and    O
peptide    B-Hormone105407119
histidine    I-Hormone105407119
isoleucine    I-Hormone105407119
help    O
to    O
regulate    O
prolactin    O
secretion    O
in    O
humans    O
,    O
but    O
the    O
functions    O
of    O
these    O
hormones    O
in    O
birds    O
can    O
be    O
quite    O
different    O
.    O

include    O
,    O
megestrol    O
acetate    O
,    O
chlormadinone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
and    O
spironolactone    O
.    O

A    O
variety    O
of    O
analogues    O
of    O
medroxyprogesterone    O
acetate    O
,    O
such    O
as    O
chlormadinone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
cyproterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
and    O
megestrol    O
acetate    O
,    O
were    O
subsequently    O
developed    O
and    O
introduced    O
as    O
well    O
.    O

In    O
1969    O
,    O
along    O
with    O
a    O
variety    O
of    O
other    O
progestogens    O
including    O
progesterone    O
,    O
chlormadinone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
megestrol    O
acetate    O
,    O
medroxyprogesterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
ethynerone    O
,    O
and    O
chloroethynyl    O
norgestrel    O
,    O
anagestone    O
acetate    O
was    O
found    O
to    O
induce    O
the    O
development    O
of    O
mammary    O
gland    O
tumors    O
in    O
Beagle    O
dogs    O
after    O
extensive    O
treatment    O
(    O
2–7    O
years    O
)    O
with    O
very    O
high    O
doses    O
(    O
10–25    O
times    O
the    O
recommended    O
human    O
dose    O
)    O
,    O
though    O
notably    O
not    O
with    O
1–2    O
times    O
the    O
human    O
dosage    O
.    O

Subsequent    O
investigation    O
found    O
that    O
17α-hydroxyprogesterone    O
derivatves    O
included    O
anagestone    O
acetate    O
,    O
chlormadinone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
medroxyprogesterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
and    O
megestrol    O
acetate    O
produced    O
similar    O
mammary    O
gland    O
tumors    O
,    O
and    O
that    O
their    O
ability    O
to    O
do    O
so    O
correlated    O
directly    O
with    O
their    O
progestogenic    O
actions    O
.    O

It    O
is    O
a    O
17α-hydroxyprogesterone    O
derivative    O
and    O
a    O
derivative    O
of    O
the    O
less    O
potent    O
chlormadinone    B-Hormone105407119
acetate    I-Hormone105407119
.    O

Combinations    O
containing    O
third-    O
or    O
fourth    O
-    O
generation    O
progestins    O
such    O
as    O
desogestrel    B-Hormone105407119
,    O
drospirenone    B-Hormone105407119
,    O
or    O
norgestimate    B-Hormone105407119
are    O
preferred    O
for    O
women    O
with    O
acne    O
due    O
to    O
their    O
stronger    O
antiandrogenic    O
effects    O
.    O

The    O
estranes    O
include    O
norethisterone    B-Hormone105407119
(    O
norethindrone    O
)    O
,    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
norethisterone    O
enanthate    O
,    O
lynestrenol    B-Hormone105407119
,    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-Hormone105407119
,    O
desogestrel    B-Hormone105407119
,    O
etonogestrel    B-Hormone105407119
,    O
gestodene    B-Hormone105407119
,    O
norgestimate    B-Hormone105407119
,    O
dienogest    B-Hormone105407119
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    B-Hormone105407119
.    O

No    O
statistically    O
significant    O
increase    O
in    O
risk    O
was    O
associated    O
with    O
the    O
other    O
formulations    O
of    O
oral    O
contraceptive    O
(    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
norgestrel    O
and    O
norgestimate    B-Hormone105407119
)    O
.    O

Dexamethasone    B-Hormone105407119
suppression    I-Hormone105407119
test    I-Hormone105407119

The    O
dexamethasone    B-Hormone105407119
suppression    I-Hormone105407119
test    I-Hormone105407119
involves    O
administering    O
dexamethasone    O
,    O
a    O
synthetic    O
glucocorticoid    O
,    O
to    O
the    O
horse    O
,    O
and    O
measuring    O
its    O
serum    O
cortisol    O
levels    O
before    O
and    O
19–24    O
hours    O
after    O
injection    O
.    O

It    O
is    O
an    O
isomer    O
of    O
the    O
related    O
19-nortestosterone    O
derivative    O
progestins    O
lynestrenol    B-Hormone105407119
and    O
cingestol    O
.    O

The    O
estranes    O
include    O
norethisterone    B-Hormone105407119
(    O
norethindrone    O
)    O
,    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
norethisterone    O
enanthate    O
,    O
lynestrenol    B-Hormone105407119
,    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-Hormone105407119
,    O
desogestrel    B-Hormone105407119
,    O
etonogestrel    B-Hormone105407119
,    O
gestodene    B-Hormone105407119
,    O
norgestimate    B-Hormone105407119
,    O
dienogest    B-Hormone105407119
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    B-Hormone105407119
.    O

Examples    O
include    O
drugs    O
such    O
as    O
Norethisterone    B-Hormone105407119
,    O
Ethisterone    B-Hormone105407119
,    O
and    O
Lynestrenol    B-Hormone105407119
.    O

Two    O
units    O
can    O
combine    O
to    O
form    O
3,3'-diiodothyronine    B-Hormone105407119
.    O

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-Hormone105407119
)    O
,    O
desogestrel    B-Hormone105407119
,    O
ethylestrenol    B-Hormone105407119
,    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
ethinylestradiol    O
,    O
gestrinone    B-Hormone105407119
,    O
levonorgestrel    B-Hormone105407119
,    O
norethisterone    B-Hormone105407119
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    B-Hormone105407119
)    O
,    O
quinestrol    B-Hormone105407119
,    O
19-norprogesterone    B-Hormone105407119
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-Hormone105407119
acetate    I-Hormone105407119
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
.    O

The    O
company    O
's    O
products    O
include    O
Botox    O
,    O
Namenda    O
,    O
Restasis    O
,    O
Linzess    O
,    O
Bystolic    O
,    O
Juvederm    O
,    O
Latisse    O
,    O
Lo    O
Loestrin    O
Fe    O
,    O
Estrace    O
,    O
Teflaro    O
,    O
Dalvance    O
,    O
Ozurdex    O
,    O
Optive    O
,    O
Natrelle    O
,    O
Viibryd    O
,    O
Liletta    B-Hormone105407119
,    O
Saphris    O
,    O
Enablex    O
,    O
Actonel    O
,    O
Androderm    O
,    O
Gelnique    O
and    O
others    O
.    O

The    O
estranes    O
include    O
norethisterone    B-Hormone105407119
(    O
norethindrone    O
)    O
,    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
norethisterone    O
enanthate    O
,    O
lynestrenol    B-Hormone105407119
,    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-Hormone105407119
,    O
desogestrel    B-Hormone105407119
,    O
etonogestrel    B-Hormone105407119
,    O
gestodene    B-Hormone105407119
,    O
norgestimate    B-Hormone105407119
,    O
dienogest    B-Hormone105407119
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    B-Hormone105407119
.    O

The    O
Yuzpe    O
Regimen    O
is    O
a    O
method    O
of    O
emergency    O
contraception    O
using    O
a    O
combination    O
of    O
estrogen    O
and    O
progestogen    O
hormones    O
(    O
100    O
μg    O
ethinylestradiol    O
and    O
0.5    O
mg    O
of    O
levonorgestrel    B-Hormone105407119
as    O
soon    O
as    O
possible    O
and    O
again    O
in    O
12    O
hrs    O
)    O
and    O
started    O
within    O
72    O
hours    O
of    O
sexual    O
intercourse    O
.    O

In    O
April    O
2005    O
,    O
Governor    O
Rod    O
Blagojevich    O
by    O
emergency    O
executive    O
order    O
required    O
all    O
pharmacists    O
to    O
provide    O
Plan    O
B    O
levonorgestrel    B-Hormone105407119
.    O

Other    O
-    O
hemodialysis    O
,    O
excessive    O
UV    O
-    O
A    O
,    O
cola    O
,    O
oral    O
contraceptive    O
pills    O
(    O
levonorgestrel    B-Hormone105407119
and    O
ethinylestradiol    O
)    O
,    O
narrowband    O
UV    O
-    O
B    O
phototherapy    O
(    O
rarely    O
)    O

Levonorgestrel    O
-    O
releasing    O
implant    O
,    O
sold    O
under    O
the    O
brand    O
name    O
Jadelle    O
among    O
others    O
,    O
is    O
a    O
device    O
made    O
up    O
of    O
a    O
two    O
rods    O
of    O
levonorgestrel    B-Hormone105407119
used    O
for    O
birth    O
control    O
.    O

The    O
original    O
Norplant    O
consisted    O
of    O
a    O
set    O
of    O
six    O
small    O
(    O
2.4    O
mm    O
×    O
34    O
mm    O
)    O
silicone    O
capsules    O
,    O
each    O
filled    O
with    O
36    O
mg    O
of    O
levonorgestrel    B-Hormone105407119
implanted    O
under    O
the    O
skin    O
in    O
the    O
upper    O
arm    O
and    O
effective    O
for    O
five    O
years    O
.    O

It    O
has    O
been    O
shown    O
to    O
prevent    O
about    O
62–85%    O
of    O
expected    O
pregnancies    O
,    O
and    O
prevents    O
more    O
pregnancies    O
than    O
emergency    O
contraception    O
with    O
levonorgestrel    B-Hormone105407119
.    O

It    O
might    O
also    O
interact    O
with    O
hormonal    O
contraceptives    O
and    O
progestogens    O
such    O
as    O
levonorgestrel    B-Hormone105407119
and    O
other    O
substrates    O
of    O
the    O
progesterone    O
receptor    O
,    O
as    O
well    O
as    O
with    O
glucocorticoids    O
.    O

Ethinylestradiol    O
/    O
levonorgestrel    O
(    O
also    O
ethinyl    O
estradiol    O
/    O
levonorgestrel    O
)    O
is    O
a    O
combined    B-Hormone105407119
birth    I-Hormone105407119
control    I-Hormone105407119
pill    I-Hormone105407119
made    O
up    O
of    O
ethinylestradiol    O
,    O
an    O
estrogen    O
and    O
levonorgestrel    B-Hormone105407119
a    O
progestin    O
.    O

A    O
2001    O
comparative    O
study    O
of    O
the    O
IMS    O
LifeLink    O
Health    O
Plan    O
Claims    O
Database    O
interpreted    O
that    O
in    O
a    O
large    O
cohort    O
of    O
women    O
using    O
oral    O
contraceptives    O
,    O
there    O
was    O
found    O
a    O
small    O
,    O
statistically    O
significant    O
increase    O
in    O
the    O
risk    O
of    O
gallbladder    O
disease    O
associated    O
with    O
desogestrel    B-Hormone105407119
,    O
drospirenone    O
and    O
norethisterone    B-Hormone105407119
compared    O
with    O
levonorgestrel    B-Hormone105407119
.    O

In    O
early    O
February    O
2006    O
,    O
Stephens    O
challenged    O
Blagojevich    O
in    O
an    O
appearance    O
on    O
"    O
The    O
Daily    O
Show    O
"    O
to    O
discuss    O
the    O
Governor    O
's    O
executive    O
order    O
that    O
pharmacists    O
must    O
dispense    O
any    O
drugs    O
for    O
which    O
a    O
customer    O
had    O
a    O
valid    O
prescription    O
,    O
including    O
birth    O
control    O
pills    O
and    O
Plan    B-Hormone105407119
B    I-Hormone105407119
Blagojevich    O
was    O
interviewed    O
by    O
Jason    O
Jones    O
,    O
who    O
repeatedly    O
pretended    O
to    O
be    O
unable    O
to    O
pronounce    O
Blagojevich    O
and    O
simply    O
called    O
him    O
"    O
Governor    O
Smith    O
"    O
.    O

Neurotrophins    B-Hormone105407119
and    O
tumor    O
necrosis    O
factor    O
α    O
(    O
TNFα    O
)    O
are    O
other    O
cellular    O
factors    O
that    O
work    O
to    O
sensitize    O
neurons    O
to    O
pain    O
.    O

Bromantane    O
has    O
been    O
found    O
to    O
increase    O
the    O
expression    O
of    O
neurotrophin    B-Hormone105407119
including    O
brain-derived    B-Hormone105407119
neurotrophic    I-Hormone105407119
factor    I-Hormone105407119
and    O
nerve    O
growth    O
factor    O
in    O
certain    O
rat    O
brain    O
areas    O
.    O

The    O
precursor    O
protein    O
exists    O
both    O
as    O
a    O
secretory    O
protein    O
and    O
as    O
an    O
integral    O
membrane    O
protein    O
and    O
has    O
neurotrophic    B-Hormone105407119
activities    O
.    O

They    O
produce    O
a    O
variety    O
of    O
factors    O
,    O
including    O
neurotrophin    B-Hormone105407119
,    O
and    O
also    O
transfer    O
essential    O
molecules    O
across    O
to    O
axons    O
.    O

It    O
has    O
been    O
proposed    O
that    O
the    O
MAGE    O
conserved    O
domain    O
of    O
MAGE    O
-    O
D    O
proteins    O
might    O
interact    O
with    O
p75    O
neurotrophin    B-Hormone105407119
or    O
related    O
receptors    O
.    O

He    O
earned    O
acclaim    O
for    O
his    O
teaching    O
and    O
initiated    O
a    O
program    O
of    O
research    O
that    O
centered    O
on    O
the    O
role    O
of    O
neurotrophins    B-Hormone105407119
in    O
the    O
growth    O
and    O
survival    O
of    O
nerve    O
cells    O
,    O
and    O
in    O
the    O
synaptic    O
activity    O
related    O
to    O
the    O
formation    O
of    O
memories    O
.    O

The    O
hippocampus    O
plays    O
a    O
significant    O
role    O
in    O
neurotrophy    B-Hormone105407119
:    O
the    O
cognitive    O
adaptation    O
to    O
changing    O
environments    O
and    O
the    O
process    O
of    O
learning    O
and    O
it    O
is    O
a    O
potent    O
stimulator    O
of    O
growth    O
hormone    O
.    O

List    O
of    O
neurosteroids    O
–    O
excitatory    O
,    O
inhibitory    O
,    O
mixed    O
,    O
neurotrophic    B-Hormone105407119
,    O
antineurotrophic    B-Hormone105407119
,    O
and    O
other    O
neurosteroids    O
,    O
as    O
well    O
as    O
pheromones    O
and    O
pherines    O

Neurotrophins    B-Hormone105407119
are    O
a    O
family    O
of    O
proteins    O
that    O
induce    O
the    O
survival    O
,    O
development    O
,    O
and    O
function    O
of    O
neurons    O
.    O

Metirosine    B-Hormone105407119
(    O
INN    O
)    O

formocortal    B-Hormone105407119
(    O
INN    O
)    O

In    O
addition    O
to    O
the    O
mineralocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
,    O
prorenone    O
also    O
binds    O
to    O
the    O
glucocorticoid    B-Hormone105407119
,    O
androgen    B-Hormone105407119
,    O
and    O
progesterone    B-Hormone105407119
receptor    I-Hormone105407119
.    O

In    O
addition    O
to    O
the    O
mineralocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
,    O
mexrenone    O
also    O
binds    O
to    O
the    O
glucocorticoid    B-Hormone105407119
,    O
androgen    B-Hormone105407119
,    O
and    O
progesterone    B-Hormone105407119
receptor    I-Hormone105407119
.    O

Glucocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
antagonist    O
(    O
Ki    O
=    O
224    O
nM    O
)    O

As    O
a    O
glucocorticoid    O
,    O
dexamethasone    O
is    O
an    O
agonist    O
of    O
the    O
glucocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
(    O
GR    O
)    O
.    O

NR3C1    B-Hormone105407119
,    O

It    O
also    O
binds    O
to    O
the    O
glucocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
,    O
but    O
is    O
only    O
a    O
weak    O
antiglucocorticoid    O
relative    O
to    O
mifepristone    O
,    O
and    O
has    O
no    O
relevant    O
affinity    O
to    O
the    O
estrogen    B-Hormone105407119
,    O
androgen    B-Hormone105407119
and    O
mineralocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
.    O

Glucocorticoid    B-Hormone105407119
receptor    I-Hormone105407119

Free    O
cortisol    O
passes    O
easily    O
through    O
cellular    O
membranes    O
,    O
where    O
they    O
bind    O
intracellular    O
cortisol    B-Hormone105407119
receptor    I-Hormone105407119
.    O

Glucocorticoids    O
are    O
corticosteroids    O
that    O
bind    O
to    O
the    O
glucocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
(    O
GR    O
)    O
,    O
that    O
is    O
present    O
in    O
almost    O
every    O
vertebrate    O
animal    O
cell    O
.    O

GCs    O
affect    O
cells    O
by    O
binding    O
to    O
the    O
glucocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
(    O
GR    O
)    O
.    O

Glucocorticoids    O
bind    O
to    O
the    O
cytosolic    O
glucocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
(    O
GR    O
)    O
,    O
a    O
type    O
of    O
nuclear    O
receptor    O
that    O
is    O
activated    O
by    O
ligand    O
binding    O
.    O

Glucocorticoid    B-Hormone105407119
receptor    I-Hormone105407119

Dexamethasone    O
-    O
a    O
synthetic    O
glucocorticoid    O
binds    O
more    O
powerfully    O
to    O
the    O
glucocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
than    O
cortisol    O
does    O
.    O

is    O
a    O
transcriptional    O
corepressor    O
for    O
nuclear    O
receptors    O
such    O
as    O
glucocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
and    O
a    O
coactivator    O
for    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
.    O

It    O
contains    O
10    O
NR    O
-    O
interacting    O
boxes    O
(    O
LXXLL    O
motifs    O
)    O
and    O
functions    O
as    O
a    O
coregulator    O
of    O
several    O
nuclear    O
receptors    O
via    O
its    O
LXXLL    O
motifs    O
including    O
ESR1    O
,    O
ESR2    O
,    O
ERR    O
-    O
alpha    O
,    O
PR    B-Hormone105407119
,    O
GR    B-Hormone105407119
,    O
AR    B-Hormone105407119
,    O
and    O
RXR    O
.    O

Glucocorticoid    B-Hormone105407119
receptor    I-Hormone105407119

The    O
"    O
O    O
"-    O
acetate    O
ester    O
of    O
cloxotestosterone    O
,    O
cloxotestosterone    O
acetate    O
(    O
brand    O
name    O
Caprosem    B-Hormone105407119
)    O
,    O
in    O
contrast    O
to    O
cloxotestosterone    O
,    O
has    O
been    O
marketed    O
.    O

Both    O
pharmacological    O
(    O
non    O
-    O
specific    O
β-blockers    O
,    O
nitrate    O
isosorbide    O
mononitrate    O
,    O
vasopressin    O
such    O
as    O
terlipressin    B-Hormone105407119
)    O
and    O
endoscopic    O
(    O
banding    O
ligation    O
)    O
treatment    O
have    O
similar    O
results    O
.    O

The    O
antidiuretic    O
hormone    O
class    O
includes    O
vasopressin    O
(    O
ADH    O
)    O
,    O
argipressin    O
,    O
desmopressin    B-Hormone105407119
,    O
lypressin    O
,    O
ornipressin    O
,    O
oxytocin    O
,    O
and    O
terlipressin    B-Hormone105407119
.    O

Endogenous    O
estrogens    O
(    O
e.g.    O
,    O
estradiol    O
,    O
estrone    O
,    O
estriol    O
,    O
estetrol    B-Hormone105407119
)    O

During    O
pregnancy    O
,    O
DHEA    O
-    O
S    O
is    O
metabolized    O
into    O
the    O
sulfates    O
of    O
16α-hydroxy    O
-    O
DHEA    O
and    O
15α-hydroxy    O
-    O
DHEA    O
in    O
the    O
fetal    O
liver    O
as    O
intermediates    O
in    O
the    O
production    O
of    O
the    O
estrogens    O
estriol    O
and    O
estetrol    B-Hormone105407119
,    O
respectively    O
.    O

Hypothalamic–pituitary–thyroid    B-Hormone105407119
axis    I-Hormone105407119
(    O
HPT    O
axis    O
)    O

Euthyroid    O
sick    O
syndrome    O
(    O
ESS    O
)    O
,    O
sick    O
euthyroid    O
syndrome    O
(    O
SES    O
)    O
,    O
thyroid    O
allostasis    O
in    O
critical    O
illness    O
,    O
tumours    O
,    O
uremia    O
and    O
starvation    O
(    O
TACITUS    O
)    O
,    O
non    O
-    O
thyroidal    O
illness    O
syndrome    O
(    O
NTIS    O
)    O
or    O
low    O
T3    O
low    O
T4    O
syndrome    O
is    O
a    O
state    O
of    O
adaptation    O
or    O
dysregulation    O
of    O
thyrotropic    B-Hormone105407119
feedback    I-Hormone105407119
control    I-Hormone105407119
where    O
the    O
levels    O
of    O
T3    O
and/or    O
T4    O
are    O
at    O
unusual    O
levels    O
,    O
but    O
the    O
thyroid    O
gland    O
does    O
not    O
appear    O
to    O
be    O
dysfunctional    O
.    O

Humoral    O
and    O
neuronal    O
inputs    O
at    O
the    O
level    O
of    O
the    O
hypothalamus    O
may    O
adjust    O
the    O
set    O
point    O
of    O
thyroid    B-Hormone105407119
homeostasis    I-Hormone105407119
.    O

Mebolazine    B-Hormone105407119
(dimethazine,    I-Hormone105407119
dymethazine)    I-Hormone105407119

Lidex    B-Hormone105407119

Amcinonide    B-Hormone105407119
,    O
budesonide    B-Hormone105407119
,    O
desonide    B-Hormone105407119
,    O
fluocinolone    B-Hormone105407119
acetonide    I-Hormone105407119
,    O
fluocinonide    B-Hormone105407119
,    O
halcinonide    B-Hormone105407119
,    O
and    O
triamcinolone    B-Hormone105407119
acetonide    I-Hormone105407119
.    O

Ointment    O
and    O
creams    O
containing    O
coal    O
tar    O
,    O
dithranol    O
,    O
corticosteroids    O
(    O
i.e.    O
desoximetasone    B-Hormone105407119
)    O
,    O
fluocinonide    B-Hormone105407119
,    O
vitamin    O
D3    O
analogs    O
(    O
for    O
example    O
,    O
calcipotriol    O
)    O
,    O
and    O
retinoids    O
are    O
routinely    O
used    O
.    O

Calorie    O
restriction    O
has    O
been    O
shown    O
to    O
increase    O
DHEA    B-Hormone105407119
in    O
primates    O
,    O
but    O
it    O
has    O
not    O
been    O
shown    O
to    O
increase    O
DHEA    B-Hormone105407119
in    O
post    O
-    O
pubescent    O
primates    O
.    O

By    O
inhibiting    O
3β-HSD    O
,    O
epostane    O
blocks    O
the    O
biosynthesis    O
of    O
progesterone    O
from    O
pregnenolone    B-Hormone105407119
(    O
and    O
also    O
the    O
conversion    O
of    O
dehydroepiandrosterone    B-Hormone105407119
to    O
androstenedione    B-Hormone105407119
)    O
,    O
thereby    O
functioning    O
as    O
an    O
antiprogestogen    O
and    O
terminating    O
pregnancy    O
.    O

A    O
Δ5    O
-    O
3-ketosteroid    O
isomerase    O
-    O
disrupted    O
mutant    O
of    O
strain    O
TA441    O
can    O
grow    O
on    O
dehydroepiandrosterone    B-Hormone105407119
,    O
which    O
has    O
a    O
double    O
bond    O
at    O
Δ5    O
,    O
but    O
can    O
not    O
grow    O
on    O
epiandrosterone    B-Hormone105407119
,    O
which    O
lacks    O
a    O
double    O
bond    O
at    O
Δ5    O
,    O
indicating    O
that    O
"    O
C.    O
testosteroni    O
"    O
KSI    O
is    O
responsible    O
for    O
transfer    O
of    O
the    O
double    O
bond    O
from    O
Δ5    O
to    O
Δ4    O
and    O
transfer    O
of    O
the    O
double    O
bond    O
by    O
hydrogenation    O
at    O
Δ5    O
and    O
following    O
dehydrogenation    O
at    O
Δ4    O
is    O
not    O
possible    O
.    O

In    O
vitro    O
"    O
cell    O
proliferation    O
assay    O
indicates    O
that    O
G6PD    O
inhibitors    O
,    O
DHEA    B-Hormone105407119
(    O
dehydroepiandrosterone    O
)    O
and    O
ANAD    O
(    O
6-aminonicotinamide    O
)    O
,    O
effectively    O
decrease    O
the    O
growth    O
of    O
AML    O
cell    O
lines    O
.    O

In    O
December    O
2009    O
,    O
a    O
urine    O
test    O
taken    O
at    O
the    O
2009    O
USPRO    O
Time    O
Trial    O
Championships    O
the    O
previous    O
August    O
,    O
in    O
which    O
Zirbel    O
came    O
second    O
,    O
tested    O
positive    O
for    O
DHEA    B-Hormone105407119
.    O

Levels    O
of    O
progesterone    O
,    O
17α-hydroxyprogesterone    O
,    O
androstenedione    B-Hormone105407119
,    O
testosterone    O
,    O
and    O
dihydrotestosterone    B-Hormone105407119
(    O
DHT    O
)    O
were    O
elevated    O
in    O
the    O
sisters    O
,    O
while    O
concentrations    O
of    O
adrenal    O
steroids    O
including    O
cortisol    B-Hormone105407119
,    O
dehydroepiandrosterone    B-Hormone105407119
(    O
DHEA    O
)    O
,    O
11β-hydroxyandrostenedione    O
,    O
11-deoxycortisol    O
,    O
and    O
21-deoxycortisol    O
were    O
within    O
normal    O
ranges    O
.    O

It    O
has    O
been    O
demonstrated    O
that    O
,    O
after    O
controlling    O
for    O
age    O
,    O
sex    O
,    O
and    O
BMI    O
,    O
larger    O
quantities    O
of    O
DHEA    B-Hormone105407119
and    O
DHEA    O
-    O
S    O
tended    O
to    O
be    O
linked    O
to    O
larger    O
pituitary    O
volume    O
.    O

Again    O
controlling    O
for    O
age    O
,    O
sex    O
,    O
and    O
BMI    O
,    O
DHEA    B-Hormone105407119
and    O
DHEA    O
-    O
S    O
have    O
been    O
found    O
to    O
be    O
predictive    O
of    O
larger    O
pituitary    O
gland    O
volume    O
,    O
which    O
was    O
also    O
associated    O
with    O
increased    O
ratings    O
of    O
social    O
anxiety    O
.    O

Dehydroepiandrosterone    B-Hormone105407119
(    O
DHEA    O
)    O
is    O
the    O
most    O
abundant    O
circulating    O
androgen    O
hormone    O
and    O
can    O
be    O
rapidly    O
metabolized    O
within    O
target    O
tissues    O
into    O
potent    O
androgens    O
and    O
estrogens    O
.    O

A    O
small    O
human    O
study    O
in    O
2011    O
found    O
that    O
monitoring    O
blood    O
dehydroepiandrosterone    B-Hormone105407119
(    O
DHEA    O
)    O
variations    O
in    O
response    O
to    O
an    O
oxidative    O
stress    O
could    O
be    O
a    O
useful    O
proxy    O
test    O
:    O
the    O
subjects    O
with    O
MCI    O
did    O
not    O
have    O
a    O
DHEA    O
variation    O
,    O
while    O
the    O
healthy    O
controls    O
did    O
.    O

The    O
17α-hydroxylase    O
activity    O
of    O
CYP17A1    O
is    O
required    O
for    O
the    O
generation    O
of    O
glucocorticoids    O
such    O
as    O
cortisol    O
,    O
but    O
both    O
the    O
hydroxylase    O
and    O
17,20-lyase    O
activities    O
of    O
CYP17A1    O
are    O
required    O
for    O
the    O
production    O
of    O
androgenic    O
and    O
oestrogenic    O
sex    O
steroids    O
by    O
converting    O
17α-hydroxypregnenolone    O
to    O
dehydroepiandrosterone    B-Hormone105407119
(DHEA)    I-Hormone105407119
.    O

Other    O
androgens    O
,    O
however    O
,    O
such    O
as    O
DHEA    B-Hormone105407119
,    O
increase    O
immune    O
response    O
.    O

It    O
produces    O
androgens    O
,    O
mainly    O
dehydroepiandrosterone    B-Hormone105407119
(    O
DHEA    O
)    O
,    O
DHEA    O
sulfate    O
(    O
DHEA    O
-    O
S    O
)    O
,    O
and    O
androstenedione    B-Hormone105407119
(    O
the    O
precursor    O
to    O
testosterone    O
)    O
in    O
humans    O
.    O

Cells    O
in    O
zona    O
reticularis    O
of    O
the    O
adrenal    O
glands    O
produce    O
male    O
sex    O
hormones    O
,    O
or    O
androgens    O
,    O
the    O
most    O
important    O
of    O
which    O
is    O
DHEA    B-Hormone105407119
.    O

During    O
early    O
childhood    O
androgen    O
synthesis    O
and    O
secretion    O
remain    O
low    O
,    O
but    O
several    O
years    O
before    O
puberty    O
(    O
from    O
6–8    O
years    O
of    O
age    O
)    O
changes    O
occur    O
in    O
both    O
anatomical    O
and    O
functional    O
aspects    O
of    O
cortical    O
androgen    O
production    O
that    O
lead    O
to    O
increased    O
secretion    O
of    O
the    O
steroids    O
DHEA    B-Hormone105407119
and    O
DHEA    O
-    O
S.    O
These    O
changes    O
are    O
part    O
of    O
a    O
process    O
called    O
adrenarche    O
,    O
which    O
has    O
only    O
been    O
described    O
in    O
humans    O
and    O
some    O
other    O
primates    O
.    O

This    O
includes    O
interconversion    O
of    O
DHEA    B-Hormone105407119
and    O
androstenediol    O
,    O
androstenedione    B-Hormone105407119
and    O
testosterone    O
,    O
and    O
estrone    O
and    O
estradiol    O
.    O

The    O
endogenous    O
steroids    O
dehydroepiandrosterone    B-Hormone105407119
(    O
DHEA    O
)    O
and    O
its    O
sulfate    O
ester    O
,    O
DHEA    O
sulfate    O
(    O
DHEA    O
-    O
S    O
)    O
,    O
have    O
been    O
identified    O
as    O
small    O
-    O
molecule    O
agonists    O
of    O
the    O
TrkA    O
and    O
p75NTR    O
with    O
high    O
affinity    O
(    O
around    O
5    O
nM    O
)    O
,    O
and    O
hence    O
as    O
so    O
-    O
called    O
"    O
microneurotrophins    O
"    O
.    O

3β-Hydroxysteroid    O
dehydrogenase/Δ5    O
-    O
4    O
isomerase    O
(    O
3β-HSD    O
)    O
is    O
an    O
enzyme    O
that    O
catalyzes    O
the    O
biosynthesis    O
of    O
progesterone    O
from    O
pregnenolone    B-Hormone105407119
,    O
17α-hydroxyprogesterone    O
from    O
17α-hydroxypregnenolone    O
,    O
and    O
androstenedione    B-Hormone105407119
from    O
dehydroepiandrosterone    B-Hormone105407119
(    O
DHEA    O
)    O
in    O
the    O
adrenal    O
gland    O
.    O

DHEA    B-Hormone105407119
to    O
androstenedione    B-Hormone105407119

Hydrocortisone-17-butyrate    O
,    O
hydrocortisone-17-valerate    O
,    O
alclometasone    O
dipropionate    O
,    O
betamethasone    O
valerate    O
,    O
betamethasone    B-Hormone105407119
dipropionate    I-Hormone105407119
,    O
prednicarbate    B-Hormone105407119
,    O
clobetasone-17-butyrate    O
,    O
Clobetasol-17    B-Hormone105407119
propionate    I-Hormone105407119
,    O
fluocortolone    O
caproate    O
,    O
fluocortolone    O
pivalate    O
,    O
fluprednidene    B-Hormone105407119
acetate    I-Hormone105407119
,    O
and    O
mometasone    B-Hormone105407119
furoate    O

Alclometasone    O
dipropionate    O
,    O
betamethasone    B-Hormone105407119
dipropionate    I-Hormone105407119
,    O
betamethasone    O
valerate    O
,    O
clobetasol    B-Hormone105407119
propionate    I-Hormone105407119
,    O
clobetasone    O
butyrate    O
,    O
fluprednidene    B-Hormone105407119
acetate    I-Hormone105407119
,    O
and    O
mometasone    B-Hormone105407119
furoate    I-Hormone105407119
.    O

|rowspan=2|    O
Plasma    B-Hormone105407119
renin    I-Hormone105407119
activity    I-Hormone105407119

1950    O
(    O
Physiology    O
or    O
Medicine    O
)    O
Edward    O
Calvin    O
Kendall    O
,    O
Tadeus    O
Reichstein    O
,    O
and    O
Philip    O
Hench    O
–    O
Structure    O
and    O
biological    O
effects    O
of    O
adrenal    B-Hormone105407119
hormones    I-Hormone105407119

Adrenocortical    B-Hormone105407119
hormone    I-Hormone105407119

:    O
N04BA04    O
Melevodopa    B-Hormone105407119

Urodilatin    B-Hormone105407119
is    O
a    O
hormone    O
that    O
causes    O
natriuresis    O
through    O
increasing    O
renal    O
blood    O
flow    O
.    O

The    O
functional    O
opposite    O
of    O
EIS    O
is    O
hyperestrogenism    B-Hormone105407119
,    O
for    O
instance    O
that    O
seen    O
in    O
aromatase    B-Hormone105407119
excess    I-Hormone105407119
syndrome    I-Hormone105407119
.    O

Hyperestrogenism    B-Hormone105407119

Together    O
they    O
are    O
often    O
referred    O
to    O
as    O
FGF15/19    B-Hormone105407119
.    O

Fluclorolone    B-Hormone105407119
acetonide    I-Hormone105407119
(    O
flucloronide    O
)    O
=    O
6α-fluoro-9α,11β-dichloro-16α,17α,21-trihydroxypregna-1,4-dien-3,20-dione    O
cyclic    O
16α,17α-acetal    O
with    O
acetone    O

1    O
)    O
insulin    O
and    O
insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119

Chlorogen    O
,    O
Inc.    O
–    O
cholera    O
,    O
anthrax    O
,    O
and    O
plague    O
vaccines    O
,    O
albumin    O
,    O
interferon    O
for    O
liver    O
diseases    O
including    O
hepatitis    O
C    O
,    O
elastin    O
,    O
4HB    O
,    O
and    O
insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
in    O
tobacco    O
chloroplasts    O
.    O

"    O
C.    O
elegans    O
"    O
has    O
been    O
a    O
model    O
organism    O
for    O
research    O
into    O
ageing    O
;    O
for    O
example    O
,    O
the    O
inhibition    O
of    O
an    O
insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
signaling    O
pathway    O
has    O
been    O
shown    O
to    O
increase    O
adult    O
lifespan    O
threefold    O
.    O

Dauricine    O
inhibits    O
insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
-    O
I    O
-    O
induced    O
(    O
IGF    O
-    O
I    O
-    O
induced    O
)    O
hypoxia    O
-    O
inducible    O
factor    O
I    O
-    O
alpha    O
(    O
HIF    O
-    O
Iα    O
)    O
protein    O
accumulation    O
and    O
vascular    O
endothelial    O
growth    O
factor    O
(    O
VEGF    O
)    O
protein    O
secretion    O
in    O
MCF-7    O
,    O
human    O
breast    O
cancer    O
cells    O
.    O

The    O
insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factors    I-Hormone105407119
(    O
IGFs    O
)    O
are    O
proteins    O
with    O
high    O
sequence    O
similarity    O
to    O
insulin    O
.    O

Insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119

Further    O
,    O
leptin    O
interacts    O
with    O
other    O
hormones    O
and    O
energy    O
regulators    O
,    O
"    O
indirectly    O
"    O
mediating    O
the    O
effects    O
of    O
:    O
insulin    O
,    O
glucagon    O
,    O
insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
,    O
growth    O
hormone    O
,    O
glucocorticoids    O
,    O
cytokines    O
,    O
and    O
metabolites    O
.    O

follitropin    B-Hormone105407119
beta    I-Hormone105407119
(    O
INN    O
)    O

Gonal-F    B-Hormone105407119
(    O
Serono    O
)    O

Follicle    O
-    O
stimulating    O
hormone    O
(    O
FSH    O
)    O
as    O
a    O
recombinant    O
gonadotropin    B-Hormone105407119
preparation    I-Hormone105407119
replaced    O
Serono    O
's    O
Pergonal    B-Hormone105407119
which    O
was    O
previously    O
isolated    O
from    O
post    O
-    O
menopausal    O
female    O
urine    O

---    O
cysteinyldopa    B-Hormone105407119

Cinchocaine    O
is    O
the    O
active    O
ingredient    O
in    O
some    O
topical    O
hemorrhoid    O
creams    O
such    O
as    O
Proctosedyl    B-Hormone105407119
.    O

Entero-oxyntin    B-Hormone105407119
is    O
a    O
hormone    O
released    O
from    O
intestinal    O
endocrine    O
cells    O
which    O
stimulates    O
gastric    O
acid    O
secretion    O
in    O
the    O
stomach    O
.    O

Flurandrenolide    B-Hormone105407119
0.05%    O
(    O
Cordran    O
)    O

As    O
the    O
sodium    O
salt    O
,    O
sodium    O
estradiol    O
sulfate    O
,    O
E2S    O
is    O
present    O
as    O
a    O
minor    O
constituent    O
(    O
0.9%    O
)    O
of    O
conjugated    O
equine    O
estrogens    O
(    O
CEEs    O
)    O
,    O
or    O
Premarin    B-Hormone105407119
.    O

Later    O
,    O
the    O
scientists    O
helped    O
form    O
the    O
company    O
Ayerst    O
,    O
McKenna    O
and    O
Harrison    O
,    O
Ltd    O
(    O
later    O
,    O
Wyeth    O
)    O
who    O
marketed    O
Premarin    B-Hormone105407119
,    O
a    O
controversial    O
HRT    O
drug    O
based    O
on    O
pregnant    O
mare    O
's    O
urine    O
.    O

Pregnant    B-Hormone105407119
mare    I-Hormone105407119
urine    I-Hormone105407119

17β-Dihydroequilin    O
,    O
or    O
β-dihydroequilin    O
,    O
also    O
known    O
as    O
7-dehydro-17β-estradiol    O
,    O
as    O
well    O
as    O
estra-1,3,5(10),7-tetraen-3,17β-diol    O
,    O
is    O
a    O
naturally    O
occurring    O
steroidal    O
estrogen    O
found    O
in    O
horses    O
that    O
is    O
closely    O
related    O
to    O
equilin    B-Hormone105407119
,    O
equilenin    B-Hormone105407119
,    O
and    O
estradiol    O
,    O
and    O
,    O
as    O
the    O
3-sulfate    O
ester    O
sodium    O
salt    O
,    O
is    O
a    O
minor    O
constituent    O
(    O
1.7%    O
)    O
of    O
conjugated    O
equine    O
estrogens    O
(    O
Premarin    B-Hormone105407119
)    O
.    O

17α-Dihydroequilenin    O
,    O
or    O
α-dihydroequilenin    O
,    O
also    O
known    O
as    O
6,8-didehydro-17α-estradiol    O
,    O
as    O
well    O
as    O
estra-1,3,5(10),6,8-pentaen-3,17α-diol    O
,    O
is    O
a    O
naturally    O
occurring    O
steroidal    O
estrogen    O
found    O
in    O
horses    O
that    O
is    O
closely    O
related    O
to    O
equilin    B-Hormone105407119
,    O
equilenin    B-Hormone105407119
,    O
and    O
17α-estradiol    O
,    O
and    O
,    O
as    O
the    O
3-sulfate    O
ester    O
sodium    O
salt    O
,    O
is    O
a    O
minor    O
constituent    O
(    O
1.2%    O
)    O
of    O
conjugated    O
equine    O
estrogens    O
(    O
Premarin    B-Hormone105407119
)    O
.    O

17β-Dihydroequilenin    O
,    O
or    O
β-dihydroequilenin    O
,    O
also    O
known    O
as    O
6,8-didehydro-17β-estradiol    O
,    O
as    O
well    O
as    O
estra-1,3,5(10),6,8-pentaen-3,17β-diol    O
,    O
is    O
a    O
naturally    O
occurring    O
steroidal    O
estrogen    O
found    O
in    O
horses    O
that    O
is    O
closely    O
related    O
to    O
equilin    B-Hormone105407119
,    O
equilenin    B-Hormone105407119
,    O
and    O
estradiol    O
,    O
and    O
,    O
as    O
the    O
3-sulfate    O
ester    O
sodium    O
salt    O
,    O
is    O
a    O
minor    O
constituent    O
(    O
0.5%    O
)    O
of    O
conjugated    O
equine    O
estrogens    O
(    O
Premarin    B-Hormone105407119
)    O
.    O

8,9-Dehydroestrone    O
,    O
or    O
Δ8-estrone    O
,    O
also    O
known    O
as    O
estra-1,3,5(10),8-tetraen-3-ol-17-one    O
,    O
is    O
a    O
naturally    O
occurring    O
steroidal    O
estrogen    O
found    O
in    O
horses    O
that    O
is    O
closely    O
related    O
to    O
equilin    B-Hormone105407119
,    O
equilenin    B-Hormone105407119
,    O
and    O
estrone    O
,    O
and    O
,    O
as    O
the    O
3-sulfate    O
ester    O
sodium    O
salt    O
,    O
is    O
a    O
minor    O
constituent    O
(    O
3.5%    O
)    O
of    O
conjugated    O
equine    O
estrogens    O
(    O
Premarin    B-Hormone105407119
)    O
.    O

3-"O"-Methyldopa    B-Hormone105407119
(    O
3-OMD    B-Hormone105407119
)    O
is    O
one    O
of    O
the    O
most    O
important    O
metabolites    O
of    O
L-DOPA    B-Hormone105407119
,    O
a    O
drug    O
used    O
in    O
the    O
treatment    O
of    O
the    O
Parkinson    O
's    O
disease    O
to    O
help    O
increase    O
the    O
dopamine    O
levels    O
.    O

Saliva    B-Hormone105407119
hormone    I-Hormone105407119
testing    I-Hormone105407119
is    O
an    O
effort    O
to    O
determine    O
the    O
amount    O
of    O
hormones    O
found    O
in    O
saliva    O
.    O

Barrios    O
originally    O
finished    O
4th    O
in    O
the    O
2012    O
Summer    O
Olympics    O
,    O
but    O
she    O
moved    O
up    O
a    O
position    O
after    O
Darya    O
Pishchalnikova    O
was    O
disqualified    O
for    O
testing    O
positive    O
for    O
the    O
anabolic    O
steroid    O
oxandrolone    B-Hormone105407119
.    O

On    O
1    O
May    O
2013    O
,    O
the    O
IOC    O
stripped    O
Russian    O
discus    O
thrower    O
Darya    O
Pishchalnikova    O
of    O
her    O
silver    O
medal    O
in    O
the    O
women    O
's    O
discus    O
throw    O
after    O
testing    O
positive    O
for    O
Oxandrolone    B-Hormone105407119
(    O
an    O
anabolic    O
steroid    O
)    O
.    O

However    O
,    O
the    O
validity    O
of    O
her    O
record    O
and    O
title    O
was    O
called    O
into    O
question    O
by    O
a    O
positive    O
blood    O
test    O
result    O
for    O
the    O
banned    O
steroids    O
oxandrolone    B-Hormone105407119
and    O
stanozolol    B-Hormone105407119
,    O
and    O
she    O
was    O
"    O
provisionally    O
suspended    O
"    O
by    O
the    O
International    O
Weightlifting    O
Federation    O
.    O

In    O
June    O
2016    O
,    O
IWF    O
announced    O
that    O
retests    O
of    O
the    O
samples    O
taken    O
from    O
the    O
2012    O
Olympics    O
indicated    O
that    O
Zulfiya    O
Chinshanlo    O
had    O
tested    O
positive    O
for    O
prohibited    O
substances    O
,    O
namely    O
Oxandrolone    B-Hormone105407119
and    O
Stanazolol    B-Hormone105407119
.    O

Anabolic-androgenic    B-Hormone105407119
steroid    I-Hormone105407119
like    O
oxandrolone    B-Hormone105407119
may    O
be    O
beneficial    O
in    O
cancer    O
cachexia    O
but    O
their    O
use    O
is    O
recommended    O
for    O
maximal    O
2    O
weeks    O
since    O
a    O
longer    O
duration    O
of    O
treatment    O
increases    O
the    O
burden    O
from    O
side    O
effects    O
.    O

Oxandrolone    B-Hormone105407119

Oxandrolone    B-Hormone105407119

The    O
infamous    O
"    O
duchess    O
"    O
cocktail    O
administered    O
to    O
Russian    O
athletes    O
at    O
the    O
Sochi    O
Winter    O
Olympics    O
consisted    O
of    O
oxandrolone    B-Hormone105407119
,    O
metenolone    O
,    O
and    O
trenbolone    B-Hormone105407119
.    O

Betamethasone    B-Hormone105407119
,    O
betamethasone    O
sodium    O
phosphate    O
,    O
dexamethasone    O
,    O
dexamethasone    O
sodium    O
phosphate    O
,    O
and    O
fluocortolone    B-Hormone105407119

Beclometasone    O
,    O
betamethasone    B-Hormone105407119
,    O
dexamethasone    O
,    O
fluocortolone    B-Hormone105407119
,    O
halometasone    B-Hormone105407119
,    O
and    O
mometasone    O
.    O

Desoxymethyltestosterone    B-Hormone105407119

Desoxymethyltestosterone    B-Hormone105407119
(DMT)    I-Hormone105407119

VGF    B-Hormone105407119
Nerve    I-Hormone105407119
Growth    I-Hormone105407119
Factor-inducible    I-Hormone105407119
,    O
a    O
protein    O
whose    O
expression    O
is    O
induced    O
by    O
NGF    O

Benorterone    O
(    O
INN    O
,    O
USAN    O
)    O
(    O
developmental    O
code    O
names    O
SKF-7690    O
,    O
FC-612    O
)    O
,    O
also    O
known    O
as    O
17α-methyl    O
-    O
B    O
-    O
nortestosterone    O
,    O
is    O
a    O
steroidal    O
,    O
pure    O
antiandrogen    B-Hormone105407119
that    O
was    O
never    O
marketed    O
.    O

Delanterone    O
(    O
INN    O
)    O
(    O
developmental    O
code    O
name    O
GBR-21162    O
)    O
,    O
also    O
known    O
as    O
1α-methylandrosta-4,16-dien-3-one    O
,    O
is    O
a    O
steroidal    O
antiandrogen    B-Hormone105407119
described    O
as    O
an    O
anti    O
-    O
acne    O
agent    O
which    O
was    O
never    O
marketed    O
.    O

Metogest    O
(    O
INN    O
,    O
USAN    O
)    O
(    O
developmental    O
code    O
name    O
SC-14207    O
)    O
,    O
also    O
known    O
as    O
16,16-dimethyl-19-nortestosterone    O
,    O
is    O
a    O
steroidal    O
antiandrogen    B-Hormone105407119
that    O
was    O
patented    O
in    O
1975    O
and    O
investigated    O
as    O
a    O
treatment    O
for    O
acne    O
but    O
was    O
never    O
marketed    O
.    O

Nordinone    O
(    O
INN    O
)    O
,    O
also    O
known    O
as    O
11α-hydroxy-17,17-dimethyl-18-norandrosta-4,13-dien-3-one    O
,    O
is    O
a    O
naturally    O
occurring    O
steroid    O
with    O
antiandrogen    B-Hormone105407119
properties    O
isolated    O
as    O
a    O
metabolite    O
from    O
the    O
fungus    O
"    O
Monocillium    O
nordinii    O
"    O
.    O

Osaterone    O
acetate    O
(    O
brand    O
name    O
Ypozane    O
;    O
former    O
developmental    O
code    O
name    O
TZP-4238    O
)    O
,    O
also    O
known    O
as    O
17α-acetoxy-6-chloro-2-oxa-6-dehydroprogesterone    O
,    O
as    O
well    O
as    O
2-oxachloromadinone    O
acetate    O
,    O
is    O
a    O
steroidal    O
antiandrogen    B-Hormone105407119
and    O
progestogen    O
used    O
in    O
veterinary    O
medicine    O
in    O
Europe    O
in    O
the    O
treatment    O
of    O
benign    O
prostatic    O
hyperplasia    O
(    O
BPH    O
)    O
in    O
dogs    O
.    O

Oxendolone    O
(    O
INN    O
,    O
USAN    O
,    O
JAN    O
)    O
(    O
brand    O
names    O
Prostetin    O
,    O
Roxenone    O
;    O
former    O
developmental    O
code    O
name    O
TSAA-291    O
)    O
,    O
also    O
known    O
as    O
16β-ethyl-19-nortestosterone    O
or    O
16β-ethylestr-4-en-17β-ol-3-one    O
,    O
is    O
a    O
steroidal    O
antiandrogen    B-Hormone105407119
and    O
progestin    O
of    O
the    O
19-nortestosterone    O
group    O
that    O
has    O
been    O
marketed    O
in    O
Japan    O
by    O
Takeda    O
for    O
the    O
treatment    O
of    O
benign    O
prostatic    O
hyperplasia    O
(    O
BPH    O
)    O
since    O
1981    O
.    O

Rosterolone    O
(    O
INN    O
)    O
(    O
developmental    O
code    O
name    O
SH-434    O
)    O
,    O
also    O
known    O
as    O
17α-propylmesterolone    O
or    O
1α-methyl-17α-propyl-5α-androstan-17β-ol-3-one    O
,    O
is    O
a    O
steroidal    O
antiandrogen    B-Hormone105407119
that    O
was    O
first    O
reported    O
in    O
1984    O
and    O
was    O
developed    O
for    O
topical    O
administration    O
but    O
was    O
never    O
marketed    O
.    O

Topterone    O
(    O
INN    O
,    O
USAN    O
)    O
(    O
developmental    O
code    O
name    O
WIN-17665    O
)    O
,    O
also    O
known    O
as    O
17α-propyltestosterone    O
or    O
17α-propylandrost-4-en-17β-ol-3-one    O
,    O
is    O
a    O
steroidal    O
antiandrogen    B-Hormone105407119
that    O
was    O
first    O
reported    O
in    O
1978    O
and    O
was    O
developed    O
for    O
topical    O
administration    O
but    O
,    O
due    O
to    O
poor    O
effectiveness    O
,    O
was    O
never    O
marketed    O
.    O

Zanoterone    O
(    O
INN    O
,    O
USAN    O
)    O
(    O
former    O
developmental    O
codename    O
WIN-49596    O
)    O
,    O
also    O
known    O
as    O
(    O
5α,17α)-1'-(methylsulfonyl)-1'-H    O
-    O
pregn-20-yno[3,2-c]pyrazol-17-ol    O
,    O
is    O
a    O
steroidal    O
antiandrogen    B-Hormone105407119
that    O
was    O
never    O
marketed    O
.    O

Relative    O
to    O
spironolactone    O
,    O
it    O
has    O
markedly    O
reduced    O
antiandrogen    B-Hormone105407119
activity    O
(    O
approximately    O
one    O
-    O
tenth    O
of    O
the    O
antimineralocorticoid    O
dosage    O
equivalent    O
antiandrogen    O
activity    O
of    O
spironolactone    O
)    O
.    O

As    O
testosterone    O
surge    O
does    O
not    O
occur    O
with    O
GnRH    O
antagonists    O
,    O
there    O
is    O
no    O
need    O
for    O
patients    O
to    O
receive    O
an    O
antiandrogen    B-Hormone105407119
as    O
flare    O
protection    O
during    O
prostate    O
cancer    O
treatment    O
.    O

Valproic    O
acid    O
has    O
been    O
found    O
to    O
be    O
an    O
antagonist    O
of    O
the    O
androgen    B-Hormone105407119
and    O
progesterone    B-Hormone105407119
receptor    I-Hormone105407119
,    O
and    O
hence    O
as    O
a    O
nonsteroidal    O
antiandrogen    B-Hormone105407119
and    O
antiprogestogen    O
,    O
at    O
concentrations    O
much    O
lower    O
than    O
therapeutic    O
serum    O
levels    O
.    O

Examples    O
of    O
progonadotropic    O
drugs    O
include    O
gonadotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
(    O
GnRH    O
)    O
agonists    O
when    O
administered    O
in    O
a    O
pulsatile    O
(    O
as    O
opposed    O
to    O
continuous    O
)    O
manner    O
,    O
antiestrogens    O
such    O
as    O
tamoxifen    O
,    O
clomifene    O
,    O
fulvestrant    O
,    O
and    O
aromatase    O
inhibitors    O
like    O
anastrozole    O
,    O
and    O
,    O
only    O
in    O
men    O
,    O
pure    O
antiandrogen    B-Hormone105407119
such    O
as    O
flutamide    O
,    O
bicalutamide    O
,    O
and    O
enzalutamide    O
.    O

Examples    O
of    O
drugs    O
commonly    O
associated    O
with    O
depressogenic    O
effects    O
include    O
some    O
anticonvulsants    O
such    O
as    O
the    O
barbiturates    O
(    O
e.g.    O
phenobarbital    O
)    O
,    O
benzodiazepines    O
(    O
e.g.    O
diazepam    O
)    O
,    O
vigabatrin    O
,    O
and    O
topiramate    O
,    O
corticosteroids    O
like    O
dexamethasone    O
and    O
prednisone    O
,    O
cytokines    O
like    O
interferon-α    O
and    O
interleukin-2    O
,    O
certain    O
antihypertensives    O
such    O
as    O
amiodarone    O
,    O
clonidine    O
,    O
methyldopa    O
,    O
reserpine    O
,    O
and    O
tetrabenazine    O
(    O
used    O
as    O
an    O
antipsychotic    O
/    O
antihyperkinetic    O
)    O
,    O
and    O
agents    O
with    O
antiandrogen    B-Hormone105407119
,    O
antiestrogen    O
,    O
and/or    O
anti    O
-    O
neurosteroid    O
activities    O
such    O
as    O
GnRH    O
agonists    O
(    O
e.g.    O
,    O
leuprolide    O
,    O
goserelin    O
)    O
,    O
anastrozole    O
(    O
an    O
aromatase    O
inhibitor    O
)    O
,    O
finasteride    O
(    O
a    O
5α-reductase    O
inhibitor    O
)    O
,    O
and    O
clomiphene    O
(    O
a    O
SERM    B-Hormone105407119
)    O
,    O
as    O
well    O
as    O
others    O
including    O
flunarizine    O
,    O
mefloquine    O
,    O
and    O
efavirenz    O
.    O

In    O
accordance    O
,    O
NOMAC    O
is    O
a    O
potent    O
antigonadotropin    O
and    O
exhibits    O
no    O
androgenic    O
,    O
estrogenic    O
,    O
glucocorticoid    O
,    O
or    O
antimineralocorticoid    O
activity    O
,    O
but    O
does    O
possess    O
some    O
antiandrogen    B-Hormone105407119
activity    O
(    O
see    O
below    O
)    O
.    O

NOMAC    O
has    O
weak    O
or    O
moderate    O
antiandrogen    B-Hormone105407119
activity    O
(    O
5    O
to    O
20    O
times    O
less    O
than    O
that    O
of    O
cyproterone    B-Hormone105407119
acetate    I-Hormone105407119
(    O
a    O
strong    O
antiandrogen    O
)    O
,    O
with    O
approximately    O
12–31%    O
of    O
the    O
of    O
testosterone    O
for    O
the    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
)    O
.    O

Medications    O
consist    O
mostly    O
of    O
antiandrogen    B-Hormone105407119
and    O
include    O
:    O

Extension    O
of    O
the    O
C17α    O
alkyl    O
chain    O
longer    O
than    O
an    O
ethyl    O
group    O
abolishes    O
androgenic    O
activity    O
and    O
converts    O
the    O
drug    O
into    O
an    O
antiandrogen    B-Hormone105407119
,    O
as    O
in    O
topterone    O
(    O
17α-propyltestosterone    O
)    O
and    O
allylestrenol    B-Hormone105407119
(    O
17α-allyl-3-deketo-19-nortestosterone    O
)    O
(    O
an    O
extended    O
-    O
chain    O
variant    O
of    O
ethylestrenol    B-Hormone105407119
)    O
.    O

In    O
contrast    O
,    O
dienogest    B-Hormone105407119
,    O
the    O
17α-cyanomethyl    O
derivative    O
of    O
dienolone    O
,    O
is    O
a    O
potent    O
progestogen    O
and    O
antiandrogen    B-Hormone105407119
.    O

Analogues    O
with    O
longer    O
C17α    O
chains    O
such    O
as    O
propyltestosterone    O
(    O
topterone    O
)    O
have    O
further    O
greatly    O
reduced    O
androgenic    O
activity    O
or    O
even    O
antiandrogen    B-Hormone105407119
activity    O
.    O

It    O
did    O
,    O
however    O
,    O
show    O
some    O
androgenic    O
and    O
antiandrogen    B-Hormone105407119
activity    O
"    O
in    O
vitro    O
"    O
.    O

Resistin    O
is    O
an    O
adipose-derived    B-Hormone105407119
hormone    I-Hormone105407119
(    O
similar    O
to    O
a    O
cytokine    O
)    O
whose    O
physiologic    O
role    O
has    O
been    O
the    O
subject    O
of    O
much    O
controversy    O
regarding    O
its    O
involvement    O
with    O
obesity    O
and    O
type    O
II    O
diabetes    O
mellitus    O
(    O
T2DM    O
)    O
.    O

The    O
antigonadotropic    O
antiandrogens    O
,    O
medroxyprogesterone    B-Hormone105407119
acetate    I-Hormone105407119
(    O
MPA    O
)    O
,    O
and    O
analogues    O
have    O
all    O
been    O
widely    O
used    O
to    O
treat    O
paraphilias    O
(    O
e.g.    O
,    O
pedophilia    O
)    O
and    O
hypersexuality    O
in    O
men    O
.    O

The    O
Food    O
and    O
Drug    O
Administration    O
approves    O
Depo-Provera    B-Hormone105407119
for    O
use    O
as    O
a    O
contraceptive    O
in    O
the    O
United    O
States    O
.    O

Medroxyprogesterone    B-Hormone105407119
acetate    I-Hormone105407119

Most    O
inhibitors    O
of    O
CYP2C9    O
are    O
competitive    O
inhibitors    O
.    O
Noncompetitive    O
inhibitors    O
of    O
CYP2C9    O
include    O
nifedipine    O
,    O
phenethyl    O
isothiocyanate    O
,    O
medroxyprogesterone    B-Hormone105407119
acetate    I-Hormone105407119
and    O
6-hydroxyflavone    O
.    O

Examples    O
of    O
important    O
progestogen    O
esters    O
include    O
the    O
17α-hydroxyprogesterone    O
derivatives    O
medroxyprogesterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
megestrol    O
acetate    O
,    O
cyproterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
and    O
hydroxyprogesterone    B-Hormone105407119
caproate    I-Hormone105407119
,    O
the    O
19-norprogesterone    B-Hormone105407119
derivative    O
nomegestrol    B-Hormone105407119
acetate    I-Hormone105407119
,    O
and    O
the    O
19-nortestosterone    O
derivatives    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
and    O
norethisterone    O
enanthate    O
.    O

Medroxyprogesterone    B-Hormone105407119
acetate    I-Hormone105407119
(    O
Provera    O
)    O
entered    O
clinical    O
use    O
and    O
became    O
widely    O
marketed    O
,    O
largely    O
superseding    O
the    O
17α-hydroxyprogesterone    O
esters    O
.    O

Medroxyprogesterone    B-Hormone105407119
acetate    I-Hormone105407119
(    O
Provera    O
)    O
,    O
the    O
most    O
popular    O
and    O
widely    O
used    O
progestogen    O
ester    O
.    O

In    O
1969    O
,    O
along    O
with    O
a    O
variety    O
of    O
other    O
progestogens    O
including    O
progesterone    O
,    O
chlormadinone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
megestrol    O
acetate    O
,    O
medroxyprogesterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
ethynerone    O
,    O
and    O
chloroethynyl    O
norgestrel    O
,    O
anagestone    O
acetate    O
was    O
found    O
to    O
induce    O
the    O
development    O
of    O
mammary    O
gland    O
tumors    O
in    O
Beagle    O
dogs    O
after    O
extensive    O
treatment    O
(    O
2–7    O
years    O
)    O
with    O
very    O
high    O
doses    O
(    O
10–25    O
times    O
the    O
recommended    O
human    O
dose    O
)    O
,    O
though    O
notably    O
not    O
with    O
1–2    O
times    O
the    O
human    O
dosage    O
.    O

Subsequent    O
investigation    O
found    O
that    O
17α-hydroxyprogesterone    O
derivatves    O
included    O
anagestone    O
acetate    O
,    O
chlormadinone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
medroxyprogesterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
and    O
megestrol    O
acetate    O
produced    O
similar    O
mammary    O
gland    O
tumors    O
,    O
and    O
that    O
their    O
ability    O
to    O
do    O
so    O
correlated    O
directly    O
with    O
their    O
progestogenic    O
actions    O
.    O

Use    O
of    O
progestin    O
-    O
only    O
contraceptives    O
,    O
such    O
as    O
Depo    B-Hormone105407119
Provera    I-Hormone105407119

A    O
phase-2    O
study    O
involving    O
the    O
administration    O
of    O
antioxidants    O
,    O
pharmaconutritional    O
support    O
,    O
progestin    O
(    O
megestrol    O
acetate    O
and    O
medroxyprogesterone    B-Hormone105407119
acetate    I-Hormone105407119
)    O
,    O
and    O
anticyclooxygenase-2    O
drugs    O
,    O
showed    O
efficacy    O
and    O
safety    O
in    O
the    O
treatment    O
of    O
patients    O
with    O
advanced    O
cancer    O
of    O
different    O
sites    O
suffering    O
cachexia    O
.    O

NOMAC    O
is    O
a    O
potent    O
and    O
pure    O
progestogen    O
,    O
acting    O
as    O
a    O
selective    O
,    O
high    O
-    O
affinity    O
full    O
agonist    O
of    O
the    O
progesterone    B-Hormone105407119
receptor    I-Hormone105407119
(    O
PR    O
)    O
(    O
Ki    O
=    O
3    O
nM    O
,    O
67–303%    O
of    O
the    O
of    O
progesterone    O
)    O
,    O
and    O
is    O
said    O
to    O
have    O
higher    O
potency    O
and    O
substantially    O
improved    O
selectivity    O
for    O
the    O
PR    O
relative    O
to    O
medroxyprogesterone    B-Hormone105407119
acetate    I-Hormone105407119
(    O
the    O
6-hydrogenated    O
or    O
non-6    O
-    O
7-double    O
bonded    O
analogue    O
of    O
megestrol    O
acetate    O
and    O
the    O
most    O
widely    O
used    O
progestin    O
)    O
.    O

Along    O
with    O
that    O
two    O
contraceptive    O
pills    O
,    O
MPA    O
(    O
Medroxyprogesterone    B-Hormone105407119
acetate    I-Hormone105407119
)    O
under    O
Antara    O
program    O
and    O
Chaya    O
(    O
earlier    O
marketed    O
as    O
Saheli    O
)    O
will    O
be    O
made    O
freely    O
available    O
to    O
all    O
government    O
hospitals    O
.    O

,    O
Keith    O
Ablow    O
responded    O
to    O
Kaplan    O
's    O
column    O
,    O
arguing    O
that    O
although    O
he    O
agreed    O
with    O
it    O
on    O
many    O
points    O
,    O
he    O
thought    O
that    O
Kaplan    O
"    O
is    O
wrong    O
to    O
suggest    O
that    O
,    O
merely    O
because    O
something    O
is    O
a    O
known    O
disorder    O
,    O
it    O
should    O
result    O
in    O
protections    O
under    O
the    O
law    O
"    O
and    O
arguing    O
that    O
"    O
If    O
a    O
pedophile    O
wants    O
to    O
not    O
attack    O
children    O
,    O
he    O
can    O
receive    O
confidential    O
psychiatric    O
treatment    O
–    O
including    O
Depo-Provera    B-Hormone105407119
to    O
lower    O
testosterone    O
levels    O
–    O
to    O
make    O
it    O
much    O
less    O
likely    O
.    O
"    O

The    O
people    O
in    O
the    O
program    O
experienced    O
injections    O
of    O
Depro-Provera    B-Hormone105407119
and    O
individual    O
and    O
group    O
therapy    O
aimed    O
at    O
helping    O
priests    O
regain    O
their    O
celibacy    O
;    O
the    O
latter    O
differed    O
from    O
secular    O
treatment    O
,    O
in    O
which    O
the    O
effort    O
was    O
to    O
get    O
the    O
men    O
to    O
transfer    O
their    O
sexual    O
attraction    O
to    O
adults    O
.    O

This    O
can    O
also    O
be    O
accomplished    O
with    O
progestational    O
agents    O
(    O
i.e.    O
,    O
medroxyprogesterone    B-Hormone105407119
acetate    I-Hormone105407119
)    O
,    O
danazol    B-Hormone105407119
,    O
gestrinone    B-Hormone105407119
,    O
or    O
gonadotropin    O
-    O
releasing    O
hormone    O
agonists    O
(    O
GnRH    B-Hormone105407119
)    O
,    O
as    O
well    O
as    O
other    O
less    O
well    O
-    O
known    O
agents    O
.    O

Non    O
-    O
permanent    O
forms    O
of    O
sterilization    O
were    O
also    O
used    O
including    O
Depo-Provera    B-Hormone105407119
and    O
Norplant    O
.    O

Medroxyprogesterone    B-Hormone105407119
acetate    I-Hormone105407119
and    O
medrogestone    B-Hormone105407119
are    O
weak    O
inhibitors    O
of    O
3β-HSD    O
which    O
may    O
substantially    O
inhibit    O
it    O
at    O
high    O
dosages    O
.    O

Low    O
-    O
dosage    O
steroidal    O
eye    O
-    O
drops    O
,    O
such    O
as    O
prednisone    O
,    O
fluorometholone    B-Hormone105407119
,    O
loteprednol    B-Hormone105407119
(    O
Lotemax    O
0.5%    O
)    O
or    O
rimexolone    B-Hormone105407119
.    O

FML    B-Hormone105407119

Commonly    O
used    O
solutions    O
are    O
of    O
fluorometholone    B-Hormone105407119
,    O
medrysone    O
,    O
betamethasone    B-Hormone105407119
or    O
dexamethasone    O
.    O

A    O
pregnadiene    B-Hormone105407119
is    O
a    O
diene    O
derivative    O
of    O
a    O
pregnane    B-Hormone105407119
.    O

Renin-angiotensin    B-Hormone105407119
system    I-Hormone105407119

The    O
kidney    O
mechanisms    O
used    O
to    O
restore    O
EABV    O
include    O
,    O
(    O
1    O
)    O
sympathetic    O
nerve    O
activity    O
;    O
(    O
2    O
)    O
Atriopeptin    B-Hormone105407119
(    O
ANP    O
)    O
secretion    O
from    O
the    O
atria    O
;    O
(    O
3    O
)    O
Starling    O
forces    O
;    O
(    O
4    O
)    O
Renin–angiotensin–aldosterone    B-Hormone105407119
system    I-Hormone105407119

Secondary    O
hyperaldosteronism    O
(    O
also    O
hyperreninism    O
,    O
or    O
hyperreninemic    O
hyperaldosteronism    O
)    O
is    O
due    O
to    O
overactivity    O
of    O
the    O
renin-angiotensin-aldosterone    B-Hormone105407119
system    I-Hormone105407119
(    O
RAAS    O
)    O
.    O

Renin    O
,    O
the    O
first    O
enzyme    O
in    O
the    O
renin–angiotensin–aldosterone    B-Hormone105407119
system    I-Hormone105407119
,    O
plays    O
a    O
role    O
in    O
blood    O
pressure    O
control    O
.    O

Pregnancy    O
:    O
Other    O
drugs    O
such    O
as    O
ACE    O
inhibitors    O
,    O
also    O
acting    O
on    O
the    O
renin-angiotensin    B-Hormone105407119
system    I-Hormone105407119
,    O
have    O
been    O
associated    O
with    O
fetal    O
malformations    O
and    O
neonatal    O
death    O
.    O

Mechanisms    O
hypothesized    O
to    O
be    O
involved    O
in    O
this    O
relationship    O
include    O
the    O
following    O
:    O
dysregulation    O
of    O
the    O
renin-angiotensin    B-Hormone105407119
system    I-Hormone105407119
,    O
elevated    O
levels    O
of    O
endothelin    O
1    O
in    O
the    O
blood    O
,    O
and    O
increased    O
oxidative    O
stress    O
.    O

The    O
human    O
body    O
has    O
evolved    O
to    O
balance    O
salt    O
intake    O
with    O
need    O
through    O
means    O
such    O
as    O
the    O
renin-angiotensin    B-Hormone105407119
system    O
.    O

Secretion    O
of    O
"    O
renin    O
"    O
,    O
which    O
is    O
a    O
key    O
part    O
of    O
the    O
renin–angiotensin–aldosterone    B-Hormone105407119
system    I-Hormone105407119
.    O

The    O
control    O
and    O
regulation    O
mechanisms    O
of    O
the    O
circulatory    O
system    O
and    O
renal    O
functions    O
and    O
their    O
interactions    O
(    O
such    O
as    O
the    O
renin/angiotensin    B-Hormone105407119
system    I-Hormone105407119
)    O
are    O
also    O
greatly    O
influenced    O
by    O
autopharmacological    O
agents    O
;    O
One    O
of    O
the    O
autopharmacology    O
pioneers    O
was    O
Professor    O
Mauricio    O
Rocha    O
e    O
Silva    O
,    O
leader    O
of    O
the    O
team    O
of    O
Brazilian    O
researchers    O
who    O
discovered    O
bradykinin    B-Hormone105407119
in    O
1948    O
,    O
an    O
endogenous    O
substance    O
involved    O
in    O
hypotension    O
in    O
circulatory    O
shock    O
.    O

It    O
produces    O
and    O
secretes    O
into    O
the    O
circulation    O
the    O
enzyme    O
renin    O
,    O
which    O
cleaves    O
angiotensin-1    O
and    O
creates    O
angiotensin-2    O
,    O
a    O
potent    O
vasoconstictor    O
:    O
the    O
renin-angiotensin    B-Hormone105407119
system    I-Hormone105407119
.    O

The    O
renin-angiotensin    B-Hormone105407119
system    I-Hormone105407119
may    O
be    O
subsequently    O
activated    O
,    O
because    O
of    O
the    O
decrease    O
in    O
perfusion    O
of    O
juxtaglomerular    O
apparatus    O
,    O
which    O
may    O
result    O
in    O
hypertension    O
.    O

This    O
type    O
of    O
adrenal    O
insufficiency    O
usually    O
does    O
not    O
affect    O
the    O
production    O
of    O
mineralocorticoids    O
,    O
which    O
are    O
under    O
regulation    O
of    O
the    O
renin-angiotensin    B-Hormone105407119
system    I-Hormone105407119
instead    O
.    O

In    O
synthesizing    O
renin    O
,    O
they    O
play    O
a    O
critical    O
role    O
in    O
the    O
renin-angiotensin    B-Hormone105407119
system    I-Hormone105407119
and    O
thus    O
in    O
autoregulation    O
of    O
the    O
kidney    O
.    O

Norboletone    B-Hormone105407119
(norbolethone)    I-Hormone105407119

Derivatives    O
of    O
ethyltestosterone    O
include    O
norethandrolone    O
(    O
ethylnandrolone    O
,    O
ethylestrenolone    O
)    O
,    O
ethylestrenol    B-Hormone105407119
(    O
ethylnandrol    O
)    O
,    O
norboletone    B-Hormone105407119
,    O
ethyldienolone    O
,    O
tetrahydrogestrinone    B-Hormone105407119
,    O
bolenol    B-Hormone105407119
(    O
ethylnorandrostenol    O
)    O
,    O
and    O
propetandrol    B-Hormone105407119
.    O

In    O
addition    O
,    O
according    O
to    O
the    O
respected    O
French    O
paper    O
"    O
L'Equipe    O
,    O
"    O
Tzekos    O
was    O
directly    O
dealing    O
with    O
the    O
creator    O
of    O
norbolethone    B-Hormone105407119
and    O
THG    O
(    O
tetrahydrogestrinone    B-Hormone105407119
)    O
Patrick    O
Arnold    O
,    O
the    O
father    O
of    O
pro    O
-    O
hormone    O
craze    O
and    O
some    O
undetectable    O
designer    O
steroids    O
.    O

By    O
comparison    O
,    O
"N"-methyldopamine    B-Hormone105407119
also    O
had    O
no    O
effect    O
in    O
caudectomized    O
mice    O
at    O
≤    O
150    O
mg    O
/    O
kg    O
,    O
and    O
only    O
a    O
weak    O
effect    O
in    O
nigral    O
-    O
lesioned    O
rats    O
at    O
25    O
mg    O
/    O
kg    O
,    O
although    O
it    O
was    O
as    O
effective    O
as    O
dopamine    O
in    O
stimulating    O
cAMP    O
in    O
the    O
adenylate    O
cyclase    O
assay    O
.    O

N-methyldopamine    B-Hormone105407119

In    O
cases    O
where    O
systemic    O
iron    O
levels    O
are    O
raised    O
,    O
or    O
where    O
inflammation    O
is    O
present    O
,    O
raised    O
levels    O
of    O
hepcidin    B-Hormone105407119
act    O
on    O
macrophage    O
ferroportin    O
channels    O
,    O
leading    O
to    O
iron    O
remaining    O
within    O
the    O
macrophages    O
.    O

Moreover    O
,    O
cytokines    O
stimulate    O
hepcidin    B-Hormone105407119
release    O
from    O
the    O
liver    O
,    O
which    O
is    O
eventually    O
responsible    O
for    O
the    O
anemia    O
of    O
chronic    O
disease    O
.    O

The    O
mechanisms    O
involved    O
are    O
multifactorial    O
and    O
not    O
limited    O
to    O
malabsorption    O
but    O
mainly    O
related    O
to    O
chronic    O
intestinal    O
inflammation    O
,    O
which    O
causes    O
dysregulation    O
of    O
hepcidin    B-Hormone105407119
that    O
leads    O
to    O
decreased    O
access    O
of    O
iron    O
to    O
the    O
circulation    O
.    O

Hepcidin    B-Hormone105407119

Brassinosteroids    B-Hormone105407119
(    O
BRs    O
)    O
are    O
a    O
class    O
of    O
polyhydroxysteroids    O
that    O
have    O
been    O
recognized    O
as    O
a    O
sixth    O
class    O
of    O

They    O
are    O
also    O
linked    O
to    O
cell    O
enlargement    O
and    O
cell    O
wall    O
changes    O
induced    O
by    O
other    O
plant    O
hormones    O
such    O
as    O
gibberellin    O
,    O
cytokinin    O
,    O
ethylene    O
and    O
brassinosteroids    B-Hormone105407119
.    O

The    O
orthologous    O
protein    O
in    O
mouse    O
is    O
FGF15    B-Hormone105407119
,    O
which    O
shares    O
about    O
50%    O
amino    O
acid    O
identity    O
and    O
has    O
similar    O
functions    O
.    O

If    O
complications    O
occur    O
in    O
children    O
,    O
patients    O
can    O
be    O
treated    O
with    O
vitamin    O
D.    O
Gamma    O
interferon    O
has    O
also    O
been    O
shown    O
to    O
be    O
effective    O
,    O
and    O
it    O
can    O
be    O
associated    O
to    O
vitamin    O
D.    O
Erythropoetin    B-Hormone105407119
has    O
been    O
used    O
to    O
treat    O
any    O
associated    O
anemia    O
.    O

This    O
increase    O
is    O
mediated    O
by    O
the    O
increased    O
levels    O
of    O
erythropoietin    B-Hormone105407119
by    O
the    O
kidneys    O
in    O
response    O
to    O
hypoxia    O
.    O

Professional    O
athletes    O
'    O
hematocrit    O
levels    O
are    O
measured    O
as    O
part    O
of    O
tests    O
for    O
blood    O
doping    O
or    O
erythropoietin    B-Hormone105407119
(    O
EPO    O
)    O
use    O
;    O
the    O
level    O
of    O
hematocrit    O
in    O
a    O
blood    O
sample    O
is    O
compared    O
with    O
the    O
long    O
-    O
term    O
level    O
for    O
that    O
athlete    O
(    O
to    O
allow    O
for    O
individual    O
variations    O
in    O
hematocrit    O
level    O
)    O
,    O
and    O
against    O
an    O
absolute    O
permitted    O
maximum    O
(    O
which    O
is    O
based    O
on    O
maximum    O
expected    O
levels    O
within    O
the    O
population    O
,    O
and    O
the    O
hematocrit    O
level    O
that    O
causes    O
increased    O
risk    O
of    O
blood    O
clots    O
resulting    O
in    O
strokes    O
or    O
heart    O
attacks    O
)    O
.    O

This    O
decreased    O
saturation    O
is    O
sensed    O
by    O
the    O
kidneys    O
,    O
resulting    O
in    O
a    O
compensatory    O
increase    O
in    O
erythropoietin    B-Hormone105407119
production    O
and    O
an    O
increased    O
production    O
of    O
red    O
blood    O
cells    O
in    O
an    O
attempt    O
to    O
increase    O
oxygen    O
delivery    O
.    O

An    O
important    O
example    O
of    O
such    O
a    O
complex    O
protein    O
is    O
the    O
hormone    O
erythropoietin    B-Hormone105407119
.    O

In    O
2001    O
,    O
she    O
shared    O
the    O
$    O
1    O
million    O
jackpot    O
of    O
the    O
IAAF    O
Golden    O
League    O
and    O
in    O
the    O
same    O
year    O
tested    O
positive    O
for    O
EPO    B-Hormone105407119
which    O
drew    O
protests    O
from    O
her    O
fellow    O
competitors    O
after    O
she    O
was    O
allowed    O
to    O
compete    O
in    O
the    O
World    O
Athletics    O
Championships    O
.    O

Today    O
CIM    O
produces    O
biopharmaceutical    O
products    O
,    O
such    O
as    O
anti    O
-    O
CD3    O
monoclonal    O
antibody    O
for    O
the    O
treatment    O
of    O
patients    O
with    O
organ    O
transplant    O
rejection    O
,    O
human    O
recombinant    O
erythropoietin    B-Hormone105407119
for    O
the    O
treatment    O
of    O
anemia    O
,    O
granulocyte    B-Hormone105407119
colony-stimulating    I-Hormone105407119
factor    I-Hormone105407119
for    O
the    O
treatment    O
of    O
neutropenia    O
,    O
and    O
a    O
humanized    O
monoclonal    O
antibody    O
that    O
recognizes    O
the    O
epidermal    O
growth    O
factor    O
receptor    O
for    O
cancer    O
treatment    O
,    O
as    O
well    O
as    O
other    O
monoclonal    O
antibodies    O
for    O
tumor    O
imaging    O
.    O

Urine    O
samples    O
taken    O
from    O
Heras    O
after    O
the    O
final    O
time    O
trial    O
proved    O
to    O
be    O
positive    O
for    O
EPO    B-Hormone105407119
.    O

Cancellara    O
was    O
later    O
awarded    O
the    O
stage    O
win    O
in    O
the    O
penultimate    O
stage    O
after    O
the    O
initial    O
winner    O
,    O
Stefan    O
Schumacher    O
,    O
tested    O
positive    O
for    O
EPO    B-Hormone105407119
.    O

Boldenone    O
will    O
increase    O
nitrogen    O
retention    O
,    O
protein    O
synthesis    O
,    O
increases    O
appetite    O
and    O
stimulates    O
the    O
release    O
of    O
erythropoietin    B-Hormone105407119
in    O
the    O
kidneys    O
.    O

The    O
specific    O
function    O
of    O
extraglomerular    O
mesangial    O
cells    O
is    O
not    O
well    O
understood    O
,    O
although    O
it    O
has    O
been    O
associated    O
with    O
the    O
secretion    O
of    O
erythropoietin    B-Hormone105407119
and    O
secretion    O
of    O
renin    O
.    O

From    O
studies    O
on    O
rats    O
and    O
mice    O
,    O
researchers    O
have    O
found    O
that    O
satellite    O
glial    O
cells    O
express    O
many    O
neurotransmitter    O
receptors    O
,    O
such    O
as    O
muscarinic    O
acetylcholine    O
and    O
erythropoietin    B-Hormone105407119
receptors    O
.    O

In    O
2009    O
,    O
he    O
was    O
suspended    O
by    O
the    O
IAAF    O
for    O
2    O
years    O
for    O
a    O
doping    O
offence    O
involving    O
the    O
drug    O
rh-EPO    B-Hormone105407119
.    O

In    O
August    O
2009    O
Hunter    O
-    O
Galvan    O
admitted    O
taking    O
the    O
banned    O
drug    O
EPO    B-Hormone105407119
three    O
times    O
,    O
after    O
failing    O
a    O
drug    O
test    O
on    O
23    O
March    O
.    O

Recent    O
challenges    O
in    O
drug    O
testing    O
include    O
the    O
development    O
of    O
effective    O
regulatory    O
methods    O
for    O
the    O
newer    O
hormonal    O
products    O
such    O
as    O
the    O
various    O
human    O
recombinant    O
erythropoietin    B-Hormone105407119
products    O
and    O
variants    O
and    O
growth    O
hormones    O
.    O

He    O
admitted    O
to    O
spending    O
up    O
to    O
US$    O
6000    O
per    O
year    O
for    O
EPO    B-Hormone105407119
.    O

Lloyd    O
Mondory    O
(    O
born    O
26    O
April    O
1982    O
)    O
is    O
a    O
French    O
professional    O
road    O
bicycle    O
racer    O
who    O
is    O
currently    O
suspended    O
for    O
four    O
years    O
for    O
use    O
of    O
EPO    B-Hormone105407119
.    O

In    O
March    O
2015    O
,    O
it    O
was    O
announced    O
that    O
Mondory    O
had    O
tested    O
positive    O
for    O
erythropoietin    B-Hormone105407119
in    O
an    O
out    O
-    O
of    O
-    O
competition    O
test    O
taken    O
on    O
17    O
February    O
.    O

Tested    O
positive    O
for    O
the    O
blood    O
-    O
booster    O
EPO    B-Hormone105407119
;    O
the    O
IOC    O
ordered    O
him    O
to    O
leave    O
the    O
Olympics    O
on    O
10    O
August    O
2012    O
.    O

He    O
failed    O
a    O
drugs    O
test    O
for    O
erythropoietin    B-Hormone105407119
(    O
EPO    O
)    O
in    O
2012    O
and    O
was    O
banned    O
for    O
two    O
years    O
.    O

She    O
was    O
removed    O
from    O
the    O
Olympic    O
squad    O
prior    O
to    O
the    O
2008    O
Summer    O
Olympics    O
,    O
as    O
she    O
failed    O
a    O
doping    O
test    O
for    O
Erythropoietin    B-Hormone105407119
(    O
EPO    O
)    O
in    O
May.    O
She    O
received    O
a    O
two    O
-    O
year    O
ban    O
from    O
the    O
sport    O
from    O
May    O
2008    O
to    O
May    O
2010    O
.    O

Erythropoietin    B-Hormone105407119
has    O
not    O
been    O
found    O
effective    O
to    O
prevent    O
or    O
treat    O
anemia    O
in    O
burn    O
cases    O
.    O

Preoperative    O
techniques    O
such    O
as    O
erythropoietin    B-Hormone105407119
(    O
EPO    O
)    O
or    O
iron    O
administration    O
are    O
designed    O
to    O
stimulate    O
the    O
patient    O
's    O
own    O
erythropoiesis    O
.    O

This    O
all    O
changed    O
in    O
1989    O
when    O
Ratcliffe    O
,    O
who    O
had    O
been    O
training    O
as    O
a    O
kidney    O
specialist    O
,    O
established    O
a    O
laboratory    O
to    O
explore    O
the    O
regulation    O
of    O
erythropoietin    B-Hormone105407119
–    O
a    O
hormone    O
responsible    O
for    O
stimulating    O
the    O
production    O
of    O
red    O
blood    O
cells    O
,    O
known    O
to    O
be    O
turned    O
on    O
in    O
kidney    O
cells    O
following    O
oxygen    O
deprivation    O
.    O

Cycling    O
:    O
British    O
cyclist    O
David    O
Millar    O
is    O
suspended    O
from    O
competition    O
by    O
British    O
Cycling    O
,    O
including    O
the    O
Olympic    O
Games    O
,    O
following    O
a    O
confession    O
to    O
a    O
French    O
investigating    O
magistrate    O
that    O
he    O
had    O
taken    O
the    O
hormone    O
EPO    B-Hormone105407119
.    O

He    O
was    O
on    O
his    O
way    O
to    O
become    O
one    O
of    O
the    O
greatest    O
stars    O
in    O
cross    O
-    O
country    O
skiing    O
history    O
,    O
until    O
he    O
was    O
caught    O
doping    O
in    O
the    O
Finnish    O
2001    O
FIS    O
Nordic    O
World    O
Ski    O
Championships    O
scandal    O
for    O
taking    O
hydroxyethyl    O
starch    O
(    O
HES    O
)    O
,    O
a    O
blood    O
plasma    O
expander    O
usually    O
used    O
to    O
cover    O
up    O
the    O
use    O
of    O
erythropoietin    B-Hormone105407119
(    O
EPO    O
)    O
in    O
athletes    O
.    O

The    O
Pacak    O
-    O
Zhuang    O
syndrome    O
is    O
a    O
recently    O
described    O
disease    O
manifestation    O
in    O
females    O
that    O
includes    O
multiple    O
paragangliomas    O
and    O
somatostatinomas    O
(    O
in    O
some    O
)    O
,    O
both    O
neuroendocrine    O
tumors    O
,    O
and    O
secondary    O
polycythemia    O
associated    O
with    O
high    O
erythropoietin    B-Hormone105407119
levels    O
.    O

They    O
are    O
diagnosed    O
with    O
typical    O
physical    O
characteristics    O
(    O
red    O
cheeks    O
,    O
flushing    O
,    O
swelling    O
of    O
the    O
extremities    O
)    O
,    O
which    O
are    O
then    O
confirmed    O
through    O
lab    O
results    O
that    O
show    O
abnormally    O
increased    O
erythropoietin    B-Hormone105407119
levels    O
.    O

Russia    O
won    O
four    O
medals    O
,    O
earned    O
by    O
the    O
men    O
's    O
team    O
(    O
sprint    O
and    O
relay    O
:    O
both    O
silvers    O
)    O
and    O
Olga    O
Zavyalova    O
,    O
but    O
also    O
had    O
to    O
suffer    O
with    O
a    O
doping    O
controversy    O
with    O
newcomer    O
Sergey    O
Shiryayev    O
being    O
disqualified    O
for    O
EPO    B-Hormone105407119
doping    O
and    O
serving    O
a    O
two    O
-    O
year    O
ban    O
as    O
a    O
result    O
.    O

The    O
blood    O
sample    O
in    O
the    O
"    O
A    O
-    O
test    O
"    O
turned    O
out    O
high    O
in    O
hemoglobin    O
,    O
so    O
the    O
"    O
B    O
-    O
test    O
"    O
was    O
evaluated    O
and    O
confirmed    O
to    O
contain    O
EPO    B-Hormone105407119
.    O

Claudio    O
Chiappucci    O
used    O
the    O
services    O
of    O
doctor    O
Francesco    O
Conconi    O
,    O
who    O
is    O
accused    O
of    O
applying    O
EPO    B-Hormone105407119
to    O
cyclists    O
.    O

On    O
29    O
July    O
2004    O
,    O
just    O
before    O
the    O
2004    O
Summer    O
Olympics    O
,    O
Meirhaeghe    O
admitted    O
to    O
having    O
used    O
EPO    B-Hormone105407119
.    O

Drugs    O
already    O
on    O
the    O
market    O
,    O
such    O
as    O
heparin    O
,    O
erythropoietin    B-Hormone105407119
and    O
a    O
few    O
anti    O
-    O
flu    O
drugs    O
have    O
proven    O
effective    O
and    O
highlight    O
the    O
importance    O
of    O
glycans    O
as    O
a    O
new    O
class    O
of    O
drug    O
.    O

Erythropoietin    B-Hormone105407119
(    O
EPO    B-Hormone105407119
)    O
,    O
also    O
known    O
as    O
hematopoietin    B-Hormone105407119
or    O
hemopoietin    B-Hormone105407119
,    O
is    O
a    O
glycoprotein    O
cytokine    O
secreted    O
by    O
the    O
kidney    O
in    O
response    O
to    O
cellular    O
hypoxia    O
;    O
it    O
stimulates    O
red    O
blood    O
cell    O
production    O
(    O
erythropoiesis    O
)    O
in    O
the    O
bone    O
marrow    O
.    O

Erythropoietin    B-Hormone105407119
,    O
a    O
hormone    O
that    O
induces    O
red    O
blood    O
cell    O
production    O
,    O
sometimes    O
used    O
for    O
doping    O
in    O
endurance    O
sports    O

Recombinant    O
erythropoietin    B-Hormone105407119
(    O
EPO    O
)    O
is    O
very    O
effective    O
in    O
treating    O
the    O
diminished    O
red    O
blood    O
cell    O
production    O
that    O
accompanies    O
end    O
-    O
stage    O
kidney    O
disease    O
.    O

A    O
hematopoietin    B-Hormone105407119
receptor    O
,    O
the    O
IL-15    O
receptor    O
,    O
that    O
binds    O
IL-15    O
propagates    O
its    O
function    O
.    O

Eugene    O
Goldwasser    O
,    O
88    O
,    O
American    O
scientist    O
,    O
first    O
to    O
purify    O
EPO    B-Hormone105407119
extracts    O
,    O
prostate    O
cancer    O
.    O

His    O
name    O
was    O
also    O
on    O
the    O
list    O
of    O
doping    O
tests    O
published    O
by    O
the    O
French    O
Senate    O
on    O
24    O
July    O
2013    O
that    O
were    O
collected    O
during    O
the    O
1998    O
Tour    O
de    O
France    O
and    O
found    O
suspicious    O
for    O
EPO    B-Hormone105407119
when    O
retested    O
in    O
2004    O
.    O

In    O
addition    O
,    O
IL-3    O
stimulates    O
proliferation    O
of    O
all    O
cells    O
in    O
the    O
myeloid    O
lineage    O
(    O
granulocytes    O
,    O
monocytes    O
,    O
and    O
dendritic    O
cells    O
)    O
,    O
in    O
conjunction    O
with    O
other    O
cytokines    O
,    O
e.g.    O
,    O
Erythropoietin    B-Hormone105407119
(    O
EPO    O
)    O
,    O
Granulocyte    O
macrophage    O
colony    O
-    O
stimulating    O
factor    O
(    O
GM    O
-    O
CSF    O
)    O
,    O
and    O
IL-6    O
.    O

Heras    O
was    O
later    O
disqualified    O
due    O
to    O
a    O
positive    O
EPO    B-Hormone105407119
test    O
,    O
making    O
Sastre    O
the    O
de    O
facto    O
second    O
placed    O
rider    O
of    O
the    O
competition    O
.    O

After    O
hinting    O
that    O
he    O
may    O
come    O
out    O
of    O
retirement    O
,    O
seven    O
-    O
time    O
Tour    O
de    O
France    O
champion    O
Lance    O
Armstrong    O
announces    O
that    O
he    O
will    O
remain    O
retired    O
,    O
indicating    O
that    O
he    O
is    O
now    O
preoccupied    O
with    O
addressing    O
recent    O
allegations    O
that    O
he    O
used    O
EPO    B-Hormone105407119
during    O
his    O
first    O
Tour    O
win    O
in    O
1999    O
.    O

An    O
erythropoiesis    O
-    O
stimulating    O
agent    O
(    O
abbreviated    O
ESA    O
)    O
,    O
also    O
known    O
as    O
an    O
erythropoiesis    O
-    O
stimulating    O
drug    O
(    O
ESD    O
)    O
is    O
a    O
medicine    O
similar    O
to    O
erythropoietin    B-Hormone105407119
,    O
which    O
stimulates    O
red    O
blood    O
cell    O
production    O
(    O
erythropoeisis    O
)    O
.    O

Erythropoietin    B-Hormone105407119
(    O
Epo    O
)    O

Dynepo    B-Hormone105407119
trademark    O
name    O
for    O
an    O
erythropoiesis    O
stimulating    O
protein    O
,    O
by    O
Shire    O
plc    O

David    O
Millar    O
was    O
handed    O
a    O
two    O
-    O
year    O
ban    O
and    O
stripped    O
of    O
his    O
world    O
time    O
trial    O
title    O
by    O
the    O
British    O
cycling    O
federation    O
for    O
taking    O
the    O
banned    O
performance    O
enhancer    O
EPO    B-Hormone105407119
.    O

Anti    O
-    O
doping    O
tests    O
at    O
the    O
2001    O
World    O
Nordic    O
skiing    O
championships    O
in    O
Lahti    O
,    O
Finland    O
revealed    O
that    O
Jari    O
Isometsä    O
,    O
Janne    O
Immonen    O
and    O
two    O
other    O
skiers    O
from    O
Finland    O
's    O
gold    O
-    O
medal    O
relay    O
team    O
,    O
Mika    O
Myllylä    O
and    O
Harri    O
Kirvesniemi    O
,    O
and    O
two    O
female    O
skiers    O
tested    O
positive    O
for    O
hydroxyethyl    O
starch    O
(    O
HES    O
)    O
,    O
a    O
blood    O
plasma    O
expander    O
usually    O
used    O
to    O
cover    O
up    O
the    O
use    O
of    O
erythropoietin    B-Hormone105407119
(    O
EPO    O
)    O
.    O

This    O
encompasses    O
all    O
functions    O
of    O
the    O
kidney    O
,    O
including    O
maintenance    O
of    O
acid    O
-    O
base    O
balance    O
;    O
regulation    O
of    O
fluid    O
balance    O
;    O
regulation    O
of    O
sodium    O
,    O
potassium    O
,    O
and    O
other    O
electrolytes    O
;    O
clearance    O
of    O
toxins    O
;    O
absorption    O
of    O
glucose    O
,    O
amino    O
acids    O
,    O
and    O
other    O
small    O
molecules    O
;    O
regulation    O
of    O
blood    O
pressure    O
;    O
production    O
of    O
various    O
hormones    O
,    O
such    O
as    O
erythropoietin    B-Hormone105407119
;    O
and    O
activation    O
of    O
vitamin    O
D.    O

Secretion    O
of    O
"    O
erythropoietin    B-Hormone105407119
"    O
,    O
which    O
regulates    O
red    O
blood    O
cell    O
production    O
in    O
the    O
bone    O
marrow    O
.    O

His    O
name    O
was    O
on    O
the    O
list    O
of    O
doping    O
tests    O
published    O
by    O
the    O
French    O
Senate    O
on    O
24    O
July    O
2013    O
that    O
were    O
collected    O
during    O
the    O
1998    O
Tour    O
de    O
France    O
and    O
found    O
suspicious    O
for    O
EPO    B-Hormone105407119
when    O
retested    O
in    O
2004    O
.    O

These    O
patients    O
usually    O
do    O
not    O
respond    O
to    O
erythropoietin    B-Hormone105407119
therapy    O
.    O

His    O
name    O
was    O
on    O
the    O
list    O
of    O
doping    O
tests    O
published    O
by    O
the    O
French    O
Senate    O
on    O
24    O
July    O
2013    O
that    O
were    O
collected    O
during    O
the    O
1998    O
Tour    O
de    O
France    O
and    O
found    O
suspicious    O
for    O
EPO    B-Hormone105407119
when    O
retested    O
in    O
2004    O
.    O

Sumgong    O
was    O
to    O
defend    O
her    O
title    O
at    O
the    O
2017    O
London    O
Marathon    O
on    O
April    O
23    O
,    O
but    O
two    O
weeks    O
prior    O
to    O
the    O
race    O
she    O
was    O
suspended    O
after    O
testing    O
positive    O
for    O
erythropoietin    B-Hormone105407119
(    O
EPO    O
)    O
in    O
an    O
out    O
-    O
of    O
-    O
competition    O
test    O
conducted    O
by    O
the    O
International    O
Association    O
of    O
Athletics    O
Federations    O
(    O
IAAF    O
)    O
in    O
Kenya    O
,    O
announced    O
on    O
April    O
6    O
,    O
2017    O
.    O

In    O
a    O
September    O
2006    O
interview    O
given    O
to    O
the    O
"    O
New    O
York    O
Times    O
"    O
,    O
Andreu    O
admitted    O
that    O
he    O
had    O
taken    O
the    O
performance    O
-    O
enhancing    O
drug    O
Erythropoietin    B-Hormone105407119
(EPO)    I-Hormone105407119
to    O
help    O
prepare    O
for    O
the    O
1999    O
Tour    O
de    O
France    O
.    O

In    O
2005    O
,    O
Andreu    O
and    O
his    O
wife    O
Betsy    O
testified    O
that    O
Lance    O
Armstrong    O
told    O
cancer    O
doctors    O
in    O
their    O
presence    O
in    O
1996    O
he    O
had    O
doped    O
with    O
EPO    O
(    O
erythropoietin    B-Hormone105407119
)    O
,    O
growth    O
hormone    O
and    O
steroids    O
.    O

On    O
30    O
December    O
2013    O
it    O
was    O
announced    O
that    O
Kiprotich    O
had    O
failed    O
a    O
drug    O
test    O
directly    O
after    O
his    O
Istanbul    O
Marathon    O
win    O
,    O
having    O
returned    O
a    O
positive    O
result    O
for    O
erythropoietin    B-Hormone105407119
(    O
EPO    O
)    O
in    O
a    O
urine    O
sample    O
.    O

He    O
was    O
later    O
disqualified    O
for    O
testing    O
positive    O
for    O
EPO    B-Hormone105407119
and    O
suspended    O
for    O
2    O
years    O
.    O

Noujani    O
tested    O
positive    O
for    O
EPO    B-Hormone105407119
at    O
a    O
competition    O
in    O
Tanger    O
26    O
April    O
2014    O
,    O
and    O
was    O
subsequently    O
handed    O
a    O
two    O
-    O
year    O
doping    O
ban    O
.    O

On    O
23    O
February    O
,    O
Austrian    O
skier    O
Johannes    O
Dürr    O
tested    O
positive    O
for    O
EPO    B-Hormone105407119
and    O
Swedish    O
ice    O
hockey    O
player    O
Nicklas    O
Bäckström    O
tested    O
positive    O
for    O
a    O
substance    O
found    O
in    O
an    O
allergy    O
medication    O
.    O

Silvia    O
Danekova    O
of    O
Bulgaria    O
was    O
the    O
first    O
athletics    O
doping    O
suspension    O
at    O
the    O
Olympics    O
,    O
as    O
the    O
sample    O
she    O
had    O
given    O
on    O
arrival    O
was    O
positive    O
for    O
EPO    B-Hormone105407119
.    O

Erythropoietin    B-Hormone105407119
,    O
a    O
hormone    O

The    O
2009    O
women    O
's    O
winner    O
,    O
Shitaye    O
Gemechu    O
,    O
was    O
disqualified    O
after    O
testing    O
positive    O
for    O
the    O
banned    O
blood    O
booster    O
EPO    B-Hormone105407119
(    O
making    O
her    O
the    O
first    O
Ethiopian    O
runner    O
to    O
be    O
banned    O
for    O
abusing    O
that    O
substance    O
)    O
.    O

On    O
April    O
26    O
,    O
2010    O
he    O
was    O
provisionally    O
suspended    O
by    O
the    O
UCI    O
for    O
a    O
suspected    O
blood    O
doping    O
offense    O
,    O
after    O
being    O
tested    O
positive    O
for    O
EPO    B-Hormone105407119
on    O
March    O
20    O
,    O
2010    O
in    O
an    O
out    O
-    O
of    O
-    O
competition    O
control    O
.    O

Erythropoietin    B-Hormone105407119

Jakobs    O
has    O
admitted    O
to    O
have    O
used    O
EPO    B-Hormone105407119
during    O
his    O
career    O
.    O

These    O
receptors    O
are    O
also    O
known    O
under    O
the    O
name    O
"    O
hemopoietin    B-Hormone105407119
receptors    O
"    O
,    O
and    O
share    O
a    O
common    O
amino    O
acid    O
motif    O
(    O
WSXWS    O
)    O
in    O
the    O
extracellular    O
portion    O
adjacent    O
to    O
the    O
cell    O
membrane    O
.    O

In    O
2012    O
,    O
he    O
tested    O
positive    O
for    O
the    O
blood    O
boosting    O
drug    O
EPO    B-Hormone105407119
by    O
the    O
South    O
African    O
Institute    O
for    O
Drug    O
-    O
Free    O
Sport    O
after    O
biological    O
passport    O
anomalies    O
were    O
detected    O
,    O
and    O
admitted    O
his    O
use    O
of    O
EPO    O
.    O

Despite    O
not    O
testing    O
positive    O
during    O
the    O
race    O
or    O
season    O
,    O
the    O
Gewiss    O
-    O
Ballan    O
team    O
has    O
since    O
been    O
speculated    O
to    O
have    O
executed    O
a    O
systematic    O
doping    O
program    O
that    O
utilized    O
EPO    B-Hormone105407119
throughout    O
the    O
1994    O
season    O
.    O

On    O
16    O
April    O
2012    O
,    O
Galimzyanov    O
was    O
provisionally    O
suspended    O
by    O
the    O
UCI    O
,    O
after    O
testing    O
positive    O
for    O
EPO    B-Hormone105407119
in    O
an    O
out    O
-    O
of    O
-    O
competition    O
drugs    O
test    O
in    O
March    O
.    O

In    O
the    O
same    O
study    O
,    O
spironolactone    O
was    O
administered    O
to    O
rats    O
and    O
found    O
to    O
produce    O
mixed    O
estrogenic    O
and    O
antiestrogenic    O
or    O
selective    B-Hormone105407119
estrogen    I-Hormone105407119
receptor    I-Hormone105407119
modulator    I-Hormone105407119
(    O
SERM)-like    O
effects    O
that    O
were    O
described    O
as    O
very    O
similar    O
to    O
those    O
of    O
tamoxifen    O
.    O

In    O
postmenopausal    O
women    O
,    O
the    O
selective    B-Hormone105407119
estrogen    I-Hormone105407119
receptor    I-Hormone105407119
modulator    I-Hormone105407119
raloxifene    O
is    O
occasionally    O
administered    O
instead    O
of    O
bisphosphonates    O
.    O

Acolbifene    O
(    O
INN    O
)    O
(    O
developmental    O
code    O
names    O
EM-652    O
,    O
SCH-57068    O
)    O
is    O
a    O
nonsteroidal    O
selective    B-Hormone105407119
estrogen    I-Hormone105407119
receptor    I-Hormone105407119
modulator    I-Hormone105407119
(    O
SERM    O
)    O
which    O
,    O
as    O
of    O
2015    O
,    O
is    O
in    O
phase    O
III    O
clinical    O
trials    O
for    O
the    O
treatment    O
of    O
breast    O
cancer    O
.    O

Enclomifene    O
(    O
tentative    O
brand    O
name    O
Androxal    O
)    O
,    O
or    O
enclomiphene    O
,    O
is    O
a    O
nonsteroidal    O
selective    B-Hormone105407119
estrogen    I-Hormone105407119
receptor    I-Hormone105407119
modulator    I-Hormone105407119
(    O
SERM    O
)    O
of    O
the    O
triphenylethylene    O
group    O
that    O
is    O
under    O
development    O
for    O
the    O
treatment    O
of    O
male    O
hypogonadism    O
.    O

Zuclomifene    O
(    O
INN    O
)    O
,    O
or    O
zuclomiphene    O
(    O
USAN    O
)    O
,    O
is    O
a    O
nonsteroidal    O
selective    B-Hormone105407119
estrogen    I-Hormone105407119
receptor    I-Hormone105407119
modulator    I-Hormone105407119
(    O
SERM    O
)    O
of    O
the    O
triphenylethylene    O
group    O
that    O
was    O
never    O
marketed    O
.    O

selective    B-Hormone105407119
oestrogen    I-Hormone105407119
receptor    I-Hormone105407119
modulators    I-Hormone105407119
,    O
hormone    O
replacement    O
therapy    O
and    O
calcitonin    O
are    O
some    O
of    O
the    O
common    O
treatments    O
.    O

Examples    O
of    O
drugs    O
commonly    O
associated    O
with    O
depressogenic    O
effects    O
include    O
some    O
anticonvulsants    O
such    O
as    O
the    O
barbiturates    O
(    O
e.g.    O
phenobarbital    O
)    O
,    O
benzodiazepines    O
(    O
e.g.    O
diazepam    O
)    O
,    O
vigabatrin    O
,    O
and    O
topiramate    O
,    O
corticosteroids    O
like    O
dexamethasone    O
and    O
prednisone    O
,    O
cytokines    O
like    O
interferon-α    O
and    O
interleukin-2    O
,    O
certain    O
antihypertensives    O
such    O
as    O
amiodarone    O
,    O
clonidine    O
,    O
methyldopa    O
,    O
reserpine    O
,    O
and    O
tetrabenazine    O
(    O
used    O
as    O
an    O
antipsychotic    O
/    O
antihyperkinetic    O
)    O
,    O
and    O
agents    O
with    O
antiandrogen    B-Hormone105407119
,    O
antiestrogen    O
,    O
and/or    O
anti    O
-    O
neurosteroid    O
activities    O
such    O
as    O
GnRH    O
agonists    O
(    O
e.g.    O
,    O
leuprolide    O
,    O
goserelin    O
)    O
,    O
anastrozole    O
(    O
an    O
aromatase    O
inhibitor    O
)    O
,    O
finasteride    O
(    O
a    O
5α-reductase    O
inhibitor    O
)    O
,    O
and    O
clomiphene    O
(    O
a    O
SERM    B-Hormone105407119
)    O
,    O
as    O
well    O
as    O
others    O
including    O
flunarizine    O
,    O
mefloquine    O
,    O
and    O
efavirenz    O
.    O

Selective    B-Hormone105407119
estrogen    I-Hormone105407119
receptor    I-Hormone105407119
modulator    I-Hormone105407119
,    O
specifically    O
tamoxifen    O
,    O
have    O
been    O
found    O
to    O
reduce    O
breast    O
cancer    O
risk    O
in    O
women    O
with    O
"    O
BRCA    O
"    O
mutations    O
who    O
do    O
not    O
have    O
their    O
breast    O
removed    O
.    O

The    O
drug    O
can    O
both    O
mimic    O
the    O
action    O
of    O
estrogen    O
and    O
antagonize    O
estrogen    O
,    O
indicating    O
that    O
it    O
is    O
a    O
selective    B-Hormone105407119
estrogen    I-Hormone105407119
receptor    I-Hormone105407119
modulator    I-Hormone105407119
(    O
SERM    O
)    O
or    O
partial    O
agonist    O
of    O
the    O
ER    O
.    O

Menerba    O
,    O
also    O
known    O
as    O
Menopause    O
Formula    O
101    O
(    O
MF-101    O
)    O
,    O
is    O
a    O
botanical    O
drug    O
candidate    O
that    O
acts    O
as    O
a    O
selective    B-Hormone105407119
estrogen    I-Hormone105407119
receptor    I-Hormone105407119
modulator    I-Hormone105407119
(    O
SERM    O
)    O
which    O
is    O
being    O
studied    O
for    O
its    O
potential    O
to    O
relieve    O
hot    O
flashes    O
associated    O
with    O
menopause    O
.    O

Selective    B-Hormone105407119
estrogen    I-Hormone105407119
receptor    I-Hormone105407119
modulator    I-Hormone105407119

It    O
is    O
a    O
fixed    O
-    O
dose    O
combination    O
drug    O
containing    O
the    O
selective    B-Hormone105407119
estrogen    I-Hormone105407119
receptor    I-Hormone105407119
modulator    I-Hormone105407119
bazedoxifene    O
and    O
conjugated    O
estrogens    O
being    O
marketed    O
by    O
the    O
pharmaceutical    O
company    O
Pfizer    O
.    O

17β-Dihydroequilenin    O
has    O
unexpectedly    O
shown    O
a    O
selective    B-Hormone105407119
estrogen    I-Hormone105407119
receptor    I-Hormone105407119
modulator    I-Hormone105407119
-    O
like    O
profile    O
of    O
estrogenic    O
activity    O
in    O
studies    O
with    O
monkeys    O
,    O
in    O
which    O
beneficial    O
effects    O
on    O
bone    O
and    O
the    O
cardiovascular    O
system    O
were    O
noted    O
but    O
proliferative    O
responses    O
in    O
breast    O
or    O
endometrium    O
were    O
not    O
observed    O
.    O

The    O
steroid    O
is    O
only    O
very    O
weakly    O
estrogenic    O
,    O
and    O
is    O
able    O
to    O
antagonize    O
the    O
estrogenic    O
effects    O
of    O
estradiol    O
,    O
indicating    O
that    O
its    O
intrinsic    O
activity    O
at    O
the    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
is    O
less    O
than    O
that    O
of    O
estradiol    O
and    O
hence    O
that    O
it    O
possesses    O
the    O
profile    O
of    O
a    O
selective    B-Hormone105407119
estrogen    I-Hormone105407119
receptor    I-Hormone105407119
modulator    I-Hormone105407119
.    O

Lasofoxifene    O
(    O
INN    O
)    O
(    O
brand    O
name    O
Fablyn    O
)    O
is    O
a    O
nonsteroidal    O
selective    B-Hormone105407119
estrogen    I-Hormone105407119
receptor    I-Hormone105407119
modulator    I-Hormone105407119
(    O
SERM    O
)    O
which    O
is    O
marketed    O
by    O
Pfizer    O
for    O
the    O
prevention    O
and    O
treatment    O
of    O
osteoporosis    O
and    O
for    O
the    O
treatment    O
of    O
vaginal    O
atrophy    O
,    O
and    O
the    O
result    O
of    O
an    O
exclusive    O
research    O
collaboration    O
with    O
Ligand    O
Pharmaceuticals    O
(    O
LGND    O
)    O
.    O

medrogestone    B-Hormone105407119
(    O
INN    O
)    O

6-Methyl-16-dehydropregnenolone    O
acetate    O
(    O
5    O
)    O
is    O
the    O
key    O
intermediate    O
to    O
the    O
preparation    O
of    O
both    O
melengesterol    O
acetate    O
and    O
medrogestone    B-Hormone105407119
.    O

Medroxyprogesterone    B-Hormone105407119
acetate    I-Hormone105407119
and    O
medrogestone    B-Hormone105407119
are    O
weak    O
inhibitors    O
of    O
3β-HSD    O
which    O
may    O
substantially    O
inhibit    O
it    O
at    O
high    O
dosages    O
.    O

The    O
next    O
binding    O
protein    O
for    O
B12    O
is    O
intrinsic    O
factor    O
(    O
IF    O
)    O
,    O
a    O
protein    O
synthesized    O
by    O
gastric    O
parietal    O
cells    O
that    O
is    O
secreted    O
in    O
response    O
to    O
histamine    O
,    O
gastrin    O
and    O
pentagastrin    B-Hormone105407119
,    O
as    O
well    O
as    O
the    O
presence    O
of    O
food    O
.    O

Pentagastrin    B-Hormone105407119
,    O
a    O
synthetic    O
gastrin    O
,    O
histamine    O
,    O
and    O
acetylcholine    O
are    O
also    O
gastric    O
secretagogues    O
.    O

In    O
addition    O
,    O
the    O
concert    O
of    O
estrogen    O
,    O
progesterone    O
(    O
again    O
specifically    O
through    O
PRB    O
)    O
,    O
prolactin    O
,    O
and    O
other    O
lactogen    B-Hormone105407119
such    O
as    O
human    B-Hormone105407119
placental    I-Hormone105407119
lactogen    I-Hormone105407119
(    O
hPL    O
)    O
and    O
PGH    O
,    O
in    O
conjunction    O
with    O
GH    O
/    O
IGF-1    O
,    O
as    O
well    O
as    O
insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
2    I-Hormone105407119
(    O
IGF-2    O
)    O
,    O
acting    O
together    O
,    O
mediate    O
the    O
completion    O
of    O
lobuloalveolar    O
development    O
of    O
the    O
breasts    O
during    O
pregnancy    O
.    O

The    O
structure    O
of    O
prolactin    O
is    O
similar    O
to    O
that    O
of    O
growth    O
hormone    O
and    O
placental    B-Hormone105407119
lactogen    I-Hormone105407119
.    O

Methyl-1-testosterone    B-Hormone105407119
(methyl-δ1-DHT)    I-Hormone105407119

Metenolone    O
itself    O
is    O
not    O
used    O
as    O
an    O
AAS    O
,    O
and    O
the    O
drug    O
is    O
instead    O
supplied    O
as    O
metenolone    O
acetate    O
for    O
oral    O
administration    O
and    O
as    O
metenolone    B-Hormone105407119
enanthate    I-Hormone105407119
for    O
depot    O
intramuscular    O
injection    O
.    O

Shavershian    O
often    O
used    O
phrases    O
such    O
as    O
"    O
riding    O
bicycles    O
"    O
,    O
which    O
,    O
according    O
to    O
"    O
The    O
Daily    O
Telegraph    O
"    O
,    O
is    O
"    O
gym    O
slang    O
for    O
using    O
a    O
cycle    B-Hormone105407119
of    I-Hormone105407119
steroids    I-Hormone105407119
"    O
.    O

Also    O
eligible    O
was    O
Rafael    O
Palmeiro    O
,    O
who    O
recorded    O
over    O
3000    O
hits    O
and    O
500    O
home    O
runs    O
,    O
which    O
would    O
typically    O
foreshadow    O
a    O
first    O
-    O
ballot    O
election    O
;    O
however    O
,    O
his    O
candidacy    O
has    O
generated    O
controversy    O
due    O
to    O
his    O
testing    O
positive    O
for    O
steroids    B-Hormone105407119
.    O

Some    O
athletes    O
and    O
body    O
builders    O
use    O
anastrozole    O
as    O
part    O
of    O
their    O
steroid    B-Hormone105407119
cycle    I-Hormone105407119
to    O
reduce    O
and    O
prevent    O
symptoms    O
of    O
excess    O
estrogen    O
--    O
gynecomastia    O
,    O
emotional    O
lability    O
and    O
water    O
retention    O
.    O

Theodrenaline    B-Hormone105407119

D5    O
receptors    O
that    O
are    O
expressed    O
in    O
kidneys    O
are    O
also    O
involved    O
in    O
the    O
regulation    O
of    O
blood    O
pressure    O
via    O
modulating    O
expression    O
of    O
renalase    B-Hormone105407119
and    O
excretion    O
of    O
sodium    O
,    O
and    O
disturbance    O
of    O
these    O
processes    O
can    O
contribute    O
to    O
hypertension    O
as    O
well    O
.    O

The    O
process    O
is    O
actually    O
quite    O
complex    O
,    O
because    O
auxin    O
transported    O
downwards    O
from    O
the    O
lead    O
shoot    O
tip    O
has    O
to    O
interact    O
with    O
several    O
other    O
plant    O
hormones    O
(    O
such    O
as    O
strigolactone    B-Hormone105407119
or    O
cytokinins    O
)    O
in    O
the    O
process    O
on    O
various    O
positions    O
along    O
the    O
growth    O
axis    O
in    O
plant    O
body    O
to    O
achieve    O
this    O
phenomenon    O
.    O

The    O
growth    O
of    O
AM    O
hyphae    O
through    O
the    O
soil    O
is    O
controlled    O
by    O
host    O
root    O
exudates    O
known    O
as    O
strigolactone    B-Hormone105407119
,    O
and    O
the    O
soil    O
phosphorus    O
concentration    O
.    O

etonogestrel    B-Hormone105407119
(    O
INN    O
)    O

The    O
estranes    O
include    O
norethisterone    B-Hormone105407119
(    O
norethindrone    O
)    O
,    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
norethisterone    O
enanthate    O
,    O
lynestrenol    B-Hormone105407119
,    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-Hormone105407119
,    O
desogestrel    B-Hormone105407119
,    O
etonogestrel    B-Hormone105407119
,    O
gestodene    B-Hormone105407119
,    O
norgestimate    B-Hormone105407119
,    O
dienogest    B-Hormone105407119
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    B-Hormone105407119
.    O

Clobetasone    B-Hormone105407119
=    O
9α-fluoro-16β-methyl-17α-hydroxy-21-chloropregna-1,4-diene-3,11,20-trione    O

Delmadinone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
a    O
progestin    O
and    O
antigonadotropin    O
used    O
as    O
an    O
antiandrogen    O

Delmadinone    B-Hormone105407119
acetate    I-Hormone105407119

L-Dopaquinone    B-Hormone105407119

"N"-Acylphosphatidylethanolamine    B-Hormone105407119

NAPEs    B-Hormone105407119

Digit    B-Hormone105407119
ratio    I-Hormone105407119

Digit    B-Hormone105407119
ratio    I-Hormone105407119

The    O
digit    B-Hormone105407119
ratio    I-Hormone105407119
is    O
the    O
ratio    O
of    O
the    O
lengths    O
of    O
different    O
digits    O
or    O
fingers    O
typically    O
measured    O
from    O
the    O
midpoint    O
of    O
bottom    O
crease    O
(    O
where    O
the    O
finger    O
joins    O
the    O
hand    O
)    O
to    O
the    O
tip    O
of    O
the    O
finger    O
.    O

A    O
2010    O
British    O
study    O
found    O
that    O
a    O
large    O
2D:4D    O
digit    B-Hormone105407119
ratio    I-Hormone105407119
,    O
an    O
indication    O
of    O
high    O
prenatal    O
estrogen    O
exposure    O
,    O
was    O
a    O
"    O
positive    O
correlate    O
of    O
psychopathy    O
in    O
females    O
,    O
and    O
a    O
positive    O
correlate    O
of    O
callous    O
affect    O
(    O
psychopathy    O
sub    O
-    O
scale    O
)    O
in    O
males    O
"    O
.    O

The    O
prothoracic    B-Hormone105407119
glands    I-Hormone105407119
are    O
either    O
of    O
a    O
pair    O
of    O
endocrine    O
glands    O
located    O
in    O
the    O
prothorax    O
of    O
certain    O
insects    O
that    O
regulate    O
molting    O
.    O

The    O
MONARCH    O
3    O
study    O
is    O
investigating    O
the    O
effectiveness    O
of    O
Abemaciclib    O
,    O
plus    O
either    O
anastrozole    O
or    O
letrozole    B-Hormone105407119
,    O
as    O
a    O
first    O
-    O
line    O
treatment    O
for    O
women    O
with    O
breast    O
cancer    O
.    O

File    O
:    O
Letrozole.svg|Structure    O
of    O
letrozole    B-Hormone105407119
,    O
an    O
oral    O
nonsteroidal    O
aromatase    O
inhibitor    O
for    O
the    O
treatment    O
of    O
certain    O
breast    O
cancers    O
.    O

Instead    O
of    O
in    O
vitro    O
fertilization    O
,    O
they    O
opted    O
to    O
switch    O
Danielle    O
to    O
Femara    B-Hormone105407119
and    O
attempted    O
intrauterine    O
insemination    O
again    O
,    O
ultimately    O
becoming    O
pregnant    O
with    O
Blayke    O
.    O

Letrozole    B-Hormone105407119
(    O
INN    O
,    O
trade    O
name    O
Femara    B-Hormone105407119
)    O
is    O
an    O
orally    O
active    O
nonsteroidal    O
aromatase    O
inhibitor    O
for    O
the    O
treatment    O
of    O
hormonally    O
-    O
responsive    O
breast    O
cancer    O
after    O
surgery    O
.    O

letrozole    B-Hormone105407119
(    O
aromatase    O
inhibitor    O
,    O
used    O
in    O
breast    O
cancer    O
)    O

estradiol    B-Hormone105407119
undecylate    I-Hormone105407119
(    O
INN    O
)    O

Estradiol    B-Hormone105407119
undecylate    I-Hormone105407119
,    O
or    O
estradiol    B-Hormone105407119
undecanoate    I-Hormone105407119
,    O
sold    O
under    O
the    O
brand    O
name    O
Progynon    B-Hormone105407119
Depot    I-Hormone105407119
100    I-Hormone105407119
among    O
others    O
,    O
is    O
an    O
estrogen    O
which    O
is    O
or    O
has    O
been    O
used    O
in    O
Europe    O
,    O
including    O
in    O
Germany    O
,    O
the    O
Netherlands    O
,    O
Switzerland    O
,    O
and    O
Monaco    O
.    O

Estradiol    B-Hormone105407119
undecylate    I-Hormone105407119

mecasermin    B-Hormone105407119
(    O
INN    O
)    O

Mecasermin    B-Hormone105407119
(    O
INN    O
)    O
(    O
brand    O
name    O
Increlex    B-Hormone105407119
)    O
,    O
also    O
known    O
as    O
recombinant    B-Hormone105407119
human    I-Hormone105407119
insulin-like    I-Hormone105407119
growth    I-Hormone105407119
factor-1    I-Hormone105407119
(    O
rhIGF-1    B-Hormone105407119
)    O
,    O
is    O
recombinant    O
form    O
of    O
human    O
insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
1    I-Hormone105407119
(    O
IGF    O
-    O
I    O
)    O
which    O
is    O
used    O
for    O
the    O
long    O
-    O
term    O
treatment    O
of    O
growth    O
failure    O
and    O
short    O
stature    O
in    O
children    O
with    O
severe    O
primary    O
IGF    O
-    O
I    O
deficiency    O
,    O
for    O
instance    O
due    O
to    O
growth    B-Hormone105407119
hormone    I-Hormone105407119
deficiency    I-Hormone105407119
or    O
Laron    B-Hormone105407119
syndrome    I-Hormone105407119
(    O
growth    O
hormone    O
insensitivity    O
)    O
.    O

The    O
alpha    B-Hormone105407119
subunits    I-Hormone105407119
of    O
the    O
glycoproteins    O
LH    O
,    O
FSH    O
,    O
TSH    O
,    O
and    O
hCG    O
are    O
identical    O
and    O
consist    O
of    O
about    O
96    O
amino    O
acids    O
,    O
while    O
the    O
beta    O
subunits    O
vary    O
.    O

In    O
humans    O
,    O
the    O
gene    O
for    O
the    O
alpha    B-Hormone105407119
subunit    I-Hormone105407119
is    O
located    O
at    O
cytogenetic    O
location    O
6q14.3    O
.    O

The    O
α    B-Hormone105407119
("alpha")    I-Hormone105407119
subunit    I-Hormone105407119
(    O
i.e.    O
,    O
chorionic    B-Hormone105407119
gonadotropin    I-Hormone105407119
alpha    I-Hormone105407119
)    O
is    O
nearly    O
identical    O
to    O
that    O
of    O
human    O
chorionic    O
gonadotropin    O
(    O
hCG    O
)    O
,    O
luteinizing    O
hormone    O
(    O
LH    O
)    O
,    O
and    O
follicle    O
-    O
stimulating    O
hormone    O
(    O
FSH    O
)    O
.    O

DHEA    O
is    O
the    O
5-dehydro    O
analogue    O
of    O
epiandrosterone    B-Hormone105407119
(    O
5α-androstan-3β-ol-17-one    O
)    O
and    O
is    O
also    O
known    O
as    O
5-dehydroepiandrosterone    O
or    O
as    O
δ5-epiandrosterone    O
.    O

These    O
isomers    O
are    O
also    O
technically    O
"    O
DHEA    O
"    O
,    O
since    O
they    O
are    O
dehydroepiandrosterones    O
in    O
which    O
hydrogens    O
are    O
removed    O
from    O
the    O
epiandrosterone    B-Hormone105407119
skeleton    O
.    O

A    O
Δ5    O
-    O
3-ketosteroid    O
isomerase    O
-    O
disrupted    O
mutant    O
of    O
strain    O
TA441    O
can    O
grow    O
on    O
dehydroepiandrosterone    B-Hormone105407119
,    O
which    O
has    O
a    O
double    O
bond    O
at    O
Δ5    O
,    O
but    O
can    O
not    O
grow    O
on    O
epiandrosterone    B-Hormone105407119
,    O
which    O
lacks    O
a    O
double    O
bond    O
at    O
Δ5    O
,    O
indicating    O
that    O
"    O
C.    O
testosteroni    O
"    O
KSI    O
is    O
responsible    O
for    O
transfer    O
of    O
the    O
double    O
bond    O
from    O
Δ5    O
to    O
Δ4    O
and    O
transfer    O
of    O
the    O
double    O
bond    O
by    O
hydrogenation    O
at    O
Δ5    O
and    O
following    O
dehydrogenation    O
at    O
Δ4    O
is    O
not    O
possible    O
.    O

It    O
follows    O
that    O
an    O
increase    O
in    O
vitamin    O
D3    O
intake    O
should    O
lead    O
to    O
a    O
decrease    O
in    O
bone    O
resorption    O
—    O
it    O
has    O
been    O
shown    O
that    O
oral    O
administration    O
of    O
vitamin    O
D    O
does    O
not    O
linearly    O
correlate    O
to    O
increased    O
serum    O
levels    O
of    O
calcifediol    B-Hormone105407119
,    O
the    O
precursor    O
to    O
calcitriol    O
.    O

T    O
-    O
cells    O
have    O
a    O
symbiotic    O
relationship    O
with    O
vitamin    O
D.    O
Not    O
only    O
does    O
the    O
T    O
-    O
cell    O
extend    O
a    O
vitamin    O
D    O
receptor    O
,    O
in    O
essence    O
asking    O
to    O
bind    O
to    O
the    O
steroid    O
hormone    O
version    O
of    O
vitamin    O
D    O
,    O
calcitriol    O
,    O
but    O
the    O
T    O
-    O
cell    O
expresses    O
the    O
gene    O
CYP27B1    O
,    O
which    O
is    O
the    O
gene    O
responsible    O
for    O
converting    O
the    O
pre    O
-    O
hormone    O
version    O
of    O
vitamin    O
D    O
,    O
calcidiol    B-Hormone105407119
into    O
the    O
steroid    O
hormone    O
version    O
,    O
calcitriol    O
.    O

|rowspan=2|    O
25-hydroxycholecalciferol    B-Hormone105407119
(    O
a    O
vitamin    O
D    O
)    O
-Standard    O
reference    O
range    O

|rowspan=2|    O
25-hydroxycholecalciferol    B-Hormone105407119
-Therapeutic    O
target    O
range    O

|rowspan=2|    O
25-hydroxycholecalciferol    B-Hormone105407119
(    O
a    O
vitamin    O
D    O
)    O

Propetandrol    B-Hormone105407119
(propethandrol)    I-Hormone105407119

Derivatives    O
of    O
ethyltestosterone    O
include    O
norethandrolone    O
(    O
ethylnandrolone    O
,    O
ethylestrenolone    O
)    O
,    O
ethylestrenol    B-Hormone105407119
(    O
ethylnandrol    O
)    O
,    O
norboletone    B-Hormone105407119
,    O
ethyldienolone    O
,    O
tetrahydrogestrinone    B-Hormone105407119
,    O
bolenol    B-Hormone105407119
(    O
ethylnorandrostenol    O
)    O
,    O
and    O
propetandrol    B-Hormone105407119
.    O

These    O
include    O
the    O
cloning    O
of    O
a    O
cDNA    O
for    O
parathyroid    O
hormone    O
,    O
the    O
identification    O
of    O
a    O
role    O
for    O
parathyroid    B-Hormone105407119
hormone-related    I-Hormone105407119
protein    I-Hormone105407119
in    O
endochondral    O
ossification    O
through    O
Indian    O
hedgehog    O
(    O
IHH    O
)    O
activation    O
,    O
and    O
studies    O
that    O
identified    O
a    O
role    O
for    O
parathyroid    O
hormone    O
in    O
the    O
regulation    O
of    O
the    O
bone    O
marrow    O
stem    O
cell    O
niche    O
.    O

Oxyphil    O
cells    O
have    O
been    O
shown    O
to    O
express    O
parathyroid    O
-    O
relevant    O
genes    O
found    O
in    O
the    O
chief    O
cells    O
and    O
have    O
the    O
potential    O
to    O
produce    O
additional    O
autocrine    O
/    O
paracrine    O
factors    O
,    O
such    O
as    O
parathyroid    B-Hormone105407119
hormone-related    I-Hormone105407119
protein    I-Hormone105407119
(PTHrP)    I-Hormone105407119
and    O
calcitriol    B-Hormone105407119
.    O

In    O
fetal    O
lung    O
,    O
leptin    O
is    O
induced    O
in    O
the    O
alveolar    O
interstitial    O
fibroblasts    O
(    O
"    O
lipofibroblasts    O
"    O
)    O
by    O
the    O
action    O
of    O
PTHrP    B-Hormone105407119
secreted    O
by    O
formative    O
alveolar    O
epithelium    O
(    O
endoderm    O
)    O
under    O
moderate    O
stretch    O
.    O

PTHLH    B-Hormone105407119
,    O

Oxabolone    B-Hormone105407119
(    O
4-hydroxy-19-NT    O
)    O

Oxabolone    B-Hormone105407119

The    O
first    O
biosynthetic    O
insulin    O
analog    O
was    O
developed    O
for    O
clinical    O
use    O
at    O
mealtime    O
(    O
prandial    O
insulin    O
)    O
,    O
Humalog    B-Hormone105407119
(    O
insulin    O
lispro    O
)    O
,    O
it    O
is    O
more    O
rapidly    O
absorbed    O
after    O
subcutaneous    O
injection    O
than    O
regular    O
insulin    O
,    O
with    O
an    O
effect    O
15    O
minutes    O
after    O
injection    O
.    O

Rapid    O
-    O
acting    O
insulin    O
analogs    O
such    O
as    O
lispro    B-Hormone105407119
(    O
brand    O
name    O
"    O
Humalog    O
"    O
,    O
made    O
by    O
Eli    O
Lilly    O
and    O
Company    O
)    O
and    O
aspart    B-Hormone105407119
(    O
brand    O
name    O
"    O
Novolog"/"Novorapid    O
"    O
,    O
made    O
by    O
Novo    O
Nordisk    O
and    O
"    O
Apidra    O
"    O
made    O
by    O
Sanofi    O
Aventis    O
)    O
are    O
preferred    O
by    O
many    O
clinicians    O
over    O
older    O
regular    O
insulin    O
for    O
meal    O
coverage    O
and    O
high    O
correction    O
.    O

Prolactin-releasing    B-Hormone105407119
hormone    I-Hormone105407119

Bolasterone    B-Hormone105407119

Bolasterone    B-Hormone105407119

Mibolerone    B-Hormone105407119

Mibolerone    B-Hormone105407119

Since    O
the    O
conversion    O
of    O
dihydroxyphenylserine    O
(    O
Droxidopa    B-Hormone105407119
;    O
trade    O
name    O
:    O
Northera    O
;    O
also    O
known    O
as    O
L    O
-    O
DOPS    O
,    O
L    O
-    O
threo    O
-    O
dihydroxyphenylserine    O
,    O
L    O
-    O
threo    O
-    O
DOPS    O
and    O
SM-5688    O
)    O
,    O
to    O
norepinephrine    O
bypasses    O
the    O
dopamine    O
beta    O
-    O
hydroxylation    O
step    O
of    O
catecholamine    O
synthesis    O
,    O
L    O
-    O
Threo    O
-    O
DOPS    O
is    O
the    O
ideal    O
therapeutic    O
agent    O
.    O

L-DOPS    B-Hormone105407119
(    O
droxidopa    O
)    O

Since    O
1985    O
,    O
recombinant    O
human    O
growth    O
hormone    O
(    O
rHGH    B-Hormone105407119
)    O
is    O
a    O
recombinant    O
form    O
of    O
human    O
GH    O
produced    O
by    O
genetically    O
engineered    O
bacteria    O
,    O
manufactured    O
by    O
recombinant    O
DNA    O
technology    O
.    O

Growth    B-Hormone105407119
hormone    I-Hormone105407119
treatment    I-Hormone105407119
refers    O
to    O
the    O
use    O
of    O
growth    O
hormone    O
(    O
GH    O
)    O
as    O
a    O
prescription    O
medication    O
—    O
it    O
is    O
one    O
form    O
of    O
hormone    O
therapy    O
.    O

In    O
the    O
late    O
1990s    O
,    O
the    O
pharmaceutical    O
manufacturer    O
Eli    O
Lilly    O
and    O
Company    O
sponsored    O
trials    O
of    O
Humatrope    B-Hormone105407119
(    O
their    O
brand    O
of    O
rHGH    B-Hormone105407119
)    O
in    O
children    O
with    O
extreme    O
ISS    O
,    O
those    O
at    O
least    O
2.25    O
standard    O
deviations    O
below    O
mean    O
(    O
in    O
the    O
lowest    O
1.2    O
percent    O
of    O
the    O
population    O
)    O
.    O

If    O
a    O
member    O
of    O
their    O
family    O
(    O
parent    O
,    O
brother    O
,    O
sister    O
or    O
child    O
)    O
has    O
suffered    O
with    O
CJD    O
(    O
Creutzfeldt    O
–    O
Jakob    O
disease    O
)    O
or    O
if    O
they    O
have    O
ever    O
received    O
human    O
pituitary    O
extract    O
(    O
which    O
was    O
used    O
in    O
some    O
growth    B-Hormone105407119
hormone    I-Hormone105407119
or    O
fertility    O
treatments    O
before    O
1985    O
)    O
.    O

On    O
March    O
19    O
,    O
"    O
Sports    O
Illustrated    O
"    O
posted    O
an    O
article    O
on    O
its    O
website    O
in    O
its    O
continuing    O
series    O
investigating    O
a    O
steroid    O
and    O
HGH    B-Hormone105407119
ring    O
used    O
by    O
a    O
number    O
of    O
professional    O
athletes    O
in    O
several    O
sports    O
.    O

On    O
March    O
19    O
,    O
2007    O
,    O
"    O
Sports    O
Illustrated    O
"    O
posted    O
on    O
its    O
website    O
an    O
article    O
in    O
its    O
continuing    O
series    O
investigating    O
a    O
steroid    O
and    O
HGH    B-Hormone105407119
ring    O
used    O
by    O
a    O
number    O
of    O
professional    O
athletes    O
in    O
several    O
sports    O
.    O

Growth    B-Hormone105407119
hormone    I-Hormone105407119
treatment    I-Hormone105407119

Economics    O
of    O
growth    B-Hormone105407119
hormone    I-Hormone105407119
treatment    I-Hormone105407119

The    O
apelin    O
receptor    O
(    O
also    O
known    O
as    O
the    O
APJ    O
receptor    O
)    O
is    O
a    O
G    O
protein    O
-    O
coupled    O
receptor    O
which    O
binds    O
apelin    B-Hormone105407119
and    O
Apela    O
/    O
ELABELA    O
/    O
Toddler    O
.    O

and    O
desmopressin    B-Hormone105407119
for    O
nocturia    O
.    O

DDAVP    O
(    O
desmopressin    B-Hormone105407119
)    O
tablets    O
are    O
a    O
synthetic    O
replacement    O
for    O
antidiuretic    O
hormone    O
,    O
the    O
hormone    O
that    O
reduces    O
urine    O
production    O
during    O
sleep    O
.    O

The    O
hormone    O
can    O
be    O
boosted    O
by    O
a    O
synthetic    O
version    O
known    O
as    O
desmopressin    B-Hormone105407119
,    O
or    O
DDAVP    O
,    O
which    O
recently    O
became    O
available    O
in    O
pill    O
form    O
.    O

Hypernatremia    O
due    O
to    O
diabetes    O
insipidus    O
as    O
a    O
result    O
of    O
a    O
brain    O
disorder    O
,    O
may    O
be    O
treated    O
with    O
the    O
medication    O
desmopressin    B-Hormone105407119
.    O

If    O
there    O
is    O
no    O
change    O
in    O
the    O
water    O
loss    O
despite    O
fluid    O
deprivation    O
,    O
desmopressin    B-Hormone105407119
may    O
be    O
administered    O
to    O
distinguish    O
between    O
the    O
two    O
types    O
of    O
diabetes    O
insipidus    O
which    O
are    O
central    O
&    O
nephrogenic    O
diabetes    O
insipidus    O
.    O

desmopressin    B-Hormone105407119

CDI    O
is    O
often    O
treated    O
with    O
desmopressin    B-Hormone105407119
acetate    I-Hormone105407119
a    O
synthetic    O
vasopressin    O
known    O
as    O
DDAVP    O
administered    O
via    O
nasal    O
spray    O
.    O

Mitchell    O
Lazar    O
(    O
born    O
1956    O
)    O
is    O
an    O
endocrinologist    O
and    O
physician    O
-    O
scientist    O
widely    O
known    O
for    O
his    O
discovery    O
of    O
the    O
hormone    O
resistin    B-Hormone105407119
and    O
his    O
contributions    O
to    O
the    O
transcriptional    O
regulation    O
of    O
metabolism    O
.    O

Resistin    B-Hormone105407119
also    O
known    O
as    O
adipose    B-Hormone105407119
tissue-specific    I-Hormone105407119
secretory    I-Hormone105407119
factor    I-Hormone105407119
(    O
ADSF    O
)    O
or    O
C/EBP-epsilon-regulated    B-Hormone105407119
myeloid-specific    I-Hormone105407119
secreted    I-Hormone105407119
cysteine-rich    I-Hormone105407119
protein    I-Hormone105407119
(    O
XCP1    O
)    O
is    O
a    O
cysteine    O
-    O
rich    O
adipose-derived    B-Hormone105407119
peptide    B-Hormone105407119
hormone    I-Hormone105407119
that    O
in    O
humans    O
is    O
encoded    O
by    O
the    O
"    O
RETN    O
"    O
gene    O
.    O

In    O
March    O
2016    O
,    O
it    O
was    O
revealed    O
that    O
Slice    O
had    O
tested    O
positive    O
for    O
nandrolone    O
and    O
an    O
elevated    O
testosterone    O
to    O
epitestosterone    B-Hormone105407119
ratio    O
(    O
T    O
/    O
E    O
ratio    O
)    O
in    O
a    O
pre    O
-    O
fight    O
drug    O
test    O
.    O

In    O
the    O
ensuing    O
years    O
nasal    O
spray    O
preparations    O
containing    O
testosterone    O
or    O
androstenedione    B-Hormone105407119
were    O
developed    O
in    O
collaboration    O
with    O
Jenapharm    O
,    O
tested    O
,    O
and    O
used    O
in    O
top    O
athletes    O
—    O
some    O
of    O
whom    O
did    O
not    O
like    O
this    O
mode    O
of    O
application    O
.    O
Doping    O
tests    O
at    O
the    O
time    O
used    O
the    O
T    O
:    O
E    O
(    O
testosterone    O
:    O
epitestosterone    B-Hormone105407119
)    O
ratio    O
.    O

Since    O
1983    O
,    O
Jenapharm    O
had    O
produced    O
preparations    O
of    O
epitestosterone    B-Hormone105407119
propionate    O
,    O
a    O
biologically    O
inactive    O
compound    O
that    O
had    O
no    O
commercial    O
value    O
but    O
was    O
prepared    O
exclusively    O
for    O
the    O
governmental    O
doping    O
system    O
.    O

In    O
June    O
that    O
year    O
she    O
tested    O
positive    O
for    O
excess    O
testosterone    O
against    O
her    O
epitestosterone    B-Hormone105407119
levels    O
and    O
the    O
IAAF    O
gave    O
her    O
a    O
two    O
-    O
year    O
ban    O
from    O
the    O
sport    O
,    O
stretching    O
from    O
June    O
2005    O
to    O
June    O
2007    O
.    O

He    O
was    O
also    O
found    O
to    O
have    O
an    O
elevated    O
testosterone    O
/    O
epitestosterone    B-Hormone105407119
(    O
T    O
/    O
E    O
)    O
ratio    O
of    O
6.4:1    O
,    O
which    O
is    O
above    O
the    O
maximum    O
allowed    O
limit    O
of    O
4:1    O
.    O

On    O
5    O
August    O
2006    O
Phonak    O
dismissed    O
Floyd    O
Landis    O
after    O
confirmation    O
that    O
a    O
urine    O
sample    O
taken    O
after    O
his    O
Stage    O
17    O
win    O
twice    O
tested    O
positive    O
for    O
synthetic    O
testosterone    O
as    O
well    O
as    O
a    O
ratio    O
of    O
testosterone    O
to    O
epitestosterone    B-Hormone105407119
nearly    O
three    O
times    O
the    O
limit    O
allowed    O
by    O
World    O
Anti    O
-    O
Doping    O
Agency    O
rules    O
.    O

gestonorone    B-Hormone105407119
caproate    I-Hormone105407119
(    O
INN    O
)    O

The    O
C17α    O
caproate    O
ester    O
of    O
gestronol    O
,    O
gestonorone    B-Hormone105407119
caproate    I-Hormone105407119
(    O
gestronol    O
hexanoate    O
)    O
,    O
in    O
contrast    O
,    O
has    O
been    O
marketed    O
.    O

Progestogen    O
esters    O
of    O
other    O
groups    O
of    O
progestins    O
have    O
also    O
been    O
introduced    O
,    O
including    O
the    O
19-norprogesterone    B-Hormone105407119
derivatives    O
gestonorone    B-Hormone105407119
caproate    I-Hormone105407119
,    O
segesterone    O
acetate    O
(    O
nestorone    O
)    O
,    O
nomegestrol    B-Hormone105407119
acetate    I-Hormone105407119
,    O
and    O
norgestomet    O
(    O
11β-methyl-17α-acetoxy-19-norprogesterone    O
)    O
,    O
and    O
the    O
19-nortestosterone    O
derivatives    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
norethisterone    O
enanthate    O
,    O
and    O
quingestanol    B-Hormone105407119
acetate    I-Hormone105407119
.    O

"    O
gastrin-14    B-Hormone105407119
"    O
(    O
"    O
minigastrin    B-Hormone105407119
"    O
)    O

Roxibolone    B-Hormone105407119

Depo-Estradiol    B-Hormone105407119

Along    O
with    O
estradiol    B-Hormone105407119
valerate    I-Hormone105407119
,    O
estradiol    B-Hormone105407119
cypionate    I-Hormone105407119
,    O
and    O
estradiol    B-Hormone105407119
benzoate    I-Hormone105407119
,    O
estradiol    O
undecylate    O
is    O
or    O
has    O
been    O
used    O
as    O
an    O
intramuscular    O
estrogen    O
in    O
hormone    O
replacement    O
therapy    O
for    O
transgender    O
women    O
.    O

Prior    O
to    O
the    O
development    O
and    O
introduction    O
of    O
estradiol    B-Hormone105407119
valerate    I-Hormone105407119
and    O
estradiol    B-Hormone105407119
cypionate    I-Hormone105407119
in    O
the    O
1950s    O
,    O
estradiol    O
dipropionate    O
and    O
estradiol    O
benzoate    O
were    O
the    O
most    O
widely    O
used    O
estradiol    O
esters    O
.    O

Examples    O
include    O
testosterone    O
cypionate    O
,    O
estradiol    B-Hormone105407119
cypionate    I-Hormone105407119
,    O
hydrocortisone    O
cypionate    O
,    O
and    O
oxabolone    B-Hormone105407119
cypionate    I-Hormone105407119
.    O

Cortisporin    B-Hormone105407119
is    O
a    O
drug    O
consisting    O
of    O
Neomycin    O
,    O
bacitracin    O
,    O
polymyxin    O
B    O
and    O
hydrocortisone    O
.    O

During    O
Caro´s    O
tenure    O
the    O
endocrine    O
portfolio    O
of    O
Lilly    O
products    O
grew    O
from    O
insulin    O
and    O
Humatrope    B-Hormone105407119
to    O
include    O
Byetta    O
,    O
Actos    O
,    O
Evista    O
and    O
Forteo    B-Hormone105407119
.    O

Strontium    O
ranelate    O
or    O
teriparatide    B-Hormone105407119
are    O
used    O
for    O
refractory    O
disease    O
.    O

In    O
cases    O
where    O
there    O
is    O
concern    O
of    O
such    O
fractures    O
occurring    O
,    O
teriparatide    B-Hormone105407119
is    O
potentially    O
a    O
good    O
alternative    O
because    O
it    O
does    O
not    O
cause    O
as    O
much    O
damage    O
as    O
a    O
bisphosphonate    O
does    O
by    O
suppressing    O
bone    O
turnover    O
.    O

MAPs    O
typically    O
comprise    O
several    O
proteins    O
,    O
of    O
which    O
the    O
most    O
common    O
repeating    O
sequence    O
is    O
Ala    O
-    O
Lys    O
-    O
Pro    O
-    O
Ser    O
-    O
Tyr    O
-    O
trans-2,3-cis-3,4-dihydroxyproline    O
(    O
DHP    O
)    O
-Hyp    O
-    O
Thr-3,4-dihydroxyphenylalanine    O
(    O
DOPA    B-Hormone105407119
)    O
-Lys    O
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
3,4-dihydroxy-L-phenylalanine    B-Hormone105407119
(    O
L    O
-    O
DOPA    O
)    O
,    O
and    O
two    O
products    O
,    O
trans    O
-    O
caffeate    O
and    O
NH3    O
.    O

Unlike    O
Parkinson    O
's    O
disease    O
,    O
manganism    O
is    O
not    O
associated    O
with    O
loss    O
of    O
smell    O
and    O
patients    O
are    O
typically    O
unresponsive    O
to    O
treatment    O
with    O
L-DOPA    B-Hormone105407119
.    O

"    O
Awakenings    O
"    O
(    O
1990    O
)    O
–    O
American    O
drama    O
film    O
based    O
on    O
British    O
neurologist    O
Oliver    O
Sacks    O
's    O
memoir    O
of    O
the    O
same    O
title    O
,    O
about    O
his    O
discovery    O
of    O
the    O
beneficial    O
effects    O
of    O
the    O
drug    O
L-DOPA    B-Hormone105407119
,    O
which    O
he    O
administered    O
to    O
catatonic    O
patients    O
,    O
who    O
awakened    O
after    O
decades    O
of    O
catatonia    O
;    O
directed    O
by    O
Penny    O
Marshall    O

Based    O
upon    O
five    O
case    O
reports    O
,    O
valproic    O
acid    O
may    O
have    O
efficacy    O
in    O
controlling    O
the    O
symptoms    O
of    O
the    O
dopamine    O
dysregulation    O
syndrome    O
that    O
arise    O
from    O
the    O
treatment    O
of    O
Parkinson    O
's    O
disease    O
with    O
levodopa    B-Hormone105407119
.    O

L-DOPA    B-Hormone105407119
and    O
4-hydroxypyruvic    O
acid    O
both    O
come    O
from    O
L    O
-    O
tyrosine    O
.    O

During    O
the    O
1960s    O
,    O
ICN    O
marketed    O
a    O
generic    O
version    O
of    O
L-Dopa    B-Hormone105407119
,    O
a    O
widely    O
used    O
Parkinson    O
's    O
disease    O
antidote    O
.    O

Diazepam    O
may    O
block    O
the    O
action    O
of    O
levodopa    B-Hormone105407119
(    O
used    O
in    O
the    O
treatment    O
of    O
Parkinson    O
's    O
disease    O
)    O
.    O

This    O
may    O
contribute    O
to    O
the    O
failure    O
of    O
levodopa    B-Hormone105407119
treatment    O
of    O
Parkinson    O
's    O
disease    O
.    O

L-Dopaquinone    B-Hormone105407119
also    O
known    O
as    O
o    O
"-    O
dopaquinone    O
"    O
'    O
is    O
a    O
metabolite    O
of    O
L-DOPA    B-Hormone105407119
and    O
a    O
precursor    O
of    O
melanin    O
.    O

L-DOPA    B-Hormone105407119
has    O
shown    O
increase    O
in    O
average    O
quantal    O
size    O
when    O
treated    O
for    O
only    O
40–90    O
minutes    O
.    O

By    O
1972    O
,    O
enantiomeric    O
excess    O
of    O
90%    O
was    O
achieved    O
,    O
and    O
the    O
first    O
industrial    O
synthesis    O
of    O
the    O
Parkinson    O
's    O
drug    O
L-DOPA    B-Hormone105407119
commenced    O
using    O
this    O
technology    O
.    O

It    O
is    O
a    O
competitive    O
inhibitor    O
of    O
the    O
enzyme    O
DOPA    O
decarboxylase    O
,    O
also    O
known    O
as    O
aromatic    O
L    O
-    O
amino    O
acid    O
decarboxylase    O
,    O
which    O
converts    O
L-DOPA    B-Hormone105407119
into    O
dopamine    O
.    O

L-DOPA    B-Hormone105407119
(    O
levodopa    O
;    O
trade    O
names    O
Sinemet    O
,    O
Parcopa    O
,    O
Atamet    O
,    O
Stalevo    O
,    O
Madopar    O
,    O
Prolopa    O
,    O
etc    O
.    O
)    O

Amine    O
Precursor    O
Uptake    O
-    O
for    O
high    O
uptake    O
of    O
amine    O
precursors    O
including    O
5-hydroxytryptophan    O
(    O
5-HTP    O
)    O
and    O
dihydroxyphenylalanine    O
(    O
DOPA    B-Hormone105407119
)    O
.    O

Initial    O
treatment    O
is    O
typically    O
with    O
the    O
antiparkinson    O
medication    O
levodopa    B-Hormone105407119
(    O
L    O
-    O
DOPA    O
)    O
,    O
with    O
dopamine    O
agonists    O
being    O
used    O
once    O
levodopa    O
becomes    O
less    O
effective    O
.    O

The    O
main    O
families    O
of    O
drugs    O
useful    O
for    O
treating    O
motor    O
symptoms    O
are    O
levodopa    B-Hormone105407119
(    O
always    O
combined    O
with    O
a    O
dopa    O
decarboxylase    O
inhibitor    O
and    O
sometimes    O
also    O
with    O
a    O
COMT    O
inhibitor    O
)    O
,    O
dopamine    O
agonists    O
and    O
MAO    O
-    O
B    O
inhibitors    O
.    O

Levodopa    B-Hormone105407119
was    O
first    O
synthesized    O
in    O
1911    O
by    O
Casimir    O
Funk    O
,    O
but    O
it    O
received    O
little    O
attention    O
until    O
the    O
mid    O
20th    O
century    O
.    O

It    O
has    O
been    O
approved    O
for    O
the    O
treatment    O
of    O
the    O
motor    O
symptoms    O
of    O
Parkinson    O
's    O
disease    O
,    O
as    O
an    O
adjunct    O
to    O
levodopa    B-Hormone105407119
,    O
in    O
a    O
few    O
countries    O
such    O
as    O
Japan    O
.    O

Methylphenidate    O
,    O
commonly    O
used    O
to    O
treat    O
ADHD    O
,    O
has    O
been    O
used    O
in    O
conjunction    O
with    O
levodopa    B-Hormone105407119
to    O
treat    O
hypokinesia    O
in    O
the    O
short    O
term    O
.    O

Low    O
doses    O
can    O
be    O
taken    O
with    O
dopaminergic    O
treatment    O
to    O
decrease    O
the    O
amount    O
of    O
L-dopa    B-Hormone105407119
needed    O
,    O
which    O
can    O
reduce    O
its    O
long    O
-    O
term    O
side    O
effects    O
and    O
improve    O
motor    O
performance    O
.    O

Dihydrobiopterin    O
is    O
a    O
compound    O
produced    O
in    O
the    O
synthesis    O
of    O
dopamine    O
,    O
norepinephrine    O
and    O
epinephrine    O
through    O
production    O
of    O
the    O
intermediate    O
L-3,4-dihydroxyphenylalanine    O
,    O
also    O
known    O
as    O
L-DOPA    B-Hormone105407119
.    O

Dihydrobiopterin    O
(    O
BH2    O
)    O
is    O
a    O
pteridine    O
compound    O
produced    O
in    O
the    O
synthesis    O
of    O
L-DOPA    B-Hormone105407119
,    O
dopamine    O
,    O
norepinephrine    O
and    O
epinephrine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
3,4-dihydroxy-L-phenylalanine    B-Hormone105407119
and    O
2-oxoglutarate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
3,4-dihydroxyphenylpyruvate    O
and    O
L    O
-    O
glutamate    O
.    O

Treatment    O
of    O
THB    O
deficiencies    O
consists    O
of    O
THB    O
supplementation    O
(    O
2–20    O
mg    O
/    O
kg    O
per    O
day    O
)    O
or    O
diet    O
to    O
control    O
blood    O
phenylalanine    O
concentration    O
and    O
replacement    O
therapy    O
with    O
neurotransmitters    O
precursors    O
(    O
L-DOPA    B-Hormone105407119
and    O
5-HTP    O
)    O
and    O
supplements    O
of    O
folinic    O
acid    O
in    O
DHPR    O
deficiency    O
.    O

The    O
enzyme    O
tyrosine    B-Hormone105407119
hydroxylase    I-Hormone105407119
converts    O
tyrosine    O
to    O
L-DOPA    B-Hormone105407119
in    O
the    O
first    O
step    O
of    O
catecholamine    O
synthesis    O
.    O

Velvet    O
bean    O
(    O
"    O
M.    O
pruriens    O
"    O
)    O
is    O
one    O
of    O
the    O
most    O
important    O
sources    O
of    O
L-dopa    B-Hormone105407119
,    O
a    O
common    O
component    O
of    O
nootropics    O
(    O
"    O
smart    O
drugs    O
"    O
)    O
;    O
it    O
also    O
contains    O
serotonin    O
,    O
5-HTP    O
,    O
nicotine    O
,    O
and    O
some    O
decidedly    O
psychoactive    O
compounds    O
(    O
see    O
below    O
)    O
.    O

The    O
use    O
of    O
lisuride    O
as    O
initial    O
anti    O
-    O
Parkinsonian    O
treatment    O
has    O
been    O
advocated    O
,    O
delaying    O
the    O
need    O
for    O
levodopa    B-Hormone105407119
until    O
lisuride    O
becomes    O
insufficient    O
for    O
controlling    O
the    O
parkinsonian    O
disability    O
.    O

Initial    O
monotherapy    O
with    O
a    O
dopamine    O
agonist    O
(    O
other    O
examples    O
include    O
pergolide    O
,    O
pramipexole    B-Hormone105407119
,    O
and    O
ropinirole    O
)    O
is    O
associated    O
with    O
reduced    O
risk    O
for    O
motor    O
complications    O
in    O
Parkinson    O
patients    O
relative    O
to    O
levodopa    B-Hormone105407119
.    O

Recent    O
evidence    O
also    O
supports    O
that    O
dopamine    O
receptor    O
agonists    O
,    O
instead    O
of    O
L-DOPA    B-Hormone105407119
may    O
slow    O
or    O
prevent    O
the    O
progression    O
of    O
Parkinson    O
's    O
disease    O
.    O

Patients    O
on    O
DHEC    O
demonstrate    O
a    O
better    O
score    O
than    O
if    O
they    O
were    O
on    O
L-Dopa    B-Hormone105407119
on    O
the    O
Webster    O
scale    O
,    O
a    O
standardized    O
rating    O
scale    O
of    O
Parkinson    O
's    O
Disease    O
symptoms    O
such    O
as    O
gait    O
parameters    O
and    O
dyskinesia    O
.    O

Another    O
clinical    O
study    O
has    O
shown    O
that    O
DHEC    O
had    O
superior    O
efficacy    O
in    O
reducing    O
the    O
clinical    O
and    O
motorcomplications    O
associated    O
with    O
long    O
-    O
term    O
L-Dopa    B-Hormone105407119
use    O
,    O
as    O
well    O
as    O
in    O
reducing    O
the    O
incidence    O
and    O
severity    O
of    O
adverse    O
effects    O
.    O

According    O
to    O
the    O
United    O
States    O
National    O
Library    O
of    O
Medicine    O
's    O
medical    O
subject    O
headings    O
,    O
the    O
term    O
"    O
neurotrophin    O
"    O
may    O
be    O
used    O
as    O
a    O
synonym    O
for    O
"    O
neurotrophic    O
factor    O
"    O
,    O
but    O
the    O
term    O
"    O
neurotrophin    O
"    O
is    O
more    O
generally    O
reserved    O
for    O
four    O
structurally    O
related    O
factors    O
:    O
nerve    O
growth    O
factor    O
(    O
NGF    O
)    O
,    O
brain-derived    B-Hormone105407119
neurotrophic    I-Hormone105407119
factor    I-Hormone105407119
(    O
BDNF    O
)    O
,    O
neurotrophin-3    B-Hormone105407119
(    O
NT-3    O
)    O
,    O
and    O
neurotrophin-4    B-Hormone105407119
(    O
NT-4    O
)    O
.    O

In    O
the    O
PNS    O
(    O
where    O
NGF    O
,    O
NT-3    O
and    O
NT-4    B-Hormone105407119
are    O
mainly    O
secreted    O
)    O
cell    O
fate    O
is    O
determined    O
by    O
a    O
single    O
growth    O
factor    O
(    O
i.e.    O
neurotrophins    O
)    O
.    O

Desowen    B-Hormone105407119

Amcinonide    B-Hormone105407119
,    O
budesonide    B-Hormone105407119
,    O
desonide    B-Hormone105407119
,    O
fluocinolone    B-Hormone105407119
acetonide    I-Hormone105407119
,    O
fluocinonide    B-Hormone105407119
,    O
halcinonide    B-Hormone105407119
,    O
and    O
triamcinolone    B-Hormone105407119
acetonide    I-Hormone105407119
.    O

GC    O
-    O
C    O
(    O
GUCY2C    O
)    O
:    O
for    O
guanylin    B-Hormone105407119
and    O
uroguanylin    O
.    O

A    O
2008    O
report    O
demonstrated    O
evidence    O
of    O
the    O
effects    O
of    O
feminizing    B-Hormone105407119
chemicals    I-Hormone105407119
on    O
male    O
development    O
in    O
each    O
class    O
of    O
vertebrate    O
species    O
as    O
a    O
worldwide    O
phenomenon    O
;    O
these    O
chemical    O
are    O
suspected    O
of    O
reducing    O
the    O
sex    O
ratio    O
and    O
sperm    O
counts    O
in    O
humans    O
.    O

A    O
2008    O
report    O
provides    O
further    O
evidence    O
of    O
effects    O
of    O
feminizing    B-Hormone105407119
chemicals    I-Hormone105407119
on    O
male    O
development    O
in    O
each    O
class    O
of    O
vertebrate    O
species    O
as    O
a    O
worldwide    O
phenomenon    O
,    O
possibly    O
leading    O
to    O
a    O
decline    O
in    O
the    O
sex    O
ratio    O
in    O
humans    O
and    O
a    O
possible    O
decline    O
in    O
sperm    O
counts    O
.    O

Alkylphenols    O
are    O
xenoestrogens    B-Hormone105407119
.    O

Xenoestrogen    B-Hormone105407119

BPA    O
is    O
a    O
xenoestrogen    B-Hormone105407119
,    O
exhibiting    O
estrogen    O
-    O
mimicking    O
,    O
hormone    O
-    O
like    O
properties    O
that    O
raise    O
concern    O
about    O
its    O
suitability    O
in    O
some    O
consumer    O
products    O
and    O
food    O
containers    O
.    O

This    O
may    O
be    O
the    O
mechanism    O
by    O
which    O
BPA    O
acts    O
as    O
a    O
xenoestrogen    B-Hormone105407119
.    O

mometasone    B-Hormone105407119
(    O
INN    O
)    O

Mometasone    B-Hormone105407119
furoate    I-Hormone105407119
,    O
an    O
inhaled    O
corticosteroid    O
(    O
anti    O
-    O
inflammatory    O
)    O

A    O
variety    O
of    O
steroid    O
medications    O
,    O
from    O
anti    O
-    O
allergy    O
nasal    O
sprays    O
(    O
Nasonex    B-Hormone105407119
,    O
Flonase    B-Hormone105407119
)    O
to    O
topical    O
skin    O
creams    O
,    O
to    O
eye    O
drops    O
(    O
Tobradex    O
)    O
,    O
to    O
prednisone    O
have    O
been    O
implicated    O
in    O
the    O
development    O
of    O
CSR    O
.    O

Alclometasone    O
dipropionate    O
,    O
betamethasone    B-Hormone105407119
dipropionate    I-Hormone105407119
,    O
betamethasone    O
valerate    O
,    O
clobetasol    B-Hormone105407119
propionate    I-Hormone105407119
,    O
clobetasone    O
butyrate    O
,    O
fluprednidene    B-Hormone105407119
acetate    I-Hormone105407119
,    O
and    O
mometasone    B-Hormone105407119
furoate    I-Hormone105407119
.    O

Methyldienolone    B-Hormone105407119

Dienedione    B-Hormone105407119
(    O
the    O
17-keto    O
analogue    O
of    O
dienolone    O
,    O
also    O
known    O
as    O
19-nor-4,9-androstadienedione    O
)    O
is    O
thought    O
to    O
be    O
a    O
prohormone    O
of    O
dienolone    O
,    O
while    O
methyldienolone    B-Hormone105407119
and    O
ethyldienolone    O
are    O
orally    O
active    O
17α-alkylated    O
AAS    O
derivatives    O
of    O
dienolone    O
.    O

desoximetasone    B-Hormone105407119
(    O
INN    O
)    O

Ointment    O
and    O
creams    O
containing    O
coal    O
tar    O
,    O
dithranol    O
,    O
corticosteroids    O
(    O
i.e.    O
desoximetasone    B-Hormone105407119
)    O
,    O
fluocinonide    B-Hormone105407119
,    O
vitamin    O
D3    O
analogs    O
(    O
for    O
example    O
,    O
calcipotriol    O
)    O
,    O
and    O
retinoids    O
are    O
routinely    O
used    O
.    O

Halog    B-Hormone105407119

Amcinonide    B-Hormone105407119
,    O
budesonide    B-Hormone105407119
,    O
desonide    B-Hormone105407119
,    O
fluocinolone    B-Hormone105407119
acetonide    I-Hormone105407119
,    O
fluocinonide    B-Hormone105407119
,    O
halcinonide    B-Hormone105407119
,    O
and    O
triamcinolone    B-Hormone105407119
acetonide    I-Hormone105407119
.    O

The    O
"    O
NTRK3    O
"    O
gene    O
codes    O
for    O
Tropomyosin    O
receptor    O
kinase    O
C    O
(    O
also    O
termed    O
TrkC    O
or    O
TEL    O
)    O
,    O
the    O
receptor    O
for    O
neurotrophin-3    B-Hormone105407119
.    O

According    O
to    O
the    O
United    O
States    O
National    O
Library    O
of    O
Medicine    O
's    O
medical    O
subject    O
headings    O
,    O
the    O
term    O
"    O
neurotrophin    O
"    O
may    O
be    O
used    O
as    O
a    O
synonym    O
for    O
"    O
neurotrophic    O
factor    O
"    O
,    O
but    O
the    O
term    O
"    O
neurotrophin    O
"    O
is    O
more    O
generally    O
reserved    O
for    O
four    O
structurally    O
related    O
factors    O
:    O
nerve    O
growth    O
factor    O
(    O
NGF    O
)    O
,    O
brain-derived    B-Hormone105407119
neurotrophic    I-Hormone105407119
factor    I-Hormone105407119
(    O
BDNF    O
)    O
,    O
neurotrophin-3    B-Hormone105407119
(    O
NT-3    O
)    O
,    O
and    O
neurotrophin-4    B-Hormone105407119
(    O
NT-4    O
)    O
.    O

Mice    O
born    O
without    O
the    O
ability    O
to    O
make    O
NT-3    B-Hormone105407119
have    O
loss    O
of    O
proprioceptive    O
and    O
subsets    O
of    O
mechanoreceptive    O
sensory    O
neurons    O
.    O

The    O
addition    O
of    O
NGF    O
(    O
for    O
TrkA    O
)    O
or    O
NT-3    B-Hormone105407119
(    O
for    O
TrkC    O
)    O
prevents    O
this    O
apoptosis    O
.    O

Acylation    B-Hormone105407119
stimulating    I-Hormone105407119
protein    I-Hormone105407119

For    O
mild    O
-    O
moderate    O
eczema    O
a    O
weak    O
steroid    O
may    O
be    O
used    O
(    O
e.g.    O
,    O
hydrocortisone    O
)    O
,    O
while    O
in    O
more    O
severe    O
cases    O
a    O
higher    O
-    O
potency    O
steroid    O
(    O
e.g.    O
,    O
clobetasol    B-Hormone105407119
propionate    I-Hormone105407119
)    O
may    O
be    O
used    O
.    O

Alclometasone    O
dipropionate    O
,    O
betamethasone    B-Hormone105407119
dipropionate    I-Hormone105407119
,    O
betamethasone    O
valerate    O
,    O
clobetasol    B-Hormone105407119
propionate    I-Hormone105407119
,    O
clobetasone    O
butyrate    O
,    O
fluprednidene    B-Hormone105407119
acetate    I-Hormone105407119
,    O
and    O
mometasone    B-Hormone105407119
furoate    I-Hormone105407119
.    O

A    O
propionate    O
ester    O
of    O
clobetasol    O
,    O
clobetasol    B-Hormone105407119
propionate    I-Hormone105407119
,    O
has    O
also    O
been    O
marketed    O
,    O
and    O
is    O
far    O
more    O
widely    O
used    O
in    O
comparison    O
.    O

Insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
2    I-Hormone105407119
(    O
IGF-2    O
,    O
or    O
sometimes    O
with    O
Roman    O
Numeral    O
as    O
IGF    O
-    O
II    O
)    O
is    O
thought    O
to    O
be    O
a    O
primary    O
growth    O
factor    O
required    O
for    O
early    O
development    O
while    O
IGF-1    B-Hormone105407119
expression    O
is    O
required    O
for    O
achieving    O
maximal    O
growth    O
.    O

Insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
2    I-Hormone105407119

For    O
example    O
,    O
the    O
gene    O
encoding    O
insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
2    I-Hormone105407119
(    O
IGF2/Igf2    O
)    O
is    O
only    O
expressed    O
from    O
the    O
allele    O
inherited    O
from    O
the    O
father    O
.    O

However    O
,    O
in    O
2004    O
,    O
experimental    O
manipulation    O
by    O
Japanese    O
researchers    O
of    O
a    O
paternal    O
methylation    O
imprint    O
controlling    O
the    O
"    O
Igf2    B-Hormone105407119
"    O
gene    O
led    O
to    O
the    O
birth    O
of    O
a    O
mouse    O
(    O
named    O
Kaguya    O
)    O
with    O
two    O
maternal    O
sets    O
of    O
chromosomes    O
,    O
though    O
it    O
is    O
not    O
a    O
true    O
parthenogenone    O
since    O
cells    O
from    O
two    O
different    O
female    O
mice    O
were    O
used    O
.    O

Insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
2    I-Hormone105407119
(    O
IGF-2    B-Hormone105407119
)    O
is    O
one    O
of    O
three    O
protein    O
hormones    O
that    O
share    O
structural    O
similarity    O
to    O
insulin    O
.    O

A    O
study    O
at    O
the    O
European    O
Neuroscience    O
Institute    O
-    O
Goettingen    O
(    O
Germany    O
)    O
found    O
that    O
fear    O
extinction    O
-    O
induced    O
IGF2    B-Hormone105407119
signalling    O
promotes    O
the    O
survival    O
of    O
17-    O
to    O
19-day    O
-    O
old    O
newborn    O
hippocampal    O
neurons    O
.    O

The    O
protein    O
CTCF    O
plays    O
a    O
heavy    O
role    O
in    O
repressing    O
the    O
insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
2    I-Hormone105407119
gene    O
,    O
by    O
binding    O
to    O
the    O
H-19    O
imprinting    O
control    O
region    O
(    O
ICR    O
)    O
along    O
with    O
differentially    O
-    O
methylated    O
region-1    O
(    O
DMR1    O
)    O
and    O
MAR3    O
.    O

However    O
,    O
some    O
genes    O
become    O
hypermethylated    O
with    O
age    O
,    O
including    O
genes    O
for    O
the    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
,    O
p16    O
,    O
and    O
insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
2    I-Hormone105407119
.    O

It    O
is    O
converted    O
to    O
α-methylnorepinephrine    B-Hormone105407119
by    O
dopamine    O
beta    O
-    O
hydroxylase    O
(    O
DBH    O
)    O
.    O

Reduced    O
sex    B-Hormone105407119
hormone-binding    I-Hormone105407119
globulin    I-Hormone105407119
(    O
SHBG    O
)    O

Prolonged    O
severe    O
CR    O
lowers    O
total    O
serum    O
and    O
free    O
testosterone    O
while    O
increasing    O
sex    B-Hormone105407119
hormone    I-Hormone105407119
binding    I-Hormone105407119
globulin    I-Hormone105407119
concentrations    O
in    O
humans    O
;    O
these    O
effects    O
are    O
independent    O
of    O
adiposity    O
.    O

Sex    B-Hormone105407119
hormone-binding    I-Hormone105407119
globulin    I-Hormone105407119
levels    O
were    O
mildly    O
elevated    O
(    O
6.0–10.0    O
nmol    O
/    O
L    O
)    O
,    O
while    O
thyroxine-binding    B-Hormone105407119
globulin    I-Hormone105407119
,    O
corticosteroid    O
-    O
binding    O
globulin    O
,    O
and    O
prolactin    O
levels    O
were    O
all    O
normal    O
.    O

Sex    B-Hormone105407119
hormone-binding    I-Hormone105407119
globulin    I-Hormone105407119
,    O
corticosteroid    O
-    O
binding    O
globulin    O
,    O
thyroxine-binding    B-Hormone105407119
globulin    I-Hormone105407119
,    O
prolactin    O
,    O
and    O
triglycerides    O
,    O
which    O
are    O
known    O
to    O
be    O
elevated    O
by    O
estrogen    O
,    O
were    O
all    O
within    O
normal    O
ranges    O
in    O
spite    O
of    O
the    O
extremely    O
high    O
levels    O
of    O
estrogen    O
,    O
and    O
inhibin    O
B    O
levels    O
were    O
also    O
normal    O
.    O

Levels    O
of    O
sex    B-Hormone105407119
hormone-binding    I-Hormone105407119
globulin    I-Hormone105407119
(    O
SHBG    O
)    O
were    O
very    O
low    O
,    O
which    O
can    O
be    O
attributed    O
to    O
the    O
absence    O
of    O
hepatic    O
actions    O
of    O
estrogen    O
.    O

It    O
is    O
97.5    O
to    O
98%    O
protein    O
-    O
bound    O
,    O
to    O
albumin    O
,    O
and    O
does    O
not    O
bind    O
to    O
sex    B-Hormone105407119
hormone-binding    I-Hormone105407119
globulin    I-Hormone105407119
or    O
corticosteroid    O
-    O
binding    O
globulin    O
.    O

Their    O
levels    O
of    O
Sex    B-Hormone105407119
hormone-binding    I-Hormone105407119
globulin    I-Hormone105407119
(    O
SHBG    B-Hormone105407119
)    O
increased    O
,    O
which    O
reduced    O
the    O
amount    O
of    O
free    O
testosterone    O
in    O
their    O
blood    O
.    O

SHBG    B-Hormone105407119
:    O
Sex    O
hormone    O
binding    O
globulin    O
(    O
17p13.1    O
)    O

It    O
also    O
has    O
the    O
effect    O
of    O
decreasing    O
the    O
steroid    O
's    O
affinity    O
for    O
sex    B-Hormone105407119
hormone-binding    I-Hormone105407119
globulin    I-Hormone105407119
,    O
a    O
protein    O
that    O
deactivates    O
steroid    O
molecules    O
and    O
prevents    O
them    O
from    O
further    O
reactions    O
with    O
the    O
body    O
.    O

sex    B-Hormone105407119
hormone-binding    I-Hormone105407119
globulin    I-Hormone105407119

Non-tropic    B-Hormone105407119
hormone    I-Hormone105407119

Rosterolone    O
is    O
a    O
derivative    O
of    O
mesterolone    B-Hormone105407119
,    O
which    O
,    O
in    O
contrast    O
,    O
is    O
an    O
androgen    O
and    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
.    O

Mesterolone    B-Hormone105407119

D-DOPA    B-Hormone105407119
(    O
dextrodopa    O
)    O

Currently    O
used    O
androgens    O
for    O
male    O
hormone    B-Hormone105407119
replacement    I-Hormone105407119
therapy    I-Hormone105407119
are    O
typically    O
injectable    O
or    O
skin    O
delivery    O
formulations    O
of    O
testosterone    O
or    O
testosterone    O
esters    O
.    O

They    O
are    O
used    O
in    O
androgen    B-Hormone105407119
replacement    I-Hormone105407119
therapy    I-Hormone105407119
(    O
ART    O
)    O
,    O
among    O
other    O
indications    O
.    O

Androgen    B-Hormone105407119
replacement    I-Hormone105407119
therapy    I-Hormone105407119

Treatment    O
includes    O
surgical    O
correction    O
of    O
mild    O
gynecomastia    O
,    O
minor    O
hypospadias    O
repair    O
,    O
and    O
testosterone    B-Hormone105407119
supplementation    I-Hormone105407119
.    O

It    O
was    O
developed    O
in    O
collaboration    O
by    O
the    O
Contraceptive    O
Development    O
Branch    O
(    O
CDB    O
)    O
of    O
the    O
National    O
Institute    O
of    O
Child    O
Health    O
and    O
Human    O
Development    O
(    O
NICHD    O
)    O
and    O
the    O
World    O
Health    O
Organization    O
(    O
WHO    O
)    O
in    O
the    O
1970s    O
and    O
early    O
1980s    O
for    O
use    O
in    O
androgen    B-Hormone105407119
replacement    I-Hormone105407119
therapy    I-Hormone105407119
for    O
male    O
hypogonadism    O
and    O
as    O
a    O
potential    O
male    O
contraceptive    O
.    O

Cloprednol    B-Hormone105407119
=    O
6-chloro-11β,17α,21-trihydroxypregna-1,4,6-triene-3,20-dione    O

Mating    O
was    O
correlated    O
with    O
a    O
surge    O
in    O
JH    O
production    O
by    O
the    O
corpus    B-Hormone105407119
allatum    I-Hormone105407119
in    O
females    O
-    O
a    O
5    O
to    O
15    O
fold    O
increase    O
compared    O
to    O
virgin    O
females    O
,    O
an    O
allototropic    O
effect    O
.    O

In    O
this    O
species    O
,    O
pheromones    O
suppress    O
activity    O
of    O
the    O
corpora    B-Hormone105407119
allata    I-Hormone105407119
and    O
juvenile    B-Hormone105407119
hormone    I-Hormone105407119
(    O
JH    O
)    O
secretion    O
.    O

#    O
Corpora    B-Hormone105407119
allata    I-Hormone105407119
are    O
small    O
,    O
paired    O
glandular    O
bodies    O
originating    O
from    O
the    O
epithelium    O
located    O
on    O
either    O
side    O
of    O
the    O
foregut    O
.    O

moxestrol    B-Hormone105407119
(    O
INN    O
)    O

Moxestrol    B-Hormone105407119

Etynodiol    B-Hormone105407119

etynodiol    B-Hormone105407119
(    O
INN    O
)    O

Kopec    O
's    O
most    O
significant    O
contribution    O
was    O
his    O
study    O
of    O
neurosecretory    O
cells    O
in    O
the    O
brains    O
of    O
insects    O
which    O
secrete    O
a    O
crucial    O
growth    O
hormone    O
,    O
prothoracicotropic    B-Hormone105407119
hormone    I-Hormone105407119
(    O
PTTH    O
)    O
,    O
which    O
regulates    O
the    O
process    O
of    O
metamorphosis    O
(    O
"    O
ecdysteroidogenesis    O
"    O
)    O
.    O

These    O
not    O
only    O
produce    O
their    O
own    O
neurohormones    O
but    O
they    O
store    O
and    O
release    O
other    O
neurohormones    O
including    O
PTTH    B-Hormone105407119
prothoracicotropic    B-Hormone105407119
hormone    I-Hormone105407119
(    O
brain    O
hormone    O
)    O
,    O
which    O
stimulates    O
the    O
secretory    O
activity    O
of    O
the    O
prothoracic    O
glands    O
,    O
playing    O
an    O
integral    O
role    O
in    O
moulting    O
.    O

The    O
chlorination    O
prevents    O
conversion    O
to    O
dihydrotestosterone    B-Hormone105407119
(    O
DHT    O
)    O
while    O
also    O
rendering    O
the    O
chemical    O
incapable    O
of    O
conversion    O
to    O
estrogen    O
.    O

Erectile    O
dysfunction    O
is    O
attributed    O
to    O
the    O
weaker    O
action    O
of    O
DHN    O
in    O
the    O
penis    O
since    O
dihydrotestosterone    B-Hormone105407119
(    O
DHT    O
)    O
is    O
a    O
known    O
sexual    O
modulator    O
.    O

This    O
is    O
attributed    O
to    O
the    O
fact    O
that    O
,    O
whereas    O
testosterone    O
is    O
potentiated    O
via    O
conversion    O
into    O
dihydrotestosterone    B-Hormone105407119
(    O
DHT    O
)    O
in    O
androgenic    O
tissues    O
,    O
the    O
opposite    O
is    O
true    O
with    O
nandrolone    O
and    O
similar    O
AAS    O
(    O
i.e.    O
,    O
other    O
19-nortestosterone    O
derivatives    O
)    O
.    O

Due    O
to    O
the    O
antiandrogenic    O
effects    O
that    O
result    O
from    O
these    O
actions    O
,    O
it    O
is    O
frequently    O
used    O
off    O
-    O
label    O
to    O
treat    O
a    O
variety    O
of    O
dermatological    O
conditions    O
in    O
which    O
androgens    O
,    O
such    O
as    O
testosterone    O
and    O
dihydrotestosterone    B-Hormone105407119
(    O
DHT    O
)    O
,    O
play    O
a    O
role    O
.    O

Metenolone    B-Hormone105407119
enanthate    I-Hormone105407119
(    O
brand    O
names    O
Nibal    B-Hormone105407119
Injection    I-Hormone105407119
,    O
Primobolan    B-Hormone105407119
Depot    I-Hormone105407119
)    O
,    O
or    O
methenolone    B-Hormone105407119
enanthate    I-Hormone105407119
,    O
is    O
an    O
injected    O
anabolic–androgenic    B-Hormone105407119
steroid    I-Hormone105407119
(    O
AAS    O
)    O
of    O
the    O
dihydrotestosterone    B-Hormone105407119
(    O
DHT    O
)    O
group    O
.    O

The    O
testes    O
begin    O
to    O
secrete    O
three    O
hormones    O
that    O
influence    O
the    O
male    O
internal    O
and    O
external    O
genitalia    O
:    O
they    O
secrete    O
anti    O
-    O
müllerian    O
hormone    O
(    O
AMH    O
)    O
,    O
testosterone    O
,    O
and    O
dihydrotestosterone    B-Hormone105407119
(    O
DHT    O
)    O
.    O

The    O
most    O
potent    O
is    O
dihydrotestosterone    B-Hormone105407119
(    O
DHT    O
)    O
,    O
generated    O
from    O
testosterone    O
in    O
skin    O
and    O
genital    O
tissue    O
by    O
the    O
action    O
of    O
5α-reductase    O
.    O

This    O
is    O
because    O
testosterone    O
is    O
converted    O
to    O
the    O
more    O
potent    O
DHT    B-Hormone105407119
by    O
5-alpha    O
reductase    O
.    O

EIS    O
is    O
analogous    O
to    O
androgen    O
insensitivity    O
syndrome    O
(    O
AIS    O
)    O
,    O
a    O
condition    O
in    O
which    O
the    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
AR    O
)    O
is    O
defective    O
and    O
insensitive    O
to    O
androgens    O
,    O
such    O
as    O
testosterone    O
and    O
dihydrotestosterone    B-Hormone105407119
(    O
DHT    O
)    O
.    O

Levels    O
of    O
progesterone    O
,    O
17α-hydroxyprogesterone    O
,    O
androstenedione    B-Hormone105407119
,    O
testosterone    O
,    O
and    O
dihydrotestosterone    B-Hormone105407119
(    O
DHT    O
)    O
were    O
elevated    O
in    O
the    O
sisters    O
,    O
while    O
concentrations    O
of    O
adrenal    O
steroids    O
including    O
cortisol    B-Hormone105407119
,    O
dehydroepiandrosterone    B-Hormone105407119
(    O
DHEA    O
)    O
,    O
11β-hydroxyandrostenedione    O
,    O
11-deoxycortisol    O
,    O
and    O
21-deoxycortisol    O
were    O
within    O
normal    O
ranges    O
.    O

Testosterone    O
can    O
be    O
metabolized    O
to    O
17b    O
-    O
estradiol    O
by    O
the    O
enzyme    O
aromatase    O
,    O
or    O
to    O
5-alpha    O
-    O
dihydrotestosterone    B-Hormone105407119
(    O
DHT    O
)    O
by    O
5a    O
-    O
reductase    O
.    O

Image    O
:    O
Dihydrotestosterone    B-Hormone105407119

Conversion    O
of    O
testosterone    O
(    O
T    O
)    O
to    O
dihydrotestosterone    B-Hormone105407119
(    O
DHT    O
)    O
may    O
be    O
impaired    O
,    O
although    O
to    O
a    O
lesser    O
extent    O
than    O
is    O
seen    O
in    O
5α-reductase    O
deficiency    O
.    O

DHT    B-Hormone105407119
(dihydrotestosterone)    I-Hormone105407119

Dihydrotestosterone    B-Hormone105407119
(DHT)    I-Hormone105407119

Beard    O
growth    O
is    O
linked    O
to    O
stimulation    O
of    O
hair    O
follicles    O
in    O
the    O
area    O
by    O
dihydrotestosterone    B-Hormone105407119
(    O
DHT    O
)    O
,    O
which    O
continues    O
to    O
affect    O
beard    O
growth    O
after    O
puberty    O
.    O

Finasteride    O
and    O
dutasteride    O
,    O
which    O
are    O
5α-reductase    O
inhibitors    O
and    O
inhibit    O
the    O
production    O
of    O
the    O
potent    O
androgen    O
dihydrotestosterone    B-Hormone105407119
(    O
DHT    O
)    O
.    O

|    O
|    O
Dihydrotestosterone    B-Hormone105407119

All    O
sublines    O
were    O
treated    O
with    O
dihydrotestosterone    B-Hormone105407119
(    O
DHT    O
)    O
,    O
a    O
high    O
-    O
affinity    O
ligand    O
for    O
AR    O
.    O

In    O
addition    O
,    O
some    O
have    O
a    O
high    O
risk    O
of    O
gynecomastia    O
due    O
to    O
uniquely    O
high    O
estrogenic    O
activity    O
,    O
although    O
this    O
does    O
not    O
apply    O
to    O
17α-alkylated    O
AAS    O
that    O
are    O
also    O
4,5α-reduced    O
or    O
19-demethylated    O
(    O
i.e.    O
,    O
that    O
are    O
also    O
dihydrotestosterone    B-Hormone105407119
(    O
DHT    O
)    O
or    O
nandrolone    O
derivatives    O
,    O
respectively    O
)    O
.    O

In    O
general    O
,    O
these    O
hormones    O
do    O
not    O
have    O
an    O
overall    O
effect    O
in    O
the    O
male    O
body    O
,    O
and    O
are    O
converted    O
to    O
more    O
potent    O
androgens    O
such    O
as    O
testosterone    O
and    O
DHT    B-Hormone105407119
or    O
to    O
estrogens    O
(    O
female    O
sex    O
hormones    O
)    O
in    O
the    O
gonads    O
,    O
acting    O
in    O
this    O
way    O
as    O
a    O
metabolic    O
intermediate    O
.    O

Metenolone    B-Hormone105407119
,    O
or    O
methenolone    B-Hormone105407119
,    O
also    O
known    O
as    O
methylandrostenolone    B-Hormone105407119
,    O
is    O
a    O
synthetic    O
,    O
orally    O
active    O
anabolic-androgenic    B-Hormone105407119
steroid    I-Hormone105407119
(    O
AAS    O
)    O
and    O
a    O
derivative    O
of    O
dihydrotestosterone    B-Hormone105407119
(    O
DHT    O
)    O
.    O

Metenolone    O
,    O
also    O
known    O
as    O
1-methyl-4,5α-dihydro-δ1-testosterone    O
(    O
1-methyl-δ1-DHT    O
)    O
or    O
as    O
1-methyl-5α-androst-1-en-17β-ol-3-one    O
,    O
is    O
a    O
synthetic    O
androstane    O
steroid    O
and    O
derivative    O
of    O
dihydrotestosterone    B-Hormone105407119
(    O
DHT    O
)    O
.    O

Dihydrotestosterone    B-Hormone105407119
↔    O
5α-Androstanedione    O
/    O
3α-Androstanediol    O
/    O
3β-Androstanediol    O

Feeding    O
11-ketotestosterone    B-Hormone105407119
coated    O
scallops    O
to    O
toadfish    O
increases    O
their    O
calling    O
behavior    O
,    O
which    O
identifies    O
11-ketotestosterone    O
,    O
an    O
androgen    O
hormone    O
,    O
as    O
a    O
mediator    O
of    O
midshipman    O
fish    O
vocalization    O
.    O

11-Ketotestosterone    B-Hormone105407119
(    O
11-KT    B-Hormone105407119
)    O
is    O
an    O
oxidized    O
form    O
of    O
testosterone    O
that    O
contains    O
a    O
keto    O
group    O
at    O
the    O
C11    O
position    O
.    O

In    O
"    O
Drosophila    O
"    O
,    O
hormones    O
such    O
as    O
ecdysone    B-Hormone105407119
and    O
juvenile    O
hormone    O
can    O
promote    O
the    O
expression    O
of    O
certain    O
miRNAs    O
.    O

Very    O
detailed    O
studies    O
have    O
been    O
done    O
on    O
JH    O
,    O
JH    O
acid    O
,    O
ecdysone    B-Hormone105407119
,    O
and    O
JH    O
titers    O
have    O
been    O
done    O
in    O
precisely    O
timed    O
larvae    O
of    O
Manduca    O
sexta    O
as    O
a    O
function    O
of    O
development    O
during    O
the    O
fifth    O
larval    O
stadium    O
.    O

(    O
A    O
very    O
similar    O
timing    O
of    O
peaks    O
of    O
JH    O
esterase    O
and    O
ecdysone    B-Hormone105407119
has    O
been    O
observed    O
in    O
"    O
Galleria    O
mellonella    O
"    O
.    O

These    O
data    O
are    O
consistent    O
with    O
a    O
classical    O
model    O
for    O
lepidopterans    O
where    O
JH    O
is    O
high    O
at    O
each    O
larval    O
molt    O
,    O
but    O
must    O
rise    O
together    O
with    O
ecdysone    B-Hormone105407119
prior    O
to    O
pupation    O
to    O
initiate    O
the    O
pupal    O
molt    O
.    O

These    O
glands    O
secrete    O
an    O
ecdysteroid    B-Hormone105407119
called    O
ecdysone    B-Hormone105407119
,    O
or    O
the    O
moulting    O
hormone    O
,    O
which    O
initiates    O
the    O
epidermal    O
moulting    O
process    O
.    O

He    O
developed    O
several    O
such    O
varieties    O
that    O
contained    O
very    O
high    O
levels    O
of    O
gossypol    B-Hormone105407119
(    O
a    O
natural    O
insect    O
toxin    O
)    O
and    O
that    O
manifested    O
physical    O
features    O
(    O
such    O
as    O
glabrous    O
leaf    O
and    O
stem    O
surfaces    O
)    O
that    O
decreased    O
their    O
suitability    O
for    O
insect    O
egg    O
deposition    O
.    O

Delta    O
-    O
cadinene    O
synthase    O
is    O
one    O
of    O
the    O
key    O
steps    O
in    O
the    O
synthesis    O
of    O
gossypol    B-Hormone105407119
,    O
a    O
toxic    O
terpenoid    O
produced    O
in    O
cotton    O
seeds    O
.    O

Determination    O
of    O
the    O
structure    O
of    O
gossypol    B-Hormone105407119
for    O
the    O
cottonseed    O
industry    O
.    O

Allylestrenol    B-Hormone105407119

Extension    O
of    O
the    O
C17α    O
alkyl    O
chain    O
longer    O
than    O
an    O
ethyl    O
group    O
abolishes    O
androgenic    O
activity    O
and    O
converts    O
the    O
drug    O
into    O
an    O
antiandrogen    B-Hormone105407119
,    O
as    O
in    O
topterone    O
(    O
17α-propyltestosterone    O
)    O
and    O
allylestrenol    B-Hormone105407119
(    O
17α-allyl-3-deketo-19-nortestosterone    O
)    O
(    O
an    O
extended    O
-    O
chain    O
variant    O
of    O
ethylestrenol    B-Hormone105407119
)    O
.    O

Progestin    B-Hormone105407119
challenge    I-Hormone105407119

Calusterone    B-Hormone105407119

Calusterone    B-Hormone105407119

Halotestin    B-Hormone105407119

Fluoxymesterone    B-Hormone105407119

Fluoxymesterone    B-Hormone105407119

"    O
'    O
Rare    O
(    O
50    O
]    O
]    O
=    O
2.5    O
nM    O
)    O
and    O
17,20-lyase    O
(    O
IC50    O
=    O
15    O
nM    O
)    O
(    O
six    O
-    O
fold    O
more    O
selective    O
for    O
inhibition    O
of    O
17α-hydroxylase    O
over    O
17,20-lyase    O
)    O
that    O
are    O
expressed    O
in    O
testicular    O
,    O
adrenal    O
,    O
and    O
prostatic    O
tumor    O
tissues    O
.    O
CYP17    O
catalyzes    O
two    O
sequential    O
reactions    O
:    O
(    O
a    O
)    O
the    O
conversion    O
of    O
pregnenolone    O
and    O
progesterone    O
to    O
their    O
17α-hydroxy    O
derivatives    O
by    O
its    O
17α-hydroxylase    O
activity    O
,    O
and    O
(    O
b    O
)    O
the    O
subsequent    O
formation    O
of    O
dehydroepiandrosterone    B-Hormone105407119
(    O
DHEA    O
)    O
and    O
androstenedione    B-Hormone105407119
,    O
respectively    O
,    O
by    O
its    O
17,20-lyase    O
activity    O
.    O
DHEA    O
and    O
androstenedione    O

In    O
1998    O
,    O
gold    O
medalist    O
Randy    O
Barnes    O
was    O
tested    O
positive    O
for    O
androstenedione    B-Hormone105407119
(    O
an    O
over    O
-    O
the    O
-    O
counter    O
supplement    O
famously    O
used    O
by    O
Mark    O
McGwire    O
)    O
,    O
and    O
was    O
subsequently    O
suspended    O
from    O
competition    O
in    O
the    O
Olympic    O
Games    O
for    O
life    O
.    O

17β-Hydroxysteroid    O
dehydrogenase    O
(    O
17β-HSD    O
)    O
inhibitors    O
prevent    O
the    O
reversible    O
conversion    O
of    O
the    O
weak    O
androgens    O
dehydroepiandrosterone    B-Hormone105407119
(    O
DHEA    O
)    O
and    O
4-androstenedione    B-Hormone105407119
into    O
the    O
more    O
potent    O
androgen    O
testosterone    O
and    O
the    O
weak    O
estrogen    O
estrone    O
into    O
the    O
more    O
potent    O
estrogen    O
estradiol    O
.    O

LH    O
induces    O
the    O
production    O
of    O
androgens    O
by    O
the    O
theca    O
cells    O
,    O
most    O
notably    O
androstendione    B-Hormone105407119
,    O
which    O
are    O
aromatized    O
by    O
granulosa    O
cells    O
to    O
produce    O
estrogens    O
,    O
primarily    O
estradiol    O
.    O

A    O
deficiency    O
in    O
the    O
HSD17B3    O
gene    O
is    O
characterized    O
biochemically    O
by    O
decreased    O
levels    O
of    O
testosterone    O
and    O
increased    O
levels    O
of    O
androstenedione    O
as    O
a    O
result    O
of    O
the    O
defect    O
in    O
conversion    O
of    O
androstenedione    O
into    O
testosterone    O
,    O
this    O
leads    O
to    O
clinically    O
important    O
higher    O
ratio    O
of    O
androstenedione    B-Hormone105407119
to    O
testosterone    O

Androstenedione    B-Hormone105407119
is    O
a    O
hormone    O
that    O
is    O
converted    O
to    O
testosterone    O
by    O
enzymatic    O
activity    O
.    O

In    O
the    O
largest    O
nandrolone    O
study    O
performed    O
on    O
621    O
athletes    O
at    O
the    O
1998    O
Nagano    O
Olympic    O
Games    O
,    O
no    O
athlete    O
tested    O
over    O
0.4    O
μg    O
/    O
L.    O
19-Norandrosterone    O
was    O
identified    O
as    O
a    O
trace    O
contaminant    O
in    O
commercial    O
preparations    O
of    O
androstenedione    B-Hormone105407119
,    O
which    O
until    O
2004    O
was    O
available    O
without    O
a    O
prescription    O
as    O
a    O
dietary    O
supplement    O
in    O
the    O
U.S.    O

By    O
inhibiting    O
3β-HSD    O
,    O
epostane    O
blocks    O
the    O
biosynthesis    O
of    O
progesterone    O
from    O
pregnenolone    B-Hormone105407119
(    O
and    O
also    O
the    O
conversion    O
of    O
dehydroepiandrosterone    B-Hormone105407119
to    O
androstenedione    B-Hormone105407119
)    O
,    O
thereby    O
functioning    O
as    O
an    O
antiprogestogen    O
and    O
terminating    O
pregnancy    O
.    O

In    O
the    O
ensuing    O
years    O
nasal    O
spray    O
preparations    O
containing    O
testosterone    O
or    O
androstenedione    B-Hormone105407119
were    O
developed    O
in    O
collaboration    O
with    O
Jenapharm    O
,    O
tested    O
,    O
and    O
used    O
in    O
top    O
athletes    O
—    O
some    O
of    O
whom    O
did    O
not    O
like    O
this    O
mode    O
of    O
application    O
.    O
Doping    O
tests    O
at    O
the    O
time    O
used    O
the    O
T    O
:    O
E    O
(    O
testosterone    O
:    O
epitestosterone    B-Hormone105407119
)    O
ratio    O
.    O

Levels    O
of    O
progesterone    O
,    O
17α-hydroxyprogesterone    O
,    O
androstenedione    B-Hormone105407119
,    O
testosterone    O
,    O
and    O
dihydrotestosterone    B-Hormone105407119
(    O
DHT    O
)    O
were    O
elevated    O
in    O
the    O
sisters    O
,    O
while    O
concentrations    O
of    O
adrenal    O
steroids    O
including    O
cortisol    B-Hormone105407119
,    O
dehydroepiandrosterone    B-Hormone105407119
(    O
DHEA    O
)    O
,    O
11β-hydroxyandrostenedione    O
,    O
11-deoxycortisol    O
,    O
and    O
21-deoxycortisol    O
were    O
within    O
normal    O
ranges    O
.    O

Valproic    O
acid    O
has    O
been    O
found    O
to    O
directly    O
stimulate    O
androgen    O
biosynthesis    O
in    O
the    O
gonads    O
via    O
inhibition    O
of    O
histone    O
deacetylases    O
and    O
has    O
been    O
associated    O
with    O
hyperandrogenism    B-Hormone105407119
in    O
women    O
and    O
increased    O
4-androstenedione    B-Hormone105407119
levels    O
in    O
men    O
.    O

Males    O
with    O
CAH    O
have    O
more    O
masculine    O
(    O
smaller    O
)    O
digit    O
ratios    O
than    O
control    O
males    O
,    O
which    O
also    O
suggests    O
that    O
prenatal    O
androgens    O
affect    O
digit    O
ratios    O
,    O
since    O
amniocentesis    O
samples    O
show    O
that    O
prenatal    O
levels    O
of    O
testosterone    O
are    O
in    O
the    O
high    O
normal    O
range    O
in    O
males    O
with    O
CAH    O
,    O
while    O
levels    O
of    O
the    O
weaker    O
androgen    O
androstenedione    B-Hormone105407119
are    O
several    O
fold    O
higher    O
than    O
in    O
control    O
males    O
.    O

|rowspan=3|    O
Androstenedione    B-Hormone105407119

Then    O
,    O
in    O
an    O
IAAF    O
out    O
-    O
of    O
-    O
competition    O
test    O
conducted    O
in    O
March    O
2005    O
,    O
Badji    O
tested    O
positive    O
for    O
the    O
illegal    O
substance    O
androstenedione    B-Hormone105407119
.    O

4-Androstene-3,17-dione    B-Hormone105407119

It    O
produces    O
androgens    O
,    O
mainly    O
dehydroepiandrosterone    B-Hormone105407119
(    O
DHEA    O
)    O
,    O
DHEA    O
sulfate    O
(    O
DHEA    O
-    O
S    O
)    O
,    O
and    O
androstenedione    B-Hormone105407119
(    O
the    O
precursor    O
to    O
testosterone    O
)    O
in    O
humans    O
.    O

This    O
includes    O
interconversion    O
of    O
DHEA    B-Hormone105407119
and    O
androstenediol    O
,    O
androstenedione    B-Hormone105407119
and    O
testosterone    O
,    O
and    O
estrone    O
and    O
estradiol    O
.    O

Androstenedione    B-Hormone105407119
↔    O
Testosterone    O

3β-Hydroxysteroid    O
dehydrogenase/Δ5    O
-    O
4    O
isomerase    O
(    O
3β-HSD    O
)    O
is    O
an    O
enzyme    O
that    O
catalyzes    O
the    O
biosynthesis    O
of    O
progesterone    O
from    O
pregnenolone    B-Hormone105407119
,    O
17α-hydroxyprogesterone    O
from    O
17α-hydroxypregnenolone    O
,    O
and    O
androstenedione    B-Hormone105407119
from    O
dehydroepiandrosterone    B-Hormone105407119
(    O
DHEA    O
)    O
in    O
the    O
adrenal    O
gland    O
.    O

DHEA    B-Hormone105407119
to    O
androstenedione    B-Hormone105407119

Androstenedione    B-Hormone105407119

They    O
occasionally    O
exhibit    O
double    B-Hormone105407119
muscling    I-Hormone105407119
.    O

Myostatin    B-Hormone105407119
,    O
a    O
TGF    O
-    O
beta    O
superfamily    O
member    O
,    O
is    O
a    O
negative    O
regulator    O
of    O
muscle    O
growth    O
.    O

The    O
Maine    O
-    O
Anjou    O
may    O
display    O
the    O
genetic    O
myostatin    B-Hormone105407119
deficiency    O
which    O
produces    O
"    O
double    O
muscling    O
"    O
,    O
but    O
has    O
not    O
been    O
selectively    O
bred    O
for    O
this    O
attribute    O
.    O

There    O
is    O
some    O
research    O
indicating    O
that    O
satellite    O
cells    O
are    O
negatively    O
regulated    O
by    O
a    O
protein    O
called    O
myostatin    B-Hormone105407119
.    O

Another    O
approach    O
to    O
increasing    O
meat    O
production    O
in    O
GM    O
fish    O
is    O
"    O
double    B-Hormone105407119
muscling    I-Hormone105407119
"    O
.    O

It    O
is    O
achieved    O
by    O
using    O
transgenes    O
expressing    O
follistatin    O
,    O
which    O
inhibits    O
myostatin    B-Hormone105407119
,    O
and    O
the    O
development    O
of    O
two    O
muscle    O
layers    O
.    O

Humans    O
are    O
widely    O
thought    O
to    O
be    O
one    O
of    O
the    O
fastest    O
muscle    O
growing    O
organisms    O
due    O
to    O
surplus    O
of    O
calories    O
,    O
specialized    O
amino    O
acids    O
,    O
and    O
one    O
of    O
the    O
lowest    O
amounts    O
of    O
myostatin    B-Hormone105407119
in    O
the    O
animal    O
kingdom    O
.    O

6-Hydroxydopamine    B-Hormone105407119
(    O
oxidopamine    O
)    O

Injection    O
of    O
the    O
neurotoxin    O
6-hydroxydopamine    B-Hormone105407119
to    O
dopaminergic    O
parts    O
of    O
the    O
basal    O
ganglia    O
as    O
an    O
animal    O
model    O
of    O
Parkinson    O
's    O
disease    O
.    O

Omigapil    O
has    O
an    O
active    O
concentration    O
range    O
from    O
about    O
10−12    O
M    O
to    O
10−5    O
M    O
,    O
with    O
a    O
maximum    O
at    O
about    O
10−9    O
M.    O
Omigapil    O
prevents    O
neurodegeneration    O
in    O
facial    O
motor    O
neuron    O
axotomy    O
animal    O
models    O
as    O
well    O
as    O
mouse    O
models    O
of    O
progressive    O
motor    O
neuronopathy    O
,    O
MPTP    O
-    O
induced    O
nigrostriatal    O
degeneration    O
,    O
and    O
oxidopamine    B-Hormone105407119
-    O
induced    O
neuronal    O
injury    O
.    O

Alclometasone    B-Hormone105407119
=    O
7α-chloro-11β,17α,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione    O

It    O
is    O
a    O
tropic    B-Hormone105407119
,    O
tripeptidal    B-Hormone105407119
hormone    I-Hormone105407119
.    O

Adrenocorticotropic    O
hormone    O
(    O
ACTH    O
,    O
also    O
adrenocorticotropin    O
,    O
corticotropin    O
)    O
is    O
a    O
polypeptide    O
tropic    B-Hormone105407119
hormone    I-Hormone105407119
produced    O
and    O
secreted    O
by    O
the    O
anterior    O
pituitary    O
gland    O
.    O

CRF2    O
receptors    O
are    O
activated    O
by    O
two    O
structurally    O
similar    O
peptides    O
,    O
urocortin    B-Hormone105407119
II    I-Hormone105407119
and    O
urocortin    B-Hormone105407119
III    I-Hormone105407119
,    O
as    O
well    O
as    O
CRH    O
.    O

Another    O
is    O
the    O
finding    O
of    O
a    O
transthyretin    B-Hormone105407119
(    O
thyroxine    O
transport    O
)    O
problem    O
in    O
the    O
cerebrospinal    O
fluid    O
of    O
some    O
patients    O
diagnosed    O
with    O
schizophrenia    O
.    O

Transthyretin    B-Hormone105407119
(    O
TTR    B-Hormone105407119
)    O
is    O
a    O
transport    O
protein    O
in    O
the    O
serum    O
and    O
cerebrospinal    O
fluid    O
that    O
carries    O
the    O
thyroid    O
hormone    O
thyroxine    O
(    O
T4    O
)    O
and    O
retinol    O
-    O
binding    O
protein    O
bound    O
to    O
retinol    O
.    O

The    O
ependymal    O
cells    O
of    O
the    O
SCO    O
,    O
are    O
also    O
involved    O
in    O
the    O
production    O
of    O
brain    O
transthyretin    B-Hormone105407119
,    O
which    O
is    O
a    O
protein    O
involved    O
in    O
the    O
transport    O
of    O
thyroid    O
hormones    O
in    O
blood    O
and    O
also    O
plays    O
a    O
role    O
in    O
transporting    O
the    O
cerebrospinal    O
fluid    O
.    O

Transthyretin    B-Hormone105407119
→    O
-    O

In    O
the    O
second    O
minor    O
pathway    O
,    O
it    O
is    O
bound    O
to    O
Retinol    O
Binding    O
Protein    O
(    O
RBP    O
)    O
and    O
Transthyretin    B-Hormone105407119
,    O
which    O
prevents    O
its    O
filtration    O
in    O
the    O
glomeruli    O
.    O

Partially    O
denatured    O
Transthyretin    B-Hormone105407119
(    O
TTR    O
)    O
can    O
promote    O
the    O
formation    O
of    O
amyloid    O
fibrils    O
in    O
cells    O
,    O
and    O
this    O
aggregation    O
can    O
lead    O
to    O
cellular    O
toxicity    O
and    O
a    O
variety    O
of    O
human    O
disease    O
pathologies    O
.    O

Congenital    O
malformation    O
syndromes    O
involving    O
early    O
overgrowth    B-Hormone105407119

A    O
number    O
of    O
other    O
overgrowth    B-Hormone105407119
syndrome    I-Hormone105407119
can    O
result    O
in    O
similar    O
problems    O
.    O

Good    O
was    O
pulled    O
from    O
his    O
initial    O
UFC    O
debut    O
on    O
November    O
12    O
,    O
2016    O
at    O
UFC    O
205    O
from    O
a    O
USADA    O
voilation    O
stemming    O
from    O
an    O
out    O
-    O
of    O
-    O
competition    O
sample    O
collected    O
ten    O
days    O
earlier    O
where    O
by    O
Good    O
ingested    O
1-androstenedione    B-Hormone105407119
and    O
he    O
was    O
given    O
a    O
six    O
month    O
ban    O
.    O

1-Androstenedione    B-Hormone105407119

Trestolone    B-Hormone105407119

Trestolone    B-Hormone105407119
(    O
MENT    O
;    O
7α-methyl-19-NT    O
)    O

Xenoestrogens    O
are    O
a    O
type    O
of    O
xenohormone    B-Hormone105407119
that    O
imitates    O
estrogen    O
.    O

Aldosterone    O
synthase    O
converts    O
11-deoxycorticosterone    B-Hormone105407119
to    O
corticosterone    O
,    O
to    O
18-hydroxycorticosterone    B-Hormone105407119
,    O
and    O
finally    O
to    O
aldosterone    O
:    O

In    O
the    O
potential    O
case    O
where    O
aldosterone    O
synthase    O
is    O
not    O
metabolically    O
active    O
the    O
body    O
accumulates    O
11-deoxycorticosterone    B-Hormone105407119
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
11-deoxycorticosterone    B-Hormone105407119
,    O
and    O
one    O
product    O
,    O
20-hydroxy-3-oxopregn-4-en-21-al    O
.    O

Fludrocortisone    B-Hormone105407119
acetate    I-Hormone105407119
and    O
deoxycorticosterone    B-Hormone105407119
acetate    I-Hormone105407119
are    O
,    O
by    O
definition    O
,    O
mineralocorticoids    O
rather    O
than    O
glucocorticoids    O
,    O
but    O
they    O
do    O
have    O
minor    O
glucocorticoid    O
potency    O
and    O
are    O
included    O
in    O
this    O
table    O
to    O
provide    O
perspective    O
on    O
mineralocorticoid    O
potency    O
.    O

New    O
York    O
New    O
York    O
Yankees    O
outfielder    O
Matt    O
Lawton    O
tested    O
positive    O
for    O
boldenone    B-Hormone105407119
,    O
in    O
violation    O
of    O
Major    O
League    O
Baseball    O
drug    O
policy    O
,    O
and    O
will    O
be    O
suspended    O
for    O
the    O
first    O
ten    O
games    O
of    O
the    O
2006    O
season    O
.    O

Anabolic    O
androgenic    O
steroid    O
(    O
AAS    O
)    O
use    O
can    O
also    O
increase    O
the    O
amount    O
of    O
RBCs    O
and    O
,    O
therefore    O
,    O
impact    O
the    O
hematocrit    O
,    O
in    O
particular    O
the    O
compounds    O
boldenone    B-Hormone105407119
and    O
oxymetholone    B-Hormone105407119
.    O

Boldenone    B-Hormone105407119
,    O
also    O
known    O
as    O
Δ1-testosterone    B-Hormone105407119
,    O
is    O
a    O
synthetic    O
anabolic-androgenic    B-Hormone105407119
steroid    I-Hormone105407119
(    O
AAS    O
)    O
and    O
the    O
1(2)-dehydrogenated    O
analogue    O
of    O
testosterone    O
.    O

Boldenone    B-Hormone105407119

The    O
drug    O
is    O
also    O
the    O
17α-methylated    O
derivative    O
of    O
boldenone    B-Hormone105407119
(    O
δ1-testosterone    O
)    O
and    O
the    O
δ1    O
analogue    O
of    O
methyltestosterone    O
(    O
17α-methyltestosterone    O
)    O
.    O

In    O
February    O
2012    O
,    O
Thompson    O
,    O
alongside    O
Comunicaciones    O
teammates    O
Adolfo    O
Machado    O
and    O
Marvin    O
Ceballos    O
,    O
was    O
temporarily    O
suspended    O
from    O
playing    O
by    O
FIFA    O
after    O
a    O
positive    O
test    O
on    O
the    O
banned    O
substance    O
boldenone    B-Hormone105407119
.    O

Alclometasone    O
dipropionate    O
,    O
betamethasone    B-Hormone105407119
dipropionate    I-Hormone105407119
,    O
betamethasone    O
valerate    O
,    O
clobetasol    B-Hormone105407119
propionate    I-Hormone105407119
,    O
clobetasone    O
butyrate    O
,    O
fluprednidene    B-Hormone105407119
acetate    I-Hormone105407119
,    O
and    O
mometasone    B-Hormone105407119
furoate    I-Hormone105407119
.    O

Gastric    B-Hormone105407119
inhibitory    I-Hormone105407119
polypeptide    I-Hormone105407119
(    O
GIP    O
)    O

Inhibitory    O
factors    O
:    O
gastric    B-Hormone105407119
inhibitory    I-Hormone105407119
peptide    I-Hormone105407119
(    O
GIP    O
)    O
,    O
secretin    B-Hormone105407119
,    O
somatostatin    B-Hormone105407119
,    O
glucagon    O
,    O
calcitonin    O

Other    O
substances    O
known    O
to    O
stimulate    O
insulin    O
release    O
include    O
the    O
amino    O
acids    O
arginine    O
and    O
leucine    O
,    O
parasympathetic    O
release    O
of    O
acetylcholine    O
(    O
acting    O
via    O
the    O
phospholipase    O
C    O
pathway    O
)    O
,    O
sulfonylurea    O
,    O
cholecystokinin    O
(    O
CCK    O
,    O
also    O
via    O
phospholipase    O
C    O
)    O
,    O
and    O
the    O
gastrointestinally    O
derived    O
incretins    B-Hormone105407119
,    O
such    O
as    O
glucagon-like    B-Hormone105407119
peptide-1    I-Hormone105407119
(    O
GLP-1    O
)    O
and    O
glucose-dependent    B-Hormone105407119
insulinotropic    I-Hormone105407119
peptide    I-Hormone105407119
(    O
GIP    O
)    O
.    O

K    O
cells    O
secrete    O
gastric    B-Hormone105407119
inhibitory    I-Hormone105407119
peptide    I-Hormone105407119
,    O
an    O
incretin    B-Hormone105407119
,    O
which    O
also    O
promotes    O
triglyceride    O
storage    O
.    O

Gastric    B-Hormone105407119
inhibitory    I-Hormone105407119
peptide    I-Hormone105407119
(    O
GIP    O
)    O
is    O
produced    O
by    O
the    O
mucosal    O
duodenal    O
cells    O
in    O
response    O
to    O
chyme    O
containing    O
high    O
amounts    O
of    O
carbohydrate    O
,    O
proteins    O
,    O
and    O
fatty    O
acids    O
.    O

norgestrienone    B-Hormone105407119
(    O
INN    O
)    O

:    O
G03AC07    O
Norgestrienone    B-Hormone105407119

"    O
gastrin-34    B-Hormone105407119
"    O
(    O
"    O
big    B-Hormone105407119
gastrin    I-Hormone105407119
"    O
)    O

Selective    B-Hormone105407119
progesterone    I-Hormone105407119
receptor    I-Hormone105407119
modulator    I-Hormone105407119

Examples    O
include    O
Selective    O
Androgen    O
Receptor    O
Modulators    O
(    O
SARMs    O
)    O
,    O
Selective    O
Estrogen    O
Receptor    O
Modulators    O
(    O
SERM    B-Hormone105407119
)    O
and    O
Selective    O
Progesterone    O
Receptor    O
Modulators    O
(    O
SPRM    B-Hormone105407119
)    O
.    O

It    O
is    O
a    O
selective    B-Hormone105407119
progesterone    I-Hormone105407119
receptor    I-Hormone105407119
modulator    I-Hormone105407119
(    O
SPRM    O
)    O
.    O

Anabolic    O
androgenic    O
steroid    O
(    O
AAS    O
)    O
use    O
can    O
also    O
increase    O
the    O
amount    O
of    O
RBCs    O
and    O
,    O
therefore    O
,    O
impact    O
the    O
hematocrit    O
,    O
in    O
particular    O
the    O
compounds    O
boldenone    B-Hormone105407119
and    O
oxymetholone    B-Hormone105407119
.    O

Oxymetholone    B-Hormone105407119

Oxymetholone    B-Hormone105407119

Prostanozol    B-Hormone105407119
–    O
17β-tetrahydropyran    O
ether    O
of    O
the    O
17α-demethylated    O
analogue    O
of    O
stanozolol    B-Hormone105407119

In    O
humans    O
and    O
primates    O
it    O
also    O
produces    O
GnRH    B-Hormone105407119
.    O

This    O
nucleus    O
has    O
been    O
shown    O
to    O
affect    O
the    O
release    O
of    O
GnRH(Gonadotropin-Releasing    B-Hormone105407119
Hormone)    I-Hormone105407119
in    O
several    O
ways    O
.    O

gonadotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
(    O
GnRH    O
)    O
secreted    O
by    O
the    O
hypothalamus    O

Gonadotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
(    O
GnRH    O
)    O
analogues    O
are    O
another    O
very    O
effective    O
option    O
for    O
antiandrogen    O
therapy    O
,    O
but    O
have    O
not    O
been    O
widely    O
employed    O
for    O
this    O
purpose    O
due    O
to    O
their    O
high    O
cost    O
and    O
limited    O
insurance    O
coverage    O
despite    O
many    O
now    O
being    O
available    O
as    O
generics    O
.    O

Gonadotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119

The    O
underlying    O
cause    O
of    O
the    O
failure    O
in    O
production    O
of    O
LH    O
and    O
FSH    O
is    O
the    O
impairment    O
of    O
the    O
hypothalamus    O
to    O
release    O
the    O
hormone    O
GnRH    B-Hormone105407119
which    O
in    O
normal    O
circumstances    O
induces    O
the    O
production    O
of    O
LH    O
and    O
FSH    O
.    O

Normally    O
the    O
hypothalamus    O
releases    O
a    O
hormone    O
called    O
gonadotropin    B-Hormone105407119
releasing    I-Hormone105407119
hormone    I-Hormone105407119
(    O
GnRH    O
)    O
.    O

Degarelix    O
has    O
an    O
immediate    O
onset    O
of    O
action    O
,    O
binding    O
to    O
gonadotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
(    O
GnRH    O
)    O
receptors    O
in    O
the    O
pituitary    O
gland    O
and    O
blocking    O
their    O
interaction    O
with    O
GnRH    O
.    O

GnRH    O
antagonists    O
compete    O
with    O
natural    O
GnRH    O
for    O
binding    O
to    O
GnRH    B-Hormone105407119
receptors    O
in    O
the    O
pituitary    O
gland    O
.    O

Deslorelin    O
acetate    O
is    O
an    O
injectable    O
gonadotropin    B-Hormone105407119
releasing    I-Hormone105407119
hormone    I-Hormone105407119
super    O
-    O
agonist    O
(    O
GnRH    O
agonist    O
)    O
also    O
known    O
as    O
an    O
LHRH    O
agonist    O
.    O

Deslorelin    O
is    O
a    O
synthetic    O
analogue    O
of    O
a    O
naturally    O
occurring    O
luteinising    O
-    O
hormone    O
releasing    O
hormone    O
(    O
LHRH    B-Hormone105407119
)    O
.    O

the    O
preoptic    O
area    O
(    O
where    O
LHRH    B-Hormone105407119
neurons    O
are    O
located    O
)    O

#    O
Progesterone    O
suppresses    O
the    O
release    O
of    O
GnRH    B-Hormone105407119
.    O

Physiologically    O
,    O
the    O
exposure    O
to    O
male    O
urine    O
induces    O
the    O
release    O
of    O
GnRH    B-Hormone105407119
,    O
which    O
provokes    O
the    O
first    O
estrus    O
.    O

Examples    O
of    O
progonadotropic    O
drugs    O
include    O
gonadotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
(    O
GnRH    O
)    O
agonists    O
when    O
administered    O
in    O
a    O
pulsatile    O
(    O
as    O
opposed    O
to    O
continuous    O
)    O
manner    O
,    O
antiestrogens    O
such    O
as    O
tamoxifen    O
,    O
clomifene    O
,    O
fulvestrant    O
,    O
and    O
aromatase    O
inhibitors    O
like    O
anastrozole    O
,    O
and    O
,    O
only    O
in    O
men    O
,    O
pure    O
antiandrogen    B-Hormone105407119
such    O
as    O
flutamide    O
,    O
bicalutamide    O
,    O
and    O
enzalutamide    O
.    O

Ghrelin    O
has    O
inhibitory    O
effects    O
on    O
gonadotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
(    O
GnRH    O
)    O
secretion    O
.    O

Insulin    O
also    O
has    O
stimulatory    O
effects    O
on    O
gonadotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
from    O
the    O
hypothalamus    O
,    O
thus    O
favoring    O
fertility    O
.    O

GnRH    B-Hormone105407119
and    O
gonadotropins    O
(    O
FSH    O
and    O
LH    O
)    O

It    O
is    O
colored    O
as    O
a    O
result    O
of    O
concentrating    O
carotenoids    O
(    O
including    O
lutein    O
)    O
from    O
the    O
diet    O
and    O
secretes    O
a    O
moderate    O
amount    O
of    O
estrogen    O
to    O
inhibit    O
further    O
release    O
of    O
gonadotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
(    O
GnRH    O
)    O
and    O
thus    O
secretion    O
of    O
luteinizing    O
hormone    O
(    O
LH    O
)    O
and    O
follicle    O
-    O
stimulating    O
hormone    O
(    O
FSH    O
)    O
.    O

Prolactin    O
within    O
the    O
normal    O
reference    O
ranges    O
can    O
act    O
as    O
a    O
weak    O
gonadotropin    O
,    O
but    O
at    O
the    O
same    O
time    O
suppresses    O
GnRH    B-Hormone105407119
secretion    O
.    O

Leptin    O
is    O
involved    O
in    O
reproduction    O
by    O
stimulating    O
gonadotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
from    O
the    O
hypothalamus    O
.    O

In    O
humans    O
,    O
via    O
white    O
adipocytes    O
(    O
fat    O
cells    O
)    O
,    O
production    O
of    O
the    O
hormone    O
leptin    B-Hormone105407119
(    O
an    O
adipokine    O
)    O
acts    O
on    O
the    O
hypothalamus    O
where    O
reproductive    O
hormone    O
Gonadotrophin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
(    O
GnRH    O
)    O
is    O
produced    O
.    O

Gonadotropin    O
-    O
releasing    O
hormone    O
(    O
GnRH    B-Hormone105407119
)    O
:    O
regulates    O
the    O
release    O
of    O
follicle    O
stimulating    O
hormone    O
and    O
luteinizing    O
hormone    O
from    O
the    O
anterior    O
pituitary    O
;    O
this    O
pathway    O
plays    O
a    O
critical    O
role    O
in    O
reproductive    O
activity    O
and    O
development    O

This    O
can    O
also    O
be    O
accomplished    O
with    O
progestational    O
agents    O
(    O
i.e.    O
,    O
medroxyprogesterone    B-Hormone105407119
acetate    I-Hormone105407119
)    O
,    O
danazol    B-Hormone105407119
,    O
gestrinone    B-Hormone105407119
,    O
or    O
gonadotropin    O
-    O
releasing    O
hormone    O
agonists    O
(    O
GnRH    B-Hormone105407119
)    O
,    O
as    O
well    O
as    O
other    O
less    O
well    O
-    O
known    O
agents    O
.    O

Endocrine    O
systems    O
controlled    O
by    O
the    O
hypothalamus    O
are    O
regulated    O
by    O
anti    O
-    O
diuretic    O
hormone    O
(    O
ADH    O
)    O
,    O
corticotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
,    O
gonadotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
,    O
growth    B-Hormone105407119
hormone-releasing    I-Hormone105407119
hormone    I-Hormone105407119
,    O
oxytocin    O
,    O
all    O
of    O
which    O
are    O
secreted    O
by    O
the    O
hypothalamus    O
.    O

CCAP    O
has    O
several    O
functions    O
including    O
regulating    O
heart    O
rate    O
,    O
allatostatin    B-Hormone105407119
and    O
proctolin    O
regulate    O
food    O
intake    O
and    O
growth    O
,    O
bursicon    B-Hormone105407119
controls    O
tanning    O
of    O
the    O
cuticle    O
and    O
corazonin    O
has    O
a    O
role    O
in    O
cuticle    O
pigmentation    O
and    O
moulting    O
.    O

It    O
is    O
the    O
C17β    O
ester    O
metenolone    B-Hormone105407119
,    O
which    O
itself    O
is    O
1-methyl-δ1    O
-    O
4,5α-dihydrotestosterone    O
(    O
1-methyl-δ1-DHT    O
)    O
or    O
1-methyl-5α-androst-1-en-17β-ol-3-one    O
.    O

In    O
2005    O
,    O
she    O
received    O
a    O
two    O
-    O
year    O
ban    O
from    O
the    O
track    O
due    O
to    O
positive    O
testing    O
for    O
illegal    O
substance    O
Metenolone    B-Hormone105407119
.    O

On    O
13    O
August    O
2012    O
,    O
the    O
International    O
Olympic    O
Committee    O
stripped    O
shot    O
putter    O
Nadzeya    O
Astapchuk    O
of    O
her    O
gold    O
medal    O
after    O
testing    O
positive    O
for    O
the    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
metenolone    B-Hormone105407119
,    O
and    O
the    O
gold    O
medal    O
was    O
subsequently    O
awarded    O
to    O
silver    O
medalist    O
Valerie    O
Adams    O
from    O
New    O
Zealand    O
.    O

On    O
August    O
13    O
,    O
International    O
Olympic    O
Committee    O
decided    O
the    O
shot    O
putter    O
Nadzeya    O
Astapchuk    O
,    O
the    O
nation    O
's    O
only    O
track    O
and    O
field    O
medalist    O
,    O
to    O
strip    O
off    O
her    O
gold    O
medal    O
at    O
the    O
London    O
games    O
after    O
she    O
was    O
tested    O
positive    O
for    O
the    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
metenolone    B-Hormone105407119
.    O

Methenolone    B-Hormone105407119

Metenolone    B-Hormone105407119
,    O
or    O
methenolone    B-Hormone105407119
,    O
also    O
known    O
as    O
methylandrostenolone    B-Hormone105407119
,    O
is    O
a    O
synthetic    O
,    O
orally    O
active    O
anabolic-androgenic    B-Hormone105407119
steroid    I-Hormone105407119
(    O
AAS    O
)    O
and    O
a    O
derivative    O
of    O
dihydrotestosterone    B-Hormone105407119
(    O
DHT    O
)    O
.    O

Steroid    B-Hormone105407119
atrophy    I-Hormone105407119

In    O
those    O
in    O
whom    O
surgery    O
is    O
not    O
effective    O
,    O
medications    O
of    O
the    O
somatostatin    B-Hormone105407119
analogue    I-Hormone105407119
or    O
GH    O
receptor    O
antagonist    O
type    O
may    O
be    O
used    O
.    O

These    O
somatostatin    O
analogues    O
are    O
synthetic    O
forms    O
of    O
a    O
brain    O
hormone    O
,    O
somatostatin    B-Hormone105407119
,    O
which    O
stops    O
GH    O
production    O
.    O

In    O
some    O
cases    O
,    O
octreotide    O
treatment    O
can    O
cause    O
diabetes    O
due    O
to    O
the    O
fact    O
that    O
somatostatin    B-Hormone105407119
and    O
its    O
analogues    O
can    O
inhibit    O
the    O
release    O
of    O
insulin    O
.    O

Surgery    O
,    O
radiotherapy    O
,    O
somatostatin    B-Hormone105407119
analogue    I-Hormone105407119
and    O
dopamine    O
agonists    O
act    O
at    O
the    O
level    O
of    O
the    O
pituitary    O
adenoma    O
,    O
while    O
GH    O
receptor    O
antagonists    O
act    O
in    O
periphery    O
by    O
blocking    O
the    O
growth    O
hormone    O
receptor    O
and    O
thus    O
impairing    O
the    O
effects    O
of    O
GH    O
on    O
the    O
different    O
tissues    O
.    O

Human    O
growth    O
hormone    O
(    O
HGH    O
)    O
,    O
also    O
referred    O
to    O
as    O
'    O
growth    O
hormone    O
'    O
(    O
GH    O
)    O
,    O
and    O
also    O
as    O
somatotropin    O
,    O
is    O
released    O
under    O
the    O
influence    O
of    O
hypothalamic    O
growth    B-Hormone105407119
hormone-releasing    I-Hormone105407119
hormone    I-Hormone105407119
(    O
GHRH    O
)    O
,    O
and    O
is    O
inhibited    O
by    O
hypothalamic    O
somatostatin    B-Hormone105407119

somatostatin    B-Hormone105407119
release    O

the    O
periventricular    O
nucleus    O
(    O
where    O
somatostatin    B-Hormone105407119
neurons    O
are    O
located    O
)    O

Somatostatin    B-Hormone105407119
is    O
also    O
produced    O
by    O
the    O
hypothalamus    O
,    O
and    O
has    O
an    O
opposite    O
effect    O
on    O
the    O
pituitary    O
production    O
of    O
TSH    O
,    O
decreasing    O
or    O
inhibiting    O
its    O
release    O
.    O

Francisco    O
Gonzalo    O
Bolívar    O
Zapata    O
,    O
Prince    O
of    O
Asturias    O
awardee    O
in    O
1991    O
,    O
developed    O
molecular    O
biology    O
-    O
based    O
techniques    O
used    O
to    O
produce    O
insulin    O
and    O
somatostatin    B-Hormone105407119
.    O

Hormones    O
secreted    O
include    O
somatostatin    B-Hormone105407119
,    O
motilin    O
,    O
cholecystokinin    O
,    O
neurotensin    O
,    O
vasoactive    B-Hormone105407119
intestinal    I-Hormone105407119
peptide    I-Hormone105407119
,    O
and    O
enteroglucagon    B-Hormone105407119
.    O

Other    O
hormones    O
produced    O
include    O
cholecystokinin    O
,    O
somatostatin    B-Hormone105407119
,    O
vasoactive    B-Hormone105407119
intestinal    I-Hormone105407119
peptide    I-Hormone105407119
,    O
substance    O
P    O
,    O
alpha    O
and    O
gamma    O
-    O
endorphin    O
.    O

Other    O
hormones    O
produced    O
include    O
somatostatin    B-Hormone105407119
,    O
pancreatic    B-Hormone105407119
polypeptide    I-Hormone105407119
,    O
amylin    B-Hormone105407119
and    O
ghrelin    O
.    O

Because    O
neprilysin    O
is    O
thought    O
to    O
be    O
the    O
rate    O
-    O
limiting    O
step    O
in    O
amyloid    O
beta    O
degradation    O
,    O
it    O
has    O
been    O
considered    O
a    O
potential    O
therapeutic    O
target    O
;    O
compounds    O
such    O
as    O
the    O
peptide    B-Hormone105407119
hormone    I-Hormone105407119
somatostatin    B-Hormone105407119
have    O
been    O
identified    O
that    O
increase    O
the    O
enzyme    O
's    O
activity    O
level    O
.    O

Its    O
secretion    O
in    O
humans    O
is    O
increased    O
after    O
a    O
protein    O
meal    O
,    O
fasting    O
,    O
exercise    O
,    O
and    O
acute    O
hypoglycemia    O
and    O
is    O
decreased    O
by    O
somatostatin    B-Hormone105407119
and    O
intravenous    O
glucose    O
.    O

Although    O
structurally    O
similar    O
to    O
somatostatin    O
receptors    O
,    O
this    O
protein    O
does    O
not    O
seem    O
to    O
bind    O
somatostatin    B-Hormone105407119
.    O

It    O
is    O
primarily    O
used    O
if    O
the    O
pituitary    O
gland    O
tumor    O
causing    O
the    O
acromegaly    O
can    O
not    O
be    O
controlled    O
with    O
surgery    O
or    O
radiation    O
,    O
and    O
the    O
use    O
of    O
somatostatin    B-Hormone105407119
analogues    O
is    O
unsuccessful    O
,    O
but    O
is    O
also    O
effective    O
as    O
a    O
monotherapy    O
.    O

Some    O
evidence    O
also    O
suggests    O
that    O
somatostatin    B-Hormone105407119
can    O
be    O
an    O
effective    O
treatment    O
with    O
respect    O
to    O
reducing    O
closure    O
time    O
and    O
improving    O
the    O
spontaneous    O
closure    O
rate    O
of    O
enterocutaneous    O
fistulas    O
.    O

Octreotide    B-Hormone105407119
or    O
Lanreotide    O
(    O
somatostatin    B-Hormone105407119
analogues    O
)    O
may    O
decrease    O
the    O
secretory    O
activity    O
of    O
the    O
carcinoid    O
,    O
and    O
may    O
also    O
have    O
an    O
anti    O
-    O
proliferative    O
effect    O
.    O

Somatotrophic    O
adenomas    O
respond    O
to    O
octreotide,    B-Hormone105407119
a    I-Hormone105407119
long-acting    I-Hormone105407119
somatostatin    I-Hormone105407119
analog    I-Hormone105407119
,    O
in    O
many    O
but    O
not    O
all    O
cases    O
according    O
to    O
a    O
review    O
of    O
the    O
medical    O
literature    O
.    O

Even    O
in    O
adults    O
it    O
continues    O
to    O
play    O
a    O
role    O
in    O
the    O
regulation    O
and    O
expression    O
of    O
genes    O
for    O
insulin    O
,    O
GLUT2    O
,    O
glucokinase    O
,    O
and    O
somatostatin    B-Hormone105407119
.    O

Somatostatin    B-Hormone105407119
is    O
a    O
hormone    O
produced    O
by    O
the    O
mucosal    O
cells    O
of    O
the    O
duodenum    O
and    O
also    O
the    O
"    O
delta    O
cells    O
"    O
of    O
the    O
pancreas    O
.    O

Quinestrol    B-Hormone105407119

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-Hormone105407119
)    O
,    O
desogestrel    B-Hormone105407119
,    O
ethylestrenol    B-Hormone105407119
,    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
ethinylestradiol    O
,    O
gestrinone    B-Hormone105407119
,    O
levonorgestrel    B-Hormone105407119
,    O
norethisterone    B-Hormone105407119
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    B-Hormone105407119
)    O
,    O
quinestrol    B-Hormone105407119
,    O
19-norprogesterone    B-Hormone105407119
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-Hormone105407119
acetate    I-Hormone105407119
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
.    O

It    O
is    O
the    O
most    O
abundant    O
neuropeptide    O
in    O
endocrine    O
cells    O
of    O
insect    O
alimentary    O
tracts    O
along    O
with    O
allatostatin    B-Hormone105407119
and    O
tachykinin    O
families    O
,    O
however    O
the    O
neuropeptide    O
’s    O
function    O
is    O
not    O
known    O
.    O

Fibronectin    B-Hormone105407119
type    I-Hormone105407119
III    I-Hormone105407119
domain-containing    I-Hormone105407119
protein    I-Hormone105407119
5    I-Hormone105407119
,    O
the    O
precursor    O
of    O
irisin    B-Hormone105407119
,    O
is    O
a    O
protein    O
that    O
is    O
encoded    O
by    O
the    O
FNDC5    B-Hormone105407119
gene    O
.    O

One    O
drug    O
sponsored    O
by    O
Taiho    O
has    O
been    O
TAS-108    B-Hormone105407119
,    O
which    O
is    O
under    O
development    O
by    O
SRI    O
International    O
.    O

Kaushansky    O
K    O
,    O
Lok    O
S    O
,    O
Holly    O
RD    O
,    O
Broudy    O
VC    O
,    O
Lin    O
N    O
,    O
Bailey    O
MC    O
,    O
Forstrom    O
JW    O
,    O
Buddle    O
M    O
,    O
Oort    O
PJ    O
,    O
Hagen    O
FS    O
,    O
Roth    O
GJ    O
,    O
Papayannopoulou    O
Th    O
,    O
Foster    O
DC    O
:    O
Promotion    O
of    O
megakaryocyte    O
progenitor    O
expansion    O
and    O
differentiation    O
by    O
the    O
c    O
-    O
Mpl    O
ligand    O
thrombopoietin    B-Hormone105407119
.    O

Lok    O
S    O
,    O
Kaushansky    O
K    O
,    O
Holly    O
RD    O
,    O
Kuijper    O
JL    O
,    O
Lofton    O
-    O
Day    O
CE    O
,    O
Oort    O
PJ    O
,    O
Grant    O
FJ    O
,    O
Heipel    O
MD    O
,    O
Burkhead    O
SK    O
,    O
Kramer    O
JM    O
,    O
Bell    O
LA    O
,    O
Sprecher    O
CA    O
,    O
Blumberg    O
H    O
,    O
Johnson    O
R    O
,    O
Prunkard    O
D    O
,    O
Ching    O
AFT    O
,    O
Mathewes    O
S    O
,    O
Bailey    O
MC    O
,    O
Forstrom    O
JW    O
,    O
Buddle    O
MM    O
,    O
Osborn    O
SG    O
,    O
Evans    O
SJ    O
,    O
Sheppard    O
PO    O
,    O
Presnell    O
SR    O
,    O
O'Hara    O
PJ    O
,    O
Hagen    O
FS    O
,    O
Roth    O
GJ    O
.    O
,    O
Foster    O
DC    O
:    O
Cloning    O
and    O
expression    O
of    O
murine    O
thrombopoietin    B-Hormone105407119
cDNA    O
and    O
stimulation    O
of    O
platelet    O
production    O
in    O
vivo    O
.    O

Kaushansky    O
K    O
,    O
Broudy    O
VC    O
,    O
Lin    O
N    O
,    O
Jorgensen    O
MJ    O
,    O
McCarty    O
J    O
,    O
Fox    O
N    O
,    O
Zucker    O
-    O
Franklin    O
D    O
,    O
Lofton    O
-    O
Day    O
C    O
:    O
Thrombopoietin    B-Hormone105407119
,    O
the    O
Mpl    O
-    O
ligand    O
,    O
is    O
essential    O
for    O
full    O
megakaryocyte    O
development    O
.    O
"    O
Proc    O
.    O
Natl    O
.    O
Acad    O
.    O
Sci    O
.    O
USA    O
"    O
92:3234    O
-    O
3238    O
,    O
1995    O
.    O

Kaushansky    O
K    O
,    O
Broudy    O
,    O
VC    O
,    O
Grossmann    O
A    O
,    O
Humes    O
J    O
,    O
Lin    O
N    O
,    O
Ren    O
H    O
-    O
P    O
,    O
Bailey    O
MC    O
,    O
Papayannopoulou    O
Th    O
,    O
Forstrom    O
JW    O
,    O
Sprugel    O
KH    O
:    O
Thrombopoietin    B-Hormone105407119
expands    O
erythroid    O
progenitors    O
,    O
increases    O
red    O
cell    O
production    O
,    O
and    O
enhances    O
erythroid    O
recovery    O
after    O
myelosuppressive    O
therapy    O
.    O
"    O
J.    O
Clin    O
.    O
Invest    O
.    O
"    O

Hitchcock    O
I    O
,    O
Chen    O
M    O
,    O
Fox    O
NE    O
,    O
Kaushansky    O
K.    O
YRRL    O
motifs    O
in    O
the    O
cytoplasmic    O
domain    O
of    O
the    O
thrombopoietin    B-Hormone105407119
receptor    O
regulate    O
receptor    O
internalization    O
and    O
degradation    O
.    O

Kaushansky    O
K    O
:    O
Thrombopoietin:    B-Hormone105407119
Biological    I-Hormone105407119
and    I-Hormone105407119
preclinical    I-Hormone105407119
properties    I-Hormone105407119
.    O
"    O
Leukemia    O
"    O
10:Suppl    O
.    O
S46    O
-    O
48    O
,    O
1996    O

It    O
is    O
a    O
small    O
molecule    O
agonist    O
of    O
the    O
c    O
-    O
mpl    O
(    O
TpoR    O
)    O
receptor    O
,    O
which    O
is    O
the    O
physiological    O
target    O
of    O
the    O
hormone    O
thrombopoietin    B-Hormone105407119
.    O

"N","N"-Dimethyldopamine    B-Hormone105407119

For    O
the    O
11S    O
protein    O
,    O
glycinin    O
,    O
to    O
fold    O
properly    O
into    O
its    O
hexagonal    O
shape(containing    O
six    O
subunits    O
,    O
a    O
hexamer    O
)    O
,    O
it    O
must    O
undergo    O
a    O
very    O
limited    O
proteolysis    O
in    O
a    O
manner    O
similar    O
to    O
the    O
cleavage    O
of    O
a    O
peptide    O
from    O
proinsulin    B-Hormone105407119
to    O
obtain    O
active    O
insulin    O
.    O

Preproinsulin    O
is    O
a    O
proinsulin    B-Hormone105407119
molecule    O
with    O
a    O
signal    O
peptide    O
attached    O
to    O
its    O
N    O
-    O
terminus    O
.    O

Sachs    O
'    O
hypothesis    O
preceded    O
the    O
discovery    O
of    O
proinsulin    B-Hormone105407119
by    O
3    O
years    O
,    O
and    O
his    O
research    O
laid    O
the    O
foundation    O
for    O
understanding    O
the    O
biosynthesis    O
of    O
all    O
brain    O
peptides    O
and    O
many    O
proteins    O
,    O
which    O
are    O
major    O
constituents    O
involved    O
in    O
brain    O
and    O
neuroendocrine    O
functions    O
.    O

Prostacyclin    O
(    O
also    O
called    O
prostaglandin    O
I2    O
or    O
PGI2    O
)    O
is    O
a    O
prostaglandin    O
member    O
of    O
the    O
eicosanoid    B-Hormone105407119
family    O
of    O
lipid    O
molecules    O
.    O

Since    O
thromboxane    O
(    O
an    O
eicosanoid    B-Hormone105407119
stimulator    O
of    O
platelet    O
aggregation    O
)    O
is    O
also    O
downstream    O
of    O
COX    O
enzymes    O
,    O
one    O
might    O
think    O
that    O
the    O
effect    O
of    O
NSAIDs    O
would    O
act    O
to    O
balance    O
.    O

Thromboxane    O
is    O
a    O
member    O
of    O
the    O
family    O
of    O
lipids    O
known    O
as    O
eicosanoids    B-Hormone105407119
.    O

Virodhamine    O
(    O
O    O
"-    O
arachidonoyl    O
ethanolamine    O
;    O
"    O
'    O
O    O
-    O
AEA    O
)    O
is    O
an    O
endocannabinoid    O
and    O
a    O
nonclassic    O
eicosanoid    B-Hormone105407119
,    O
derived    O
from    O
arachidonic    O
acid    O
.    O
"    O

This    O
polyunsaturated    O
fatty    O
acid    O
is    O
metabolized    O
by    O
cyclooxygenases    O
to    O
various    O
prostaglandin    O
,    O
thromboxane    O
,    O
and    O
prostacyclin    O
metabolites    O
in    O
what    O
has    O
been    O
termed    O
the    O
first    O
pathway    O
of    O
eicosanoid    B-Hormone105407119
production    O
;    O
it    O
is    O
also    O
metabolized    O
by    O
various    O
lipoxygenases    O
to    O
hydroxyeicosatetraenoic    O
acids    O
(    O
e.g.    O
5-Hydroxyeicosatetraenoic    O
acid    O
,    O
12-Hydroxyeicosatetraenoic    O
acid    O
,    O
15-hydroxyicosatetraenoic    O
acid    O
)    O
and    O
leukotrienes    B-Hormone105407119
(    O
e.g.    O
leukotriene    O
B4    O
,    O
leukotriene    O
C4    O
)    O
in    O
what    O
has    O
been    O
termed    O
the    O
second    O
pathway    O
of    O
eicosanoid    O
production    O
.    O

HxA3    O
,    O
HxB3    O
,    O
and    O
their    O
isomers    O
are    O
distinguished    O
from    O
most    O
other    O
eicosanoid    B-Hormone105407119
(    O
i.e.    O
signaling    O
molecules    O
made    O
by    O
oxidation    O
of    O
20-carbon    O
fatty    O
acids    O
)    O
in    O
that    O
they    O
contain    O
both    O
epoxide    O
and    O
hydroxyl    O
residues    O
;    O
they    O
are    O
structurally    O
differentiated    O
in    O
particular    O
from    O
two    O
other    O
classes    O
of    O
arachidonic    O
acid    O
-    O
derived    O
eicosanoids    O
,    O
the    O
leukotriene    B-Hormone105407119
and    O
lipoxins    O
,    O
in    O
that    O
they    O
lack    O
conjugated    O
double    O
bonds    O
.    O
HxA4    O
and    O
HxB4    O
are    O
distinguished    O
from    O
HxA3    O
and    O
HxB3    O
by    O
possessing    O
four    O
rather    O
than    O
three    O
double    O
bonds    O
.    O

Fish    O
oils    O
contain    O
the    O
omega-3    O
fatty    O
acids    O
eicosapentaenoic    O
acid    O
(    O
EPA    O
)    O
and    O
docosahexaenoic    O
acid    O
(    O
DHA    O
)    O
,    O
precursors    O
of    O
certain    O
eicosanoid    B-Hormone105407119
that    O
are    O
known    O
to    O
reduce    O
inflammation    O
in    O
the    O
body    O
,    O
and    O
have    O
other    O
health    O
benefits    O
,    O
such    O
as    O
treating    O
hypertriglyceridemia    O
,    O
although    O
claims    O
of    O
preventing    O
heart    O
attacks    O
or    O
strokes    O
have    O
not    O
been    O
supported    O
.    O

Inflammation    O
is    O
produced    O
by    O
eicosanoid    B-Hormone105407119
and    O
cytokines    O
,    O
which    O
are    O
released    O
by    O
injured    O
or    O
infected    O
cells    O
.    O

15-Hydroxyeicosatetraenoic    O
acid    O
(    O
also    O
termed    O
15-HETE    O
,    O
15("S")-HETE    O
,    O
and    O
15"S    O
"-    O
HETE    O
)    O
is    O
an    O
eicosanoid    B-Hormone105407119
,    O
i.e.    O
a    O
metabolite    O
of    O
arachidonic    O
acid    O
.    O

both    O
suppresses    O
phospholipase    O
A2    O
,    O
thereby    O
blocking    O
eicosanoid    B-Hormone105407119
production    O
,    O
and    O
inhibits    O
various    O
leukocyte    O
inflammatory    O
events    O
(    O
epithelial    O
adhesion    O
,    O
emigration    O
,    O
chemotaxis    O
,    O
phagocytosis    O
,    O
respiratory    O
burst    O
,    O
etc    O
.    O
)    O
.    O

This    O
occurs    O
by    O
altering    O
the    O
metabolic    O
flux    O
of    O
platelet    O
's    O
eicosanoid    B-Hormone105407119
synthesis    O
pathway    O
,    O
which    O
involves    O
enzymes    O
phospholipase    O
A2    O
,    O
cyclo    O
-    O
oxygenase    O
1    O
,    O
and    O
thromboxane    O
-    O
A    O
synthase    O
.    O

Szczeklik    O
's    O
main    O
research    O
interest    O
included    O
:    O
cardiopulmonary    O
diseases    O
,    O
aspirin    O
-    O
induced    O
asthma    O
,    O
chemical    O
mediators    O
in    O
diseases    O
of    O
circulatory    O
and    O
respiratory    O
systems    O
with    O
special    O
reference    O
to    O
eicosanoid    B-Hormone105407119
.    O

The    O
resulting    O
substances    O
,    O
called    O
"    O
eicosanoid    B-Hormone105407119
"    O
:    O
prostaglandins    O
(    O
PG    O
)    O
,    O
leukotriene    B-Hormone105407119
(    O
LT    O
)    O
,    O
lipoxins    O
and    O
thromboxane    O
(    O
TX    O
)    O
;    O
and    O
docosanoids    O
:    O
resolvins    O
,    O
protectins    O
,    O
and    O
maresins    O
,    O
are    O
powerful    O
lipid    O
mediators    O
that    O
produce    O
specific    O
actions    O
in    O
the    O
organism    O
;    O
they    O
organize    O
inflammation    O
,    O
hemodynamic    O
,    O
immune    O
response    O
and    O
the    O
repair    O
of    O
tissue    O
.    O

Future    O
attacks    O
of    O
hereditary    O
angioedema    O
can    O
be    O
prevented    O
by    O
the    O
use    O
of    O
androgens    O
such    O
as    O
danazol    B-Hormone105407119
,    O
oxandrolone    B-Hormone105407119
or    O
methyltestosterone    O
.    O

Danazol    B-Hormone105407119
may    O
also    O
be    O
prescribed    O
to    O
treat    O
this    O
condition    O
and    O
it    O
is    O
usually    O
considered    O
in    O
patients    O
on    O
whom    O
the    O
non    O
-    O
medical    O
treatment    O
fails    O
and    O
the    O
symptoms    O
are    O
intense    O
.    O

Steroid    O
sulfatase    O
(    O
STS    O
)    O
inhibitors    O
such    O
as    O
estradiol    O
sulfamate    O
,    O
estrone    O
sulfamate    O
,    O
irosustat    O
,    O
and    O
danazol    B-Hormone105407119
inhibit    O
the    O
conversion    O
of    O
steroid    O
sulfates    O
such    O
as    O
estrone    B-Hormone105407119
sulfate    I-Hormone105407119
and    O
DHEA    O
sulfate    O
into    O
their    O
hormonally    O
active    O
forms    O
.    O

Danazol    B-Hormone105407119
is    O
a    O
steroid    O
compound    O
that    O
has    O
been    O
labelled    O
as    O
an    O
"    O
Anterior    O
pituitary    O
suppressant    O
"    O
.    O

This    O
can    O
also    O
be    O
accomplished    O
with    O
progestational    O
agents    O
(    O
i.e.    O
,    O
medroxyprogesterone    B-Hormone105407119
acetate    I-Hormone105407119
)    O
,    O
danazol    B-Hormone105407119
,    O
gestrinone    B-Hormone105407119
,    O
or    O
gonadotropin    O
-    O
releasing    O
hormone    O
agonists    O
(    O
GnRH    B-Hormone105407119
)    O
,    O
as    O
well    O
as    O
other    O
less    O
well    O
-    O
known    O
agents    O
.    O

Treatment(s    O
)    O
with    O
mixed    O
success    O
:    O
omalizumab    O
(    O
anti    O
-    O
IgE    O
therapy    O
)    O
,    O
danazol    B-Hormone105407119
(    O
synthetic    O
androgen    O
)    O
,    O
propranolol    O
(    O
beta    O
blocker    O
)    O
,    O
zileuton    O
(    O
antileukotriene    O
)    O
.    O

Hydroxycorticosteroids    B-Hormone105407119
(    O
OHCSs    B-Hormone105407119
)    O
are    O
corticosteroids    O
that    O
have    O
an    O
additional    O
hydroxy    O
(    O
-OH    O
)    O
group    O
.    O

Signalling    O
molecules    O
released    O
by    O
adipose    O
tissue    O
are    O
referred    O
to    O
as    O
adipokine    B-Hormone105407119
.    O

These    O
fatty    O
acids    O
can    O
be    O
released    O
by    O
adipokine    B-Hormone105407119
signaling    O
of    O
high    O
glucagon    O
and    O
epinephrine    O
levels    O
,    O
which    O
inversely    O
corresponds    O
to    O
low    O
insulin    O
levels    O
.    O

Leptin    O
was    O
the    O
first    O
fat    O
cell    O
-    O
derived    O
hormone    O
(    O
adipokine    B-Hormone105407119
)    O
to    O
be    O
discovered    O
.    O

Ciclesonide    B-Hormone105407119
,    O
cortisone    O
acetate    O
,    O
hydrocortisone    B-Hormone105407119
aceponate    I-Hormone105407119
,    O
hydrocortisone    O
acetate    O
,    O
hydrocortisone    B-Hormone105407119
buteprate    I-Hormone105407119
,    O
hydrocortisone    B-Hormone105407119
butyrate    I-Hormone105407119
,    O
hydrocortisone    O
valerate    O
,    O
prednicarbate    B-Hormone105407119
,    O
and    O
tixocortol    B-Hormone105407119
pivalate    I-Hormone105407119
.    O

SPM    O
join    O
the    O
long    O
list    O
of    O
other    O
physiological    O
agents    O
which    O
tend    O
to    O
limit    O
inflammation    O
(    O
see    O
)    O
including    O
glucocorticoids    O
,    O
annexin    O
A1    O
,    O
melanocortin    B-Hormone105407119
,    O
and    O
the    O
gaseous    O
resolvins    O
,    O
carbon    O
monoxide    O
(    O
see    O
)    O
,    O
nitric    O
oxide    O
(    O
see    O
)    O
,    O
and    O
hydrogen    O
sulfide    O
(    O
see    O
and    O
)    O
.    O

The    O
melanocortins    B-Hormone105407119
are    O
a    O
group    O
of    O
peptide    B-Hormone105407119
hormone    I-Hormone105407119
which    O
include    O
adrenocorticotropic    O
hormone    O
(    O
ACTH    O
)    O
and    O
the    O
different    O
forms    O
of    O
melanocyte    O
-    O
stimulating    O
hormone    O
(    O
MSH    O
)    O
,    O
and    O
are    O
derived    O
from    O
proopiomelanocortin    B-Hormone105407119
(    O
POMC    O
)    O
in    O
the    O
pituitary    O
gland    O
.    O

melanocortin    B-Hormone105407119

Isolated    B-Hormone105407119
17,20-lyase    I-Hormone105407119
deficiency    I-Hormone105407119
;    O
;    O
CYP17A1    O

Mutations    O
in    O
this    O
gene    O
are    O
associated    O
with    O
rare    O
forms    O
of    O
congenital    O
adrenal    O
hyperplasia    O
,    O
specifically    O
17α-hydroxylase    O
deficiency/17,20-lyase    O
deficiency    O
and    O
isolated    B-Hormone105407119
17,20-lyase    I-Hormone105407119
deficiency    I-Hormone105407119
.    O

Dimepregnen    O
(    O
INN    O
,    O
BAN    O
)    O
(    O
developmental    O
code    O
name    O
ST-1411    O
)    O
,    O
or    O
6α,16α-dimethylpregn-4-en-3β-ol-20-one    O
,    O
is    O
a    O
pregnene    B-Hormone105407119
steroid    O
described    O
as    O
an    O
antiestrogen    O
that    O
was    O
synthesized    O
in    O
1968    O
and    O
was    O
never    O
marketed    O
.    O

α-Methyldopamine    B-Hormone105407119

Spironolactone    O
is    O
closely    O
structurally    O
related    O
to    O
other    O
clinically    O
used    O
spirolactones    O
such    O
as    O
canrenone    O
,    O
potassium    O
canrenoate    O
,    O
drospirenone    B-Hormone105407119
,    O
and    O
eplerenone    B-Hormone105407119
,    O
as    O
well    O
as    O
to    O
the    O
never    O
-    O
marketed    O
spirolactones    O
SC-5233    O
(    O
6,7-dihydrocanrenone    O
;    O
7α-desthioacetylspironolactone    O
)    O
,    O
SC-8109    O
(    O
19-nor-6,7-dihydrocanrenone    O
)    O
,    O
spiroxasone    O
,    O
prorenone    O
(    O
SC-23133    O
)    O
,    O
mexrenone    O
(    O
SC-25152    O
,    O
ZK-32055    O
)    O
,    O
dicirenone    O
(    O
SC-26304    O
)    O
,    O
spirorenone    O
(    O
ZK-35973    O
)    O
,    O
and    O
mespirenone    O
(    O
ZK-94679    O
)    O
.    O

Difficult    O
or    O
resistant    O
cases    O
of    O
hypokalemia    O
may    O
be    O
amenable    O
to    O
a    O
potassium    O
-    O
sparing    O
diuretic    O
,    O
such    O
as    O
amiloride    O
,    O
triamterene    O
,    O
spironolactone    O
,    O
or    O
eplerenone    B-Hormone105407119
.    O

Eplerenone    B-Hormone105407119
is    O
the    O
9    O
-    O
11α-epoxy    O
analogue    O
of    O
mexrenone    O
.    O

Important    O
antimineralocorticoids    O
are    O
spironolactone    O
and    O
eplerenone    B-Hormone105407119
.    O

After    O
an    O
insect    O
attack    O
tomato    O
plants    O
produce    O
systemin    B-Hormone105407119
,    O
a    O
plant    B-Hormone105407119
peptide    I-Hormone105407119
hormone    I-Hormone105407119
.    O

Fludrocortisone    B-Hormone105407119
is    O
also    O
used    O
,    O
although    O
based    O
on    O
more    O
limited    O
evidence    O
.    O

Fluorine    O
-    O
containing    O
fludrocortisone    B-Hormone105407119
is    O
one    O
of    O
the    O
most    O
common    O
of    O
these    O
drugs    O
.    O

Hyporeninemic    O
hypoaldosteronism    O
is    O
amenable    O
to    O
fludrocortisone    B-Hormone105407119
treatment    O
,    O
but    O
the    O
accompanying    O
hypertension    O
and    O
edema    O
can    O
prove    O
a    O
problem    O
in    O
these    O
patients    O
,    O
so    O
often    O
a    O
diuretic    O
(    O
such    O
as    O
the    O
thiazide    O
diuretic    O
,    O
bendrofluazide    O
,    O
or    O
a    O
loop    O
diuretic    O
,    O
such    O
as    O
furosemide    O
)    O
is    O
used    O
to    O
control    O
the    O
hyperkalemia    O
.    O

Fludrocortisone    B-Hormone105407119
acetate    I-Hormone105407119
and    O
deoxycorticosterone    B-Hormone105407119
acetate    I-Hormone105407119
are    O
,    O
by    O
definition    O
,    O
mineralocorticoids    O
rather    O
than    O
glucocorticoids    O
,    O
but    O
they    O
do    O
have    O
minor    O
glucocorticoid    O
potency    O
and    O
are    O
included    O
in    O
this    O
table    O
to    O
provide    O
perspective    O
on    O
mineralocorticoid    O
potency    O
.    O

An    O
example    O
of    O
a    O
synthetic    O
mineralocorticoid    O
is    O
fludrocortisone    B-Hormone105407119
(    O
Florinef    O
)    O
.    O

Fludrocortisone    B-Hormone105407119
,    O
a    O
synthetic    O
mineralocorticoid    O
.    O

Because    O
of    O
saralasin    B-Hormone105407119
,    O
the    O
first    O
Ang    O
II    O
antagonist    O
,    O
and    O
the    O
development    O
of    O
the    O
first    O
ACE    O
inhibitor    O
captopril    O
,    O
it    O
was    O
generally    O
acknowledged    O
that    O
Ang    O
II    O
receptor    O
antagonists    O
might    O
be    O
promising    O
as    O
effective    O
antihypertensive    O
agents    O
.    O

Ciclesonide    B-Hormone105407119
,    O
cortisone    O
acetate    O
,    O
hydrocortisone    B-Hormone105407119
aceponate    I-Hormone105407119
,    O
hydrocortisone    O
acetate    O
,    O
hydrocortisone    B-Hormone105407119
buteprate    I-Hormone105407119
,    O
hydrocortisone    B-Hormone105407119
butyrate    I-Hormone105407119
,    O
hydrocortisone    O
valerate    O
,    O
prednicarbate    B-Hormone105407119
,    O
and    O
tixocortol    B-Hormone105407119
pivalate    I-Hormone105407119
.    O

Equol    B-Hormone105407119

Estradiol    B-Hormone105407119
acetate    I-Hormone105407119

For    O
comparison    O
,    O
the    O
ester    O
chains    O
of    O
estradiol    B-Hormone105407119
acetate    I-Hormone105407119
,    O
estradiol    B-Hormone105407119
valerate    I-Hormone105407119
,    O
and    O
estradiol    B-Hormone105407119
enanthate    I-Hormone105407119
have    O
2    O
,    O
5    O
,    O
and    O
7    O
carbon    O
atoms    O
,    O
respectively    O
.    O

Estradiol    B-Hormone105407119
acetate    I-Hormone105407119

Bolandiol    B-Hormone105407119

Bolandiol    B-Hormone105407119
(    O
19-nor-4-androstenediol    O
)    O

Bolandiol    B-Hormone105407119

Flumetasone    B-Hormone105407119
=    O
6α,9α-difluoro-11β,17α,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione    O

Locorten    B-Hormone105407119

Aromatase    B-Hormone105407119
excess    I-Hormone105407119
syndrome    I-Hormone105407119
,    O
an    O
extremely    O
rare    O
condition    O
characterized    O
by    O
marked    O
hyperestrogenism    B-Hormone105407119
,    O
is    O
associated    O
with    O
precocious    O
breast    O
development    O
and    O
macromastia    O
in    O
females    O
and    O
similarly    O
precocious    O
gynecomastia    O
(    O
women    O
's    O
breasts    O
)    O
in    O
males    O
.    O

The    O
functional    O
opposite    O
of    O
EIS    O
is    O
hyperestrogenism    B-Hormone105407119
,    O
for    O
instance    O
that    O
seen    O
in    O
aromatase    B-Hormone105407119
excess    I-Hormone105407119
syndrome    I-Hormone105407119
.    O

Aromatase    B-Hormone105407119
excess    I-Hormone105407119
syndrome    I-Hormone105407119

Some    O
other    O
examples    O
of    O
putative    O
EDCs    O
are    O
polychlorinated    O
dibenzo    O
-    O
dioxins    O
(    O
PCDDs    O
)    O
and    O
-furans    O
(    O
PCDFs    O
)    O
,    O
polycyclic    O
aromatic    O
hydrocarbons    O
(    O
PAHs    O
)    O
,    O
phenol    O
derivatives    O
and    O
a    O
number    O
of    O
pesticides    O
(    O
most    O
prominent    O
being    O
organochlorine    O
insecticides    O
like    O
endosulfan    O
,    O
kepone    O
(    O
chlordecone    O
)    O
and    O
DDT    O
and    O
its    O
derivatives    O
,    O
the    O
herbicide    O
atrazine    O
,    O
and    O
the    O
fungicide    O
vinclozolin    O
)    O
,    O
the    O
contraceptive    O
17-alpha    O
ethinylestradiol    O
,    O
as    O
well    O
as    O
naturally    O
occurring    O
phytoestrogens    B-Hormone105407119
such    O
as    O
genistein    B-Hormone105407119
and    O
mycoestrogens    B-Hormone105407119
such    O
as    O
zearalenone    O
.    O

Kudzu    O
contains    O
isoflavones    B-Hormone105407119
,    O
including    O
puerarin    O
(    O
about    O
60%    O
of    O
the    O
total    O
isoflavones    O
)    O
,    O
daidzein    O
,    O
daidzin    O
(    O
structurally    O
related    O
to    O
genistein    B-Hormone105407119
)    O
,    O
mirificin    O
,    O
and    O
salvianolic    O
acid    O
,    O
among    O
numerous    O
others    O
identified    O
.    O

Phytoestrogen    B-Hormone105407119
,    O
plant    O
compounds    O
with    O
estrogen    O
-    O
like    O
biological    O
activity    O
,    O
such    O
as    O
genistein    B-Hormone105407119
,    O
formononetin    B-Hormone105407119
,    O
biochanin    O
A    O
and    O
daidzein    O
,    O
as    O
well    O
as    O
a    O
mixture    O
of    O
these    O
phytoestrogens    O
were    O
found    O
able    O
to    O
reduce    O
E    O
-    O
selectin    O
as    O
well    O
as    O
VCAM-1    O
and    O
ICAM-1    O
on    O
cell    O
surface    O
and    O
in    O
culture    O
supernatant    O
.    O

The    O
dried    O
flower    O
buds    O
may    O
contain    O
as    O
much    O
as    O
20%    O
rutin    O
with    O
some    O
quercetin    O
.    O
"    O
S.    O
japonicum    O
"    O
dried    O
fruit    O
contain    O
the    O
flavonoid    O
glycosides    O
sophoricoside    O
,    O
genistin    O
and    O
rutin    O
and    O
the    O
flavonoid    O
aglycones    O
genistein    B-Hormone105407119
,    O
quercetin    O
and    O
kaempferol    O
.    O

Although    O
there    O
is    O
only    O
preclinical    O
evidence    O
for    O
a    O
possible    O
mechanism    O
,    O
the    O
meta    O
-    O
analysis    O
report    O
stated    O
that    O
soy    O
phytoestrogens    B-Hormone105407119
–    O
the    O
isoflavones    B-Hormone105407119
,    O
genistein    B-Hormone105407119
and    O
daidzein    O
–    O
may    O
be    O
involved    O
in    O
reducing    O
serum    O
cholesterol    O
levels    O
.    O

Genistein    B-Hormone105407119

Chemically    O
,    O
amygdalin    O
and    O
prunasin    O
,    O
the    O
derivatives    O
of    O
which    O
produce    O
prussic    O
acid    O
as    O
well    O
as    O
Genistein    B-Hormone105407119
can    O
be    O
extracted    O
from    O
"    O
P.    O
maximowiczii    O
"    O
.    O

Antimicrobial    O
chemicals    O
,    O
including    O
reactive    O
oxygen    O
species    O
such    O
as    O
hydrogen    O
peroxide    O
or    O
peroxynitrite    O
,    O
or    O
more    O
complex    O
phytoalexins    O
such    O
as    O
genistein    B-Hormone105407119
or    O
camalexin    O

"    O
Eclipta    O
prostrata    O
"    O
contains    O
coumestan    B-Hormone105407119
such    O
as    O
wedelolactone    O
and    O
demethylwedelolactone    O
,    O
polypeptides    O
,    O
polyacetylenes    O
,    O
thiophene    O
derivatives    O
,    O
steroids    O
,    O
triterpenes    O
and    O
flavonoids    O
.    O

Plicadin    O
is    O
a    O
coumestan    B-Hormone105407119
found    O
in    O
"    O
Psoralea    O
plicata    O
"    O
.    O

Blood    O
-    O
borne    O
stimuli    O
,    O
including    O
leptin    B-Hormone105407119
,    O
ghrelin    O
,    O
angiotensin    O
,    O
insulin    O
,    O
pituitary    O
hormones    O
,    O
cytokines    O
,    O
plasma    O
concentrations    O
of    O
glucose    O
and    O
osmolarity    O
etc    O
.    O

In    O
the    O
case    O
of    O
prolactin    O
and    O
leptin    B-Hormone105407119
,    O
there    O
is    O
evidence    O
of    O
active    O
uptake    O
at    O
the    O
choroid    O
plexus    O
from    O
the    O
blood    O
into    O
the    O
cerebrospinal    O
fluid    O
(    O
CSF    O
)    O
.    O

The    O
vagus    O
also    O
conveys    O
a    O
variety    O
of    O
visceral    O
information    O
,    O
including    O
for    O
instance    O
signals    O
arising    O
from    O
gastric    O
distension    O
or    O
emptying    O
,    O
to    O
suppress    O
or    O
promote    O
feeding    O
,    O
by    O
signalling    O
the    O
release    O
of    O
leptin    B-Hormone105407119
or    O
gastrin    O
,    O
respectively    O
.    O

It    O
has    O
been    O
evident    O
that    O
a    O
hormone    O
leptin    B-Hormone105407119
acts    O
on    O
the    O
hypothalamus    O
to    O
decrease    O
food    O
intake    O
and    O
increase    O
energy    O
output    O
.    O

Huntington    O
's    O
disease    O
has    O
also    O
been    O
linked    O
to    O
imbalances    O
in    O
leptin    B-Hormone105407119
and    O
ghrelin    O
levels    O
.    O

Licinio    O
is    O
known    O
for    O
his    O
research    O
into    O
leptin    B-Hormone105407119
and    O
its    O
role    O
in    O
conveying    O
a    O
feeling    O
of    O
satiety    O
.    O

For    O
example    O
,    O
in    O
2002    O
,    O
he    O
identified    O
three    O
people    O
from    O
Turkey    O
who    O
suffered    O
from    O
a    O
genetic    O
disorder    O
called    O
leptin    B-Hormone105407119
deficiency    O
–    O

He    O
discovered    O
that    O
despite    O
being    O
produced    O
by    O
a    O
dispersed    O
mass    O
of    O
fat    O
cells    O
,    O
leptin    B-Hormone105407119
is    O
secreted    O
in    O
a    O
highly    O
organised    O
manner    O
with    O
distinct    O
pulsatility    O
and    O
circadian    O
rhythm    O
and    O
that    O
it    O
appears    O
to    O
regulate    O
the    O
minute    O
-    O
to    O
-    O
minute    O
rhythms    O
of    O
several    O
endocrine    O
axes    O
,    O
such    O
as    O
the    O
hypothalamic    O
-    O
pituitary    O
-    O
adrenal    O
axis    O
,    O
the    O
hypothalamic    O
–    O
pituitary–    O

Licinio    O
and    O
his    O
colleagues    O
were    O
the    O
first    O
to    O
suggest    O
that    O
leptin    B-Hormone105407119
may    O
have    O
antidepressant    O
effects    O
,    O
a    O
concept    O
that    O
was    O
subsequently    O
extended    O
by    O
other    O
groups    O
.    O

The    O
receptor    O
for    O
ghrelin    O
,    O
the    O
ghrelin    O
/    O
growth    O
hormone    O
secretagogue    O
receptor    O
(    O
GHS    O
-    O
R    O
)    O
,    O
is    O
found    O
on    O
the    O
same    O
cells    O
in    O
the    O
brain    O
as    O
the    O
receptor    O
for    O
leptin    B-Hormone105407119
,    O
the    O
satiety    O
hormone    O
that    O
has    O
opposite    O
effects    O
from    O
ghrelin    O
.    O

Alteration    O
of    O
control    O
loop    O
:    O
High    O
levels    O
of    O
leptin    B-Hormone105407119
,    O
a    O
hormone    O
secreted    O
by    O
adipocytes    O
,    O
block    O
the    O
release    O
of    O
Neuropeptide    B-Hormone105407119
Y    I-Hormone105407119
)    O
,    O
which    O
is    O
the    O
most    O
potent    O
feeding    O
-    O
stimulatory    O
peptide    O
in    O
the    O
hypothalamic    O
orexigenic    O
network    O
,    O
leading    O
to    O
decreased    O
energy    O
intake    O
,    O
but    O
high    O
metabolic    O
demand    O
for    O
nutrients    O
.    O

Treatment    O
of    O
Rabson    O
–    O
Mendenhall    O
syndrome    O
with    O
pharmacologic    O
doses    O
of    O
human    O
leptin    B-Hormone105407119
may    O
result    O
in    O
improvement    O
of    O
fasting    O
hyperglycemia    O
,    O
hyperinsulinemia    O
,    O
basal    O
glucose    O
,    O
and    O
glucose    O
and    O
insulin    O
tolerance    O
.    O

For    O
example    O
,    O
mammalian    O
fathers    O
that    O
care    O
for    O
their    O
young    O
may    O
undergo    O
systematic    O
changes    O
in    O
body    O
mass    O
and    O
in    O
circulating    O
or    O
excreted    O
concentrations    O
of    O
a    O
number    O
of    O
hormones    O
(    O
e.g.    O
,    O
androgens    O
,    O
glucocorticoids    O
,    O
leptin    B-Hormone105407119
)    O
as    O
a    O
function    O
of    O
reproductive    O
status    O
,    O
and    O
several    O
of    O
these    O
hormones    O
have    O
important    O
effects    O
on    O
body    O
composition    O
,    O
metabolism    O
,    O
and    O
organismal    O
performance    O
.    O

His    O
work    O
predicted    O
that    O
the    O
ob    O
gene    O
encoded    O
the    O
hormone    O
leptin    B-Hormone105407119
,    O
later    O
co    O
-    O
discovered    O
in    O
1994    O
by    O
Jeffrey    O
Friedman    O
,    O
Rudolph    O
Leibel    O
and    O
their    O
research    O
teams    O
at    O
Rockefeller    O
University    O
.    O

Leptin    B-Hormone105407119
(    O
from    O
Greek    O
λεπτός    O
"    O
leptos    O
"    O
,    O
"    O
thin    O
"    O
)    O
,    O
the    O
"    O
satiety    O
hormone    O
"    O
,    O
is    O
a    O
hormone    O
made    O
by    O
adipose    O
cells    O
that    O
helps    O
to    O
regulate    O
energy    O
balance    O
by    O
inhibiting    O
hunger    O
.    O

Delivery    O
of    O
miRNA-210    O
to    O
an    O
ischemic    O
heart    O
improves    O
heart    O
function    O
,    O
possibly    O
by    O
promoting    O
the    O
release    O
of    O
angiogenic    O
factors    O
like    O
interleukin-1α    O
(    O
IL-1α    O
)    O
,    O
tumor    O
necrosis    O
factor-α    O
(    O
TNF-α    O
)    O
and    O
leptin    B-Hormone105407119
,    O
as    O
seen    O
in    O
HL-1    O
cardiomyocytes    O
injected    O
with    O
miRNA-210    O
.    O

A    O
peptide    O
,    O
leptin    B-Hormone105407119
,    O
has    O
profound    O
effects    O
on    O
metabolism    O
and    O
eating    O
.    O

Jeffrey    O
M.    O
Friedman    O
,    O
discovered    O
leptin    B-Hormone105407119
,    O
a    O
key    O
hormone    O
in    O
the    O
area    O
of    O
human    O
obesity    O

In    O
humans    O
,    O
via    O
white    O
adipocytes    O
(    O
fat    O
cells    O
)    O
,    O
production    O
of    O
the    O
hormone    O
leptin    B-Hormone105407119
(    O
an    O
adipokine    O
)    O
acts    O
on    O
the    O
hypothalamus    O
where    O
reproductive    O
hormone    O
Gonadotrophin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
(    O
GnRH    O
)    O
is    O
produced    O
.    O

Blood    O
plasma    O
of    O
these    O
mice    O
showed    O
elevated    O
levels    O
of    O
non    O
-    O
high    O
-    O
density    O
lipoproteins    O
,    O
cholesterol    O
,    O
triglycerides    O
,    O
non    O
-    O
esterified    O
fatty    O
acids    O
,    O
and    O
leptin    B-Hormone105407119
,    O
but    O
low    O
adiponectin    B-Hormone105407119
content    O
.    O

Prinaberel    B-Hormone105407119

Prinaberel    B-Hormone105407119

Prinaberel    B-Hormone105407119

As    O
indicated    O
above    O
,    O
ACTH    O
is    O
a    O
cleavage    O
product    O
of    O
the    O
pro    O
-    O
hormone    O
,    O
proopiomelanocortin    B-Hormone105407119
(    O
POMC    O
)    O
,    O
which    O
also    O
produces    O
other    O
hormones    O
including    O
α-MSH    B-Hormone105407119
that    O
stimulates    O
the    O
production    O
of    O
melanin    O
.    O

α-MSH    B-Hormone105407119
and    O
ACTH    O
are    O
both    O
peptides    O
derived    O
from    O
processed    O
POMC    B-Hormone105407119
,    O
and    O
both    O
activate    O
the    O
other    O
MCR    O
's    O
,    O
but    O
ACTH    O
is    O
the    O
only    O
agonist    O
ligand    O
for    O
MC2R    O
(    O
ACTH    O
receptor    O
)    O
.    O

Activation    O
of    O
these    O
dopamine    O
receptors    O
leads    O
to    O
the    O
inhibition    O
of    O
proopiomelanocortin    B-Hormone105407119
(    O
POMC    O
)    O
production    O
from    O
these    O
cells    O
.    O

The    O
insulin    O
-    O
pI3    O
K    O
pathway    O
can    O
cause    O
POMC    B-Hormone105407119
neurons    O
to    O
become    O
insensitive    O
to    O
leptin    O
through    O
hyperpolarization    O
.    O

The    O
nucleotide    O
sequence    O
of    O
the    O
human    O
gene    O
for    O
proopiomelanocortin    B-Hormone105407119
(    O
POMC    O
)    O
was    O
characterized    O
in    O
1980    O
.    O

CLIP    O
is    O
generated    O
as    O
a    O
proteolyic    O
cleavage    O
product    O
of    O
adrenocorticotropic    O
hormone    O
(    O
ACTH    O
)    O
,    O
which    O
in    O
turn    O
is    O
a    O
cleavage    O
product    O
of    O
proopiomelanocortin    B-Hormone105407119
(    O
POMC    O
)    O
.    O

5-Androstenedione    B-Hormone105407119
is    O
a    O
prohormone    O
of    O
testosterone    O
.    O

α-MSH    B-Hormone105407119
and    O
ACTH    O
are    O
both    O
peptides    O
derived    O
from    O
processed    O
POMC    B-Hormone105407119
,    O
and    O
both    O
activate    O
the    O
other    O
MCR    O
's    O
,    O
but    O
ACTH    O
is    O
the    O
only    O
agonist    O
ligand    O
for    O
MC2R    O
(    O
ACTH    O
receptor    O
)    O
.    O

Alpha-Melanocyte-stimulating    B-Hormone105407119
hormone    I-Hormone105407119

promoting    O
the    O
synthesis    O
of    O
α-MSH    B-Hormone105407119
,    O
a    O
hunger    O
suppressant    O

Leptin    O
receptor    O
activation    O
inhibits    O
neuropeptide    B-Hormone105407119
Y    I-Hormone105407119
(    O
NPY    O
)    O
and    O
agouti    O
-    O
related    O
peptide    O
(    O
AgRP    O
)    O
,    O
and    O
activates    O
α-melanocyte-stimulating    B-Hormone105407119
hormone    I-Hormone105407119
(    O
α-MSH    O
)    O
.    O

Algestone    B-Hormone105407119

Mepitiostane    B-Hormone105407119

Oral    O
contraceptive    O
produced    O
by    O
Jenapharm    O
containing    O
ethinylestradiol    O
and    O
dienogest    B-Hormone105407119

It    O
is    O
said    O
to    O
be    O
a    O
weaker    O
antiandrogen    O
than    O
dienogest    B-Hormone105407119
(    O
another    O
commonly    O
used    O
progestin    O
with    O
antiandrogen    O
activity    O
)    O
,    O
but    O
still    O
may    O
be    O
useful    O
in    O
alleviating    O
acne    O
,    O
seborrhea    O
,    O
and    O
other    O
androgen    O
-    O
dependent    O
symptoms    O
in    O
women    O
.    O

Dienogest    B-Hormone105407119
,    O
which    O
is    O
antiandrogenic    O
,    O
features    O
extension    O
of    O
the    O
C17α    O
chain    O
in    O
the    O
form    O
of    O
a    O
cyanomethyl    O
group    O
at    O
the    O
C17α    O
position    O
.    O

In    O
contrast    O
,    O
dienogest    B-Hormone105407119
,    O
the    O
17α-cyanomethyl    O
derivative    O
of    O
dienolone    O
,    O
is    O
a    O
potent    O
progestogen    O
and    O
antiandrogen    B-Hormone105407119
.    O

It    O
has    O
since    O
been    O
elucidated    O
that    O
androgens    O
like    O
testosterone    O
and    O
function    O
as    O
trophic    B-Hormone105407119
factor    I-Hormone105407119
for    O
the    O
prostate    O
gland    O
,    O
stimulating    O
cell    O
division    O
and    O
proliferation    O
and    O
producing    O
tissue    O
growth    O
and    O
glandular    O
enlargement    O
,    O
which    O
,    O
in    O
the    O
context    O
of    O
prostate    O
cancer    O
,    O
results    O
in    O
stimulation    O
of    O
tumors    O
and    O
a    O
considerable    O
acceleration    O
of    O
disease    O
progression    O
.    O

Other    O
hormones    O
produced    O
include    O
somatostatin    B-Hormone105407119
,    O
pancreatic    B-Hormone105407119
polypeptide    I-Hormone105407119
,    O
amylin    B-Hormone105407119
and    O
ghrelin    O
.    O

Pancreatic    B-Hormone105407119
polypeptide    I-Hormone105407119
(    O
PP    B-Hormone105407119
)    O
is    O
a    O
polypeptide    O
secreted    O
by    O
PP    O
cells    O
in    O
the    O
endocrine    O
pancreas    O
predominantly    O
in    O
the    O
head    O
of    O
the    O
pancreas    O
.    O

Pancreatic    B-Hormone105407119
polypeptide    I-Hormone105407119

File    O
:    O
Dydrogesterone    B-Hormone105407119
(    O
progestin    O
)    O

Progesterone    O
and    O
non    O
-    O
androgenic    O
progestins    O
,    O
such    O
as    O
dydrogesterone    B-Hormone105407119
,    O
do    O
not    O
affect    O
serum    O
IGF-1    O
levels    O
regardless    O
of    O
route    O
of    O
administration    O
.    O

Gynorest    B-Hormone105407119

:    O
"    O
Not    O
to    O
be    O
confused    O
with    O
Osteocalcin    B-Hormone105407119
,    O
Osteonectin    O
or    O
Osteoprotegerin    O
(    O
OPG    O
)    O
.    O
"    O

The    O
organic    O
part    O
of    O
bone    O
is    O
about    O
20%    O
of    O
the    O
dry    O
weight    O
,    O
and    O
counts    O
in    O
,    O
other    O
than    O
osteopontin    O
,    O
collagen    O
type    O
I    O
,    O
osteocalcin    B-Hormone105407119
,    O
osteonectin    O
,    O
bone    O
sialo    O
protein    O
,    O
and    O
alkaline    O
phosphatase    O
.    O

C4    O
-    O
2B    O
cells    O
also    O
express    O
higher    O
levels    O
of    O
osteoprotegerin    O
(    O
OPG    O
)    O
,    O
alkaline    O
phosphatase    O
,    O
bone    O
sialoprotein    O
(    O
BSP    O
)    O
,    O
Osteocalcin    B-Hormone105407119
(    O
OCN    O
)    O
,    O
RANKL    O
,    O
and    O
Osteonectin    O
(    O
OSN    O
)    O
mRNA    O
,    O
all    O
of    O
which    O
are    O
highly    O
expressed    O
by    O
osteoblasts    O
.    O

Some    O
of    O
the    O
regulatory    O
proteins    O
in    O
mineralized    O
tissues    O
are    O
osteonectin    O
,    O
osteopontin    O
,    O
osteocalcin    B-Hormone105407119
,    O
bone    O
sialoprotein    O
and    O
dentin    O
phosphophoryn    O
.    O

The    O
clinical    O
state    O
of    O
DKA    O
is    O
associated    O
,    O
in    O
addition    O
to    O
the    O
above    O
,    O
with    O
the    O
release    O
of    O
various    O
counterregulatory    B-Hormone105407119
hormone    I-Hormone105407119
such    O
as    O
glucagon    O
and    O
adrenaline    O
as    O
well    O
as    O
cytokines    O
,    O
the    O
latter    O
of    O
which    O
leads    O
to    O
increased    O
markers    O
of    O
inflammation    O
,    O
even    O
in    O
the    O
absence    O
of    O
infection    O
.    O

Insulin    B-Hormone105407119
analog    I-Hormone105407119

Long    O
-    O
acting    O
insulin    B-Hormone105407119
analog    I-Hormone105407119
such    O
as    O
insulin    B-Hormone105407119
glargine    I-Hormone105407119
(    O
brand    O
name    O
"    O
Lantus    O
"    O
,    O
made    O
by    O
Sanofi    O
-    O
Aventis    O
)    O
and    O
insulin    O
detemir    O
(    O
brand    O
name    O
"    O
Levemir    O
"    O
,    O
made    O
by    O
Novo    O
Nordisk    O
)    O
are    O
also    O
used    O
,    O
with    O
insulin    O
glargine    O
used    O
more    O
than    O
insulin    O
detemir    O
.    O

Insulin    B-Hormone105407119
degludec    I-Hormone105407119
(    O
INN    O
/    O
USAN    O
)    O
is    O
an    O
ultralong    O
-    O
acting    O
basal    O
insulin    B-Hormone105407119
analogue    I-Hormone105407119
that    O
was    O
developed    O
by    O
Novo    O
Nordisk    O
under    O
the    O
brand    O
name    O
Tresiba    B-Hormone105407119
.    O

Chloroprednisone    B-Hormone105407119

Between    O
1957    O
and    O
1962    O
Gerhard    O
Langbein    O
further    O
expanded    O
the    O
gamut    O
of    O
steroids    O
that    O
Jenapharm    O
produced    O
using    O
its    O
unique    O
process    O
to    O
include    O
testosterone    O
,    O
4-chlorotestosterone    B-Hormone105407119
,    O
cortexolone    O
,    O
cortisone    O
,    O
cortisol    B-Hormone105407119
and    O
prednisone    O
.    O

Clostebol    B-Hormone105407119

On    O
20    O
September    O
2013    O
the    O
UCI    O
announced    O
that    O
Agostini    O
was    O
provisionally    O
suspended    O
for    O
an    O
adverse    O
analytical    O
finding    O
for    O
0.7    O
nanogram    O
per    O
millilitre    O
clostebol    B-Hormone105407119
in    O
an    O
out    O
-    O
of    O
-    O
competition    O
test    O
taken    O
on    O
21    O
August    O
2013    O
.    O

4-OHT    O
has    O
moderate    O
anabolic    O
,    O
mild    O
androgenic    O
,    O
and    O
anti    O
-    O
aromatase    O
properties    O
and    O
is    O
similar    O
to    O
the    O
steroid    O
clostebol    B-Hormone105407119
(    O
4-chlorotestosterone    O
)    O
.    O

Androstadienol    O
is    O
then    O
sequentially    O
converted    O
into    O
androstenol    O
by    O
3β-hydroxysteroid    O
dehydrogenase    O
(    O
androstadienol    O
to    O
androstadienone    B-Hormone105407119
)    O
,    O
5α-reductase    O
(    O
androstadienone    O
to    O
androstenone    O
)    O
,    O
and    O
3α-hydroxysteroid    O
dehydrogenase    O
(    O
androstenone    O
to    O
androstenol    O
)    O
,    O
in    O
a    O
manner    O
analogous    O
to    O
the    O
biosynthesis    O
of    O
3α-androstanediol    O
from    O
dehydroepiandrosterone    B-Hormone105407119
(    O
DHEA    O
)    O
.    O

Androstadienol    O
to    O
androstadienone    B-Hormone105407119

Fluticasone    B-Hormone105407119
furoate    I-Hormone105407119

It    O
contains    O
fluticasone    B-Hormone105407119
furoate    I-Hormone105407119
,    O
an    O
inhaled    O
corticosteroid    O
,    O
and    O
vilanterol    O
,    O
an    O
ultra    O
-    O
long    O
-    O
acting    O
β2    O
agonist    O
(    O
ultra    O
-    O
LABA    O
)    O
.    O

17β-Dihydroequilenin    O
,    O
or    O
β-dihydroequilenin    O
,    O
also    O
known    O
as    O
6,8-didehydro-17β-estradiol    O
,    O
as    O
well    O
as    O
estra-1,3,5(10),6,8-pentaen-3,17β-diol    O
,    O
is    O
a    O
naturally    O
occurring    O
steroidal    O
estrogen    O
found    O
in    O
horses    O
that    O
is    O
closely    O
related    O
to    O
equilin    B-Hormone105407119
,    O
equilenin    B-Hormone105407119
,    O
and    O
estradiol    O
,    O
and    O
,    O
as    O
the    O
3-sulfate    O
ester    O
sodium    O
salt    O
,    O
is    O
a    O
minor    O
constituent    O
(    O
0.5%    O
)    O
of    O
conjugated    O
equine    O
estrogens    O
(    O
Premarin    B-Hormone105407119
)    O
.    O

8,9-Dehydroestrone    O
,    O
or    O
Δ8-estrone    O
,    O
also    O
known    O
as    O
estra-1,3,5(10),8-tetraen-3-ol-17-one    O
,    O
is    O
a    O
naturally    O
occurring    O
steroidal    O
estrogen    O
found    O
in    O
horses    O
that    O
is    O
closely    O
related    O
to    O
equilin    B-Hormone105407119
,    O
equilenin    B-Hormone105407119
,    O
and    O
estrone    O
,    O
and    O
,    O
as    O
the    O
3-sulfate    O
ester    O
sodium    O
salt    O
,    O
is    O
a    O
minor    O
constituent    O
(    O
3.5%    O
)    O
of    O
conjugated    O
equine    O
estrogens    O
(    O
Premarin    B-Hormone105407119
)    O
.    O

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-Hormone105407119
)    O
,    O
desogestrel    B-Hormone105407119
,    O
ethylestrenol    B-Hormone105407119
,    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
ethinylestradiol    O
,    O
gestrinone    B-Hormone105407119
,    O
levonorgestrel    B-Hormone105407119
,    O
norethisterone    B-Hormone105407119
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    B-Hormone105407119
)    O
,    O
quinestrol    B-Hormone105407119
,    O
19-norprogesterone    B-Hormone105407119
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-Hormone105407119
acetate    I-Hormone105407119
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
.    O

The    O
estranes    O
include    O
norethisterone    B-Hormone105407119
(    O
norethindrone    O
)    O
,    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
norethisterone    O
enanthate    O
,    O
lynestrenol    B-Hormone105407119
,    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-Hormone105407119
,    O
desogestrel    B-Hormone105407119
,    O
etonogestrel    B-Hormone105407119
,    O
gestodene    B-Hormone105407119
,    O
norgestimate    B-Hormone105407119
,    O
dienogest    B-Hormone105407119
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    B-Hormone105407119
.    O

A    O
2001    O
comparative    O
study    O
of    O
the    O
IMS    O
LifeLink    O
Health    O
Plan    O
Claims    O
Database    O
interpreted    O
that    O
in    O
a    O
large    O
cohort    O
of    O
women    O
using    O
oral    O
contraceptives    O
,    O
there    O
was    O
found    O
a    O
small    O
,    O
statistically    O
significant    O
increase    O
in    O
the    O
risk    O
of    O
gallbladder    O
disease    O
associated    O
with    O
desogestrel    B-Hormone105407119
,    O
drospirenone    O
and    O
norethisterone    B-Hormone105407119
compared    O
with    O
levonorgestrel    B-Hormone105407119
.    O

Examples    O
of    O
important    O
progestogen    O
esters    O
include    O
the    O
17α-hydroxyprogesterone    O
derivatives    O
medroxyprogesterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
megestrol    O
acetate    O
,    O
cyproterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
and    O
hydroxyprogesterone    B-Hormone105407119
caproate    I-Hormone105407119
,    O
the    O
19-norprogesterone    B-Hormone105407119
derivative    O
nomegestrol    B-Hormone105407119
acetate    I-Hormone105407119
,    O
and    O
the    O
19-nortestosterone    O
derivatives    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
and    O
norethisterone    O
enanthate    O
.    O

Progestogen    O
esters    O
of    O
other    O
groups    O
of    O
progestins    O
have    O
also    O
been    O
introduced    O
,    O
including    O
the    O
19-norprogesterone    B-Hormone105407119
derivatives    O
gestonorone    B-Hormone105407119
caproate    I-Hormone105407119
,    O
segesterone    O
acetate    O
(    O
nestorone    O
)    O
,    O
nomegestrol    B-Hormone105407119
acetate    I-Hormone105407119
,    O
and    O
norgestomet    O
(    O
11β-methyl-17α-acetoxy-19-norprogesterone    O
)    O
,    O
and    O
the    O
19-nortestosterone    O
derivatives    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
norethisterone    O
enanthate    O
,    O
and    O
quingestanol    B-Hormone105407119
acetate    I-Hormone105407119
.    O

Estradiol    O
undecylate    O
,    O
in    O
combination    O
with    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
(    O
at    O
doses    O
of    O
5    O
mg    O
and    O
50    O
mg    O
,    O
respectively    O
)    O
,    O
was    O
studied    O
as    O
a    O
combined    O
injectable    O
contraceptive    O
,    O
but    O
ultimately    O
was    O
not    O
marketed    O
for    O
this    O
purpose    O
.    O

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-Hormone105407119
)    O
,    O
desogestrel    B-Hormone105407119
,    O
ethylestrenol    B-Hormone105407119
,    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
ethinylestradiol    O
,    O
gestrinone    B-Hormone105407119
,    O
levonorgestrel    B-Hormone105407119
,    O
norethisterone    B-Hormone105407119
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    B-Hormone105407119
)    O
,    O
quinestrol    B-Hormone105407119
,    O
19-norprogesterone    B-Hormone105407119
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-Hormone105407119
acetate    I-Hormone105407119
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
.    O

The    O
estranes    O
include    O
norethisterone    B-Hormone105407119
(    O
norethindrone    O
)    O
,    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
norethisterone    O
enanthate    O
,    O
lynestrenol    B-Hormone105407119
,    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-Hormone105407119
,    O
desogestrel    B-Hormone105407119
,    O
etonogestrel    B-Hormone105407119
,    O
gestodene    B-Hormone105407119
,    O
norgestimate    B-Hormone105407119
,    O
dienogest    B-Hormone105407119
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    B-Hormone105407119
.    O

After    O
the    O
loss    O
of    O
TH+    O
(    O
tyrosine    B-Hormone105407119
hydroxylase    I-Hormone105407119
-    O
positive    O
)    O
substantia    O
nigra    O
compacta    O
(    O
SNc    O
)    O
neurons    O
due    O
to    O
Parkinson’s    O
-    O
induced    O
neurodegeneration    O
,    O
the    O
number    O
of    O
these    O
neurons    O
can    O
partially    O
recover    O
via    O
a    O
cell    O
phenotype    O
“    O
shift    O
”    O
from    O
TH-    O
(    O
tyrosine    O
hydroxylase    O
-    O
negative    O
)    O
to    O
TH+    O
.    O

The    O
increase    O
in    O
activity    O
of    O
synthesis    O
of    O
norepinephrine    O
and    O
epinephrine    O
within    O
the    O
medulla    O
is    O
done    O
from    O
glucocorticoids    O
through    O
the    O
increase    O
in    O
reaction    O
rate    O
of    O
certain    O
enzymes    O
,    O
such    O
as    O
:    O
tyrosine    B-Hormone105407119
hydroxylase    I-Hormone105407119
,    O
aromatic    O
L    O
-    O
amino    O
acid    O
decarboxylase    O
,    O
dopamine-β-hydroxylase    O
,    O
and    O
phenylethanolamine    O
N    O
-    O
methyltransferase    O
.    O

PAH    O
is    O
unusual    O
among    O
the    O
aromatic    O
amino    O
acid    O
hydroxylases    O
for    O
its    O
involvement    O
in    O
catabolism    O
;    O
tyrosine    B-Hormone105407119
and    O
tryptophan    O
hydroxylases    O
,    O
on    O
the    O
other    O
hand    O
,    O
are    O
primarily    O
expressed    O
in    O
the    O
central    O
nervous    O
system    O
and    O
catalyze    O
rate    O
-    O
limiting    O
steps    O
in    O
neurotransmitter    O
/    O
hormone    O
biosynthesis    O
.    O

tyrosine    B-Hormone105407119
hydroxylase    I-Hormone105407119
(    O
EC    O
number    O
1.14.16.2    O
)    O
,    O
which    O
controls    O
levels    O
of    O
dopamine    O
,    O
epinephrine    O
,    O
and    O
norepinephrine    O
in    O
the    O
brain    O
and    O
the    O
adrenal    O
medulla    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
tyrosine    B-Hormone105407119
3-monooxygenase    I-Hormone105407119
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
[    O
[    O
phospho-[tyrosine-3-monooxygenase    O
]    O
]    O
]    O
.    O

Group    O
A15    O
exists    O
in    O
a    O
few    O
species    O
,    O
such    O
as    O
sheep    O
,    O
and    O
immunoreactive    O
for    O
tyrosine    B-Hormone105407119
hydroxylase    I-Hormone105407119
,    O
a    O
precursor    O
of    O
dopamine    O
,    O
in    O
many    O
other    O
species    O
including    O
rodents    O
and    O
primates    O
.    O

The    O
steroid    O
is    O
known    O
to    O
compete    O
with    O
catecholamines    O
for    O
binding    O
to    O
catechol    O
O    O
-    O
methyltransferase    O
and    O
tyrosine    B-Hormone105407119
hydroxylase    I-Hormone105407119
and    O
to    O
directly    O
and    O
competitively    O
inhibit    O
these    O
enzymes    O
.    O

The    O
enzyme    O
tyrosine    B-Hormone105407119
hydroxylase    I-Hormone105407119
converts    O
tyrosine    O
to    O
L-DOPA    B-Hormone105407119
in    O
the    O
first    O
step    O
of    O
catecholamine    O
synthesis    O
.    O

Tyrosine    B-Hormone105407119
hydroxylase    I-Hormone105407119
-    O
expressing    O
interneurons    O

Choh    O
Hao    O
Li    O
(    O
李卓皓    O
)    O
-    O
biochemist    O
,    O
discovered    O
growth    O
hormone    O
,    O
beta-endorphin    B-Hormone105407119
and    O
isolated    O
luteinizing    O
hormone    O

Upon    O
examining    O
the    O
studies    O
on    O
hypoxia    O
he    O
found    O
that    O
"    O
abnormalities    O
in    O
the    O
cerebral    O
neurochemistry    O
involving    O
one    O
or    O
more    O
of    O
the    O
interconnected    O
neurotransmitters    O
,    O
dopamine    O
,    O
5-hydroxytryptamine    O
,    O
and    O
β-endorphin    B-Hormone105407119
had    O
been    O
reported    O
in    O
all    O
the    O
conditions    O
associated    O
with    O
hallucinations    O
.    O
"    O

In    O
these    O
cases    O
,    O
it    O
is    O
believed    O
that    O
the    O
self    O
-    O
injury    O
is    O
being    O
done    O
to    O
release    O
beta-endorphin    B-Hormone105407119
,    O
which    O
binds    O
to    O
the    O
same    O
receptors    O
as    O
heroin    O
and    O
morphine    O
.    O

The    O
POMC    O
gene    O
codes    O
for    O
endogenous    O
opioids    O
such    O
as    O
β-endorphin    B-Hormone105407119
and    O
γ-endorphin    O
.    O

Exercise    O
is    O
known    O
to    O
affect    O
dopamine    O
signaling    O
in    O
the    O
nucleus    O
accumbens    O
,    O
producing    O
euphoria    O
as    O
a    O
result    O
,    O
through    O
increased    O
biosynthesis    O
of    O
three    O
particular    O
neurochemicals    O
:    O
anandamide    O
(    O
an    O
endocannabinoid    O
)    O
,    O
β-endorphin    B-Hormone105407119
(    O
an    O
endogenous    O
opioid    O
)    O
,    O
and    O
phenethylamine    O
(    O
a    O
trace    O
amine    O
and    O
amphetamine    O
analog    O
)    O
.    O

Hypothalamic    O
disease    O
may    O
cause    O
insufficient    O
or    O
inhibited    O
signalling    O
to    O
the    O
pituitary    O
leading    O
to    O
deficiencies    O
of    O
one    O
or    O
more    O
of    O
the    O
following    O
hormones    O
:    O
thyroid    O
-    O
stimulating    O
hormone    O
,    O
adrenocorticotropic    O
hormone    O
,    O
beta-endorphin    B-Hormone105407119
,    O
luteinizing    O
hormone    O
,    O
follicle    O
-    O
stimulating    O
hormone    O
,    O
and    O
melanocyte    O
–    O
stimulating    O
hormones    O
.    O

The    O
C    O
-    O
terminal    O
(    O
G3    O
)    O
globular    O
domain    O
consists    O
of    O
one    O
or    O
two    O
Epidermal    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
(    O
EGF    O
)    O
repeats    O
,    O
a    O
C    O
-    O
type    O
lectin    O
domain    O
and    O
complement    O
regulatory    O
protein    O
(    O
CRP)-like    O
domain    O
.    O

Molecular    O
triggers    O
that    O
lead    O
to    O
this    O
scar    O
formation    O
include    O
epidermal    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
(    O
EGF    O
)    O
,    O
fibroblast    O
growth    O
factor    O
(    O
FGF    O
)    O
,    O
endothelin    B-Hormone105407119
1    I-Hormone105407119
and    O
adenosine    O
triphosphate    O
(    O
ATP    O
)    O
.    O

The    O
notch    O
extracellular    O
domain    O
is    O
composed    O
primarily    O
of    O
small    O
cystine    O
-    O
rich    O
motifs    O
called    O
EGF    B-Hormone105407119
-    O
like    O
repeats    O
.    O

Members    O
of    O
this    O
Type    O
1    O
transmembrane    O
protein    O
family    O
share    O
structural    O
characteristics    O
including    O
an    O
extracellular    O
domain    O
consisting    O
of    O
multiple    O
epidermal    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
-    O
like    O
(    O
EGF    O
)    O
repeats    O
,    O
and    O
an    O
intracellular    O
domain    O
consisting    O
of    O
multiple    O
,    O
different    O
domain    O
types    O
.    O

PITP    O
has    O
been    O
also    O
shown    O
to    O
be    O
an    O
essential    O
component    O
of    O
the    O
polyphosphoinositide    O
synthesis    O
machinery    O
and    O
is    O
hence    O
required    O
for    O
proper    O
signalling    O
by    O
epidermal    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
and    O
f    O
-    O
Met    O
-    O
Leu    O
-    O
Phe    O
,    O
as    O
well    O
as    O
for    O
exocytosis    O
.    O

Growth    O
factors    O
,    O
such    O
as    O
Epidermal    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
can    O
also    O
suppress    O
miR-203    O
in    O
epitheilal    O
cells    O
...    O

Epidermal    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
.    O

Together    O
with    O
signals    O
arising    O
from    O
receptors    O
for    O
soluble    O
growth    O
factors    O
like    O
VEGF    O
,    O
EGF    B-Hormone105407119
,    O
and    O
many    O
others    O
,    O
they    O
enforce    O
a    O
cellular    O
decision    O
on    O
what    O
biological    O
action    O
to    O
take    O
,    O
be    O
it    O
attachment    O
,    O
movement    O
,    O
death    O
,    O
or    O
differentiation    O
.    O

In    O
particular    O
,    O
Gq    O
stimulates    O
cell    O
signal    O
pathways    O
involving    O
a    O
)    O
phospholipase    O
C    O
/    O
IP3/cell    O
Ca2    O
+    O
mobilization    O
/    O
diacylglycerol    O
/    O
protein    O
kinase    O
Cs    O
;    O
calmodulin    O
-    O
modulated    O
myosin    O
light    O
chain    O
kinase    O
;    O
RAF    O
/    O
MEK    O
/    O
Mitogen    O
-    O
activated    O
protein    O
kinases    O
;    O
PKC    O
/    O
Ca2+/Calcineurin    O
/    O
Nuclear    O
factor    O
of    O
activated    O
T    O
-    O
cells    O
;    O
and    O
the    O
EGF    B-Hormone105407119
cellular    O
receptor    O
.    O

When    O
bound    O
to    O
PGI2    O
or    O
other    O
of    O
its    O
agonists    O
,    O
IP    O
stimulates    O
one    O
or    O
more    O
of    O
three    O
types    O
of    O
G    O
protein    O
complexes    O
,    O
depending    O
on    O
cell    O
type    O
:    O
a    O
)    O
Gs    O
alpha    O
subunit    O
-    O
Gβγ    O
complexes    O
which    O
release    O
Gs    O
that    O
then    O
stimulates    O
adenyl    O
cyclase    O
to    O
raise    O
intracellular    O
levels    O
of    O
cAMP    O
and    O
thereby    O
activate    O
cAMP    O
-    O
regulated    O
protein    O
kinases    O
A    O
-    O
dependent    O
cell    O
signaling    O
pathways    O
(    O
see    O
PKA    O
)    O
;    O
b    O
)    O
Gq    O
alpha    O
subunit    O
-    O
Gβγ    O
complexes    O
which    O
release    O
Gq    O
that    O
then    O
stimulates    O
other    O
cell    O
signaling    O
pathways    O
(    O
e.g.    O
phospholipase    O
C    O
/    O
IP3/cell    O
Ca2    O
+    O
mobilization    O
/    O
diacylglycerol    O
/    O
protein    O
kinase    O
Cs    O
,    O
calmodulin    O
-    O
modulated    O
myosin    O
light    O
chain    O
kinase    O
,    O
RAF    O
/    O
MEK    O
/    O
Mitogen    O
-    O
activated    O
protein    O
kinases    O
,    O
PKC    O
/    O
Ca2+/Calcineurin    O
/    O
Nuclear    O
factor    O
of    O
activated    O
T    O
-    O
cells    O
;    O
and    O
EGF    B-Hormone105407119
cellular    O
receptors    O
;    O
and    O
c    O
)    O
Gi    O
alpha    O
subunit    O
-    O
Giβγ    O
)    O
complexes    O
which    O
releases    O
Gi    O
that    O
then    O
simulates    O
phospholipase    O
C    O
to    O
cleave    O
phosphatidylinositol    O
triphosphate    O
into    O
inositol    O
triphosphate    O
that    O
raises    O
intracellular    O
CaCa2    O
levels    O
thereby    O
regulating    O
Calcium    O
signaling    O
pathways    O
and    O
diacylglycerol    O
that    O
activates    O
certain    O
protein    O
kinase    O
C    O
enzymes    O
)    O
that    O
phosphorylate    O
and    O
thereby    O
regulate    O
target    O
proteins    O
involved    O
in    O
cell    O
signaling    O
(    O
see    O
Protein    O
kinase    O
C#Function    O
)    O
.    O

It    O
is    O
postulated    O
that    O
these    O
proteins    O
are    O
receptors    O
involved    O
in    O
contact    O
-    O
mediated    O
communication    O
,    O
with    O
cadherin    O
domains    O
acting    O
as    O
homophilic    O
binding    O
regions    O
and    O
the    O
EGF    B-Hormone105407119
-    O
like    O
domains    O
involved    O
in    O
cell    O
adhesion    O
and    O
receptor    O
-    O
ligand    O
interactions    O
.    O

For    O
example    O
,    O
Src    O
kinase    O
which    O
binds    O
to    O
inactive    O
GR    O
,    O
is    O
released    O
when    O
a    O
glucocorticoid    O
binds    O
to    O
GR    O
,    O
and    O
phosphorylates    O
a    O
protein    O
that    O
in    O
turn    O
displaces    O
an    O
adaptor    O
protein    O
from    O
a    O
receptor    O
important    O
in    O
inflammation    O
,    O
epidermal    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
(    O
EGF    O
)    O
,    O
reducing    O
its    O
activity    O
,    O
which    O
in    O
turn    O
results    O
in    O
reduced    O
creation    O
of    O
arachidonic    O
acid    O
-    O
a    O
key    O
proinflammatory    O
molecule    O
.    O

Platelets    O
release    O
platelet    O
-    O
derived    O
growth    O
factor    O
(    O
PDGF    O
)    O
,    O
a    O
potent    O
chemotactic    O
agent    O
;    O
and    O
TGF    O
beta    O
,    O
which    O
stimulates    O
the    O
deposition    O
of    O
extracellular    O
matrix    O
;    O
fibroblast    O
growth    O
factor    O
,    O
insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
1    I-Hormone105407119
,    O
platelet    O
-    O
derived    O
epidermal    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
,    O
and    O
vascular    O
endothelial    O
growth    O
factor    O
.    O

Fibronectin    O
-    O
like    O
(    O
FN    O
-    O
like    O
)    O
repeats    O
of    O
Tenascin    O
-    O
C    O
and    O
Tenascin    O
-    O
R    O
bind    O
with    O
beta    O
2    O
in    O
contrast    O
to    O
the    O
Epidermal    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
-    O
like    O
(    O
EGF    O
-    O
like    O
)    O
repeats    O
that    O
repel    O
beta2    O
.    O

Gastric    O
organoids    O
have    O
been    O
generated    O
directly    O
from    O
pluripotent    O
stem    O
cells    O
through    O
the    O
temporal    O
manipulation    O
of    O
the    O
FGF    O
,    O
WNT    O
,    O
BMP    O
,    O
retinoic    O
acid    O
and    O
EGF    B-Hormone105407119
signalling    O
pathways    O
in    O
three    O
-    O
dimensional    O
culture    O
conditions    O
.    O

Epithelial    O
lingual    O
organoids    O
have    O
been    O
generated    O
using    O
BMI1    O
expressing    O
epithelial    O
stem    O
cells    O
in    O
three    O
-    O
dimensional    O
culture    O
conditions    O
through    O
the    O
manipulation    O
of    O
EGF    B-Hormone105407119
,    O
WNT    O
,    O
and    O
TGF-β.    O
This    O
organoid    O
culture    O
,    O
however    O
,    O
lacks    O
taste    O
receptors    O
,    O
as    O
these    O
cells    O
do    O
not    O
arise    O
from    O
Bmi1    O
expressing    O
epithelial    O
stem    O
cells    O
.    O

Epidermal    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
,    O
a    O
growth    O
factor    O
in    O
biology    O

Other    O
genetic    O
causes    O
of    O
hypomagnesemia    O
,    O
such    O
as    O
mutations    O
in    O
"    O
TRPM6    O
"    O
,    O
"    O
CNNM2    O
"    O
,    O
"    O
EGF    B-Hormone105407119
"    O
,    O
"    O
EGFR    O
"    O
,    O
"    O
KCNA1    O
"    O
or    O
"    O
FAM111A    O
"    O
.    O

These    O
LRRs    O
are    O
followed    O
by    O
six    O
repeats    O
similar    O
to    O
epidermal    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
(    O
EGF    O
)    O
as    O
well    O
as    O
a    O
β-sandwich    O
domain    O
similar    O
to    O
laminin    O
G.    O
Directly    O
after    O
these    O
sequences    O
,    O
invertebrates    O
have    O
one    O
EGF    O
repeat    O
,    O
whereas    O
vertebrates    O
have    O
three    O
EGF    O
repeats    O
.    O

In    O
addition    O
,    O
JDP2    O
overexpression    O
reverses    O
the    O
epithelial    O
-    O
to    O
-    O
mesenchymal    O
transition    O
(    O
EMT    O
)    O
induced    O
by    O
co    O
-    O
treatment    O
with    O
TGF-β1    O
and    O
EGF    B-Hormone105407119
in    O
human    O
pancreatic    O
BxPC3    O
cells    O
,    O
suggesting    O
that    O
JDP2    O
may    O
be    O
a    O
molecular    O
target    O
for    O
pancreatic    O
carcinoma    O
intervention    O
.    O

Argos    O
binds    O
the    O
epidermal    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
domain    O
of    O
Spitz    O
,    O
preventing    O
interaction    O
between    O
Spitz    O
and    O
EGFR    O
.    O

CRF2    O
receptors    O
are    O
activated    O
by    O
two    O
structurally    O
similar    O
peptides    O
,    O
urocortin    B-Hormone105407119
II    I-Hormone105407119
and    O
urocortin    B-Hormone105407119
III    I-Hormone105407119
,    O
as    O
well    O
as    O
CRH    O
.    O

Long    O
-    O
term    O
exposure    O
to    O
glucocorticoid    O
medications    O
,    O
such    O
as    O
asthma    O
and    O
anti    O
-    O
inflammatory    O
medication    O
,    O
has    O
been    O
shown    O
to    O
create    O
deficits    O
in    O
memory    O
and    O
attention    O
both    O
during    O
and    O
,    O
to    O
a    O
lesser    O
extent    O
,    O
after    O
treatment    O
,    O
a    O
condition    O
known    O
as    O
"    O
steroid    B-Hormone105407119
dementia    I-Hormone105407119
.    O
"    O

Fibroblast    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
19    I-Hormone105407119
is    O
a    O
protein    O
that    O
in    O
humans    O
is    O
encoded    O
by    O
the    O
"    O
FGF19    O
"    O
gene    O
.    O

Reduced    O
median    O
levels    O
of    O
FGF19    B-Hormone105407119
,    O
an    O
ileal    O
hormone    O
that    O
regulates    O
increased    O
hepatic    O
bile    O
acid    O
synthesis    O
,    O
have    O
been    O
found    O
in    O
this    O
condition    O
.    O

Delalutin    B-Hormone105407119

hydroxyprogesterone    B-Hormone105407119
caproate    I-Hormone105407119
(    O
INN    O
)    O

Examples    O
of    O
important    O
progestogen    O
esters    O
include    O
the    O
17α-hydroxyprogesterone    O
derivatives    O
medroxyprogesterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
megestrol    O
acetate    O
,    O
cyproterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
and    O
hydroxyprogesterone    B-Hormone105407119
caproate    I-Hormone105407119
,    O
the    O
19-norprogesterone    B-Hormone105407119
derivative    O
nomegestrol    B-Hormone105407119
acetate    I-Hormone105407119
,    O
and    O
the    O
19-nortestosterone    O
derivatives    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
and    O
norethisterone    O
enanthate    O
.    O

The    O
first    O
progestogen    O
esters    O
were    O
not    O
introduced    O
until    O
the    O
mid-1950s    O
,    O
and    O
were    O
esters    O
of    O
17α-hydroxyprogesterone    O
(    O
which    O
,    O
unlike    O
progesterone    O
,    O
has    O
a    O
hydroxy    O
group    O
available    O
for    O
esterification    O
)    O
rather    O
than    O
of    O
progesterone    O
;    O
they    O
included    O
17α-hydroxyprogesterone    B-Hormone105407119
caproate    I-Hormone105407119
(    O
Delalutin    O
,    O
Proluton    O
)    O
and    O
17α-hydroxyprogesterone    O
acetate    O
(    O
Prodrox    O
)    O
.    O

Hydroxyprogesterone    B-Hormone105407119
caproate    I-Hormone105407119
(    O
Delalutin    O
,    O
Proluton    O
)    O
,    O
the    O
first    O
progestogen    O
ester    O
.    O

Hydroxyprogesterone    B-Hormone105407119
caproate    I-Hormone105407119

Of    O
the    O
eight    O
planned    O
phase    O
III    O
clinical    O
trials    O
of    O
weekly    O
taspoglutide    O
(    O
four    O
against    O
exenatide    O
,    O
sitagliptin    B-Hormone105407119
,    O
insulin    B-Hormone105407119
glargine    I-Hormone105407119
,    O
and    O
pioglitazone    O
)    O
,    O
at    O
least    O
five    O
were    O
active    O
in    O
2009    O
.    O

The    O
2011    O
Award    O
Recipients    O
were    O
Nancy    O
Thornberry    O
and    O
Dr.    O
Ann    O
Weber    O
,    O
the    O
leaders    O
behind    O
the    O
development    O
of    O
Merck    O
's    O
Januvia    B-Hormone105407119
.    O

Drugs    O
:    O
diuretics    O
(    O
e.g.    O
,    O
thiazides    O
,    O
furosemide    O
)    O
,    O
gliptins    O
(    O
e.g.    O
,    O
vildagliptin    O
,    O
sitagliptin    B-Hormone105407119
,    O
saxagliptin    O
,    O
linagliptin    O
)    O
,    O
tetracycline    O
,    O
sulfonamides    O
,    O
estrogens    O
,    O
azathioprine    O
and    O
mercaptopurine    O
,    O
pentamidine    O
,    O
salicylates    O
,    O
steroids    O
,    O
Depakote    O

Sitagliptin    O
/    O
metformin    O
(    O
trade    O
name    O
Janumet    O
)    O
is    O
an    O
anti    O
-    O
diabetic    O
drug    O
,    O
being    O
a    O
combination    O
drug    O
of    O
sitagliptin    B-Hormone105407119
(    O
a    O
dipeptidyl    O
peptidase-4    O
inhibitor    O
)    O
and    O
metformin    O
.    O

Those    O
with    O
values    O
below    O
10    O
µg    O
/    O
mL    O
could    O
benefit    O
from    O
nutritional    O
counseling    O
,    O
and    O
medications    O
which    O
target    O
post    O
meal    O
glucose    O
spikes    O
,    O
such    O
as    O
pramlintide    B-Hormone105407119
,    O
exenatide    O
,    O
sitagliptin    B-Hormone105407119
,    O
saxagliptin    O
,    O
repaglinide    O
or    O
rapid    O
acting    O
insulins    O
.    O

Estradiol    B-Hormone105407119
dipropionate    I-Hormone105407119
(    O
BAN    O
,    O
JAN    O
)    O
(    O
brand    O
names    O
Agofollin    B-Hormone105407119
,    O
Di-Ovocyclin    B-Hormone105407119
,    O
Progynon    B-Hormone105407119
DP    I-Hormone105407119
,    O
others    O
)    O
is    O
a    O
semisynthetic    O
,    O
steroidal    O
estrogen    O
that    O
is    O
or    O
has    O
been    O
marketed    O
in    O
the    O
United    O
States    O
and    O
Europe    O
.    O

Along    O
with    O
estradiol    B-Hormone105407119
benzoate    I-Hormone105407119
,    O
estradiol    O
dipropionate    O
was    O
one    O
of    O
the    O
first    O
estradiol    O
esters    O
to    O
be    O
developed    O
,    O
having    O
been    O
patented    O
in    O
1937    O
,    O
was    O
assessed    O
in    O
clinical    O
studies    O
by    O
1939    O
,    O
and    O
has    O
been    O
marketed    O
by    O
Schering    O
as    O
Progynon    B-Hormone105407119
DP    I-Hormone105407119
and    O
Ciba    O
Pharmaceutical    O
Products    O
as    O
Di-Ovocylin    B-Hormone105407119
since    O
at    O
least    O
1940    O
.    O

Otobiotic    B-Hormone105407119
Otic    I-Hormone105407119
is    O
a    O
liquid    O
antibiotic    O
solution    O
used    O
to    O
treat    O
bacterial    O
infections    O
of    O
the    O
ear    O
.    O

Beclomethasone    B-Hormone105407119
dipropionate    I-Hormone105407119

One    O
commonly    O
used    O
therapy    O
is    O
beclometasone    B-Hormone105407119
dipropionate    I-Hormone105407119
.    O

They    O
may    O
be    O
found    O
anywhere    O
along    O
the    O
splenic    O
vessels    O
,    O
in    O
the    O
gastrosplenic    O
ligament    O
,    O
the    O
splenorenal    O
ligament    O
,    O
the    O
walls    O
of    O
the    O
stomach    O
or    O
intestines    O
,    O
the    O
pancreatic    O
tail    O
,    O
the    O
greater    O
omentum    O
,    O
the    O
mesentery    O
or    O
the    O
gonads    O
and    O
their    O
path    O
of    O
descent    B-Hormone105407119
.    O

Gonadogenesis    B-Hormone105407119

Melanotan    B-Hormone105407119
II    I-Hormone105407119

Melanotan    B-Hormone105407119
II    I-Hormone105407119

Melanotan    B-Hormone105407119
II    I-Hormone105407119

lipokine    B-Hormone105407119
”    O
and    O
showed    O
its    O
beneficial    O
actions    O
on    O
lipid    O
and    O
glucose    O
metabolism    O
.    O

Telapristone    B-Hormone105407119
(    O
INN    O
)    O
,    O
as    O
telapristone    B-Hormone105407119
acetate    I-Hormone105407119
(    O
proposed    O
brand    O
names    O
Proellex    B-Hormone105407119
,    O
Progenta    B-Hormone105407119
;    O
former    O
code    O
name    O
CDB-4124    B-Hormone105407119
)    O
,    O
is    O
a    O
synthetic    O
,    O
steroidal    O
selective    B-Hormone105407119
progesterone    I-Hormone105407119
receptor    I-Hormone105407119
modulator    I-Hormone105407119
(    O
SPRM    O
)    O
related    O
to    O
mifepristone    O
which    O
is    O
under    O
development    O
by    O
Repros    O
Therapeutics    O
for    O
the    O
treatment    O
of    O
breast    O
cancer    O
,    O
endometriosis    O
,    O
and    O
uterine    O
fibroids    O
.    O

telapristone    B-Hormone105407119
(    O
USAN    O
,    O
INN    O
)    O

Sulfonylureas    O
,    O
as    O
opposed    O
to    O
metformin    O
,    O
the    O
thiazolidinediones    O
,    O
exenatide    O
,    O
symlin    B-Hormone105407119
and    O
other    O
newer    O
treatment    O
agents    O
may    O
induce    O
hypoglycemia    O
as    O
a    O
result    O
of    O
excesses    O
in    O
insulin    O
production    O
and    O
release    O
.    O

Those    O
with    O
values    O
below    O
10    O
µg    O
/    O
mL    O
could    O
benefit    O
from    O
nutritional    O
counseling    O
,    O
and    O
medications    O
which    O
target    O
post    O
meal    O
glucose    O
spikes    O
,    O
such    O
as    O
pramlintide    B-Hormone105407119
,    O
exenatide    O
,    O
sitagliptin    B-Hormone105407119
,    O
saxagliptin    O
,    O
repaglinide    O
or    O
rapid    O
acting    O
insulins    O
.    O

The    O
only    O
brand    O
of    O
liotrix    O
available    O
in    O
the    O
U.S.    O
is    O
Thyrolar    B-Hormone105407119
,    O
manufactured    O
by    O
Forest    O
Laboratories    O
.    O

Local    B-Hormone105407119
hormone    I-Hormone105407119

In    O
contrast    O
to    O
however    O
,    O
they    O
are    O
non    O
-    O
selective    O
,    O
also    O
binding    O
to    O
other    O
steroid    B-Hormone105407119
hormone    I-Hormone105407119
receptor    I-Hormone105407119
,    O
and    O
exhibit    O
a    O
variety    O
of    O
other    O
activities    O
including    O
progestogenic    O
,    O
antigonadotropic    O
,    O
glucocorticoid    O
,    O
and/or    O
antimineralocorticoid    O
.    O

Additionally    O
,    O
one    O
study    O
found    O
that    O
soldiers    O
whose    O
leukocytes    O
had    O
greater    O
numbers    O
of    O
glucocorticoid    B-Hormone105407119
receptors    I-Hormone105407119
were    O
more    O
prone    O
to    O
developing    O
PTSD    O
after    O
experiencing    O
trauma    O
.    O

Steroid    B-Hormone105407119
hormone    I-Hormone105407119
receptor    I-Hormone105407119

For    O
example    O
,    O
a    O
recent    O
report    O
indicated    O
that    O
T    O
cells    O
could    O
be    O
modified    O
to    O
inactivate    O
the    O
glucocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
;    O
the    O
resulting    O
immune    O
cells    O
are    O
fully    O
functional    O
but    O
resistant    O
to    O
the    O
effects    O
of    O
commonly    O
used    O
corticosteroids    O
.    O

Guggulsterone    O
is    O
a    O
broad    O
-    O
spectrum    O
ligand    O
of    O
steroid    B-Hormone105407119
hormone    I-Hormone105407119
receptor    I-Hormone105407119
,    O
and    O
is    O
known    O
to    O
possess    O
the    O
following    O
activities    O
:    O

Although    O
inactive    O
at    O
steroid    B-Hormone105407119
hormone    I-Hormone105407119
receptor    I-Hormone105407119
,    O
E2S    O
has    O
been    O
found    O
to    O
act    O
as    O
a    O
potent    O
inhibitor    O
of    O
glutathione    O
S    O
-    O
transferase    O
,    O
an    O
enzyme    O
that    O
contributes    O
to    O
the    O
inactivation    O
of    O
estradiol    O
via    O
conversion    O
of    O
it    O
into    O
an    O
estradiol    O
-    O
glutathione    O
conjugate    O
.    O

Steroid    B-Hormone105407119
hormone    I-Hormone105407119
receptor    I-Hormone105407119

It    O
can    O
also    O
associate    O
with    O
two    O
heat    O
shock    O
proteins    O
(    O
hsp90    O
and    O
hsp70    O
)    O
and    O
thus    O
may    O
play    O
a    O
role    O
in    O
the    O
intracellular    O
trafficking    O
of    O
hetero    O
-    O
oligomeric    O
forms    O
of    O
the    O
steroid    B-Hormone105407119
hormone    I-Hormone105407119
receptor    I-Hormone105407119
.    O

Silandrone    B-Hormone105407119

Rapid    O
-    O
acting    O
insulin    O
analogs    O
such    O
as    O
lispro    B-Hormone105407119
(    O
brand    O
name    O
"    O
Humalog    O
"    O
,    O
made    O
by    O
Eli    O
Lilly    O
and    O
Company    O
)    O
and    O
aspart    B-Hormone105407119
(    O
brand    O
name    O
"    O
Novolog"/"Novorapid    O
"    O
,    O
made    O
by    O
Novo    O
Nordisk    O
and    O
"    O
Apidra    O
"    O
made    O
by    O
Sanofi    O
Aventis    O
)    O
are    O
preferred    O
by    O
many    O
clinicians    O
over    O
older    O
regular    O
insulin    O
for    O
meal    O
coverage    O
and    O
high    O
correction    O
.    O

This    O
allows    O
the    O
creation    O
of    O
a    O
novel    O
formulation    O
that    O
retains    O
the    O
smooth    O
control    O
of    O
a    O
long    O
-    O
acting    O
basal    O
with    O
rapid    O
-    O
acting    O
mealtime    O
control    O
from    O
insulin    B-Hormone105407119
aspart    I-Hormone105407119
.    O

3α,5α-Tetrahydrocorticosterone    B-Hormone105407119
(    O
3α,5α-THB    B-Hormone105407119
)    O
,    O
or    O
simply    O
tetrahydrocorticosterone    B-Hormone105407119
(    O
THB    B-Hormone105407119
or    O
THCC    B-Hormone105407119
)    O
,    O
is    O
an    O
endogenous    O
glucocorticoid    O
hormone    O
.    O

Ciclesonide    B-Hormone105407119

In    O
this    O
case    O
,    O
the    O
main    O
compounds    O
used    O
are    O
beclometasone    O
,    O
budesonide    B-Hormone105407119
,    O
fluticasone    B-Hormone105407119
,    O
mometasone    O
and    O
ciclesonide    B-Hormone105407119
.    O

Mestanolone    B-Hormone105407119

Mestanolone    B-Hormone105407119
(methylandrostanolone)    I-Hormone105407119

Delmadinone    B-Hormone105407119

Androisoxazole    B-Hormone105407119

The    O
astonishing    O
quantity    O
of    O
vitellogenin    B-Hormone105407119
,    O
a    O
precursor    O
of    O
lipo-    O
and    O
phosphoproteins    O
that    O
make    O
up    O
egg    O
-    O
yolk    O
protein    O
,    O
in    O
the    O
male    O
trout    O
population    O
from    O
River    O
Lea    O
of    O
England    O
exceeded    O
that    O
of    O
females    O
just    O
before    O
ovulation    O
.    O

vaccine    O
-    O
vacuole    O
-    O
valence    O
-    O
valine    O
-    O
van    O
der    O
Waals    O
force    O
-    O
van    O
der    O
Waals    O
radius    O
-    O
vapor    O
pressure    O
-    O
vapour    O
pressure    O
-    O
vasoactive    B-Hormone105407119
intestinal    I-Hormone105407119
peptide    I-Hormone105407119
-    O
vasoactive    O
intestinal    O
peptide    O
receptor    O
-    O
vasopressin    O
-    O
vasopressin    O
receptor    O
-    O
venom    O
-    O
vertebrate    O
photoreceptor    O
-    O
vesicle    O
-    O
vestibular    O
system    O
-    O
vimentin    O
-    O
viral    O
envelope    O
protein    O
-    O
viral    O
oncogene    O
protein    O
-    O
viral    O
protein    O
-    O
virology    O
-    O
virus    O
(    O
biology    O
)    O
-    O
vitamin    O
-    O
vitamin    O
D    O
-    O
dependent    O
calcium    O
-    O
binding    O
protein    O
-    O
vitellogenin    B-Hormone105407119
-    O
vitronectin    O
-    O
von    O
Willebrand    O
factor    O
-    O

Vitellogenin    B-Hormone105407119
,    O
a    O
sex    O
-    O
specific    O
protein    O
,    O
is    O
synthesized    O
in    O
the    O
liver    O
of    O
fish    O
in    O
response    O
to    O
estrogen    O
,    O
a    O
female    O
hormone    O
.    O

This    O
application    O
has    O
now    O
been    O
applied    O
to    O
,    O
human    O
growth    O
hormones    O
,    O
follistim    B-Hormone105407119
(    O
for    O
treating    O
infertility    O
)    O
,    O
human    O
albumin    O
,    O
monoclonal    O
antibodies    O
,    O
antihemophilic    O
factors    O
,    O
vaccines    O
and    O
many    O
other    O
drugs    O
.    O

Follistim    B-Hormone105407119

Ouabain    B-Hormone105407119

Within    O
the    O
last    O
decade    O
[    O
when    O
?    O
]    O
,    O
many    O
independent    O
labs    O
have    O
demonstrated    O
that    O
,    O
in    O
addition    O
to    O
the    O
classical    O
ion    O
transporting    O
,    O
this    O
membrane    O
protein    O
can    O
also    O
relay    O
extracellular    O
ouabain    B-Hormone105407119
-    O
binding    O
signalling    O
into    O
the    O
cell    O
through    O
regulation    O
of    O
protein    O
tyrosine    O
phosphorylation    O
.    O

For    O
instance    O
,    O
--ATPase    O
found    O
in    O
the    O
membrane    O
of    O
heart    O
cells    O
is    O
an    O
important    O
target    O
of    O
cardiac    O
glycosides    O
(    O
for    O
example    O
digoxin    O
and    O
ouabain    B-Hormone105407119
)    O
,    O
inotropic    O
drugs    O
used    O
to    O
improve    O
heart    O
performance    O
by    O
increasing    O
its    O
force    O
of    O
contraction    O
.    O

Post    O
had    O
recently    O
discovered    O
that    O
three    O
sodium    O
ions    O
were    O
pumped    O
out    O
of    O
the    O
cell    O
for    O
every    O
two    O
potassium    O
ions    O
pumped    O
in    O
,    O
and    O
in    O
his    O
research    O
he    O
had    O
made    O
use    O
of    O
a    O
substance    O
called    O
ouabain    B-Hormone105407119
which    O
had    O
recently    O
been    O
shown    O
to    O
inhibit    O
the    O
pump    O
.    O

An    O
increase    O
in    O
extracellular    O
K+    O
has    O
been    O
shown    O
to    O
activate    O
an    O
ouabain    B-Hormone105407119
-    O
sensitive    O
electrogenic    O
Na+–K+-ATPase    O
followed    O
by    O
hyperpolarization    O
and    O
smooth    O
muscle    O
cell    O
relaxation    O
.    O

Promestriene    B-Hormone105407119
(    O
Colpotrofin    O
,    O
Colpotrophine    O
,    O
Delipoderm    O
)    O
–    O
the    O
3-propyl    O
and    O
17β-methyl    O
diether    O
of    O
estradiol    O

For    O
instance    O
,    O
19-norsteroids    O
(    O
e.g.    O
,    O
19-norprogesterone    B-Hormone105407119
)    O
constitute    O
an    O
important    O
class    O
of    O
natural    O
and    O
synthetic    O
steroids    O
derived    O
by    O
removal    O
of    O
the    O
methyl    O
group    O
of    O
the    O
natural    O
product    O
progesterone    O
;    O
the    O
equivalent    O
change    O
between    O
testosterone    O
and    O
19-nortestosterone    O
(    O
nandrolone    O
)    O
is    O
illustrated    O
below    O
.    O

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-Hormone105407119
)    O
,    O
desogestrel    B-Hormone105407119
,    O
ethylestrenol    B-Hormone105407119
,    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
ethinylestradiol    O
,    O
gestrinone    B-Hormone105407119
,    O
levonorgestrel    B-Hormone105407119
,    O
norethisterone    B-Hormone105407119
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    B-Hormone105407119
)    O
,    O
quinestrol    B-Hormone105407119
,    O
19-norprogesterone    B-Hormone105407119
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-Hormone105407119
acetate    I-Hormone105407119
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
.    O

The    O
elaboration    O
of    O
a    O
method    O
for    O
the    O
reduction    O
of    O
aromatic    O
rings    O
to    O
the    O
corresponding    O
dihydrobenzenes    O
under    O
controlled    O
conditions    O
by    O
A.    O
J.    O
Birch    O
opened    O
a    O
convenient    O
route    O
to    O
compounds    O
related    O
to    O
the    O
putative    O
19-norprogesterone    B-Hormone105407119
.    O

NOMAC    O
is    O
a    O
norpregnane    O
steroid    O
and    O
a    O
derivative    O
of    O
progesterone    O
belonging    O
to    O
the    O
19-norprogesterone    B-Hormone105407119
and    O
17α-hydroxyprogesterone    O
groups    O
.    O

Norelgestromin    B-Hormone105407119

The    O
estranes    O
include    O
norethisterone    B-Hormone105407119
(    O
norethindrone    O
)    O
,    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
norethisterone    O
enanthate    O
,    O
lynestrenol    B-Hormone105407119
,    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-Hormone105407119
,    O
desogestrel    B-Hormone105407119
,    O
etonogestrel    B-Hormone105407119
,    O
gestodene    B-Hormone105407119
,    O
norgestimate    B-Hormone105407119
,    O
dienogest    B-Hormone105407119
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    B-Hormone105407119
.    O

Nidoflor    O
(    O
cream    O
,    O
combined    O
with    O
neomycin    O
sulfate    O
and    O
triamcinolone    B-Hormone105407119
acetonide    I-Hormone105407119
)    O

Animax    O
(    O
veterinary    O
topical    O
ointment    O
or    O
cream    O
;    O
combined    O
with    O
neomycin    O
sulfate    O
,    O
thiostrepton    O
and    O
triamcinolone    B-Hormone105407119
acetonide    I-Hormone105407119
)    O

Amcinonide    B-Hormone105407119
,    O
budesonide    B-Hormone105407119
,    O
desonide    B-Hormone105407119
,    O
fluocinolone    B-Hormone105407119
acetonide    I-Hormone105407119
,    O
fluocinonide    B-Hormone105407119
,    O
halcinonide    B-Hormone105407119
,    O
and    O
triamcinolone    B-Hormone105407119
acetonide    I-Hormone105407119
.    O

Triamcinolone    B-Hormone105407119
acetonide    I-Hormone105407119

It    O
is    O
injected    O
into    O
the    O
heel    O
when    O
treating    O
plantar    O
fasciitis    O
,    O
sometimes    O
in    O
conjunction    O
with    O
triamcinolone    B-Hormone105407119
acetonide    I-Hormone105407119
.    O

Additionally    O
,    O
intralesional    O
injection    O
with    O
a    O
corticosteroid    O
such    O
as    O
Kenalog    B-Hormone105407119
does    O
appear    O
to    O
aid    O
in    O
the    O
reduction    O
of    O
inflammation    O
and    O
pruritus    O
.    O

Work    O
has    O
been    O
reported    O
in    O
the    O
scientific    O
literature    O
into    O
the    O
incorporation    O
of    O
lispro    B-Hormone105407119
(    O
Humalog    B-Hormone105407119
rapidly    O
acting    O
insulin    B-Hormone105407119
analogues    I-Hormone105407119
,    O
and    O
the    O
glargine    B-Hormone105407119
(    O
Lantus    B-Hormone105407119
)    O
very    O
long    O
-    O
acting    O
insulin    O
analogue    O
,    O
into    O
the    O
freeware    O
diabetes    O
simulator    O
.    O

The    O
other    O
type    O
is    O
long    O
acting    O
insulin    O
;    O
the    O
first    O
of    O
these    O
was    O
Lantus    B-Hormone105407119
(    O
insulin    O
glargine    O
)    O
.    O

Long    O
-    O
acting    O
insulin    B-Hormone105407119
analog    I-Hormone105407119
such    O
as    O
insulin    B-Hormone105407119
glargine    I-Hormone105407119
(    O
brand    O
name    O
"    O
Lantus    O
"    O
,    O
made    O
by    O
Sanofi    O
-    O
Aventis    O
)    O
and    O
insulin    O
detemir    O
(    O
brand    O
name    O
"    O
Levemir    O
"    O
,    O
made    O
by    O
Novo    O
Nordisk    O
)    O
are    O
also    O
used    O
,    O
with    O
insulin    O
glargine    O
used    O
more    O
than    O
insulin    O
detemir    O
.    O

It    O
has    O
a    O
duration    O
of    O
action    O
that    O
lasts    O
up    O
to    O
42    O
hours    O
(    O
compared    O
to    O
18    O
to    O
26    O
hours    O
provided    O
by    O
other    O
marketed    O
long    O
-    O
acting    O
insulins    O
such    O
as    O
insulin    B-Hormone105407119
glargine    I-Hormone105407119
and    O
insulin    O
detemir    O
)    O
,    O
making    O
it    O
a    O
once    O
-    O
daily    O
basal    O
insulin    O
,    O
that    O
is    O
one    O
that    O
provides    O
a    O
base    O
insulin    O
level    O
,    O
as    O
opposed    O
to    O
the    O
fast    O
and    O
short    O
acting    O
bolus    O
insulins    O
.    O

Most    O
applications    O
have    O
been    O
oriented    O
in    O
detecting    O
environmentally    O
harmful    O
chemicals    O
like    O
environmental    B-Hormone105407119
hormones    I-Hormone105407119
.    O

Methylprednisolone    B-Hormone105407119

However    O
,    O
most    O
vasculitis    O
in    O
general    O
are    O
treated    O
with    O
steroids    O
(    O
e.g.    O
methylprednisolone    B-Hormone105407119
)    O
because    O
the    O
underlying    O
cause    O
of    O
the    O
vasculitis    O
is    O
due    O
to    O
hyperactive    O
immunological    O
damage    O
.    O

Hydrocortisone    O
,    O
methylprednisolone    B-Hormone105407119
,    O
prednisolone    O
,    O
prednisone    O
,    O
and    O
triamcinolone    O
(    O
short-    O
to    O
medium    O
-    O
acting    O
glucocorticoids    O
)    O
.    O

The    O
preservative    O
-    O
free    O
methylprednisolone    B-Hormone105407119
acetate    O
(    O
MPA    O
)    O
injection    O
caused    O
limited    O
immunological    O
responsiveness    O
at    O
the    O
site    O
of    O
inoculation    O
,    O
allowed    O
the    O
fungus    O
to    O
be    O
vasculotropic    O
thus    O
resulting    O
in    O
a    O
necrotizing    O
fatal    O
disease    O
of    O
the    O
Central    O
nervous    O
system    O
(    O
CNS    O
)    O
.    O

In    O
adrenal    O
insufficiency    O
and    O
Addison    O
's    O
disease    O
,    O
dexamethasone    O
is    O
prescribed    O
when    O
the    O
patient    O
does    O
not    O
respond    O
well    O
to    O
prednisone    O
or    O
methylprednisolone    B-Hormone105407119
.    O

Methylprednisolone    B-Hormone105407119
therapy    O
shows    O
some    O
promise    O
in    O
short    O
-    O
term    O
prevention    O
of    O
attacks    O
,    O
even    O
though    O
its    O
mechanism    O
of    O
action    O
is    O
yet    O
to    O
be    O
discovered    O
.    O

The    O
patient    O
had    O
complete    O
resolution    O
of    O
symptoms    O
after    O
intravenous    O
therapy    O
with    O
methylprednisolone    B-Hormone105407119
.    O

High    O
dose    O
immunosuppression    O
is    O
required    O
(    O
intravenous    O
methylprednisolone    B-Hormone105407119
)    O
and    O
cyclophosphamide    O
,    O
plus    O
plasmapheresis    O
.    O

In    O
2007    O
Kyyrö    O
was    O
found    O
guilty    O
of    O
methylprednisolone    B-Hormone105407119
doping    O
.    O

Urgent    O
medical    O
attention    O
in    O
this    O
phase    O
consists    O
of    O
fluid    O
resuscitation    O
efforts    O
,    O
mainly    O
the    O
intravenous    O
administration    O
of    O
saline    O
solution    O
plus    O
hetastarch    O
or    O
albumin    O
and    O
colloids    O
(    O
to    O
increase    O
the    O
remaining    O
blood    O
flow    O
to    O
vital    O
organs    O
like    O
the    O
kidneys    O
)    O
,    O
as    O
well    O
as    O
glucocorticoids    O
(    O
steroids    O
like    O
methylprednisolone    B-Hormone105407119
,    O
to    O
reduce    O
or    O
stop    O
the    O
capillary    O
leak    O
)    O
.    O

Bolenol    B-Hormone105407119
(ethylnorandrostenol)    I-Hormone105407119

Derivatives    O
of    O
ethyltestosterone    O
include    O
norethandrolone    O
(    O
ethylnandrolone    O
,    O
ethylestrenolone    O
)    O
,    O
ethylestrenol    B-Hormone105407119
(    O
ethylnandrol    O
)    O
,    O
norboletone    B-Hormone105407119
,    O
ethyldienolone    O
,    O
tetrahydrogestrinone    B-Hormone105407119
,    O
bolenol    B-Hormone105407119
(    O
ethylnorandrostenol    O
)    O
,    O
and    O
propetandrol    B-Hormone105407119
.    O

Gastrin    O
and    O
secretin    B-Hormone105407119
may    O
also    O
act    O
as    O
secretagogues    O
.    O

"    O
They    O
take    O
a    O
similar    O
viewpoint    O
with    O
regard    O
to    O
the    O
use    O
of    O
secretin    B-Hormone105407119
.    O

S    O
cells    O
secrete    O
secretin    B-Hormone105407119
from    O
the    O
duodenum    O
and    O
jejunum    O
,    O
and    O
stimulate    O
exocrine    O
pancreatic    O
secretion    O
.    O

There    O
are    O
several    O
different    O
types    O
which    O
secrete    O
the    O
hormones    O
secretin    B-Hormone105407119
,    O
cholecystokinin    O
and    O
several    O
others    O
.    O

These    O
cells    O
are    O
commonly    O
known    O
as    O
duct    O
cells    O
,    O
and    O
secrete    O
an    O
aqueous    O
bicarbonate    O
solution    O
under    O
stimulation    O
by    O
the    O
hormone    O
secretin    B-Hormone105407119
.    O

The    O
excitation    O
of    O
the    O
vagus    O
nerve    O
,    O
the    O
administration    O
of    O
gastrin    O
,    O
secretin    B-Hormone105407119
or    O
cholecystokinin    O
induce    O
PP    O
secretion    O
.    O

Secretin    B-Hormone105407119

Ductal    O
cells    O
are    O
stimulated    O
by    O
the    O
hormone    O
secretin    B-Hormone105407119
and    O
are    O
responsible    O
for    O
maintenance    O
of    O
the    O
duodenal    O
pH    O
and    O
prevention    O
of    O
duodenal    O
injury    O
from    O
acidic    O
chyme    O
.    O

Originally    O
,    O
Laidler    O
was    O
not    O
only    O
an    O
outspoken    O
advocate    O
of    O
alternative    O
autism    O
therapies    O
,    O
and    O
often    O
spoke    O
at    O
Defeat    O
Autism    O
Now    O
!    O
conferences    O
,    O
but    O
had    O
used    O
many    O
of    O
them    O
on    O
his    O
own    O
sons    O
,    O
including    O
chelation    O
therapy    O
,    O
secretin    B-Hormone105407119
,    O
and    O
a    O
number    O
of    O
dietary    O
supplements    O
such    O
as    O
dimethylglycine    O
.    O

Ductal    O
cells    O
of    O
the    O
pancreas    O
are    O
stimulated    O
by    O
the    O
hormone    O
secretin    B-Hormone105407119
to    O
produce    O
their    O
bicarbonate    O
-    O
rich    O
secretions    O
,    O
in    O
what    O
is    O
in    O
essence    O
a    O
bio    O
-    O
feedback    O
mechanism    O
;    O
highly    O
acidic    O
stomach    O
chyme    O
entering    O
the    O
duodenum    O
stimulates    O
duodenal    O
cells    O
called    O
"    O
S    O
cells    O
"    O
to    O
produce    O
the    O
hormone    O
secretin    O
and    O
release    O
to    O
the    O
bloodstream    O
.    O

secretin    B-Hormone105407119
:    O
This    O
is    O
an    O
endocrine    O
hormone    O
produced    O
by    O
the    O
duodenal    O
"    O
S    O
cells    O
"    O
in    O
response    O
to    O
the    O
acidity    O
of    O
the    O
gastric    O
chyme    O
.    O

anti-Müllerian    B-Hormone105407119
hormone    I-Hormone105407119
(    O
AMH    O
)    O
—    O
secreted    O
during    O
the    O
early    O
stages    O
of    O
fetal    O
life    O
.    O

These    O
receptors    O
bind    O
members    O
of    O
the    O
TGFβ    O
superfamily    O
of    O
growth    O
factor    O
and    O
cytokine    O
signaling    O
proteins    O
such    O
as    O
TGFβs    O
(    O
TGFβ1    O
,    O
TGFβ2    O
,    O
TGFβ3    O
)    O
,    O
bone    O
morphogenetic    O
proteins    O
(    O
BMPs    O
)    O
,    O
growth    O
differentiation    O
factors    O
(    O
GDFs    O
)    O
,    O
activin    O
and    O
inhibin    O
,    O
myostatin    B-Hormone105407119
,    O
anti-Müllerian    B-Hormone105407119
hormone    I-Hormone105407119
(    O
AMH    O
)    O
,    O
and    O
nodal    O
.    O

AMHR2    B-Hormone105407119
(    O
AMHR    O
)    O

Subsequent    O
development    O
of    O
one    O
set    O
and    O
degeneration    O
of    O
the    O
other    O
depends    O
on    O
the    O
presence    O
or    O
absence    O
of    O
two    O
testicular    O
hormones    O
:    O
testosterone    O
and    O
anti-müllerian    B-Hormone105407119
hormone    I-Hormone105407119
(AMH)    I-Hormone105407119
.    O

In    O
the    O
older    O
sister    O
,    O
anti-Müllerian    B-Hormone105407119
hormone    I-Hormone105407119
(    O
AMH    O
)    O
levels    O
were    O
normal    O
,    O
while    O
levels    O
of    O
inhibin    O
A    O
and    O
inhibin    O
B    O
were    O
significantly    O
increased    O
.    O

It    O
should    O
start    O
with    O
response    O
prediction    O
by    O
e.g.    O
age    O
,    O
antral    O
follicle    O
count    O
and    O
level    O
of    O
anti-Müllerian    B-Hormone105407119
hormone    I-Hormone105407119
.    O

In    O
women    O
with    O
cancer    O
,    O
a    O
testing    O
for    O
the    O
level    O
of    O
anti-Müllerian    B-Hormone105407119
hormone    I-Hormone105407119
(    O
AMH    O
)    O
is    O
useful    O
in    O
predicting    O
the    O
long    O
-    O
term    O
post    O
-    O
chemotherapy    O
loss    O
of    O
ovarian    O
function    O
,    O
in    O
turn    O
predicting    O
the    O
need    O
for    O
fertility    O
preservation    O
strategies    O
.    O

|rowspan=2|    O
Anti-Müllerian    B-Hormone105407119
hormone    I-Hormone105407119
(    O
AMH    O
)    O

These    O
tumors    O
also    O
lead    O
to    O
an    O
excess    O
of    O
GH    O
,    O
either    O
because    O
they    O
produce    O
GH    O
themselves    O
or    O
,    O
more    O
frequently    O
,    O
because    O
they    O
produce    O
GHRH    B-Hormone105407119
(    O
growth    O
hormone    O
releasing    O
hormone    O
)    O
,    O
the    O
hormone    O
that    O
stimulates    O
the    O
pituitary    O
to    O
make    O
GH    O
.    O

Human    O
growth    O
hormone    O
(    O
HGH    O
)    O
,    O
also    O
referred    O
to    O
as    O
'    O
growth    O
hormone    O
'    O
(    O
GH    O
)    O
,    O
and    O
also    O
as    O
somatotropin    O
,    O
is    O
released    O
under    O
the    O
influence    O
of    O
hypothalamic    O
growth    B-Hormone105407119
hormone-releasing    I-Hormone105407119
hormone    I-Hormone105407119
(    O
GHRH    O
)    O
,    O
and    O
is    O
inhibited    O
by    O
hypothalamic    O
somatostatin    B-Hormone105407119

Growth    B-Hormone105407119
hormone-releasing    I-Hormone105407119
hormone    I-Hormone105407119
(    O
GHRH    O
)    O

Delta    O
wave    O
signalling    O
arising    O
either    O
in    O
the    O
thalamus    O
or    O
in    O
the    O
cortex    O
influences    O
the    O
secretion    O
of    O
releasing    O
hormones    O
;    O
GHRH    B-Hormone105407119
and    O
prolactin    O
are    O
stimulated    O
whilst    O
TRH    O
is    O
inhibited    O
.    O

Growth    O
hormone    O
-    O
releasing    O
hormone    O
(    O
GHRH    B-Hormone105407119
)    O
:    O
regulates    O
the    O
release    O
of    O
growth    O
hormone    O
from    O
the    O
anterior    O
pituitary    O
;    O
as    O
the    O
name    O
suggests    O
,    O
its    O
main    O
function    O
is    O
to    O
help    O
control    O
cell    O
growth    O
,    O
metabolism    O
,    O
and    O
reproduction    O

Endocrine    O
systems    O
controlled    O
by    O
the    O
hypothalamus    O
are    O
regulated    O
by    O
anti    O
-    O
diuretic    O
hormone    O
(    O
ADH    O
)    O
,    O
corticotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
,    O
gonadotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
,    O
growth    B-Hormone105407119
hormone-releasing    I-Hormone105407119
hormone    I-Hormone105407119
,    O
oxytocin    O
,    O
all    O
of    O
which    O
are    O
secreted    O
by    O
the    O
hypothalamus    O
.    O

Growth    B-Hormone105407119
hormone-releasing    I-Hormone105407119
hormone    I-Hormone105407119
(    O
GHRH    O
)    O
is    O
another    O
releasing    O
factor    O
secreted    O
by    O
the    O
hypothalamus    O
.    O

Phytoecdysteroids    O
are    O
plant    O
-    O
derived    O
ecdysteroid    B-Hormone105407119
.    O

Various    O
species    O
contain    O
apigenin    O
,    O
luteolin    O
,    O
quercetin    O
,    O
other    O
flavonoids    O
and    O
ecdysteroid    B-Hormone105407119
.    O

These    O
glands    O
secrete    O
an    O
ecdysteroid    B-Hormone105407119
called    O
ecdysone    B-Hormone105407119
,    O
or    O
the    O
moulting    O
hormone    O
,    O
which    O
initiates    O
the    O
epidermal    O
moulting    O
process    O
.    O

18-Hydroxycorticosterone    B-Hormone105407119
is    O
a    O
derivative    O
of    O
corticosterone    O
.    O

According    O
to    O
the    O
report    O
,    O
Bigbie    O
admitted    O
to    O
purchasing    O
and    O
using    O
a    O
variety    O
of    O
performance    O
-    O
enhancing    O
substances    O
from    O
Kirk    O
Radomski    O
from    O
2001    O
to    O
2005    O
,    O
including    O
human    B-Hormone105407119
growth    I-Hormone105407119
hormone    I-Hormone105407119
,    O
Deca    O
-    O
Durabolin    O
,    O
Sustanon    B-Hormone105407119
,    O
testosterone    O
,    O
and    O
anti    O
-    O
estrogen    O
drugs    O
.    O

Products    O
include    O
:    O
Bridion    O
,    O
Esmirtazapine    O
,    O
Remeron    O
,    O
Remeron    O
SolTab    O
,    O
Sustanon    B-Hormone105407119
,    O
Deca    O
-    O
Durabolin    O
,    O
Pregnyl    O
,    O
Implanon    O
,    O
NuvaRing    O
,    O
Marvelon    O
,    O
Desolett    O
and    O
a    O
variety    O
of    O
other    O
contraceptive    O
products    O
.    O

dopexamine    B-Hormone105407119
(    O
INN    O
)    O

Modified    B-Hormone105407119
GRF    I-Hormone105407119
(1-29)    I-Hormone105407119

The    O
rubiscolins    B-Hormone105407119
are    O
a    O
group    O
of    O
opioid    O
peptides    O
that    O
are    O
formed    O
during    O
digestion    O
of    O
the    O
ribulose    O
bisphosphate    O
carboxylase    O
/    O
oxygenase    O
(    O
Rubisco    O
)    O
protein    O
from    O
spinach    O
leaves    O
.    O

The    O
most    O
studied    O
roles    O
of    O
PDE3B    O
have    O
been    O
in    O
the    O
areas    O
of    O
insulin    O
,    O
IGF1    B-Hormone105407119
,    O
and    O
leptin    B-Hormone105407119
signaling    O
.    O

Diagnosis    O
is    O
by    O
measuring    O
growth    O
hormone    O
after    O
a    O
person    O
has    O
drunk    O
glucose    O
or    O
by    O
measuring    O
insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
I    I-Hormone105407119
in    O
the    O
blood    O
.    O

IGF1    B-Hormone105407119
provides    O
the    O
most    O
sensitive    O
lab    O
test    O
for    O
the    O
diagnosis    O
of    O
acromegaly    O
,    O
and    O
a    O
GH    O
suppression    O
test    O
following    O
an    O
oral    O
glucose    O
load    O
,    O
which    O
is    O
a    O
very    O
specific    O
lab    O
test    O
,    O
will    O
confirm    O
the    O
diagnosis    O
following    O
a    O
positive    O
screening    O
test    O
for    O
IGF1    O
.    O

However    O
,    O
bromocriptine    O
lowers    O
GH    O
and    O
IGF-1    B-Hormone105407119
levels    O
and    O
reduces    O
tumor    O
size    O
in    O
fewer    O
than    O
half    O
of    O
patients    O
with    O
acromegaly    O
.    O

Recently    O
,    O
deer    O
antler    O
extract    O
has    O
become    O
popular    O
among    O
Western    O
athletes    O
and    O
body    O
builders    O
because    O
the    O
extract    O
,    O
with    O
its    O
trace    O
amounts    O
of    O
IGF-1    B-Hormone105407119
,    O
is    O
believed    O
to    O
help    O
build    O
and    O
repair    O
muscle    O
tissue    O
,    O
however    O
,    O
one    O
double    O
-    O
blind    O
study    O
did    O
not    O
find    O
evidence    O
of    O
intended    O
effects    O
.    O

Gluckman    O
had    O
success    O
with    O
his    O
innovative    O
studies    O
of    O
IGF-1    B-Hormone105407119
,    O
but    O
could    O
not    O
immediately    O
translate    O
this    O
to    O
clinical    O
practice    O
.    O

Growth    O
hormone    O
is    O
an    O
important    O
regulator    O
of    O
bone    O
growth    O
and    O
remodeling    O
in    O
adults    O
,    O
and    O
it    O
acts    O
via    O
insulin    O
-    O
like    O
growth    O
factor    O
I    O
(    O
IGF1    B-Hormone105407119
)    O
to    O
stimulate    O
osteoblastic    O
differentiation    O
.    O

Although    O
the    O
pathogenesis    O
of    O
cancer    O
cachexia    O
is    O
poorly    O
understood    O
,    O
multiple    O
biologic    O
pathways    O
are    O
known    O
to    O
be    O
involved    O
,    O
including    O
proinflammatory    O
cytokines    O
such    O
as    O
TNF    O
-    O
alpha    O
,    O
neuroendocrine    O
hormones    O
,    O
IGF-1    B-Hormone105407119
,    O
and    O
tumor    O
-    O
specific    O
factors    O
such    O
as    O
proteolysis    O
-    O
inducing    O
factor    O
.    O

This    O
complex    O
system    O
(    O
often    O
referred    O
to    O
as    O
the    O
IGF    O
"    O
axis    O
"    O
)    O
consists    O
of    O
two    O
cell    O
-    O
surface    O
receptors    O
(    O
IGF1R    O
and    O
IGF2R    O
)    O
,    O
two    O
ligands    O
(    O
Insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
1    I-Hormone105407119
(    O
IGF-1    O
)    O
and    O
Insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
2    I-Hormone105407119
(    O
IGF-2    O
)    O
)    O
,    O
a    O
family    O
of    O
six    O
high    O
-    O
affinity    O
IGF    O
-    O
binding    O
proteins    O
(    O
IGFBP-1    O
to    O
IGFBP-6    O
)    O
,    O
as    O
well    O
as    O
associated    O
IGFBP    O
degrading    O
enzymes    O
,    O
referred    O
to    O
collectively    O
as    O
proteases    O
.    O

Insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
1    I-Hormone105407119
(    O
IGF-1    O
,    O
or    O
sometimes    O
with    O
Roman    O
Numeral    O
as    O
IGF    O
-    O
I    O
)    O
is    O
mainly    O
secreted    O
by    O
the    O
liver    O
as    O
a    O
result    O
of    O
stimulation    O
by    O
growth    O
hormone    O
(    O
GH    O
)    O
.    O

Insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
2    I-Hormone105407119
(    O
IGF-2    O
,    O
or    O
sometimes    O
with    O
Roman    O
Numeral    O
as    O
IGF    O
-    O
II    O
)    O
is    O
thought    O
to    O
be    O
a    O
primary    O
growth    O
factor    O
required    O
for    O
early    O
development    O
while    O
IGF-1    B-Hormone105407119
expression    O
is    O
required    O
for    O
achieving    O
maximal    O
growth    O
.    O

The    O
IGF-1    O
receptor    O
is    O
the    O
"    O
physiological    O
"    O
receptor    O
—    O
IGF-1    B-Hormone105407119
binds    O
to    O
it    O
at    O
significantly    O
higher    O
affinity    O
than    O
it    O
binds    O
the    O
insulin    O
receptor    O
.    O

Insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
1    I-Hormone105407119

High    O
doses    O
of    O
insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
1    I-Hormone105407119
has    O
also    O
been    O
effective    O
in    O
patients    O
with    O
Rabson    O
–    O
Mendenhall    O
syndrome    O
.    O

There    O
may    O
also    O
be    O
an    O
effect    O
of    O
high    O
levels    O
of    O
insulin    O
to    O
activate    O
insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
1    I-Hormone105407119
(    O
IGF-1    O
)    O
receptor    O
in    O
those    O
same    O
cells    O
.    O

|rowspan=4|    O
IGF-1    B-Hormone105407119

Pegvisomant    O
blocks    O
the    O
action    O
of    O
growth    O
hormone    O
at    O
the    O
growth    O
hormone    O
receptor    O
to    O
reduce    O
the    O
production    O
of    O
IGF-1    B-Hormone105407119
.    O

It    O
is    O
thought    O
that    O
HGF    O
activates    O
satellite    O
cells    O
,    O
while    O
insulin    O
growth    O
factor    O
-    O
I    O
(    O
IGF-1    B-Hormone105407119
)    O
and    O
fibroblast    O
growth    O
factor    O
(    O
FGF    O
)    O
enhance    O
satellite    O
cell    O
proliferation    O
rate    O
following    O
activation    O
.    O

It    O
is    O
believed    O
to    O
be    O
a    O
major    O
fetal    O
growth    O
factor    O
in    O
contrast    O
to    O
Insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
1    I-Hormone105407119
,    O
which    O
is    O
a    O
major    O
growth    O
factor    O
in    O
adults    O
"    O
.    O

JCCC    O
scientists    O
also    O
identified    O
IGF-1    B-Hormone105407119
as    O
a    O
pathway    O
as    O
one    O
pathway    O
for    O
the    O
growth    O
of    O
tumors    O
.    O

Platelets    O
release    O
platelet    O
-    O
derived    O
growth    O
factor    O
(    O
PDGF    O
)    O
,    O
a    O
potent    O
chemotactic    O
agent    O
;    O
and    O
TGF    O
beta    O
,    O
which    O
stimulates    O
the    O
deposition    O
of    O
extracellular    O
matrix    O
;    O
fibroblast    O
growth    O
factor    O
,    O
insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
1    I-Hormone105407119
,    O
platelet    O
-    O
derived    O
epidermal    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
,    O
and    O
vascular    O
endothelial    O
growth    O
factor    O
.    O

The    O
effects    O
of    O
8β-VE2    O
and    O
ERβ    O
may    O
be    O
mediated    O
,    O
in    O
part    O
,    O
by    O
local    O
stimulation    O
of    O
insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
1    I-Hormone105407119
(    O
IGF-1)-induced    O
myogenic    O
protein    O
synthesis    O
,    O
as    O
8β-VE2    O
has    O
been    O
found    O
to    O
strongly    O
induce    O
expression    O
of    O
IGF-1    O
in    O
the    O
rat    O
levator    O
ani    O
muscle    O
.    O

Halobetasol    B-Hormone105407119
propionate    O
0.05%    O
(    O
Ultravate    O
,    O
Halox    O
)    O

The    O
antihistamine    O
azelastine    O
,    O
applied    O
as    O
a    O
nasal    O
spray    O
,    O
may    O
be    O
effective    O
for    O
vasomotor    O
rhinitis    O
.    O
Fluticasone    B-Hormone105407119
propionate    I-Hormone105407119
or    O
budesonide    B-Hormone105407119
(    O
both    O
are    O
steroids    O
)    O
in    O
nostril    O
spray    O
form    O

Fluticasone    B-Hormone105407119
propionate    I-Hormone105407119
,    O
C25H31F3O5S    O

A    O
variety    O
of    O
steroid    O
medications    O
,    O
from    O
anti    O
-    O
allergy    O
nasal    O
sprays    O
(    O
Nasonex    B-Hormone105407119
,    O
Flonase    B-Hormone105407119
)    O
to    O
topical    O
skin    O
creams    O
,    O
to    O
eye    O
drops    O
(    O
Tobradex    O
)    O
,    O
to    O
prednisone    O
have    O
been    O
implicated    O
in    O
the    O
development    O
of    O
CSR    O
.    O

Fluticasone    B-Hormone105407119
propionate    I-Hormone105407119

IL-17    O
induces    O
the    O
production    O
of    O
many    O
other    O
cytokines    O
(    O
such    O
as    O
IL-6    O
,    O
G-CSF    B-Hormone105407119
,    O
GM    O
-    O
CSF    O
,    O
IL-1β    O
,    O
TGF-β    O
,    O
TNF-α    O
)    O
,    O
chemokines    O
(    O
including    O
IL-8    O
,    O
GRO-α    O
,    O
and    O
MCP-1    O
)    O
,    O
and    O
prostaglandins    O
(    O
e.g.    O
,    O
PGE2    O
)    O
from    O
many    O
cell    O
types    O
(    O
fibroblasts    O
,    O
endothelial    O
cells    O
,    O
epithelial    O
cells    O
,    O
keratinocytes    O
,    O
and    O
macrophages    O
)    O
.    O

Recombinant    O
proteins    O
,    O
such    O
as    O
insulin    O
,    O
hepatitis    O
B    O
vaccine    O
,    O
interferon    O
,    O
granulocyte    B-Hormone105407119
colony-stimulating    I-Hormone105407119
factor    I-Hormone105407119
,    O
streptokinase    O
and    O
others    O
are    O
also    O
made    O
this    O
way    O
.    O

His    O
work    O
has    O
assisted    O
in    O
the    O
understanding    O
of    O
"    O
Chronic    O
HBV    O
Infection    O
"    O
,    O
Liver    O
cancer    O
and    O
the    O
B    O
and    O
C    O
variants    O
of    O
Hepatitis    O
and    O
his    O
recent    O
studies    O
on    O
"    O
acute    O
-    O
on    O
-    O
chronic    O
liver    O
failure    O
"    O
(    O
ACLF    O
)    O
disease    O
and    O
its    O
therapy    O
using    O
Granulocyte    B-Hormone105407119
colony-stimulating    I-Hormone105407119
factor    I-Hormone105407119
(    O
G    O
-    O
CSF    O
)    O
,    O
a    O
glycoprotein    O
is    O
known    O
to    O
have    O
been    O
successful    O
in    O
clinical    O
trials    O
.    O

Other    O
treatments    O
may    O
include    O
allopurinol    O
and    O
human    B-Hormone105407119
granulocyte    I-Hormone105407119
colony    I-Hormone105407119
stimulating    I-Hormone105407119
factor    I-Hormone105407119
.    O

Drug    O
-    O
induced    O
psoriasis    O
may    O
occur    O
with    O
beta    O
blockers    O
,    O
lithium    O
,    O
antimalarial    O
medications    O
,    O
non    O
-    O
steroidal    O
anti    O
-    O
inflammatory    O
drugs    O
,    O
terbinafine    O
,    O
calcium    O
channel    O
blockers    O
,    O
captopril    O
,    O
glyburide    O
,    O
granulocyte    B-Hormone105407119
colony-stimulating    I-Hormone105407119
factor    I-Hormone105407119
,    O
interleukins    O
,    O
interferons    O
,    O
lipid    O
-    O
lowering    O
drugs    O
,    O
and    O
paradoxically    O
TNF    O
inhibitors    O
such    O
as    O
infliximab    O
or    O
adalimumab    O
.    O

Together    O
with    O
Interleukin-2    O
(    O
IL-2    O
)    O
,    O
Interleukin-4    O
(    O
IL-4    O
)    O
,    O
Interleukin-7    O
(    O
IL-7    O
)    O
,    O
Interleukin-9    O
(    O
IL-9    O
)    O
,    O
granulocyte    B-Hormone105407119
colony-stimulating    I-Hormone105407119
factor    I-Hormone105407119
(    O
G-CSF    B-Hormone105407119
)    O
,    O
and    O
granulocyte    O
-    O
macrophage    O
colony    O
-    O
stimulating    O
factor    O
(    O
GM    O
-    O
CSF    O
)    O
,    O
IL-15    O
belongs    O
to    O
the    O
four    O
α-helix    O
bundle    O
family    O
of    O
cytokine    O
.    O

G-CSF    B-Hormone105407119
is    O
used    O
clinically    O
(    O
see    O
Neutropenia    O
)    O
but    O
tests    O
in    O
mice    O
suggest    O
it    O
may    O
lead    O
to    O
bone    O
loss    O
.    O

Atkinson    O
has    O
led    O
or    O
contributed    O
to    O
clinical    O
trials    O
utilizing    O
several    O
types    O
of    O
interventions    O
to    O
stop    O
the    O
progression    O
of    O
or    O
reverse    O
type    O
1    O
diabetes    O
,    O
including    O
prophylactic    O
insulin    O
,    O
glutamic    O
acid    O
decarboxylase    O
,    O
cord    O
blood    O
,    O
cord    O
blood    O
plus    O
Omega-3    O
FA    O
,    O
granulocyte    B-Hormone105407119
colony-stimulating    I-Hormone105407119
factor    I-Hormone105407119
(    O
GCSF    O
)    O
,    O
and    O
anti    O
-    O
thymocyte    O
globulin    O
(    O
ATG    O
)    O
plus    O
GCSF    O
.    O

These    O
are    O
difficult    O
to    O
distinguish    O
from    O
the    O
red    O
marrow    O
hyperplasia    O
of    O
hematopoiesis    O
,    O
as    O
can    O
occur    O
with    O
tobacco    O
smoking    O
,    O
chronically    O
anemic    O
disease    O
states    O
like    O
sickle    O
cell    O
anemia    O
or    O
beta    O
thalassemia    O
,    O
medications    O
such    O
as    O
granulocyte    B-Hormone105407119
colony-stimulating    I-Hormone105407119
factor    I-Hormone105407119
,    O
or    O
during    O
recovery    O
from    O
chronic    O
nutritional    O
anemias    O
or    O
therapeutic    O
bone    O
marrow    O
suppression    O
.    O

There    O
is    O
now    O
good    O
evidence    O
that    O
treatment    O
with    O
hematopoietic    O
growth    O
factors    O
—    O
including    O
granulocyte    B-Hormone105407119
colony-stimulating    I-Hormone105407119
factor    I-Hormone105407119
(    O
G    O
-    O
CSF    O
)    O
,    O
which    O
is    O
used    O
to    O
treat    O
AML    O
,    O
and    O
granulocyte    O
-    O
macrophage    O
colony    O
-    O
stimulating    O
factor    O
—    O
can    O
cause    O
SS    O
.    O
Lesions    O
typically    O
occur    O
when    O
the    O
patient    O
has    O
leukocytosis    O
and    O
neutrophilia    O
but    O
not    O
when    O
the    O
patient    O
is    O
neutropenic    O
.    O

Pegfilgrastim    O
(    O
Neulasta    O
)    O
–    O
PEGylated    O
recombinant    O
methionyl    O
human    O
granulocyte    B-Hormone105407119
colony-stimulating    I-Hormone105407119
factor    I-Hormone105407119
for    O
severe    O
cancer    O
chemotherapy    O
-    O
induced    O
neutropenia    O
(    O
Amgen    O
,    O
2002    O
)    O

At    O
the    O
current    O
time    O
,    O
G-CSF    B-Hormone105407119
is    O
the    O
main    O
drug    O
used    O
for    O
mobilization    O
;    O
it    O
indirectly    O
activates    O
CD117    O
.    O

A    O
brand    O
name    O
of    O
co-cyprindiol    B-Hormone105407119
(    O
cyproterone    O
acetate    O
/    O
ethinylestradiol    O
)    O
,    O
an    O
oral    O
contraceptive    O

Cyproterone    B-Hormone105407119
acetate    I-Hormone105407119

A    O
phase    O
III    O
clinical    O
trial    O
comparing    O
high    O
-    O
dose    O
intramuscular    O
cyproterone    B-Hormone105407119
acetate    I-Hormone105407119
(    O
300    O
mg    O
/    O
week    O
)    O
and    O
high    O
-    O
dose    O
intramuscular    O
estradiol    O
undecylate    O
(    O
100    O
mg    O
/    O
month    O
)    O
in    O
the    O
treatment    O
of    O
prostate    O
cancer    O
found    O
that    O
estradiol    O
undecylate    O
suppressed    O
testosterone    O
levels    O
into    O
the    O
castrate    O
range    O
(    O
<    O
50    O
ng    O
/    O
dL    O
)    O
within    O
at    O
least    O
3    O
months    O
whereas    O
testosterone    O
levels    O
with    O
cyproterone    O
acetate    O
were    O
significantly    O
higher    O
and    O
above    O
the    O
castrate    O
range    O
even    O
after    O
6    O
months    O
of    O
treatment    O
.    O

Spironolactone    O
is    O
frequently    O
used    O
as    O
a    O
component    O
of    O
hormone    O
replacement    O
therapy    O
in    O
transgender    O
women    O
,    O
especially    O
in    O
the    O
United    O
States    O
(    O
where    O
cyproterone    B-Hormone105407119
acetate    I-Hormone105407119
is    O
not    O
available    O
)    O
,    O
usually    O
in    O
addition    O
to    O
an    O
estrogen    O
.    O

Spironolactone    O
,    O
cyproterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
and    O
flutamide    O
are    O
some    O
of    O
the    O
most    O
well    O
-    O
known    O
and    O
widely    O
used    O
drugs    O
.    O

Spironolactone    O
,    O
similarly    O
to    O
other    O
steroidal    O
antiandrogens    O
such    O
as    O
cyproterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
is    O
actually    O
not    O
a    O
pure    O
,    O
or    O
"    O
silent    O
"    O
,    O
antagonist    O
of    O
the    O
AR    O
,    O
but    O
rather    O
is    O
a    O
weak    O
partial    O
agonist    O
with    O
the    O
capacity    O
for    O
both    O
antagonistic    O
and    O
agonistic    O
effects    O
.    O

Unlike    O
other    O
steroidal    O
antiandrogens    O
such    O
as    O
cyproterone    B-Hormone105407119
acetate    I-Hormone105407119
(    O
CPA    O
)    O
,    O
it    O
is    O
not    O
also    O
a    O
progestogen    O
,    O
instead    O
acting    O
as    O
a    O
selective    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
antagonist    O
similarly    O
to    O
nonsteroidal    O
antiandrogens    O
such    O
as    O
bicalutamide    O
.    O

The    O
binding    O
affinity    O
of    O
oxendolone    O
for    O
the    O
AR    O
is    O
far    O
lower    O
than    O
that    O
of    O
cyproterone    B-Hormone105407119
acetate    I-Hormone105407119
.    O

A    O
brand    O
name    O
of    O
the    O
oral    O
contraceptive    O
co-cyprindiol    B-Hormone105407119
(    O
cyproterone    O
acetate    O
/    O
ethinylestradiol    O
)    O

NOMAC    O
has    O
weak    O
or    O
moderate    O
antiandrogen    B-Hormone105407119
activity    O
(    O
5    O
to    O
20    O
times    O
less    O
than    O
that    O
of    O
cyproterone    B-Hormone105407119
acetate    I-Hormone105407119
(    O
a    O
strong    O
antiandrogen    O
)    O
,    O
with    O
approximately    O
12–31%    O
of    O
the    O
of    O
testosterone    O
for    O
the    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
)    O
.    O

Cyproterone    B-Hormone105407119
acetate    I-Hormone105407119
:    O
A    O
dual    O
antiandrogen    O
and    O
progestogen    O
.    O

A    O
brand    O
name    O
of    O
co-cyprindiol    B-Hormone105407119
(    O
cyproterone    O
acetate    O
/    O
ethinylestradiol    O
)    O
,    O
an    O
oral    O
contraceptive    O

Image    O
:    O
Calcitriol.svg    O
Calcitriol    B-Hormone105407119

Oxyphil    O
cells    O
have    O
been    O
shown    O
to    O
express    O
parathyroid    O
-    O
relevant    O
genes    O
found    O
in    O
the    O
chief    O
cells    O
and    O
have    O
the    O
potential    O
to    O
produce    O
additional    O
autocrine    O
/    O
paracrine    O
factors    O
,    O
such    O
as    O
parathyroid    B-Hormone105407119
hormone-related    I-Hormone105407119
protein    I-Hormone105407119
(PTHrP)    I-Hormone105407119
and    O
calcitriol    B-Hormone105407119
.    O

Calcitroic    O
acid    O
(    O
1α-hydroxy-23-carboxy-24,25,26,27-tetranorvitamin    O
D3    O
)    O
is    O
a    O
major    O
metabolite    O
of    O
1α,25-dihydroxyvitamin    B-Hormone105407119
D3    I-Hormone105407119
(    O
calcitriol    O
)    O
.    O

Synthesis    O
of    O
1,25-dihydroxyvitamin    B-Hormone105407119
D3    I-Hormone105407119
in    O
the    O
skin    O
,    O
however    O
,    O
is    O
dependent    O
on    O
ultraviolet    O
B    O
light    O
.    O

Calcitriol    B-Hormone105407119
,    O
the    O
active    O
form    O
of    O
vitamin    O
D    O
,    O
binds    O
to    O
the    O
VDR    O
,    O
which    O
then    O
forms    O
a    O
heterodimer    O
with    O
the    O
retinoid    O
-    O
X    O
receptor    O
.    O

Apo    O
A1    O
production    O
is    O
decreased    O
by    O
calcitriol    B-Hormone105407119
,    O
and    O
increased    O
by    O
a    O
drug    O
that    O
antagonizes    O
it    O
.    O

Calcitriol    B-Hormone105407119
(    O
1,25-dihydroxycholecalciferol    O
)    O
is    O
the    O
active    O
form    O
of    O
vitamin    O
D3    O
.    O

This    O
is    O
essentially    O
a    O
signaling    O
device    O
that    O
allows    O
the    O
T    O
-    O
cell    O
to    O
bind    O
to    O
the    O
active    O
form    O
of    O
vitamin    O
D    O
,    O
the    O
steroid    O
hormone    O
calcitriol    B-Hormone105407119
.    O

Expression    O
of    O
calbindin    O
-    O
D9k    O
,    O
like    O
that    O
of    O
calbindin    O
-    O
D28k    O
,    O
is    O
stimulated    O
by    O
the    O
active    O
vitamin    O
D    O
metabolite    O
,    O
calcitriol    B-Hormone105407119
although    O
the    O
precise    O
mechanisms    O
are    O
still    O
controversial    O
.    O

Secretion    O
of    O
the    O
active    O
form    O
of    O
vitamin    O
D    O
(    O
calcitriol    B-Hormone105407119
)    O
and    O
prostaglandins    O
.    O

Synthesis    O
of    O
osteopontin    O
is    O
stimulated    O
by    O
calcitriol    B-Hormone105407119
(    O
1,25-dihydroxy    O
-    O
vitamin    O
D3    O
)    O
.    O

Suppressed    O
calcitriol    B-Hormone105407119
levels    O

Dimethisterone    O
(    O
INN    O
,    O
USAN    O
,    O
BAN    O
)    O
(    O
brand    O
names    O
Lutagan    O
,    O
Secrosteron    O
)    O
,    O
also    O
known    O
as    O
6α,21-dimethylethisterone    O
,    O
is    O
a    O
steroidal    O
progestin    O
related    O
to    O
ethisterone    B-Hormone105407119
(    O
17α-ethinyltestosterone    O
)    O
.    O

ethisterone    B-Hormone105407119
(    O
INN    O
)    O

Nandrolone    O
,    O
together    O
with    O
ethisterone    B-Hormone105407119
(    O
17α-ethynyltestosterone    O
)    O
,    O
is    O
also    O
the    O
parent    O
compound    O
of    O
a    O
large    O
group    O
of    O
progestins    O
,    O
the    O
norethisterone    B-Hormone105407119
(    O
17α-ethynyl-19-nortestosterone    O
)    O
derivatives    O
.    O

Examples    O
include    O
drugs    O
such    O
as    O
Norethisterone    B-Hormone105407119
,    O
Ethisterone    B-Hormone105407119
,    O
and    O
Lynestrenol    B-Hormone105407119
.    O

Conversely    O
,    O
replacement    O
of    O
the    O
C17α    O
alkyl    O
group    O
with    O
an    O
ethynyl    O
group    O
greatly    O
reduces    O
but    O
does    O
not    O
abolish    O
androgenic    O
activity    O
,    O
as    O
in    O
ethisterone    B-Hormone105407119
(    O
17α-ethynyltestosterone    O
)    O
and    O
norethisterone    B-Hormone105407119
(    O
17α-ethynyl-19-nortestosterone    O
)    O
.    O

Thymosin    B-Hormone105407119
α1    I-Hormone105407119

GSTK1    O
has    O
been    O
observed    O
in    O
promoting    O
adiponectin    B-Hormone105407119
multimerization    O
in    O
the    O
endoplasmic    O
reticulum    O
(    O
ER    O
)    O
.    O

adiponectin    B-Hormone105407119

Osteocalcin    O
acts    O
as    O
a    O
hormone    O
in    O
the    O
body    O
,    O
causing    O
beta    O
cells    O
in    O
the    O
pancreas    O
to    O
release    O
more    O
insulin    O
,    O
and    O
at    O
the    O
same    O
time    O
directing    O
fat    O
cells    O
to    O
release    O
the    O
hormone    O
adiponectin    B-Hormone105407119
,    O
which    O
increases    O
sensitivity    O
to    O
insulin    O
.    O

A    O
2017    O
study    O
found    O
CLA    O
supplementation    O
has    O
been    O
associated    O
with    O
an    O
increase    O
plasma    O
C    O
-    O
reactive    O
protein    O
concentrations    O
and    O
a    O
reduction    O
in    O
serum    O
adiponectin    B-Hormone105407119
concentrations    O
,    O
which    O
indicates    O
that    O
CLA    O
supplements    O
have    O
a    O
pro    O
-    O
inflammatory    O
effect    O
.    O

This    O
dysregulation    O
contributes    O
to    O
excessive    O
visceral    O
fat    O
accumulation    O
and    O
reduced    O
adiponectin    B-Hormone105407119
release    O
from    O
abdominal    O
adipose    O
tissue    O
,    O
and    O
further    O
to    O
the    O
onset    O
of    O
several    O
cardiometabolic    O
risk    O
factors    O
that    O
are    O
associated    O
with    O
obesity    O
and    O
type    O
2    O
diabetes    O
.    O

Blood    O
plasma    O
of    O
these    O
mice    O
showed    O
elevated    O
levels    O
of    O
non    O
-    O
high    O
-    O
density    O
lipoproteins    O
,    O
cholesterol    O
,    O
triglycerides    O
,    O
non    O
-    O
esterified    O
fatty    O
acids    O
,    O
and    O
leptin    B-Hormone105407119
,    O
but    O
low    O
adiponectin    B-Hormone105407119
content    O
.    O

Starting    O
in    O
2011    O
,    O
POGO    O
conducted    O
an    O
investigation    O
into    O
conflicts    O
of    O
interest    O
of    O
an    O
advisory    O
committee    O
at    O
the    O
Food    O
and    O
Drug    O
Administration    O
that    O
was    O
reviewing    O
the    O
Yaz    O
and    O
Yasmin    B-Hormone105407119
birth    O
control    O
pills    O
.    O

Drospirenone    B-Hormone105407119

This    O
was    O
determined    O
to    O
be    O
due    O
to    O
metabolic    O
conversion    O
of    O
spirorenone    O
into    O
drospirenone    B-Hormone105407119
(    O
1,2-dihydrospirorenone    O
)    O
by    O
the    O
enzyme    O
Δ1-hydrase    O
,    O
a    O
transformation    O
that    O
occurs    O
only    O
in    O
monkeys    O
and    O
humans    O
.    O

Spironolactone    O
is    O
closely    O
structurally    O
related    O
to    O
other    O
clinically    O
used    O
spirolactones    O
such    O
as    O
canrenone    O
,    O
potassium    O
canrenoate    O
,    O
drospirenone    B-Hormone105407119
,    O
and    O
eplerenone    B-Hormone105407119
,    O
as    O
well    O
as    O
to    O
the    O
never    O
-    O
marketed    O
spirolactones    O
SC-5233    O
(    O
6,7-dihydrocanrenone    O
;    O
7α-desthioacetylspironolactone    O
)    O
,    O
SC-8109    O
(    O
19-nor-6,7-dihydrocanrenone    O
)    O
,    O
spiroxasone    O
,    O
prorenone    O
(    O
SC-23133    O
)    O
,    O
mexrenone    O
(    O
SC-25152    O
,    O
ZK-32055    O
)    O
,    O
dicirenone    O
(    O
SC-26304    O
)    O
,    O
spirorenone    O
(    O
ZK-35973    O
)    O
,    O
and    O
mespirenone    O
(    O
ZK-94679    O
)    O
.    O

Some    O
,    O
such    O
as    O
those    O
containing    O
cyproterone    O
acetate    O
or    O
drospirenone    B-Hormone105407119
,    O
also    O
have    O
additional    O
direct    O
antiandrogen    O
activity    O
.    O

A    O
new    O
4th    O
generation    O
progestin    O
,    O
drospirenone    B-Hormone105407119
,    O
used    O
in    O
some    O
oral    O
contraceptives    O
may    O
further    O
heighten    O
the    O
risk    O
of    O
gallstone    O
disease    O
and    O
cholecystectomy    O
;    O
however    O
,    O
the    O
increased    O
risk    O
is    O
quite    O
modest    O
and    O
not    O
likely    O
to    O
be    O
clinically    O
meaningful    O
.    O

4-Hydroxytestosterone    B-Hormone105407119
(    O
4-OHT    B-Hormone105407119
)    O
,    O
also    O
known    O
as    O
4,17β-dihydroxyandrost-4-en-3-one    B-Hormone105407119
,    O
is    O
a    O
synthetic    O
anabolic-androgenic    B-Hormone105407119
steroid    I-Hormone105407119
(    O
AAS    O
)    O
and    O
a    O
derivative    O
of    O
testosterone    O
that    O
was    O
never    O
marketed    O
.    O

Juvenile    B-Hormone105407119
hormone    I-Hormone105407119
(    O
JH    O
)    O
controls    O
insect    O
metamorphosis    O
.    O

Juvenile    B-Hormone105407119
hormone    I-Hormone105407119
esterase    O
is    O
induced    O
by    O
factors    O
naturally    O
occurring    O
in    O
the    O
head    O
of    O
insects    O
.    O

In    O
addition    O
,    O
it    O
is    O
induced    O
by    O
treatment    O
of    O
insects    O
with    O
either    O
natural    O
juvenile    B-Hormone105407119
hormone    I-Hormone105407119
,    O
with    O
JH    O
I    O
being    O
the    O
most    O
potent    O
inducer    O
.    O

The    O
role    O
of    O
juvenile    O
hormone    O
binding    O
proteins    O
are    O
also    O
important    O
,    O
as    O
they    O
afford    O
juvenile    B-Hormone105407119
hormone    I-Hormone105407119
protection    O
from    O
hydrolytic    O
enzymes    O
.    O

Injection    O
of    O
an    O
esterase    O
inhibitor    O
,    O
EPPAT    O
,    O
was    O
found    O
to    O
increase    O
juvenile    B-Hormone105407119
hormone    I-Hormone105407119
titers    O
,    O
and    O
starvation    O
was    O
found    O
to    O
increase    O
juvenile    O
hormone    O
titers    O
.    O

They    O
secrete    O
the    O
juvenile    B-Hormone105407119
hormone    I-Hormone105407119
,    O
which    O
regulate    O
reproduction    O
and    O
metamorphosis    O
.    O

Fluperolone    B-Hormone105407119
acetate    I-Hormone105407119

On    O
August    O
24    O
,    O
2007    O
,    O
Food    O
&    O
Water    O
Watch    O
announced    O
success    O
in    O
its    O
effort    O
to    O
get    O
Starbucks    O
Coffee    O
to    O
stop    O
using    O
milk    O
originating    O
from    O
rBGH    B-Hormone105407119
-    O
treated    O
cows    O
,    O
after    O
Starbucks    O
,    O
in    O
a    O
letter    O
to    O
executive    O
director    O
Wenonah    O
Hauter    O
,    O
stated    O
that    O
by    O
December    O
31    O
,    O
2007    O
,    O
all    O
of    O
the    O
dairy    O
products    O
used    O
in    O
company    O
-    O
operated    O
stores    O
would    O
be    O
produced    O
with    O
rBGH    O
-    O
free    O
milk    O
.    O

Efforts    O
to    O
prevent    O
sourcing    O
of    O
milk    O
from    O
cows    O
treated    O
with    O
rBGH    B-Hormone105407119
.    O

Bovine    B-Hormone105407119
somatotropin    I-Hormone105407119
,    O
a    O
type    O
of    O
growth    O
hormone    O

In    O
1998    O
and    O
1999    O
,    O
Chopra    O
,    O
along    O
with    O
two    O
co    O
-    O
workers    O
,    O
Drs    O
.    O
Margaret    O
Haydon    O
and    O
Gerard    O
Lambert    O
,    O
testified    O
to    O
the    O
Canadian    O
Senate    O
"    O
Standing    O
Committee    O
on    O
Agriculture    O
and    O
Forestry    O
"    O
that    O
they    O
were    O
pressured    O
by    O
senior    O
supervisors    O
to    O
approve    O
multiple    O
drugs    O
of    O
questionable    O
safety    O
,    O
including    O
Bovine    B-Hormone105407119
Growth    I-Hormone105407119
Hormone    I-Hormone105407119
(    O
rBST    O
)    O
and    O
Baytril    O
,    O
which    O
in    O
the    O
words    O
of    O
Chopra    O
,    O
"    O
is    O
even    O
more    O
controversial    O
.    O

Bovine    B-Hormone105407119
somatotropin    I-Hormone105407119
,    O
or    O
bovine    O
growth    O
hormone    O
,    O
is    O
a    O
naturally    O
produced    O
protein    O
in    O
cattle    O
.    O

As    O
a    O
side    O
effect    O
of    O
rBGH    B-Hormone105407119
,    O
Emily    O
suffered    O
from    O
uterine    O
cancer    O
and    O
died    O
on    O
March    O
30    O
,    O
2003    O
.    O

In    O
addition    O
to    O
270    O
scientific    O
articles    O
,    O
he    O
has    O
published    O
12    O
books    O
,    O
and    O
has    O
been    O
active    O
in    O
publicizing    O
claims    O
on    O
the    O
carcinogenic    O
properties    O
of    O
chlordane    O
pesticides    O
,    O
growth    B-Hormone105407119
hormones    I-Hormone105407119
in    O
milk    O
,    O
nitrosamines    O
in    O
bacon    O
,    O
saccharin    O
,    O
beverage    O
preservatives    O
,    O
and    O
other    O
food    O
additives    O
.    O

Kinevac    B-Hormone105407119

Gestaclone    B-Hormone105407119
(    O
INN    O
,    O
USAN    O
)    O
(    O
developmental    O
code    O
name    O
SH-1040    B-Hormone105407119
)    O
,    O
also    O
known    O
as    O
6-chloro-1α,2α:16α,17-"bis"methylene-4,6-pregnadiene-3,20-dione    B-Hormone105407119
,    O
is    O
a    O
steroidal    O
progestin    O
of    O
unique    O
chemical    O
structure    O
derived    O
from    O
progesterone    O
that    O
was    O
first    O
described    O
in    O
1967    O
and    O
was    O
never    O
marketed    O
.    O

Other    O
extracted    O
compounds    O
that    O
are    O
cytotoxic    O
towards    O
cancer    O
cells    O
include    O
xanthones    O
,    O
fellutamide    B-Hormone105407119
,    O
and    O
anthraquinones    O
.    O

Phytoestrogen    B-Hormone105407119
,    O
plant    O
compounds    O
with    O
estrogen    O
-    O
like    O
biological    O
activity    O
,    O
such    O
as    O
genistein    B-Hormone105407119
,    O
formononetin    B-Hormone105407119
,    O
biochanin    O
A    O
and    O
daidzein    O
,    O
as    O
well    O
as    O
a    O
mixture    O
of    O
these    O
phytoestrogens    O
were    O
found    O
able    O
to    O
reduce    O
E    O
-    O
selectin    O
as    O
well    O
as    O
VCAM-1    O
and    O
ICAM-1    O
on    O
cell    O
surface    O
and    O
in    O
culture    O
supernatant    O
.    O

Formononetin    B-Hormone105407119

Unlike    O
5α-dihydroprogesterone    O
,    O
5β-DHP    O
does    O
not    O
possess    O
affinity    O
for    O
the    O
progesterone    B-Hormone105407119
receptor    I-Hormone105407119
,    O
and    O
hence    O
,    O
is    O
not    O
a    O
progestogen    O
.    O

One    O
example    O
of    O
this    O
is    O
the    O
loss    O
of    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
ER    O
)    O
and    O
progesterone    B-Hormone105407119
receptor    I-Hormone105407119
(    O
PR    O
)    O
upon    O
anti    O
-    O
estrogen    O
treatment    O
of    O
breast    O
cancer    O

It    O
binds    O
to    O
the    O
progesterone    B-Hormone105407119
receptor    I-Hormone105407119
with    O
approximately    O
22%    O
of    O
the    O
affinity    O
of    O
progesterone    O
.    O

Progesterone    B-Hormone105407119
receptor    I-Hormone105407119
(    O
PR    O
)    O
agonist    O

It    O
binds    O
to    O
the    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
AR    O
)    O
(    O
Ki    O
=    O
320    O
nM    O
)    O
and    O
progesterone    B-Hormone105407119
receptor    I-Hormone105407119
(    O
Ki    O
=    O
20    O
nM    O
)    O
and    O
acts    O
as    O
a    O
weak    O
but    O
clinically    O
relevant    O
inhibitor    O
of    O
5α-reductase    O
(    O
IC50    O
=    O
1.4    O
μM    O
)    O
.    O

In    O
addition    O
to    O
the    O
mineralocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
,    O
prorenone    O
also    O
binds    O
to    O
the    O
glucocorticoid    B-Hormone105407119
,    O
androgen    B-Hormone105407119
,    O
and    O
progesterone    B-Hormone105407119
receptor    I-Hormone105407119
.    O

In    O
addition    O
to    O
the    O
mineralocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
,    O
mexrenone    O
also    O
binds    O
to    O
the    O
glucocorticoid    B-Hormone105407119
,    O
androgen    B-Hormone105407119
,    O
and    O
progesterone    B-Hormone105407119
receptor    I-Hormone105407119
.    O

Progesterone    B-Hormone105407119
receptor    I-Hormone105407119
partial    O
agonist    O
(    O
Ki    O
=    O
201    O
nM    O
)    O

Valproic    O
acid    O
has    O
been    O
found    O
to    O
be    O
an    O
antagonist    O
of    O
the    O
androgen    B-Hormone105407119
and    O
progesterone    B-Hormone105407119
receptor    I-Hormone105407119
,    O
and    O
hence    O
as    O
a    O
nonsteroidal    O
antiandrogen    B-Hormone105407119
and    O
antiprogestogen    O
,    O
at    O
concentrations    O
much    O
lower    O
than    O
therapeutic    O
serum    O
levels    O
.    O

In    O
general    O
,    O
ERs    O
and    O
progesterone    B-Hormone105407119
receptor    I-Hormone105407119
(    O
PRs    O
)    O
are    O
gene    O
activators    O
,    O
with    O
increased    O
mRNA    O
and    O
subsequent    O
protein    O
synthesis    O
following    O
hormone    O
exposure    O
.    O

NOMAC    O
is    O
a    O
potent    O
and    O
pure    O
progestogen    O
,    O
acting    O
as    O
a    O
selective    O
,    O
high    O
-    O
affinity    O
full    O
agonist    O
of    O
the    O
progesterone    B-Hormone105407119
receptor    I-Hormone105407119
(    O
PR    O
)    O
(    O
Ki    O
=    O
3    O
nM    O
,    O
67–303%    O
of    O
the    O
of    O
progesterone    O
)    O
,    O
and    O
is    O
said    O
to    O
have    O
higher    O
potency    O
and    O
substantially    O
improved    O
selectivity    O
for    O
the    O
PR    O
relative    O
to    O
medroxyprogesterone    B-Hormone105407119
acetate    I-Hormone105407119
(    O
the    O
6-hydrogenated    O
or    O
non-6    O
-    O
7-double    O
bonded    O
analogue    O
of    O
megestrol    O
acetate    O
and    O
the    O
most    O
widely    O
used    O
progestin    O
)    O
.    O

Women    O
affected    O
with    O
triple    O
negative    O
breast    O
cancer    O
(    O
TNBC    O
)    O
(    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
negative    O
,    O
progesterone    B-Hormone105407119
receptor    I-Hormone105407119
negative    O
,    O
and    O
HER2/neu    O
negative    O
)    O
under    O
the    O
age    O
of    O
50    O

As    O
a    O
SPRM    O
,    O
ulipristal    O
acetate    O
has    O
partial    O
agonistic    O
as    O
well    O
as    O
antagonistic    O
effects    O
on    O
the    O
progesterone    B-Hormone105407119
receptor    I-Hormone105407119
.    O

It    O
has    O
been    O
found    O
to    O
possess    O
slightly    O
lower    O
affinity    O
for    O
the    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
AR    O
)    O
and    O
progesterone    B-Hormone105407119
receptor    I-Hormone105407119
(    O
PR    O
)    O
relative    O
to    O
nandrolone    O
in    O
rat    O
and    O
rabbit    O
tissue    O
bioassays    O
,    O
whereas    O
trenbolone    O
was    O
found    O
to    O
possess    O
the    O
same    O
affinity    O
for    O
the    O
AR    O
as    O
dienolone    O
but    O
several    O
-    O
fold    O
increased    O
affinity    O
for    O
the    O
PR    O
.    O

It    O
contains    O
10    O
NR    O
-    O
interacting    O
boxes    O
(    O
LXXLL    O
motifs    O
)    O
and    O
functions    O
as    O
a    O
coregulator    O
of    O
several    O
nuclear    O
receptors    O
via    O
its    O
LXXLL    O
motifs    O
including    O
ESR1    O
,    O
ESR2    O
,    O
ERR    O
-    O
alpha    O
,    O
PR    B-Hormone105407119
,    O
GR    B-Hormone105407119
,    O
AR    B-Hormone105407119
,    O
and    O
RXR    O
.    O

In    O
addition    O
,    O
JDP2    O
has    O
been    O
shown    O
to    O
directly    O
associate    O
with    O
the    O
progesterone    B-Hormone105407119
receptor    I-Hormone105407119
(    O
PR    O
)    O
and    O
functionally    O
acts    O
as    O
a    O
coactivator    O
of    O
progesterone    O
-    O
dependent    O
PR    O
-    O
mediated    O
gene    O
transcription    O
.    O

Upregulation    O
of    O
GFAP    O
,    O
which    O
is    O
induced    O
by    O
FGF    O
,    O
TGFB    O
,    O
and    O
ciliary    B-Hormone105407119
neurotrophic    I-Hormone105407119
factor    I-Hormone105407119
(    O
CNTF    O
)    O
,    O
is    O
a    O
classic    O
marker    O
for    O
reactive    O
gliosis    O
.    O

The    O
progenitor    O
cells    O
and    O
radial    O
glial    O
cells    O
respond    O
to    O
extracellular    O
trophic    O
factors    O
-    O
like    O
ciliary    B-Hormone105407119
neurotrophic    I-Hormone105407119
factor    I-Hormone105407119
(    O
CNTF    O
)    O
,    O
cytokines    O
or    O
neuregulin    O
1    O
(    O
NRG1    O
)    O
-    O
that    O
can    O
determine    O
whether    O
the    O
cells    O
will    O
differentiate    O
into    O
either    O
neurons    O
or    O
glia    O
.    O

The    O
term    O
"    O
neurotrophic    O
factor    O
"    O
generally    O
refers    O
to    O
these    O
four    O
neurotrophins    O
,    O
the    O
GDNF    O
family    O
of    O
ligands    O
,    O
and    O
ciliary    B-Hormone105407119
neurotrophic    I-Hormone105407119
factor    I-Hormone105407119
(    O
CNTF    O
)    O
,    O
among    O
other    O
biomolecules    O
.    O
Neurotrophin-6    O
and    O

There    O
are    O
many    O
other    O
proteins    O
which    O
associate    O
with    O
gp130    O
,    O
such    O
as    O
cardiotrophin    O
1    O
(    O
CT-1    O
)    O
,    O
leukemia    O
inhibitory    O
factor    O
(    O
LIF    O
)    O
,    O
ciliary    B-Hormone105407119
neurotrophic    I-Hormone105407119
factor    I-Hormone105407119
(    O
CNTF    O
)    O
,    O
oncostatin    O
M    O
(    O
OSM    O
)    O
,    O
and    O
IL-11    O
.    O

The    O
results    O
came    O
in    O
on    O
the    O
day    O
of    O
the    O
announcement    O
and    O
revealed    O
Silva    O
tested    O
positive    O
for    O
drostanolone    B-Hormone105407119
metabolites    O
,    O
which    O
is    O
an    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
.    O

However    O
,    O
Casey    O
later    O
failed    O
a    O
post    O
-    O
fight    O
drug    O
test    O
for    O
drostanolone    B-Hormone105407119
,    O
a    O
form    O
of    O
anabolic    O
steroid    O
.    O

Drostanolone    B-Hormone105407119

However    O
,    O
Lawal    O
tested    O
positive    O
for    O
anabolic    O
steroids    O
(    O
Drostanolone    B-Hormone105407119
)    O
and    O
as    O
a    O
result    O
of    O
the    O
banned    O
substance    O
,    O
the    O
fight    O
's    O
result    O
has    O
been    O
changed    O
to    O
a    O
no    O
contest    O
while    O
Lawal    O
will    O
have    O
his    O
license    O
suspended    O
for    O
one    O
year    O
.    O

Balykina    O
tested    O
positive    O
for    O
drostanolone    B-Hormone105407119
in    O
an    O
out    O
-    O
of    O
-    O
competition    O
doping    O
test    O
in    O
June    O
2013    O
and    O
was    O
banned    O
from    O
competitive    O
athletics    O
for    O
two    O
years    O
.    O

She    O
tested    O
positive    O
for    O
the    O
banned    O
steroid    O
drostanolone    B-Hormone105407119
right    O
after    O
winning    O
the    O
60    O
metres    O
event    O
at    O
the    O
2013    O
European    O
Athletics    O
Indoor    O
Championships    O
held    O
in    O
Gothenburg    O
in    O
March    O
.    O

Difluoromethyldopa    B-Hormone105407119

Flunisolide    B-Hormone105407119

Flunisolide    B-Hormone105407119

For    O
those    O
who    O
are    O
unresponsive    O
to    O
somatostatin    O
analogues    O
,    O
or    O
for    O
whom    O
they    O
are    O
otherwise    O
contraindicated    O
,    O
it    O
is    O
possible    O
to    O
treat    O
using    O
one    O
of    O
the    O
dopamine    O
agonists    O
,    O
bromocriptine    B-Hormone105407119
or    O
cabergoline    B-Hormone105407119
.    O

Cabergoline    B-Hormone105407119
is    O
derived    O
from    O
a    O
number    O
of    O
ergot    O
alkaloids    O
one    O
of    O
which    O
is    O
lysergic    O
acid    O
and    O
Simvastatin    O
is    O
based    O
on    O
Lovastatin    O
.    O

Dopamine    O
agonists    O
include    O
bromocriptine    B-Hormone105407119
,    O
pergolide    O
,    O
pramipexole    B-Hormone105407119
,    O
ropinirole    O
,    O
piribedil    O
,    O
cabergoline    B-Hormone105407119
,    O
apomorphine    O
and    O
lisuride    O
.    O

The    O
D2    O
receptor    O
is    O
involved    O
in    O
the    O
regulation    O
of    O
prolactin    O
secretion    O
,    O
and    O
agonists    O
of    O
the    O
receptor    O
such    O
as    O
bromocriptine    B-Hormone105407119
and    O
cabergoline    B-Hormone105407119
decrease    O
prolactin    O
levels    O
while    O
antagonists    O
of    O
the    O
receptor    O
such    O
as    O
domperidone    O
,    O
metoclopramide    O
,    O
haloperidol    O
,    O
risperidone    O
,    O
and    O
sulpiride    O
increase    O
prolactin    O
levels    O
.    O

Prolactinomas    O
are    O
most    O
often    O
treated    O
with    O
cabergoline    B-Hormone105407119
or    O
quinagolide    O
(    O
both    O
dopamine    O
agonists    O
)    O
,    O
which    O
decrease    O
tumor    O
size    O
as    O
well    O
as    O
alleviates    O
symptoms    O
,    O
followed    O
by    O
serial    O
imaging    O
to    O
detect    O
any    O
increase    O
in    O
size    O
.    O

Another    O
chemical    O
which    O
is    O
considered    O
to    O
be    O
responsible    O
for    O
the    O
male    O
refractory    O
period    O
is    O
prolactin    O
,    O
which    O
represses    O
dopamine    O
,    O
which    O
is    O
responsible    O
for    O
sexual    O
arousal    O
.    O
Because    O
of    O
this    O
,    O
there    O
is    O
currently    O
an    O
experimental    O
interest    O
in    O
drugs    O
which    O
inhibit    O
prolactin    O
,    O
such    O
as    O
cabergoline    B-Hormone105407119
(    O
also    O
known    O
as    O
Cabeser    O
,    O
or    O
Dostinex    O
)    O
.    O

Cabergoline    B-Hormone105407119

Corticosteroids    O
such    O
as    O
prednisolone    O
and    O
deflazacort    B-Hormone105407119
lead    O
to    O
short    O
-    O
term    O
improvements    O
in    O
muscle    O
strength    O
and    O
function    O
up    O
to    O
2    O
years    O
.    O

Ghrelin    O
and    O
synthetic    O
ghrelin    O
mimetics    O
(    O
growth    O
hormone    O
secretagogues    O
)    O
increase    O
body    O
weight    O
and    O
fat    O
mass    O
by    O
triggering    O
receptors    O
in    O
the    O
arcuate    O
nucleus    O
that    O
include    O
the    O
orexigenic    O
neuropeptide    B-Hormone105407119
Y    I-Hormone105407119
(    O
NPY    O
)    O
and    O
agouti    O
-    O
related    O
protein    O
(    O
AgRP    O
)    O
neurons    O
.    O

Alteration    O
of    O
control    O
loop    O
:    O
High    O
levels    O
of    O
leptin    B-Hormone105407119
,    O
a    O
hormone    O
secreted    O
by    O
adipocytes    O
,    O
block    O
the    O
release    O
of    O
Neuropeptide    B-Hormone105407119
Y    I-Hormone105407119
)    O
,    O
which    O
is    O
the    O
most    O
potent    O
feeding    O
-    O
stimulatory    O
peptide    O
in    O
the    O
hypothalamic    O
orexigenic    O
network    O
,    O
leading    O
to    O
decreased    O
energy    O
intake    O
,    O
but    O
high    O
metabolic    O
demand    O
for    O
nutrients    O
.    O

Changes    O
in    O
the    O
expression    O
of    O
neuropeptides    O
such    O
as    O
corticotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
and    O
neuropeptide    B-Hormone105407119
Y    I-Hormone105407119
may    O
play    O
a    O
role    O
in    O
benzodiazepine    O
dependence    O
.    O

Neuropeptide    B-Hormone105407119
Y    I-Hormone105407119
(    O
endogenous    O
agonist    O
,    O
non    O
subtype    O
selective    O
)    O

counteracting    O
the    O
effects    O
of    O
neuropeptide    B-Hormone105407119
Y    I-Hormone105407119
,    O
a    O
potent    O
hunger    O
promoter    O
secreted    O
by    O
cells    O
in    O
the    O
gut    O
and    O
in    O
the    O
hypothalamus    O

Leptin    O
binds    O
to    O
neuropeptide    B-Hormone105407119
Y    I-Hormone105407119
(    O
NPY    O
)    O
neurons    O
in    O
the    O
arcuate    O
nucleus    O
in    O
such    O
a    O
way    O
as    O
to    O
decrease    O
the    O
activity    O
of    O
these    O
neurons    O
.    O

Leptin    O
receptor    O
activation    O
inhibits    O
neuropeptide    B-Hormone105407119
Y    I-Hormone105407119
(    O
NPY    O
)    O
and    O
agouti    O
-    O
related    O
peptide    O
(    O
AgRP    O
)    O
,    O
and    O
activates    O
α-melanocyte-stimulating    B-Hormone105407119
hormone    I-Hormone105407119
(    O
α-MSH    O
)    O
.    O

A    O
number    O
of    O
brain    O
-    O
signalling    O
molecules    O
(    O
neuropeptides    O
and    O
neurotransmitters    O
)    O
have    O
been    O
found    O
in    O
bone    O
,    O
including    O
adrenaline    O
,    O
noradrenaline    O
,    O
serotonin    O
,    O
calcitonin    O
gene    O
-    O
related    O
peptide    O
,    O
vasoactive    B-Hormone105407119
intestinal    I-Hormone105407119
peptide    I-Hormone105407119
and    O
neuropeptide    B-Hormone105407119
Y    I-Hormone105407119
Leptin    O
binds    O
to    O
its    O
receptors    O
in    O
the    O
hypothalamus    O
,    O
where    O
it    O
acts    O
through    O
the    O
sympathetic    O
nervous    O
system    O
to    O
regulate    O
bone    O
metabolism    O
.    O

Neuropeptide    B-Hormone105407119
Y    I-Hormone105407119
(NPY)    I-Hormone105407119
in    O
the    O
lateral    O
hypothalamus    O
induces    O
ravenous    O
eating    O
;    O
neurons    O
that    O
secrete    O
NPY    O
are    O
targeted    O
by    O
ghrelin    O
in    O
the    O
hypothalamus    O
.    O

Velneperit    O
(    O
S-2367    O
)    O
is    O
a    O
drug    O
developed    O
by    O
Shionogi    O
,    O
which    O
acts    O
as    O
a    O
potent    O
and    O
selective    O
antagonist    O
for    O
the    O
Neuropeptide    B-Hormone105407119
Y    I-Hormone105407119
receptor    O
Y5    O
.    O

Unlike    O
the    O
classical    O
preganglionic    O
Edinger    O
–    O
Westphal    O
neurons    O
that    O
contain    O
choline    O
acetyltransferase    O
,    O
neurons    O
of    O
the    O
non    O
-    O
preganglionic    O
Edinger    O
–    O
Westphal    O
nucleus    O
contain    O
various    O
neuropeptides    O
,    O
such    O
as    O
Urocortin    B-Hormone105407119
and    O
cocaine-    O
and    O
amphetamine    O
-    O
regulated    O
transcript    O
.    O

Urocortin    B-Hormone105407119
,    O
a    O
human    O
gene    O

Along    O
with    O
estradiol    B-Hormone105407119
valerate    I-Hormone105407119
,    O
estradiol    B-Hormone105407119
cypionate    I-Hormone105407119
,    O
and    O
estradiol    B-Hormone105407119
benzoate    I-Hormone105407119
,    O
estradiol    O
undecylate    O
is    O
or    O
has    O
been    O
used    O
as    O
an    O
intramuscular    O
estrogen    O
in    O
hormone    O
replacement    O
therapy    O
for    O
transgender    O
women    O
.    O

Along    O
with    O
estradiol    B-Hormone105407119
benzoate    I-Hormone105407119
,    O
estradiol    O
dipropionate    O
was    O
one    O
of    O
the    O
first    O
estradiol    O
esters    O
to    O
be    O
developed    O
,    O
having    O
been    O
patented    O
in    O
1937    O
,    O
was    O
assessed    O
in    O
clinical    O
studies    O
by    O
1939    O
,    O
and    O
has    O
been    O
marketed    O
by    O
Schering    O
as    O
Progynon    B-Hormone105407119
DP    I-Hormone105407119
and    O
Ciba    O
Pharmaceutical    O
Products    O
as    O
Di-Ovocylin    B-Hormone105407119
since    O
at    O
least    O
1940    O
.    O

Estradiol    B-Hormone105407119
benzoate    I-Hormone105407119

equine    B-Hormone105407119
chorionic    I-Hormone105407119
gonadotropin    I-Hormone105407119
–    O
gonadotropic    O
hormone    O
used    O
to    O
induce    O
ovulation    O
in    O
livestock    O
prior    O
to    O
artificial    O
insemination    O

eCG    O
-    O
equine    B-Hormone105407119
chorionic    I-Hormone105407119
gonadotropin    I-Hormone105407119
-    O
also    O
called    O
PMSG    O
(    O
pregnant    O
mare    O
serum    O
gonadotropin    O
)    O
:    O
chorionic    O
gonadotropins    O
secreted    O
if    O
the    O
mare    O
conceives    O
.    O

The    O
ligands    O
for    O
LPL    O
-    O
R    O
group    O
are    O
the    O
lysophospholipid    O
extracellular    O
signaling    O
molecules    O
,    O
lysophosphatidic    O
acid    O
(    O
LPA    O
)    O
and    O
sphingosine    B-Hormone105407119
1-phosphate    I-Hormone105407119
(    O
S1P    O
)    O
.    O

Sphingosine    O
kinase    O
1    O
phosphorylates    O
sphingosine    O
to    O
sphingosine-1-phosphate    B-Hormone105407119
(    O
S1P    O
)    O
SK1    O
is    O
normally    O
a    O
cytosolic    O
protein    O
but    O
is    O
recruited    O
to    O
membranes    O
rich    O
in    O
phosphatidate    O
(    O
PA    O
)    O
,    O
a    O
product    O
of    O
Phospholipase    O
D    O
(    O
PLD    O
)    O

Sphingosine-1-phosphate    B-Hormone105407119
(    O
S1P    O
)    O
is    O
a    O
novel    O
lipid    O
messenger    O
with    O
both    O
intracellular    O
and    O
extracellular    O
functions    O
.    O

It    O
has    O
been    O
proposed    O
that    O
sphingosine    B-Hormone105407119
1-phosphate    I-Hormone105407119
(    O
S1P    O
)    O
and    O
sphingosylphosphorylcholine    O
(    O
SPC    O
)    O
are    O
GPR3    O
ligands    O
,    O
however    O
this    O
result    O
was    O
not    O
confirmed    O
in    O
a    O
β-arrestin    O
recruitment    O
assay    O
.    O

Siponimod    O
(    O
INN    O
,    O
code    O
name    O
BAF312    O
)    O
is    O
a    O
selective    O
sphingosine-1-phosphate    B-Hormone105407119
receptor    O
modulator    O
for    O
oral    O
use    O
that    O
is    O
an    O
investigational    O
drug    O
for    O
multiple    O
sclerosis    O
(    O
MS    O
)    O
.    O

Interestingly    O
,    O
however    O
,    O
this    O
catalytic    O
triad    O
is    O
essential    O
for    O
the    O
dephosphorylation    O
of    O
lysophosphatidic    O
acid    O
,    O
phosphatidic    O
acid    O
,    O
and    O
sphingosine-1-phosphate    B-Hormone105407119
,    O
but    O
is    O
not    O
essential    O
in    O
its    O
entirety    O
for    O
the    O
enzyme    O
's    O
native    O
substrate    O
,    O
phosphatidylglycerol    O
phosphate    O
;    O
His-207    O
alone    O
is    O
sufficient    O
to    O
hydrolyze    O
PGP    O
.    O

Cyproterone    B-Hormone105407119

However    O
,    O
although    O
it    O
is    O
described    O
as    O
not    O
being    O
a    O
progestogen    O
,    O
benorterone    O
was    O
found    O
to    O
produce    O
"    O
a    O
highly    O
variable    O
decrease    O
in    O
plasma    O
testosterone    O
levels    O
"    O
(    O
the    O
reasons    O
for    O
this    O
are    O
unclear    O
,    O
as    O
other    O
pure    O
antiandrogens    O
such    O
as    O
cyproterone    B-Hormone105407119
(    O
"    O
not    O
"    O
CPA    O
)    O
and    O
bicalutamide    O
do    O
not    O
do    O
this    O
and    O
instead    O
produce    O
consistent    O
increases    O
in    O
testosterone    O
levels    O
)    O
.    O

#    O
#    O
GnRH    B-Hormone105407119
antagonist    I-Hormone105407119

analogues    O
include    O
agonists    O
like    O
leuprorelin    O
or    O
goserelin    O
and    O
antagonist    B-Hormone105407119
like    O
cetrorelix    O
.    O

Using    O
a    O
(    O
usually    O
longer    O
)    O
GnRH    O
agonist    O
protocol    O
or    O
a    O
(    O
usually    O
shorter    O
)    O
GnRH    B-Hormone105407119
antagonist    I-Hormone105407119
protocol    O
.    O

IVF    O
using    O
ovarian    O
hyperstimulation    O
,    O
including    O
gonadotropins    O
,    O
but    O
with    O
a    O
GnRH    B-Hormone105407119
antagonist    I-Hormone105407119
protocol    O
so    O
that    O
the    O
cycle    O
initiates    O
from    O
natural    O
mechanisms    O
.    O

Prokineticin    B-Hormone105407119
is    O
a    O
secreted    O
protein    O
that    O
potently    O
contracts    O
gastrointestinal    O
smooth    O
muscle    O
.    O

Growth    B-Hormone105407119
hormone    I-Hormone105407119
deficiency    I-Hormone105407119
is    O
treated    O
by    O
replacing    O
GH    O
.    O

The    O
FDA    O
issued    O
a    O
Safety    O
Alert    O
in    O
August    O
2011    O
,    O
communicating    O
the    O
fact    O
that    O
a    O
French    O
study    O
found    O
that    O
persons    O
with    O
certain    O
kinds    O
of    O
short    O
stature    O
(    O
idiopathic    O
growth    B-Hormone105407119
hormone    I-Hormone105407119
deficiency    I-Hormone105407119
and    O
idiopathic    O
or    O
gestational    O
short    O
stature    O
)    O
treated    O
with    O
recombinant    O
human    O
growth    O
hormone    O
during    O
childhood    O
and    O
who    O
were    O
followed    O
over    O
a    O
long    O
period    O
of    O
time    O
,    O
were    O
at    O
a    O
small    O
increased    O
risk    O
of    O
death    O
when    O
compared    O
to    O
individuals    O
in    O
the    O
general    O
population    O
of    O
France    O
.    O

Perhaps    O
the    O
most    O
famous    O
person    O
who    O
exemplified    O
the    O
appearance    O
of    O
untreated    O
congenital    O
growth    B-Hormone105407119
hormone    I-Hormone105407119
deficiency    I-Hormone105407119
was    O
Charles    O
Sherwood    O
Stratton    O
(    O
1838–1883    O
)    O
,    O
who    O
was    O
exhibited    O
by    O
P.    O
T.    O
Barnum    O
as    O
General    O
Tom    O
Thumb    O
,    O
and    O
married    O
Lavinia    O
Warren    O
.    O

Everyone    O
agrees    O
on    O
the    O
nature    O
and    O
diagnosis    O
of    O
severe    O
GH    B-Hormone105407119
deficiency    I-Hormone105407119
,    O
but    O
what    O
are    O
the    O
edges    O
and    O
variations    O
?    O

Idiopathic    B-Hormone105407119
growth    I-Hormone105407119
hormone    I-Hormone105407119
deficiency    I-Hormone105407119

Children    O
with    O
generalized    O
disorders    O
such    O
as    O
renal    O
diseases    O
,    O
cystic    O
fibrosis    O
,    O
diabetes    O
mellitus    O
,    O
growth    B-Hormone105407119
hormone    I-Hormone105407119
deficiency    I-Hormone105407119
,    O
and    O
osteogenesis    O
imperfecta    O
disorders    O
are    O
at    O
risk    O
.    O

Milonakis    O
has    O
growth    B-Hormone105407119
hormone    I-Hormone105407119
deficiency    I-Hormone105407119
,    O
which    O
gives    O
him    O
the    O
appearance    O
of    O
an    O
adolescent    O
boy    O
,    O
even    O
as    O
an    O
adult    O
.    O

Children    O
who    O
fall    O
significantly    O
below    O
the    O
normal    O
range    O
of    O
growth    O
curves    O
for    O
body    O
height    O
can    O
be    O
tested    O
for    O
growth    B-Hormone105407119
hormone    I-Hormone105407119
deficiency    I-Hormone105407119
and    O
might    O
be    O
treatable    O
with    O
hormone    O
injections    O
.    O

Newson    O
,    O
who    O
was    O
born    O
with    O
growth    B-Hormone105407119
hormone    I-Hormone105407119
deficiency    I-Hormone105407119
,    O
tried    O
out    O
powerlifting    O
for    O
the    O
first    O
time    O
in    O
2006    O
,    O
joining    O
the    O
Suffolk    O
Spartans    O
club    O
in    O
Colchester    O
in    O
2007    O
.    O

They    O
include    O
:    O
congenital    O
adrenal    O
hyperplasia    O
,    O
precocious    O
puberty    O
,    O
growth    B-Hormone105407119
hormone    I-Hormone105407119
deficiency    I-Hormone105407119
(    O
both    O
adults    O
and    O
children    O
)    O
,    O
panhypopituitarism    O
,    O
McCune    O
-    O
Albright    O
syndrome    O
,    O
Turner    O
syndrome    O
,    O
Russell    O
-    O
Silver    O
syndrome    O
,    O
thyroid    O
disorders    O
(    O
both    O
congenital    O
and    O
acquired    O
)    O
,    O
optic    O
nerve    O
hypoplasia    O
,    O
and    O
other    O
rare    O
disorders    O
.    O

In    O
the    O
GI    O
and    O
genitourinary    O
systems    O
,    O
anal    O
atresia    O
,    O
hypospadia    O
(    O
misplaced    O
urethra    O
)    O
,    O
and    O
hydronephrosis    O
may    O
exist    O
.    O
Adrenal    O
hypoplasia    O
and    O
growth    B-Hormone105407119
hormone    I-Hormone105407119
deficiency    I-Hormone105407119

Estraguard    B-Hormone105407119

Dienestrol    B-Hormone105407119

#    O
Nonsteroidal    O
stilbestrol    O
estrogens    O
including    O
:    O
diethylstilbestrol    O
,    O
dienestrol    B-Hormone105407119
and    O
Hexestrol    O

meprednisone    B-Hormone105407119
(    O
INN    O
)    O

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-Hormone105407119
)    O
,    O
desogestrel    B-Hormone105407119
,    O
ethylestrenol    B-Hormone105407119
,    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
ethinylestradiol    O
,    O
gestrinone    B-Hormone105407119
,    O
levonorgestrel    B-Hormone105407119
,    O
norethisterone    B-Hormone105407119
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    B-Hormone105407119
)    O
,    O
quinestrol    B-Hormone105407119
,    O
19-norprogesterone    B-Hormone105407119
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-Hormone105407119
acetate    I-Hormone105407119
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
.    O

Notable    O
examples    O
include    O
the    O
non-17α-alkylated    O
trenbolone    B-Hormone105407119
and    O
the    O
17α-alkylated    O
ethylestrenol    B-Hormone105407119
(    O
ethylnandrol    O
)    O
and    O
metribolone    B-Hormone105407119
(    O
R-1881    O
)    O
,    O
as    O
well    O
as    O
the    O
17α-alkylated    O
designer    O
steroids    O
norboletone    B-Hormone105407119
and    O
tetrahydrogestrinone    B-Hormone105407119
(    O
THG    O
)    O
.    O

Metribolone    B-Hormone105407119
(    O
methyltrienolone    O
,    O
R-1881    O
;    O
17α-methyl-δ9,11    O
-    O
19-NT    O
)    O

Metribolone    B-Hormone105407119

Metribolone    B-Hormone105407119
(methyltrienolone)    I-Hormone105407119

Sequencing    O
of    O
the    O
agouti    B-Hormone105407119
signalling    I-Hormone105407119
peptide    I-Hormone105407119
in    O
the    O
agouti    B-Hormone105407119
gene    I-Hormone105407119
coding    O
region    O
revealed    O
a    O
2-base    O
pair    O
deletion    O
in    O
black    O
domestic    O
cats    O
.    O

This    O
breed    O
has    O
erect    O
ears    O
with    O
a    O
wide    O
space    O
in    O
between    O
them    O
,    O
a    O
medium    O
to    O
long    O
muzzle    O
,    O
and    O
a    O
double    O
coat    O
of    O
various    O
shades    O
of    O
agouti    B-Hormone105407119
.    O

However    O
,    O
more    O
modern    O
study    O
attributes    O
the    O
variation    O
to    O
3    O
different    O
alleles    O
of    O
the    O
Agouti    B-Hormone105407119
gene    I-Hormone105407119
.    O

Each    O
individual    O
guard    O
hair    O
is    O
agouti    B-Hormone105407119
banded    O
along    O
its    O
length    O
.    O

Dermabet    B-Hormone105407119

Diprolene    B-Hormone105407119

Diprosone    B-Hormone105407119

Lotrisone    B-Hormone105407119

He    O
tested    O
positive    O
for    O
betamethasone    B-Hormone105407119
,    O
a    O
substance    O
that    O
was    O
banned    O
in    O
2016    O
.    O

Treatment    O
usually    O
involves    O
topical    O
corticosteroids    O
(    O
such    O
as    O
betamethasone    B-Hormone105407119
,    O
clobetasol    O
,    O
dexamethasone    O
,    O
and    O
triamcinolone    O
)    O
and    O
analgesics    O
,    O
or    O
if    O
these    O
are    O
ineffective    O
and    O
the    O
condition    O
is    O
severe    O
,    O
the    O
systemic    O
corticosteroids    O
may    O
be    O
used    O
.    O

Betamethasone    B-Hormone105407119

Beclometasone    O
,    O
betamethasone    B-Hormone105407119
,    O
dexamethasone    O
,    O
fluocortolone    B-Hormone105407119
,    O
halometasone    B-Hormone105407119
,    O
and    O
mometasone    O
.    O

Commonly    O
used    O
solutions    O
are    O
of    O
fluorometholone    B-Hormone105407119
,    O
medrysone    O
,    O
betamethasone    B-Hormone105407119
or    O
dexamethasone    O
.    O

South    O
Korea    O
originally    O
won    O
the    O
bronze    O
medal    O
,    O
but    O
was    O
later    O
disqualified    O
after    O
Park    O
Tae    O
-    O
hwan    O
tested    O
positive    O
for    O
Nebido    B-Hormone105407119
.    O

South    O
Korea    O
originally    O
won    O
the    O
bronze    O
medal    O
,    O
but    O
was    O
later    O
disqualified    O
after    O
Park    O
Tae    O
-    O
hwan    O
tested    O
positive    O
for    O
Nebido    B-Hormone105407119
.    O

Park    O
Tae    O
-    O
hwan    O
of    O
South    O
Korea    O
originally    O
won    O
the    O
bronze    O
medal    O
,    O
but    O
was    O
later    O
disqualified    O
after    O
he    O
tested    O
positive    O
for    O
Nebido    B-Hormone105407119
.    O

Along    O
with    O
testosterone    O
cypionate    O
,    O
testosterone    O
enanthate    O
,    O
testosterone    O
propionate    O
,    O
and    O
testosterone    B-Hormone105407119
undecanoate    I-Hormone105407119
,    O
testosterone    O
buciclate    O
is    O
one    O
of    O
the    O
most    O
studied    O
testosterone    O
esters    O
.    O

Testosterone    O
buciclate    O
also    O
lasts    O
longer    O
than    O
testosterone    B-Hormone105407119
undecanoate    I-Hormone105407119
,    O
which    O
has    O
elimination    O
half    O
-    O
lives    O
and    O
mean    O
residence    O
times    O
of    O
20.9    O
days    O
and    O
34.9    O
days    O
in    O
tea    O
seed    O
oil    O
and    O
33.9    O
days    O
and    O
36.0    O
days    O
in    O
castor    O
oil    O
,    O
respectively    O
.    O

1-Testosterone    B-Hormone105407119

1-Testosterone    B-Hormone105407119
(    O
dihydroboldenone    O
;    O
δ1-DHT    O
)    O

Mesabolone    O
–    O
17β-(1-methyloxycyclohexyl    O
)    O
ether    O
of    O
1-testosterone    B-Hormone105407119
(    O
dihydroboldenone    O
)    O

Ciclesonide    B-Hormone105407119
,    O
cortisone    O
acetate    O
,    O
hydrocortisone    B-Hormone105407119
aceponate    I-Hormone105407119
,    O
hydrocortisone    O
acetate    O
,    O
hydrocortisone    B-Hormone105407119
buteprate    I-Hormone105407119
,    O
hydrocortisone    B-Hormone105407119
butyrate    I-Hormone105407119
,    O
hydrocortisone    O
valerate    O
,    O
prednicarbate    B-Hormone105407119
,    O
and    O
tixocortol    B-Hormone105407119
pivalate    I-Hormone105407119
.    O

Stenbolone    B-Hormone105407119
(    O
2-methyl-δ1-DHT    O
)    O

Stenbolone    B-Hormone105407119

Exemestane    B-Hormone105407119
,    O
a    O
drug    O
used    O
in    O
the    O
treatment    O
of    O
breast    O
cancer    O
,    O
is    O
an    O
inhibitor    O
of    O
the    O
aromatase    O
enzyme    O
.    O

Certain    O
medications    O
that    O
block    O
the    O
effect    O
of    O
estrogen    O
(    O
i.e.    O
tamoxifen    O
,    O
raloxifen    O
,    O
exemestane    B-Hormone105407119
)    O
can    O
reduce    O
the    O
risk    O
by    O
about    O
50%    O
but    O
also    O
have    O
side    O
effects    O
.    O

Breast    O
cancer    O
in    O
post    O
-    O
menopausal    O
women    O
with    O
advanced    O
hormone    O
-    O
receptor    O
positive    O
,    O
HER2-negative    O
type    O
cancer    O
,    O
in    O
conjunction    O
with    O
exemestane    B-Hormone105407119
(    O
US    O
FDA    O
July    O
2012    O
)    O

Interim    O
phase    O
III    O
trial    O
results    O
in    O
2011    O
showed    O
that    O
adding    O
Afinitor    O
(    O
everolimus    O
)    O
to    O
exemestane    B-Hormone105407119
therapy    O
against    O
advanced    O
breast    O
cancer    O
can    O
significantly    O
improve    O
progression    O
-    O
free    O
survival    O
compared    O
with    O
exemestane    O
therapy    O
alone    O
.    O

Of    O
the    O
synthesis    O
problems    O
,    O
congenital    O
adrenal    O
hyperplasia    O
is    O
the    O
most    O
common    O
(    O
in    O
various    O
forms    O
:    O
21-hydroxylase    O
,    O
17α-hydroxylase    O
,    O
11β-hydroxylase    O
and    O
3β-hydroxysteroid    O
dehydrogenase    O
)    O
,    O
lipoid    B-Hormone105407119
CAH    I-Hormone105407119
due    O
to    O
deficiency    O
of    O
StAR    O
and    O
mitochondrial    O
DNA    O
mutations    O
.    O

Mutations    O
in    O
the    O
CYP11A1    O
gene    O
result    O
in    O
a    O
steroid    O
hormone    O
deficiency    O
,    O
causing    O
a    O
minority    O
of    O
cases    O
of    O
the    O
rare    O
and    O
potentially    O
fatal    O
condition    O
lipoid    B-Hormone105407119
congenital    I-Hormone105407119
adrenal    I-Hormone105407119
hyperplasia    I-Hormone105407119
.    O

The    O
bradykinin    O
receptor    O
family    O
is    O
a    O
group    O
of    O
G    O
-    O
protein    O
coupled    O
receptors    O
whose    O
principal    O
ligand    O
is    O
the    O
protein    O
bradykinin    B-Hormone105407119
.    O

It    O
can    O
be    O
converted    O
to    O
bradykinin    B-Hormone105407119
by    O
the    O
aminopeptidase    O
enzyme    O
.    O

Kallidin    O
is    O
identical    O
to    O
bradykinin    B-Hormone105407119
with    O
an    O
additional    O
lysine    O
residue    O
added    O
at    O
the    O
N    O
-    O
terminal    O
end    O
and    O
signals    O
through    O
the    O
bradykinin    O
receptor    O
.    O

It    O
is    O
a    O
peptidomimetic    O
consisting    O
of    O
ten    O
amino    O
acids    O
,    O
which    O
is    O
a    O
selective    O
and    O
specific    O
antagonist    O
of    O
bradykinin    B-Hormone105407119
B2    O
receptors    O
.    O

Surplus    O
bradykinin    B-Hormone105407119
is    O
responsible    O
for    O
the    O
typical    O
symptoms    O
of    O
inflammation    O
,    O
such    O
as    O
swelling    O
,    O
redness    O
,    O
overheating    O
and    O
pain    O
.    O

Neprilysin    O
is    O
a    O
zinc    O
-    O
dependent    O
metalloprotease    O
that    O
cleaves    O
peptides    O
at    O
the    O
amino    O
side    O
of    O
hydrophobic    O
residues    O
and    O
inactivates    O
several    O
peptide    O
hormones    O
including    O
glucagon    O
,    O
enkephalins    O
,    O
substance    O
P    O
,    O
neurotensin    O
,    O
oxytocin    O
,    O
and    O
bradykinin    B-Hormone105407119
.    O

The    O
injection    O
of    O
IP    O
activators    O
into    O
the    O
skin    O
of    O
rodents    O
increases    O
local    O
capillary    O
permeability    O
and    O
swelling    O
;    O
IP(-/-    O
)    O
mice    O
fail    O
to    O
show    O
this    O
increased    O
capillary    O
permeability    O
and    O
swelling    O
in    O
response    O
not    O
only    O
to    O
IP    O
activators    O
but    O
also    O
in    O
a    O
model    O
of    O
carrageenan-    O
or    O
bradykinin    B-Hormone105407119
-    O
induced    O
paw    O
edema    O
.    O

Astacin    O
protease    O
domains    O
also    O
share    O
common    O
features    O
with    O
serralysins    O
,    O
matrix    O
metalloendopeptidases    O
,    O
and    O
snake    O
venom    O
proteases    O
;    O
they    O
cleave    O
peptide    O
bonds    O
in    O
polypeptides    O
such    O
as    O
insulin    O
B    O
chain    O
and    O
bradykinin    B-Hormone105407119
,    O
and    O
in    O
proteins    O
such    O
as    O
casein    O
and    O
gelatin    O
;    O
and    O
they    O
have    O
arylamidase    O
activity    O
.    O

The    O
control    O
and    O
regulation    O
mechanisms    O
of    O
the    O
circulatory    O
system    O
and    O
renal    O
functions    O
and    O
their    O
interactions    O
(    O
such    O
as    O
the    O
renin/angiotensin    B-Hormone105407119
system    I-Hormone105407119
)    O
are    O
also    O
greatly    O
influenced    O
by    O
autopharmacological    O
agents    O
;    O
One    O
of    O
the    O
autopharmacology    O
pioneers    O
was    O
Professor    O
Mauricio    O
Rocha    O
e    O
Silva    O
,    O
leader    O
of    O
the    O
team    O
of    O
Brazilian    O
researchers    O
who    O
discovered    O
bradykinin    B-Hormone105407119
in    O
1948    O
,    O
an    O
endogenous    O
substance    O
involved    O
in    O
hypotension    O
in    O
circulatory    O
shock    O
.    O

Bradykinin    B-Hormone105407119

Furthermore    O
,    O
platelets    O
-    O
derived    O
polyphosphates    O
activate    O
blood    O
coagulation    O
factor    O
XII    O
(    O
Hageman    O
factor    O
)    O
that    O
initiates    O
fibrin    O
formation    O
and    O
the    O
generation    O
of    O
a    O
proinflammatory    O
mediator    O
,    O
bradykinin    B-Hormone105407119
that    O
contributes    O
to    O
leakage    O
from    O
the    O
blood    O
vessels    O
and    O
thrombosis    O
.    O

Maurício    O
Rocha    O
e    O
Silva    O
,    O
professor    O
of    O
Pharmacology    O
,    O
discoverer    O
of    O
bradykinin    B-Hormone105407119

Steroid    B-Hormone105407119
atrophy,    I-Hormone105407119
or    O
corticosteroid-induced    B-Hormone105407119
dermal    I-Hormone105407119
atrophy    I-Hormone105407119
,    O
is    O
a    O
side    O
effect    O
of    O
prolonged    O
application    O
of    O
topical    B-Hormone105407119
corticosteroids    I-Hormone105407119
.    O

A    O
mild    O
topical    B-Hormone105407119
steroid    I-Hormone105407119
that    O
works    O
on    O
the    O
face    O
may    O
achieve    O
little    O
on    O
the    O
palm    O
.    O

Topical    B-Hormone105407119
steroid    I-Hormone105407119

Misdiagnosis    O
and    O
treatment    O
of    O
ringworm    O
with    O
a    O
topical    B-Hormone105407119
steroid    I-Hormone105407119
,    O
a    O
standard    O
treatment    O
of    O
the    O
superficially    O
similar    O
pityriasis    O
rosea    O
,    O
can    O
result    O
in    O
tinea    O
incognito    O
,    O
a    O
condition    O
where    O
ringworm    O
fungus    O
grows    O
without    O
typical    O
features    O
,    O
such    O
as    O
a    O
distinctive    O
raised    O
border    O
.    O

Tibolone    B-Hormone105407119

Tibolone    B-Hormone105407119

Tibolone    B-Hormone105407119

Estradiol    B-Hormone105407119
enanthate    I-Hormone105407119

For    O
comparison    O
,    O
the    O
ester    O
chains    O
of    O
estradiol    B-Hormone105407119
acetate    I-Hormone105407119
,    O
estradiol    B-Hormone105407119
valerate    I-Hormone105407119
,    O
and    O
estradiol    B-Hormone105407119
enanthate    I-Hormone105407119
have    O
2    O
,    O
5    O
,    O
and    O
7    O
carbon    O
atoms    O
,    O
respectively    O
.    O

Fluprednisolone    B-Hormone105407119
=    O
6α-fluoro-11β,17α,21-trihydroxypregna-1,4-diene-3,20-dione    O

Besides    O
functioning    O
as    O
antioxidant    O
and    O
anthelmintic    O
,    O
many    O
isoflavone    B-Hormone105407119
have    O
been    O
shown    O
to    O
interact    O
with    O
animal    O
and    O
human    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
,    O
causing    O
effects    O
in    O
the    O
body    O
similar    O
to    O
those    O
caused    O
by    O
the    O
hormone    O
estrogen    O
.    O

Isoflavone    B-Hormone105407119
also    O
produce    O
non    O
-    O
hormonal    O
effects    O
.    O

Genistein    O
may    O
act    O
as    O
direct    O
antioxidant    O
,    O
similar    O
to    O
many    O
other    O
isoflavone    B-Hormone105407119
,    O
and    O
thus    O
may    O
alleviate    O
damaging    O
effects    O
of    O
free    O
radicals    O
in    O
tissues    O
.    O

The    O
same    O
molecule    O
of    O
genistein    O
,    O
similar    O
to    O
many    O
other    O
isoflavone    B-Hormone105407119
,    O
by    O
generation    O
of    O
free    O
radicals    O
poison    O
topoisomerase    O
II    O
,    O
an    O
enzyme    O
important    O
for    O
maintaining    O
DNA    O
stability    O
.    O

While    O
investigating    O
its    O
anthelmintic    O
activity    O
,    O
genistein    O
was    O
found    O
to    O
be    O
the    O
major    O
isoflavone    B-Hormone105407119
responsible    O
for    O
the    O
deworming    O
property    O
.    O

Genistein    O
and    O
other    O
isoflavone    B-Hormone105407119
have    O
been    O
identified    O
as    O
angiogenesis    O
inhibitors    O
,    O
and    O
found    O
to    O
inhibit    O
the    O
uncontrolled    O
cell    O
growth    O
of    O
cancer    O
,    O
most    O
likely    O
by    O
inhibiting    O
the    O
activity    O
of    O
substances    O
in    O
the    O
body    O
that    O
regulate    O
cell    O
division    O
and    O
cell    O
survival    O
(    O
growth    O
factors    O
)    O
.    O

The    O
observation    O
that    O
transition    O
of    O
normal    O
lymphocytes    O
from    O
quiescence    O
(    O
G0    O
)    O
to    O
the    O
G1    O
phase    O
of    O
the    O
cell    O
cycle    O
is    O
particularly    O
sensitive    O
to    O
genistein    O
prompted    O
the    O
authors    O
to    O
suggest    O
that    O
this    O
isoflavone    B-Hormone105407119
may    O
be    O
potential    O
immunosuppressant    O
.    O

The    O
isoflavone    B-Hormone105407119
and    O
its    O
10-atom    O
benzopyran    O
"    O
fused    O
ring    O
"    O
system    O
,    O
also    O
a    O
structural    O
feature    O
here    O
,    O
is    O
common    O
in    O
polyphenols    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
isoflavone    B-Hormone105407119
,    O
whereas    O
its    O
two    O
products    O
are    O
S    O
-    O
adenosylhomocysteine    O
and    O
4'-O    O
-    O
methylisoflavone    O
.    O

Kudzu    O
contains    O
isoflavones    B-Hormone105407119
,    O
including    O
puerarin    O
(    O
about    O
60%    O
of    O
the    O
total    O
isoflavones    O
)    O
,    O
daidzein    O
,    O
daidzin    O
(    O
structurally    O
related    O
to    O
genistein    B-Hormone105407119
)    O
,    O
mirificin    O
,    O
and    O
salvianolic    O
acid    O
,    O
among    O
numerous    O
others    O
identified    O
.    O

Although    O
there    O
is    O
only    O
preclinical    O
evidence    O
for    O
a    O
possible    O
mechanism    O
,    O
the    O
meta    O
-    O
analysis    O
report    O
stated    O
that    O
soy    O
phytoestrogens    B-Hormone105407119
–    O
the    O
isoflavones    B-Hormone105407119
,    O
genistein    B-Hormone105407119
and    O
daidzein    O
–    O
may    O
be    O
involved    O
in    O
reducing    O
serum    O
cholesterol    O
levels    O
.    O

Rotenoids    O
are    O
related    O
to    O
the    O
isoflavone    B-Hormone105407119
.    O

Metanephrine    B-Hormone105407119
or    O
normetanephrine    O
to    O
vanillylmandelic    O
acid    O
(    O
VMA    O
)    O

Epinephrine    O
→    O
Metanephrine    B-Hormone105407119

Melengestrol    B-Hormone105407119
acetate    I-Hormone105407119

There    O
are    O
three    O
natural    O
hormones    O
(    O
estradiol    O
,    O
progesterone    O
,    O
and    O
testosterone    O
)    O
and    O
their    O
synthetic    O
alternatives    O
(    O
zeranol    O
,    O
melengestrol    B-Hormone105407119
acetate    I-Hormone105407119
,    O
and    O
trenbolone    O
acetate    O
)    O
have    O
been    O
approved    O
by    O
the    O
for    O
use    O
in    O
Canadian    O
beef    O
production    O
.    O

References    O
to    O
elephants    O
in    O
musth    O
(    O
whose    O
temporin    B-Hormone105407119
secretion    O
is    O
often    O
referred    O
to    O
as    O
"    O
ichor    O
"    O
)    O
are    O
frequent    O
in    O
classical    O
Indian    O
poetry    O
and    O
prose    O
;    O
for    O
example    O
,    O
in    O
the    O
"    O
Raghuvaṃśa    O
"    O
,    O
Kalidasa    O
says    O
that    O
the    O
king    O
’s    O
elephants    O
drip    O
ichor    O
in    O
seven    O
streams    O
to    O
match    O
the    O
scent    O
put    O
forth    O
by    O
the    O
seven    O
-    O
leaved    O
'    O
sapta    O
-    O
cchada    O
'    O
(=    O
"    O
seven    O
-    O
leaf    O
"    O
)    O
tree    O
(    O
perhaps    O
"    O
Alstonia    O
scholaris    O
"    O
)    O
.    O

The    O
frog    O
's    O
skin    O
also    O
secretes    O
temporin    B-Hormone105407119
,    O
a    O
tarlike    O
mixture    O
of    O
various    O
peptides    O
,    O
for    O
which    O
the    O
latter    O
part    O
of    O
its    O
scientific    O
name    O
is    O
denoted    O
translated    O
in    O
Latin    O
.    O

It    O
is    O
a    O
prodrug    O
of    O
norethisterone    B-Hormone105407119
,    O
with    O
both    O
quingestanol    B-Hormone105407119
and    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
serving    O
as    O
intermediates    O
in    O
the    O
transformation    O
.    O

Normethandrone    B-Hormone105407119
(    O
methylestrenolone    O
;    O
17α-methyl-19-NT    O
)    O

Normethandrone    B-Hormone105407119
(methylestrenolone,    I-Hormone105407119
normethisterone)    I-Hormone105407119

anabolic    O
to    O
androgenic    O
ratio    O
in    O
pharmacology    O
applications    O
such    O
as    O
methasterone    B-Hormone105407119

Methasterone    B-Hormone105407119
(methyldrostanolone)    I-Hormone105407119

Tiomesterone    B-Hormone105407119

Levothyroxine    B-Hormone105407119
,    O
also    O
known    O
as    O
-thyroxine    B-Hormone105407119
,    O
is    O
a    O
manufactured    O
form    O
of    O
the    O
thyroid    O
hormone    O
,    O
thyroxine    O
(    O
T4    O
)    O
.    O

The    O
generic    O
name    O
is    O
levothyroxine    B-Hormone105407119
,    O
and    O
several    O
brands    O
are    O
available    O
.    O

Levothyroxine    B-Hormone105407119
,    O
by    O
the    O
trade    O
name    O
"    O
Letter    O
"    O

Physicians    O
are    O
cautioned    O
to    O
avoid    O
switching    O
patients    O
from    O
branded    O
to    O
generic    O
,    O
or    O
between    O
different    O
generic    O
manufacturers    O
,    O
when    O
prescriping    O
anti    O
-    O
epileptic    O
drugs    O
,    O
warfarin    O
,    O
and    O
levothyroxine    B-Hormone105407119
.    O

After    O
the    O
removal    O
of    O
a    O
thyroid    O
,    O
patients    O
usually    O
take    O
a    O
prescribed    O
oral    O
synthetic    O
thyroid    O
hormone    O
—    O
levothyroxine    B-Hormone105407119
(    O
Synthroid)—to    O
prevent    O
hypothyroidism    O
.    O

Women    O
with    O
symptoms    O
or    O
a    O
very    O
high    O
TSH    O
level    O
,    O
or    O
both    O
,    O
are    O
usually    O
prescribed    O
a    O
course    O
of    O
levothyroxine    B-Hormone105407119
.    O

Animals    O
resistant    O
to    O
weight    O
loss    O
,    O
despite    O
diet    O
and    O
exercise    O
changes    O
,    O
can    O
be    O
placed    O
on    O
levothyroxine    B-Hormone105407119
to    O
increase    O
metabolism    O
.    O

Levothyroxine    B-Hormone105407119

diflorasone    B-Hormone105407119
(    O
INN    O
)    O

hexoprenaline    B-Hormone105407119

Pancreatic    B-Hormone105407119
hormone    I-Hormone105407119

Phytosulfokines    B-Hormone105407119
are    O
plant    O
hormones    O
that    O
belong    O
to    O
the    O
growing    O
class    O
of    O
plant    O
peptide    B-Hormone105407119
hormone    I-Hormone105407119
.    O

19-Norandrostenedione    B-Hormone105407119

Dienedione    B-Hormone105407119

Dienedione    B-Hormone105407119
(    O
the    O
17-keto    O
analogue    O
of    O
dienolone    O
,    O
also    O
known    O
as    O
19-nor-4,9-androstadienedione    O
)    O
is    O
thought    O
to    O
be    O
a    O
prohormone    O
of    O
dienolone    O
,    O
while    O
methyldienolone    B-Hormone105407119
and    O
ethyldienolone    O
are    O
orally    O
active    O
17α-alkylated    O
AAS    O
derivatives    O
of    O
dienolone    O
.    O

Haldrone    B-Hormone105407119

A    O
variety    O
of    O
functional    O
subtypes    O
of    O
signals    O
are    O
known    O
,    O
including    O
pheromones    O
,    O
allomone    B-Hormone105407119
,    O
kairomones    O
,    O
and    O
attractants    O
and    O
repellents    O
.    O

The    O
allomone    B-Hormone105407119
produced    O
by    O
an    O
orchid    O
is    O
specific    O
to    O
its    O
pollinator    O
,    O
of    O
which    O
it    O
usually    O
only    O
has    O
one    O
(    O
Ayasse    O
et    O
al    O
.    O
2007    O
;    O
Gogler    O
et    O
al    O
.    O
2009    O
,    O

The    O
allomone    B-Hormone105407119
is    O
a    O
mixture    O
of    O
alkenes    O
and    O
alkanes    O
(    O
Schiestl    O
and    O
Cozzolino    O
2008    O
)    O
.    O

Pollinators    O
and    O
orchids    O
use    O
the    O
same    O
chemical    O
compounds    O
in    O
the    O
same    O
absolute    O
amounts    O
in    O
their    O
pheromones    O
and    O
allomones    B-Hormone105407119
,    O
respectively    O
(    O
Schiestl    O
2008    O
)    O
.    O

The    O
RAMP1    O
protein    O
can    O
also    O
interact    O
with    O
the    O
calcitonin    O
receptor    O
(    O
CT    O
)    O
protein    O
,    O
where    O
heteromerisation    O
of    O
RAMP1    O
with    O
CT    O
converts    O
CT    O
from    O
a    O
calcitonin    O
receptor    O
to    O
the    O
amylin    B-Hormone105407119
receptor    O
AMY1    O

Insulin    O
pumps    O
are    O
being    O
used    O
for    O
infusing    O
pramlintide    O
(    O
brand    O
name    O
Symlin    O
,    O
or    O
synthetic    O
amylin    B-Hormone105407119
)    O
with    O
insulin    O
for    O
improved    O
postprandial    O
glycemic    O
control    O
compared    O
to    O
insulin    O
alone    O
.    O

Other    O
hormones    O
produced    O
include    O
somatostatin    B-Hormone105407119
,    O
pancreatic    B-Hormone105407119
polypeptide    I-Hormone105407119
,    O
amylin    B-Hormone105407119
and    O
ghrelin    O
.    O

Leptin    O
is    O
known    O
to    O
interact    O
with    O
amylin    B-Hormone105407119
,    O
a    O
hormone    O
involved    O
in    O
gastric    O
emptying    O
and    O
creating    O
a    O
feeling    O
of    O
fullness    O
.    O

Valeric    O
acid    O
appears    O
similar    O
in    O
structure    O
to    O
GHB    O
and    O
the    O
neurotransmitter    O
GABA    B-Hormone105407119
in    O
that    O
it    O
is    O
a    O
short    O
-    O
chain    O
carboxylic    O
acid    O
,    O
although    O
it    O
lacks    O
the    O
alcohol    O
and    O
amine    O
functional    O
groups    O
that    O
contribute    O
to    O
the    O
biological    O
activities    O
of    O
GHB    O
and    O
GABA    O
,    O
respectively    O
.    O

After    O
the    O
depolarization    O
,    O
inhibitory    O
GABA    B-Hormone105407119
mediated    O
neurotransmission    O
is    O
reduced    O
.    O

These    O
groups    O
were    O
studying    O
the    O
responses    O
of    O
large    O
pyramidal    O
projection    O
neurons    O
to    O
GABA    B-Hormone105407119
,    O
the    O
main    O
inhibitory    O
neurotransmitter    O
in    O
the    O
central    O
nervous    O
system    O
.    O

GABA    B-Hormone105407119
is    O
typically    O
released    O
by    O
small    O
interneurons    O
in    O
many    O
regions    O
of    O
the    O
brain    O
,    O
where    O
its    O
job    O
is    O
to    O
inhibit    O
the    O
activity    O
of    O
primary    O
neurons    O
,    O
such    O
as    O
the    O
CA1    O
pyramidal    O
neurons    O
of    O
the    O
hippocampus    O
or    O
the    O
Purkinje    O
cells    O
of    O
the    O
cerebellum    O
.    O

The    O
entorhinal    O
cortex    O
is    O
no    O
exception    O
:    O
like    O
the    O
hippocampus    O
,    O
it    O
receives    O
cholinergic    O
and    O
GABA    B-Hormone105407119
input    O
from    O
the    O
medial    O
septal    O
area    O
,    O
the    O
central    O
controller    O
of    O
theta    O
.    O

It    O
has    O
neuroprotective    O
effects    O
via    O
stimulation    O
of    O
GABA    B-Hormone105407119
release    O
in    O
the    O
brain    O
.    O

GABA    O
-    O
ergic    O
neurons    O
use    O
gamma-aminobutyric    B-Hormone105407119
acid    I-Hormone105407119
(    O
GABA    O
)    O
as    O
a    O
neurotransmitter    O
.    O

This    O
was    O
done    O
mostly    O
through    O
the    O
modification    O
of    O
the    O
GABA    B-Hormone105407119
,    O
dopamine    O
,    O
and    O
serotonin    O
receptors    O
which    O
did    O
seem    O
to    O
show    O
positive    O
results    O
in    O
the    O
primary    O
stages    O
of    O
the    O
experimentation    O
.    O

An    O
established    O
mode    O
of    O
controlling    O
the    O
microenvironment    O
in    O
sensory    O
ganglia    O
is    O
the    O
uptake    O
of    O
substances    O
by    O
specialized    O
transporters    O
which    O
carry    O
neurotransmitters    O
into    O
cells    O
when    O
coupled    O
with    O
Na+    O
and    O
Cl−.    O
Transporters    O
for    O
glutamate    O
and    O
gamma-Aminobutyric    B-Hormone105407119
acid    I-Hormone105407119
(    O
GABA    O
)    O
have    O
been    O
found    O
in    O
SGCs    O
.    O

Low    O
levels    O
of    O
GABA    B-Hormone105407119
,    O
a    O
neurotransmitter    O
that    O
reduces    O
activity    O
in    O
the    O
central    O
nervous    O
system    O
,    O
contribute    O
to    O
anxiety    O
.    O

Proposed    O
mechanisms    O
include    O
affecting    O
GABA    B-Hormone105407119
levels    O
,    O
blocking    O
voltage    O
-    O
gated    O
sodium    O
channels    O
,    O
and    O
inhibiting    O
histone    O
deacetylases    O
.    O

Although    O
the    O
mechanism    O
of    O
action    O
of    O
valproate    O
is    O
not    O
fully    O
understood    O
,    O
traditionally    O
,    O
its    O
anticonvulsant    O
effect    O
has    O
been    O
attributed    O
to    O
the    O
blockade    O
of    O
voltage    O
-    O
gated    O
sodium    O
channels    O
and    O
increased    O
brain    O
levels    O
of    O
gamma-aminobutyric    B-Hormone105407119
acid    I-Hormone105407119
(    O
GABA    O
)    O
.    O

Gabapentin    O
,    O
atypical    O
GABA    B-Hormone105407119
-    O
related    O
anticonvulsant    O
and    O
mood    O
stabilizer    O

Topiramate    O
,    O
GABA    B-Hormone105407119
-    O
receptor    O
related    O
anticonvulsant    O
and    O
mood    O
-    O
stabilizer    O

Radial    O
glia    O
give    O
rise    O
to    O
neurons    O
that    O
are    O
pyramidal    O
in    O
shape    O
and    O
use    O
glutamate    O
as    O
a    O
neurotransmitter    O
,    O
however    O
these    O
migrating    O
cells    O
contribute    O
neurons    O
that    O
are    O
stellate    O
-    O
shaped    O
and    O
use    O
GABA    B-Hormone105407119
as    O
their    O
main    O
neurotransmitter    O
.    O

Apoptotic    O
cell    O
death    O
caused    O
by    O
an    O
excess    O
of    O
glutamate    O
activity    O
and    O
GABA    B-Hormone105407119
withdrawal    O
is    O
thought    O
to    O
play    O
a    O
role    O
in    O
the    O
loss    O
of    O
neuronal    O
fibers    O
critical    O
for    O
normal    O
brain    O
development    O
.    O

Similarly    O
,    O
GABA    B-Hormone105407119
,    O
although    O
associated    O
with    O
inhibitory    O
functions    O
at    O
many    O
CNS    O
synapses    O
,    O
sometimes    O
shows    O
a    O
positive    O
correlation    O
with    O
aggression    O
,    O
including    O
when    O
potentiated    O
by    O
alcohol    O
.    O

Specifically    O
,    O
alcohol    O
inhibits    O
the    O
glutamate    O
receptor    O
function    O
,    O
enhances    O
GABA    B-Hormone105407119
receptor    O
function    O
,    O
as    O
well    O
as    O
raises    O
dopamine    O
and    O
endorphin    O
levels    O
.    O

Withdrawal    O
from    O
GABA    B-Hormone105407119
-    O
acting    O
sedative    O
–    O
hypnotic    O
drugs    O
causes    O
acute    O
GABA    O
underactivity    O
as    O
well    O
as    O
glutamate    O
overactivity    O
,    O
which    O
can    O
lead    O
to    O
sensitization    O
and    O
hyper    O
-    O
excitability    O
of    O
the    O
central    O
nervous    O
system    O
,    O
excito    O
-    O
neurotoxicity    O
,    O
and    O
increasingly    O
profound    O
neuroadaptions    O
.    O

Some    O
medications    O
and    O
the    O
heavy    O
use    O
of    O
drugs    O
such    O
as    O
opiates    O
or    O
GABA    B-Hormone105407119
-    O
ergic    O
drugs    O
may    O
bring    O
apathy    O
as    O
a    O
side    O
effect    O
.    O

Its    O
mechanism    O
of    O
action    O
is    O
by    O
increasing    O
the    O
effect    O
of    O
the    O
neurotransmitter    O
"gamma"-Aminobutyric    B-Hormone105407119
acid    I-Hormone105407119
(    O
GABA    O
)    O
.    O

Opiates    O
affect    O
dopamine    O
neurotransmission    O
in    O
the    O
nucleus    O
accumbens    O
via    O
the    O
disinhibition    O
of    O
dopaminergic    O
pathways    O
as    O
a    O
result    O
of    O
inhibiting    O
the    O
GABA    B-Hormone105407119
-    O
based    O
projections    O
to    O
the    O
ventral    O
tegmental    O
area    O
(    O
VTA    O
)    O
from    O
the    O
rostromedial    O
tegmental    O
nucleus    O
(    O
RMTg    O
)    O
,    O
which    O
negatively    O
modulate    O
dopamine    O
neurotransmission    O
.    O

A    O
2011    O
study    O
reported    O
that    O
"    O
L.    O
rhamnosus    O
"    O
may    O
have    O
an    O
effect    O
on    O
GABA    B-Hormone105407119
neurotransmitter    O
receptors    O
.    O

GABA    B-Hormone105407119
is    O
the    O
second    O
-    O
most    O
-    O
common    O
neurotransmitter    O
in    O
the    O
central    O
nervous    O
system    O
(    O
the    O
most    O
common    O
being    O
glutamate    O
)    O
and    O
by    O
far    O
the    O
most    O
abundant    O
inhibitory    O
neurotransmitter    O
;    O
roughly    O
one    O
-    O
quarter    O
to    O
one    O
-    O
third    O
of    O
synapses    O
use    O
GABA    O
.    O

With    O
chronic    O
benzodiazepine    O
use    O
,    O
tolerance    O
develops    O
rapidly    O
to    O
most    O
of    O
its    O
effects    O
,    O
so    O
that    O
,    O
when    O
benzodiazepines    O
are    O
withdrawn    O
,    O
various    O
neurotransmitter    O
systems    O
go    O
into    O
overdrive    O
due    O
to    O
the    O
lack    O
of    O
inhibitory    O
GABA    B-Hormone105407119
-    O
ergic    O
activity    O
.    O

Gamma-Aminobutyric    B-Hormone105407119
acid    I-Hormone105407119
(    O
GABA    B-Hormone105407119
)    O
is    O
the    O
major    O
inhibitory    O
neurotransmitter    O
of    O
the    O
central    O
nervous    O
system    O
;    O
roughly    O
one    O
-    O
quarter    O
to    O
one    O
-    O
third    O
of    O
synapses    O
use    O
GABA    O
.    O

This    O
is    O
probably    O
the    O
result    O
of    O
their    O
GABA    B-Hormone105407119
antagonistic    O
effects    O
as    O
they    O
have    O
been    O
found    O
to    O
competitively    O
displace    O
benzodiazepines    O
from    O
benzodiazepine    O
receptor    O
sites    O
.    O

NNC-711    O
is    O
an    O
anticonvulsant    O
,    O
acting    O
as    O
a    O
gamma-aminobutyric    B-Hormone105407119
acid    I-Hormone105407119
uptake    O
inhibitor    O
via    O
inhibition    O
of    O
GAT-1    O
.    O

A    O
second    O
important    O
company    O
is    O
GABA    B-Hormone105407119
Deutschland    O
GmbH    O
,    O
a    O
pharmaceutical    O
company    O
that    O
produces    O
the    O
famous    O
elmex    O
,    O
meridol    O
and    O
aronal    O
toothpastes    O
.    O

Glutamate    O
agonists    O
,    O
cytokine    O
inhibitors    O
,    O
vanilloid    O
-    O
receptor    O
agonists    O
,    O
catecholamine    O
modulators    O
,    O
ion    O
-    O
channel    O
blockers    O
,    O
anticonvulsants    O
,    O
GABA    B-Hormone105407119
agonists    I-Hormone105407119
(    O
including    O
opioids    O
and    O
cannabinoids    O
)    O
,    O
COX    O
inhibitors    O
,    O
acetylcholine    O
modulators    O
,    O
melatonin    O
analogs    O
(    O
such    O
as    O
Ramelton    O
)    O
,    O
adenosine    O
receptor    O
antagonists    O
and    O
several    O
miscellaneous    O
drugs    O
(    O
including    O
biologics    O
like    O
Passiflora    O
edulis    O
)    O
are    O
being    O
studied    O
for    O
their    O
psychoneuroimmunological    O
effects    O
.    O

Studies    O
suggest    O
that    O
this    O
kind    O
of    O
inhibition    O
can    O
be    O
attributed    O
in    O
part    O
to    O
GABA    B-Hormone105407119
receptor    O
-    O
mediated    O
synapses    O
.    O

This    O
state    O
leads    O
to    O
inhibition    O
and    O
thus    O
are    O
their    O
inhibitory    O
interneurons    O
that    O
modulate    O
this    O
shift    O
and    O
if    O
so    O
are    O
inhibitory    O
neurotransmitters    O
such    O
as    O
GABA    B-Hormone105407119
involved    O
?    O

Theanine    O
increases    O
serotonin    O
,    O
dopamine    O
,    O
GABA    B-Hormone105407119
,    O
and    O
glycine    O
levels    O
in    O
various    O
areas    O
of    O
the    O
brain    O
,    O
as    O
well    O
as    O
BDNF    B-Hormone105407119
and    O
NGF    O
levels    O
in    O
certain    O
brain    O
areas    O
.    O

GABA    B-Hormone105407119
is    O
the    O
principal    O
inhibitory    O
neurotransmitter    O
in    O
the    O
mammalian    O
central    O
nervous    O
system    O
(    O
CNS    O
)    O
.    O

Barbiturates    O
bind    O
to    O
the    O
GABAA    O
receptor    O
at    O
multiple    O
homologous    O
transmembrane    O
pockets    O
located    O
at    O
subunit    O
interfaces    O
,    O
which    O
are    O
binding    O
sites    O
distinct    O
from    O
GABA    B-Hormone105407119
itself    O
and    O
also    O
distinct    O
from    O
the    O
benzodiazepine    O
binding    O
site    O
.    O

Green    O
arrows    O
refer    O
to    O
excitatory    O
glutamatergic    O
pathways    O
,    O
red    O
arrows    O
refer    O
to    O
inhibitory    O
GABAergic    B-Hormone105407119
pathways    O
and    O
turquoise    O
arrows    O
refer    O
to    O
dopaminergic    O
pathways    O
that    O
are    O
excitatory    O
on    O
the    O
direct    O
pathway    O
and    O
inhibitory    O
on    O
the    O
indirect    O
pathway    O
.    O

Connectivity    O
diagram    O
showing    O
excitatory    O
glutamatergic    O
pathways    O
as    O
red    O
,    O
inhibitory    O
GABA    B-Hormone105407119
pathways    O
as    O
blue    O
,    O
and    O
modulatory    O
dopaminergic    O
as    O
magenta    O
.    O

Optically    O
inactive    O
Aze    O
was    O
obtained    O
in    O
small    O
yield    O
from    O
γ-aminobutyric    B-Hormone105407119
acid    I-Hormone105407119
by    O
α-bromination    O
,    O
followed    O
by    O
removal    O
of    O
hydrogen    O
bromide    O
from    O
the    O
intermediate    O
γ-amino-α-butyric    O
acid    O
and    O
ring    O
closure    O
by    O
treatment    O
with    O
a    O
barium    O
hydroxide    O
solution    O
.    O

It    O
is    O
also    O
known    O
to    O
modulate    O
GABAergic    B-Hormone105407119
and    O
glutamatergic    O
neurotransmission    O
.    O

The    O
inhibitory    O
neurotransmitter    O
GABA    B-Hormone105407119
and    O
the    O
excitatory    O
glutamate    O
are    O
found    O
in    O
many    O
parts    O
of    O
the    O
central    O
nervous    O
system    O
,    O
including    O
in    O
the    O
motor    O
pathways    O
that    O
involve    O
hypokinesia    O
.    O

Caged    O
neurotransmitters    O
,    O
including    O
photolable    O
precursors    O
of    O
glutamate    O
,    O
dopamine    O
,    O
serotonin    O
,    O
and    O
GABA    B-Hormone105407119
,    O
are    O
commercially    O
available    O
.    O

The    O
citric    O
acid    O
cycle    O
is    O
a    O
central    O
metabolic    O
pathway    O
involved    O
in    O
the    O
regulation    O
of    O
carbohydrate    O
,    O
lipid    O
,    O
and    O
amino    O
acid    O
metabolism    O
,    O
and    O
its    O
disruption    O
due    O
to    O
thiamine    O
deficiency    O
inhibits    O
the    O
production    O
of    O
many    O
molecules    O
including    O
the    O
neurotransmitters    O
glutamic    O
acid    O
and    O
GABA    B-Hormone105407119
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
4-aminobutanoate    B-Hormone105407119
(    O
GABA    B-Hormone105407119
)    O
and    O
2-oxoglutarate    O
.    O

Fipronil    O
disrupts    O
the    O
insect    O
central    O
nervous    O
system    O
by    O
blocking    O
GABA    B-Hormone105407119
-    O
gated    O
chloride    O
channels    O
and    O
glutamate    O
-    O
gated    O
chloride    O
(    O
GluCl    O
)    O
channels    O
.    O

Positive    O
modulation    O
of    O
GABA    B-Hormone105407119
at    O
GABAA    O
receptors    O
by    O
barbiturates    O
or    O
benzodiazepines    O

It    O
is    O
also    O
known    O
as    O
GABA    O
rice    O
,    O
as    O
the    O
germination    O
process    O
greatly    O
increases    O
its    O
gamma-Aminobutyric    B-Hormone105407119
acid    I-Hormone105407119
content    O
.    O

Fluralaner    O
inhibits    O
γ-aminobutyric    B-Hormone105407119
acid    I-Hormone105407119
(    O
GABA)-gated    O
chloride    O
channels    O
(    O
GABACls    O
)    O
and    O
L    O
-    O
glutamate    O
-    O
gated    O
chloride    O
channels    O
(    O
GluCls    O
)    O
.    O

Dr.    O
Salomon    O
Z.    O
Langer    O
was    O
the    O
first    O
to    O
describe    O
pre    O
-    O
synaptic    O
autoreceptors    O
for    O
DA    O
,    O
5HT    O
,    O
ACh    O
,    O
GABA    B-Hormone105407119
and    O
glutamate    O
.    O

The    O
third    O
memory    O
trace    O
is    O
the    O
reduction    O
of    O
activity    O
of    O
the    O
anterior    O
-    O
paired    O
lateral    O
neuron    O
,    O
which    O
acts    O
as    O
a    O
memory    O
formation    O
suppressor    O
through    O
one    O
of    O
its    O
inhibitory    O
GABA    B-Hormone105407119
receptors    O
.    O

Decrease    O
in    O
calcium    O
response    O
of    O
APL    O
neurons    O
and    O
subsequent    O
decrease    O
in    O
GABA    B-Hormone105407119
release    O
onto    O
the    O
mushroom    O
bodies    O
persisted    O
up    O
to    O
5    O
minutes    O
after    O
odor    O
conditioning    O
.    O

This    O
is    O
thought    O
to    O
be    O
a    O
result    O
of    O
GABA    B-Hormone105407119
changing    O
from    O
excitatory    O
to    O
inhibitory    O
during    O
continual    O
retinal    O
development    O
.    O

In    O
certain    O
species    O
,    O
GABA    B-Hormone105407119
is    O
seen    O
to    O
play    O
a    O
role    O
in    O
the    O
frequency    O
and    O
duration    O
of    O
the    O
bursts    O
in    O
ganglion    O
cells    O
.    O

In    O
2016    O
kavain    O
was    O
shown    O
to    O
bind    O
at    O
the    O
α4β2δ    O
GABAA    O
receptor    O
and    O
potentiate    O
GABA    B-Hormone105407119
efficacy    O
.    O

Tetanus    O
toxin    O
causes    O
violent    O
spastic    O
paralysis    O
by    O
blocking    O
the    O
release    O
of    O
γ-aminobutyric    O
acid    O
(    O
GABA    B-Hormone105407119
)    O
.    O

The    O
action    O
of    O
the    O
A    O
-    O
chain    O
stops    O
the    O
affected    O
neurons    O
from    O
releasing    O
the    O
inhibitory    O
neurotransmitters    O
GABA    B-Hormone105407119
and    O
glycine    O
,    O
but    O
also    O
excitatory    O
transmitters    O
,    O
by    O
degrading    O
the    O
protein    O
synaptobrevin    O
2    O
.    O

Alcohol    O
produces    O
a    O
sedative    O
effect    O
by    O
acting    O
on    O
receptors    O
of    O
the    O
inhibitory    O
neurotransmitter    O
GABA    B-Hormone105407119
.    O

He    O
is    O
widely    O
recognized    O
for    O
demonstrating    O
that    O
gamma    O
-    O
aminobutyric    O
acid    O
(    O
GABA    B-Hormone105407119
)    O
functions    O
as    O
a    O
neurotransmitter    O
.    O

Almost    O
immediately    O
,    O
he    O
began    O
working    O
with    O
Steve    O
Kuffler    O
,    O
Dave    O
Potter    O
and    O
Nico    O
van    O
Gelder    O
on    O
the    O
experiments    O
that    O
would    O
eventually    O
demonstrate    O
that    O
GABA    B-Hormone105407119
functions    O
as    O
a    O
neurotransmitter    O
.    O

Clonazepam    O
functions    O
by    O
increasing    O
GABA    B-Hormone105407119
activity    O
at    O
the    O
GABAA    O
receptor    O
.    O

While    O
the    O
hyperglycemia    O
itself    O
is    O
not    O
the    O
cause    O
of    O
the    O
hemiballistic    O
movements    O
,    O
it    O
has    O
been    O
suggested    O
that    O
petechial    O
hemorrhage    O
or    O
a    O
decreased    O
production    O
of    O
GABA    B-Hormone105407119
and    O
acetylcholine    O
could    O
result    O
secondary    O
to    O
the    O
hyperglycemia    O
.    O

Therefore    O
,    O
investigators    O
have    O
explored    O
the    O
effects    O
of    O
genetic    O
variation    O
in    O
the    O
endogenous    O
opioid    O
system    O
and    O
the    O
GABAergic    B-Hormone105407119
system    O
on    O
SR    O
.    O

These    O
projections    O
are    O
inhibitory    O
and    O
have    O
been    O
found    O
to    O
utilize    O
both    O
GABA    B-Hormone105407119
and    O
substance    O
P.    O
The    O
indirect    O
pathway    O
,    O
which    O
projects    O
to    O
the    O
globus    O
pallidus    O
external    O
(    O
GPe    O
)    O
,    O
is    O
also    O
inhibitory    O
and    O
uses    O
GABA    O
and    O
enkephalin    O
.    O

Interneurons    O
in    O
the    O
CNS    O
are    O
primarily    O
inhibitory    O
,    O
and    O
use    O
the    O
neurotransmitter    O
GABA    B-Hormone105407119
or    O
glycine    O
.    O

In    O
one    O
6-year    O
-    O
old    O
patient    O
antibodies    O
to    O
GABA    B-Hormone105407119
-    O
producing    O
enzyme    O
glutamate    O
decarboxylase    O
were    O
detected    O
.    O

Mecloqualone    O
(    O
Nubarene    O
,    O
Casfen    O
)    O
is    O
a    O
quinazolinone    O
-    O
class    O
GABAergic    B-Hormone105407119
and    O
is    O
an    O
analogue    O
of    O
methaqualone    O
that    O
was    O
first    O
made    O
in    O
1960    O
and    O
marketed    O
mainly    O
in    O
France    O
and    O
some    O
other    O
European    O
countries    O
.    O

Gamma-Aminobutyric    B-Hormone105407119
acid    I-Hormone105407119

Cloroqualone    O
is    O
a    O
quinazolinone    O
-    O
class    O
GABAergic    B-Hormone105407119
and    O
is    O
an    O
analogue    O
of    O
methaqualone    O
developed    O
in    O
the    O
1980s    O
and    O
marketed    O
mainly    O
in    O
France    O
and    O
some    O
other    O
European    O
countries    O
.    O

Gamma-Aminobutyric    B-Hormone105407119
acid    I-Hormone105407119

Diproqualone    O
is    O
a    O
quinazolinone    O
class    O
GABAergic    B-Hormone105407119
and    O
is    O
an    O
analogue    O
of    O
methaqualone    O
developed    O
in    O
the    O
late    O
1950s    O
by    O
a    O
team    O
at    O
Nogentaise    O
de    O
Produits    O
Chimique    O
.    O

Gamma-Aminobutyric    B-Hormone105407119
acid    I-Hormone105407119

etilevodopa    B-Hormone105407119
(    O
USAN    O
)    O

A    O
prehormone    B-Hormone105407119
is    O
a    O
biochemical    O
substance    O
secreted    O
by    O
glandular    O
tissue    O
and    O
has    O
minimal    O
or    O
no    O
significant    O
biological    O
activity    O
,    O
but    O
it    O
is    O
converted    O
in    O
peripheral    O
tissues    O
into    O
an    O
active    O
hormone    O
.    O

Estropipate    B-Hormone105407119
(    O
Ogen    O
,    O
Ortho    O
-    O
Est    O
)    O
(    O
a    O
salt    O
of    O
estrone    O
sulfate    O
and    O
piperazine    O
)    O

Uterine    B-Hormone105407119
serpins    I-Hormone105407119
are    O
members    O
of    O
the    O
A    O
clade    O
of    O
the    O
serine    O
protease    O
inhibitor    O
(    O
serpin    O
)    O
superfamily    O
of    O
proteins    O
and    O
are    O
encoded    O
by    O
the    O
SERPINA14    B-Hormone105407119
gene    O
.    O

Ciclesonide    B-Hormone105407119
,    O
cortisone    O
acetate    O
,    O
hydrocortisone    B-Hormone105407119
aceponate    I-Hormone105407119
,    O
hydrocortisone    O
acetate    O
,    O
hydrocortisone    B-Hormone105407119
buteprate    I-Hormone105407119
,    O
hydrocortisone    B-Hormone105407119
butyrate    I-Hormone105407119
,    O
hydrocortisone    O
valerate    O
,    O
prednicarbate    B-Hormone105407119
,    O
and    O
tixocortol    B-Hormone105407119
pivalate    I-Hormone105407119
.    O

Melengestrol    B-Hormone105407119

Chlorotrianisene    B-Hormone105407119

Chlorotrianisene    B-Hormone105407119

Chlorotrianisene    B-Hormone105407119

Kallidin    B-Hormone105407119
also    O
signals    O
through    O
the    O
B2    O
receptor    O
.    O

Kallidin    B-Hormone105407119
is    O
a    O
bioactive    O
kinin    O
formed    O
in    O
response    O
to    O
injury    O
from    O
kininogen    O
precursors    O
through    O
the    O
action    O
of    O
kallikreins    O
.    O

Mirapex    B-Hormone105407119

With    O
his    O
neuropsychiatric    O
research    O
group    O
he    O
described    O
eight    O
new    O
treatment    O
options    O
for    O
this    O
disease    O
:    O
Pramipexol    B-Hormone105407119
,    O
Quetiapine    O
,    O
Minocycline    O
,    O
Mirtazapine    O
,    O
Zotepine    O
,    O
Ziprasidone    O
,    O
Venlafaxine    O
and    O
antipsychotic    O
drug    O
holidays    O
in    O
Huntington    O
’s    O
disease    O
.    O

Pramipexole    B-Hormone105407119
–    O
also    O
D3    O
,    O
D4    O
receptor    O
agonist    O

Dopamine    O
agonists    O
include    O
bromocriptine    B-Hormone105407119
,    O
pergolide    O
,    O
pramipexole    B-Hormone105407119
,    O
ropinirole    O
,    O
piribedil    O
,    O
cabergoline    B-Hormone105407119
,    O
apomorphine    O
and    O
lisuride    O
.    O

Initial    O
monotherapy    O
with    O
a    O
dopamine    O
agonist    O
(    O
other    O
examples    O
include    O
pergolide    O
,    O
pramipexole    B-Hormone105407119
,    O
and    O
ropinirole    O
)    O
is    O
associated    O
with    O
reduced    O
risk    O
for    O
motor    O
complications    O
in    O
Parkinson    O
patients    O
relative    O
to    O
levodopa    B-Hormone105407119
.    O

KNS-760704    O
is    O
the    O
enantiomer    O
of    O
pramipexole    B-Hormone105407119
,    O
and    O
has    O
been    O
shown    O
to    O
improve    O
mitochondrial    O
function    O
and    O
to    O
confer    O
significant    O
cellular    O
protection    O
in    O
neurons    O
under    O
stress    O
.    O

Pramipexole    B-Hormone105407119
,    O
the    O
racemic    O
mixture    O
of    O
dexpramipexole    O

Lotemax    B-Hormone105407119

loteprednol    B-Hormone105407119
(    O
INN    O
)    O

The    O
use    O
of    O
hormone    O
replacement    O
therapy    O
in    O
transgender    O
and    O
intersex    O
people    O
and    O
people    O
with    O
sex    B-Hormone105407119
hormone    I-Hormone105407119
imbalances    O
(    O
e.g.    O
,    O
hypogonadism    O
or    O
hyperandrogenism    B-Hormone105407119
)    O
to    O
change    O
the    O
secondary    O
sexual    O
characteristics    O
from    O
masculine    O
to    O
feminine    O
and    O
vice    O
versa    O

progesterone    O
(    O
sex    B-Hormone105407119
hormone    I-Hormone105407119
)    O

They    O
may    O
inhibit    O
the    O
production    O
of    O
cholesterol    O
and    O
other    O
sterols    O
,    O
sex    B-Hormone105407119
steroid    I-Hormone105407119
such    O
as    O
androgens    O
,    O
estrogens    O
,    O
and    O
progestogens    O
,    O
corticosteroids    O
such    O
as    O
glucocorticoids    O
and    O
mineralocorticoids    O
,    O
and    O
neurosteroids    O
.    O

The    O
prototypical    O
progestogen    O
is    O
progesterone    O
,    O
an    O
endogenous    O
sex    B-Hormone105407119
hormone    I-Hormone105407119
.    O

Sex    B-Hormone105407119
steroids    I-Hormone105407119
such    O
as    O
estrogens    O
and    O
androgens    O
,    O
as    O
well    O
as    O
thyroid    O
hormones    O
,    O
are    O
subject    O
to    O
feedback    O
regulation    O
,    O
which    O
tends    O
to    O
limit    O
the    O
sensitivity    O
of    O
these    O
glands    O
.    O

While    O
sex    B-Hormone105407119
hormone    I-Hormone105407119
levels    O
in    O
parthenogenetic    O
"    O
Cnemidophorus    O
uniparens    O
"    O
mimic    O
the    O
cycles    O
seen    O
in    O
their    O
sexual    O
relatives    O
,    O
their    O
nervous    O
systems    O
appear    O
to    O
have    O
evolved    O
unique    O
responses    O
to    O
female    O
sex    O
hormones    O
.    O

Sex    B-Hormone105407119
hormone    I-Hormone105407119
(    O
androgen    O
/    O
estrogen    O
)    O

In    O
1927    O
,    O
Selmar    O
Ascheim    O
(    O
1878–1965    O
)    O
and    O
Bernhard    O
Zondek    O
(    O
1891–1966    O
)    O
discovered    O
that    O
urine    O
of    O
pregnant    O
women    O
had    O
a    O
high    O
concentration    O
of    O
steroid    B-Hormone105407119
sex    I-Hormone105407119
hormones    I-Hormone105407119
;    O
a    O
subsequent    O
discovery    O
was    O
made    O
that    O
urine    O
contained    O
sex    O
hormones    O
of    O
androgens    O
and    O
estrogens    O
,    O
as    O
well    O
as    O
the    O
pituitary    O
hormone    O
gonadotrophin    O
.    O

An    O
alternative    O
proposed    O
cause    O
is    O
inhibition    O
of    O
17α-hydroxylase    O
and    O
hence    O
sex    B-Hormone105407119
steroid    I-Hormone105407119
metabolism    O
by    O
spironolactone    O
and    O
consequent    O
changes    O
in    O
sex    O
hormone    O
levels    O
.    O

Because    O
rheumatoid    O
arthritis    O
is    O
more    O
common    O
in    O
women    O
,    O
perhaps    O
sex    B-Hormone105407119
hormones    I-Hormone105407119
may    O
play    O
a    O
role    O
in    O
causing    O
or    O
modulating    O
arthritis    O
.    O

As    O
an    O
adult    O
ages    O
,    O
it    O
is    O
normal    O
for    O
the    O
pituitary    O
to    O
produce    O
diminishing    O
amounts    O
of    O
GH    O
and    O
many    O
other    O
hormones    O
,    O
particularly    O
the    O
sex    B-Hormone105407119
steroid    I-Hormone105407119
.    O

The    O
term    O
hypogonadism    O
describes    O
a    O
low    O
level    O
of    O
circulating    O
sex    B-Hormone105407119
hormones    I-Hormone105407119
;    O
testosterone    O
in    O
males    O
and    O
oestrogen    O
and    O
progesterone    O
in    O
females    O
.    O

LH    O
and    O
FSH    O
are    O
essential    O
for    O
stimulating    O
the    O
development    O
of    O
secondary    O
sexual    O
characteristics    O
seen    O
at    O
puberty    O
and    O
for    O
maintaining    O
the    O
normal    O
sexual    O
function    O
of    O
both    O
men    O
and    O
women    O
,    O
including    O
maintaining    O
the    O
correct    O
levels    O
of    O
the    O
sex    B-Hormone105407119
steroids    I-Hormone105407119
:    O
testosterone    O
in    O
men    O
and    O
oestrogen    O
and    O
progesterone    O
in    O
women    O
.    O

Although    O
the    O
pharmacological    O
action    O
of    O
catalpol    O
as    O
well    O
as    O
many    O
other    O
iridoids    O
has    O
not    O
been    O
fully    O
established    O
,    O
there    O
is    O
evidence    O
that    O
their    O
primary    O
function    O
is    O
to    O
stimulate    O
the    O
production    O
of    O
adrenal    O
cortical    O
hormones    O
,    O
which    O
increases    O
the    O
production    O
of    O
sex    B-Hormone105407119
hormone    I-Hormone105407119
.    O

Other    O
striking    O
functional    O
dimorphisms    O
are    O
in    O
the    O
behavioral    O
responses    O
to    O
ovarian    B-Hormone105407119
steroids    I-Hormone105407119
of    O
the    O
adult    O
.    O

Sex    B-Hormone105407119
steroid    I-Hormone105407119
are    O
not    O
the    O
only    O
important    O
influences    O
upon    O
hypothalamic    O
development    O
;    O
in    O
particular    O
,    O
pre    O
-    O
pubertal    O
stress    O
in    O
early    O
life    O
(    O
of    O
rats    O
)    O
determines    O
the    O
capacity    O
of    O
the    O
adult    O
hypothalamus    O
to    O
respond    O
to    O
an    O
acute    O
stressor    O
.    O

Steroids    O
,    O
including    O
gonadal    B-Hormone105407119
steroids    I-Hormone105407119
and    O
corticosteroids    O

This    O
,    O
in    O
turn    O
,    O
results    O
in    O
increased    O
function    O
and    O
maintenance    O
of    O
the    O
gonads    O
and    O
increased    O
gonadal    O
steroidogenesis    O
of    O
sex    B-Hormone105407119
hormone    I-Hormone105407119
such    O
as    O
androgens    O
,    O
estrogens    O
,    O
and    O
progestogens    O
.    O

At    O
puberty    O
,    O
they    O
are    O
virilized    O
by    O
male    B-Hormone105407119
hormones    I-Hormone105407119
,    O
recognized    O
as    O
boys    O
,    O
and    O
raised    O
henceforth    O
as    O
boys    O
.    O

For    O
example    O
,    O
female    B-Hormone105407119
sex    I-Hormone105407119
hormones    I-Hormone105407119
are    O
known    O
immunostimulators    O
of    O
both    O
adaptive    O
and    O
innate    O
immune    O
responses    O
.    O

These    O
include    O
changes    O
in    O
cardiac    O
output    O
,    O
vitamin    O
D    O
,    O
inflammation    O
,    O
sex    B-Hormone105407119
hormone    I-Hormone105407119
activity    O
,    O
lipoprotein    O
lipase    O
activity    O
,    O
and    O
GLUT4    O
activity    O
due    O
to    O
long    O
periods    O
of    O
muscular    O
unloading    O
,    O
among    O
others    O
.    O

An    O
intersex    O
human    O
or    O
other    O
animal    O
is    O
one    O
possessing    O
any    O
of    O
several    O
variations    O
in    O
sex    O
characteristics    O
including    O
chromosomes    O
,    O
gonads    O
,    O
sex    B-Hormone105407119
hormones    I-Hormone105407119
,    O
or    O
genitals    O
that    O
,    O
according    O
to    O
the    O
UN    O
Office    O
of    O
the    O
High    O
Commissioner    O
for    O
Human    O
Rights    O
,    O
"    O
do    O
not    O
fit    O
typical    O
binary    O
notions    O
of    O
male    O
or    O
female    O
bodies    O
"    O
.    O

The    O
development    O
of    O
both    O
is    O
controlled    O
by    O
sex    B-Hormone105407119
hormone    I-Hormone105407119
produced    O
by    O
the    O
body    O
after    O
the    O
initial    O
fetal    O
stage    O
where    O
the    O
presence    O
or    O
absence    O
of    O
the    O
Y    O
-    O
chromosome    O
and/or    O
the    O
SRY    O
gene    O
determine    O
development    O
.    O

When    O
ovulation    O
is    O
about    O
to    O
occur    O
,    O
the    O
sex    B-Hormone105407119
hormones    I-Hormone105407119
activate    O
the    O
fimbriae    O
,    O
causing    O
it    O
to    O
swell    O
with    O
blood    O
and    O
hit    O
the    O
ovary    O
in    O
a    O
gentle    O
,    O
sweeping    O
motion    O
.    O

Sex    B-Hormone105407119
hormone    I-Hormone105407119
(    O
androgens    O
and    O
estrogens    O
)    O

Glucocorticoids    O
are    O
distinguished    O
from    O
mineralocorticoids    O
and    O
sex    B-Hormone105407119
steroid    I-Hormone105407119
by    O
their    O
specific    O
receptors    O
,    O
target    O
cells    O
,    O
and    O
effects    O
.    O

Prolactin    O
levels    O
may    O
be    O
checked    O
as    O
part    O
of    O
a    O
sex    B-Hormone105407119
hormone    I-Hormone105407119
workup    O
,    O
as    O
elevated    O
prolactin    O
secretion    O
can    O
suppress    O
the    O
secretion    O
of    O
FSH    O
and    O
GnRH    O
,    O
leading    O
to    O
hypogonadism    O
and    O
sometimes    O
causing    O
erectile    O
dysfunction    O
.    O

In    O
humans    O
,    O
biological    O
sex    O
is    O
determined    O
by    O
five    O
factors    O
present    O
at    O
birth    O
:    O
the    O
presence    O
or    O
absence    O
of    O
a    O
Y    O
chromosome    O
,    O
the    O
type    O
of    O
gonads    O
,    O
the    O
sex    B-Hormone105407119
hormone    I-Hormone105407119
,    O
the    O
internal    O
reproductive    O
anatomy    O
(    O
such    O
as    O
the    O
uterus    O
in    O
females    O
)    O
,    O
and    O
the    O
external    O
genitalia    O
.    O

Miss    O
Gay    O
America    O
is    O
unique    O
in    O
that    O
it    O
is    O
the    O
only    O
national    O
pageant    O
that    O
prohibits    O
contestants    O
from    O
using    O
female    B-Hormone105407119
hormones    I-Hormone105407119
or    O
having    O
undergone    O
any    O
feminizing    O
plastic    O
surgery    O
,    O
such    O
as    O
breast    O
implants    O
or    O
liquid    O
-    O
silicone    O
injections    O
below    O
the    O
neck    O
.    O

At    O
the    O
game    O
,    O
bisexual    O
drama    O
teacher    O
Andrew    O
LeGustambos    O
attempts    O
to    O
grab    O
the    O
attention    O
of    O
both    O
Larry    O
and    O
Miracle    O
,    O
but    O
the    O
whole    O
school    O
stands    O
in    O
shock    O
as    O
Stuart    O
arrives    O
with    O
two    O
full    O
and    O
augmented    O
breasts    O
;    O
the    O
pills    O
he    O
had    O
taken    O
were    O
actually    O
librarian    O
Helen    O
Klench    O
's    O
female    B-Hormone105407119
hormone    I-Hormone105407119
replacements    I-Hormone105407119
.    O

Hormones    B-Hormone105407119
and    O
genetic    O
factors    O
are    O
likely    O
to    O
be    O
important    O
in    O
the    O
pathogenesis    O
of    O
the    O
disease    O
.    O

iolopride    B-Hormone105407119
(123    I-Hormone105407119
I)    I-Hormone105407119
(    O
INN    O
)    O

When    O
the    O
lumen    O
of    O
the    O
small    O
intestine    O
comes    O
into    O
contact    O
with    O
nutrients    O
,    O
a    O
number    O
of    O
hormones    O
are    O
released    O
,    O
including    O
cholecystokinin    O
from    O
the    O
duodenum    O
and    O
PYY    B-Hormone105407119
and    O
GLP-1    B-Hormone105407119
from    O
the    O
ileum    O
.    O

In    O
a    O
paper    O
published    O
by    O
Ye    O
and    O
colleagues    O
in    O
2011    O
,    O
melanopsin    O
was    O
utilized    O
to    O
create    O
an    O
optogenetic    O
synthetic    O
transcription    O
device    O
that    O
was    O
tested    O
in    O
a    O
therapeutic    O
setting    O
to    O
produce    O
glucagon-like    B-Hormone105407119
peptide    I-Hormone105407119
1    I-Hormone105407119
(    O
GLP-1    O
)    O
,    O
a    O
protein    O
that    O
helps    O
control    O
blood    O
glucose    O
levels    O
in    O
mammals    O
with    O
Type    O
II    O
Diabetes    O
.    O

GLP1R    O
binds    O
glucagon-like    B-Hormone105407119
peptide-1    I-Hormone105407119
(    O
GLP1    O
)    O
and    O
glucagon    O
as    O
its    O
natural    O
endogenous    O
agonists    O
.    O

GLP-1    B-Hormone105407119
-    O
endogenous    O
in    O
humans    O

Glucagon-like    B-Hormone105407119
peptide-1    I-Hormone105407119

Other    O
substances    O
known    O
to    O
stimulate    O
insulin    O
release    O
include    O
the    O
amino    O
acids    O
arginine    O
and    O
leucine    O
,    O
parasympathetic    O
release    O
of    O
acetylcholine    O
(    O
acting    O
via    O
the    O
phospholipase    O
C    O
pathway    O
)    O
,    O
sulfonylurea    O
,    O
cholecystokinin    O
(    O
CCK    O
,    O
also    O
via    O
phospholipase    O
C    O
)    O
,    O
and    O
the    O
gastrointestinally    O
derived    O
incretins    B-Hormone105407119
,    O
such    O
as    O
glucagon-like    B-Hormone105407119
peptide-1    I-Hormone105407119
(    O
GLP-1    O
)    O
and    O
glucose-dependent    B-Hormone105407119
insulinotropic    I-Hormone105407119
peptide    I-Hormone105407119
(    O
GIP    O
)    O
.    O

L    O
cells    O
secrete    O
glucagon-like    B-Hormone105407119
peptide-1    I-Hormone105407119
,    O
an    O
incretin    O
,    O
pancreatic    B-Hormone105407119
peptide    I-Hormone105407119
YY3-36    I-Hormone105407119
,    O
oxyntomodulin    O
and    O
glucagon    O
-    O
like    O
peptide-2    O
.    O

Hypergonadism    B-Hormone105407119

"    O
Obestatin    B-Hormone105407119
"    O
is    O
presumed    O
to    O
be    O
cleaved    O
from    O
C    O
-    O
ghrelin    O
.    O

In    O
addition    O
,    O
though    O
17α-MP    O
itself    O
was    O
never    O
introduced    O
for    O
medical    O
use    O
,    O
progestogen    O
derivatives    O
of    O
the    O
compound    O
,    O
including    O
medrogestone    B-Hormone105407119
(    O
1966    O
)    O
and    O
the    O
19-norprogesterone    O
derivatives    O
demegestone    O
(    O
1974    O
)    O
,    O
promegestone    O
(    O
1983    O
)    O
,    O
and    O
trimegestone    B-Hormone105407119
(    O
2001    O
)    O
,    O
have    O
been    O
marketed    O
.    O

Trimegestone    B-Hormone105407119

Quinbolone    B-Hormone105407119
,    O
the    O
17-cyclopentenyl    O
enol    O
ether    O
of    O
boldenone    O
.    O

Quinbolone    B-Hormone105407119

The    O
key    O
phytochemical    O
constituents    O
of    O
the    O
herb    O
are    O
pregnane    B-Hormone105407119
glycosides    O
,    O
flavone    O
glycosides    O
,    O
megastigmane    O
glycosides    O
,    O
and    O
saponins    O
.    O

Estrane    O
and    O
pregnane    B-Hormone105407119

Dexamethasone    O
is    O
a    O
synthetic    O
pregnane    B-Hormone105407119
corticosteroid    O
and    O
derivative    O
of    O
cortisol    B-Hormone105407119
(    O
hydrocortisone    O
)    O
and    O
is    O
also    O
known    O
as    O
1-dehydro-9α-fluoro-16α-methylhydrocortisone    O
or    O
as    O
9α-fluoro-11β,17α,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione    O
.    O

Prednisone    O
is    O
a    O
synthetic    O
pregnane    B-Hormone105407119
corticosteroid    O
and    O
derivative    O
of    O
cortisone    O
and    O
is    O
also    O
known    O
as    O
δ1-cortisone    O
or    O
1,2-dehydrocortisone    O
or    O
as    O
17α,21-dihydroxypregna-1,4-diene-3,11,20-trione    O
.    O

Hydrocortisone    O
,    O
also    O
known    O
as    O
11β,17α,21-trihydroxypregn-4-ene-3,20-dione    O
,    O
is    O
a    O
naturally    O
occurring    O
pregnane    B-Hormone105407119
steroid    O
.    O

Cortisone    O
(    O
or    O
)    O
,    O
also    O
known    O
as    O
17α,21-dihydroxypregn-4-ene-3,11,20-trione    O
,    O
is    O
a    O
pregnane    B-Hormone105407119
(    O
21-carbon    O
)    O
steroid    O
hormone    O
.    O

It    O
has    O
also    O
been    O
found    O
to    O
act    O
as    O
an    O
agonist    O
of    O
the    O
human    O
pregnane    O
X    O
receptor    O
,    O
albeit    O
with    O
an    O
EC50    O
that    O
is    O
more    O
than    O
an    O
order    O
of    O
magnitude    O
lower    O
than    O
that    O
of    O
other    O
endogenous    O
pregnane    B-Hormone105407119
like    O
pregnenolone    B-Hormone105407119
,    O
pregnanediol    O
,    O
allopregnanedione    O
,    O
and    O
allopregnanolone    O
.    O

Tesamorelin    B-Hormone105407119
,    O
under    O
the    O
trade    O
name    O
Egrifta    O
,    O
received    O
U.S.    O
Food    O
and    O
Drug    O
Administration    O
approval    O
in    O
2010    O
for    O
the    O
treatment    O
of    O
lipodystrophy    O
in    O
HIV    O
patients    O
under    O
highly    O
active    O
antiretroviral    O
therapy    O
,    O
and    O
,    O
in    O
2011    O
,    O
was    O
investigated    O
for    O
effects    O
on    O
certain    O
cognitive    O
tests    O
in    O
the    O
elderly    O
.    O

A    O
pregnenedione    B-Hormone105407119
is    O
an    O
unsaturated    O
diketone    O
derivative    O
of    O
a    O
pregnane    B-Hormone105407119
.    O

Adrenalone    B-Hormone105407119
is    O
an    O
adrenergic    O
agonist    O
used    O
as    O
a    O
topical    O
vasoconstrictor    O
and    O
hemostatic    O
.    O

A    O
message    O
for    O
the    O
preprohormone    B-Hormone105407119
is    O
transcribed    O
in    O
the    O
heart    O
and    O
kidneys    O
from    O
the    O
gene    O
of    O
NP    O
type    O
A    O
,    O
resulting    O
in    O
a    O
cGMP    O
-    O
dependent    O
signal    O
transduction    O
which    O
induces    O
diuresis    O
and    O
natriuresis    O
,    O
differentially    O
processed    O
to    O
a    O
peptide    O
of    O
32    O
amino    O
acids    O
from    O
the    O
same    O
precursor    O
as    O
renal    O
ANP    O
,    O
may    O
not    O
be    O
identical    O
to    O
the    O
circulating    O
cardiac    O
hormone    O
ANP    O
.    O

4-Androstene-3,6,17-trione    B-Hormone105407119

BMC    O
Endocrine    O
Disorders    O
is    O
an    O
open    O
access    O
peer    O
-    O
reviewed    O
scientific    O
journal    O
publishing    O
original    O
research    O
articles    O
in    O
all    O
aspects    O
of    O
the    O
prevention    O
,    O
diagnosis    O
and    O
management    O
of    O
endocrine    B-Hormone105407119
disorders    I-Hormone105407119
,    O
as    O
well    O
as    O
related    O
molecular    O
genetics    O
,    O
pathophysiology    O
,    O
and    O
epidemiology    O
.    O

Saliva    O
testing    O
is    O
a    O
diagnostic    O
technique    O
that    O
involves    O
laboratory    O
analysis    O
of    O
saliva    O
to    O
identify    O
markers    O
of    O
endocrine    B-Hormone105407119
,    O
immunologic    O
,    O
inflammatory    O
,    O
infectious    O
,    O
and    O
other    O
types    O
of    O
conditions    O
.    O

Other    O
endocrine    B-Hormone105407119
disorders    I-Hormone105407119

Myasthenic    O
syndromes    O
in    O
endocrine    B-Hormone105407119
diseases    I-Hormone105407119

Myopathy    O
in    O
endocrine    B-Hormone105407119
diseases    I-Hormone105407119

Other    O
transitory    O
neonatal    O
endocrine    B-Hormone105407119
disorders    I-Hormone105407119

He    O
went    O
on    O
to    O
become    O
an    O
expert    O
in    O
the    O
treatment    O
of    O
thyroid    O
and    O
other    O
endocrine    B-Hormone105407119
disease    I-Hormone105407119
,    O
migraine    O
,    O
and    O
frostbite    O
.    O

Hormone    B-Hormone105407119
imbalance    I-Hormone105407119

A    O
number    O
of    O
endocrine    B-Hormone105407119
disease    I-Hormone105407119
involve    O
dysfunctions    O
of    O
the    O
adrenal    O
gland    O
.    O

These    O
muscle    O
cramps    O
can    O
have    O
many    O
possible    O
causes    O
directly    O
resulting    O
from    O
high    O
or    O
low    O
pH    O
or    O
substrate    O
concentrations    O
in    O
the    O
blood    O
,    O
including    O
hormonal    B-Hormone105407119
imbalance    I-Hormone105407119
,    O
dehydration    O
,    O
low    O
levels    O
of    O
magnesium    O
,    O
potassium    O
or    O
calcium    O
(    O
although    O
the    O
evidence    O
has    O
been    O
mixed    O
)    O
,    O
side    O
effects    O
of    O
medication    O
,    O
or    O
,    O
more    O
seriously    O
,    O
diseases    O
such    O
as    O
amyotrophic    O
lateral    O
sclerosis    O
and    O
neuropathy    O
.    O

Delestrogen    B-Hormone105407119

estradiol    B-Hormone105407119
valerate    I-Hormone105407119
(    O
INN    O
)    O

Along    O
with    O
estradiol    B-Hormone105407119
valerate    I-Hormone105407119
,    O
estradiol    B-Hormone105407119
cypionate    I-Hormone105407119
,    O
and    O
estradiol    B-Hormone105407119
benzoate    I-Hormone105407119
,    O
estradiol    O
undecylate    O
is    O
or    O
has    O
been    O
used    O
as    O
an    O
intramuscular    O
estrogen    O
in    O
hormone    O
replacement    O
therapy    O
for    O
transgender    O
women    O
.    O

For    O
comparison    O
,    O
the    O
ester    O
chains    O
of    O
estradiol    B-Hormone105407119
acetate    I-Hormone105407119
,    O
estradiol    B-Hormone105407119
valerate    I-Hormone105407119
,    O
and    O
estradiol    B-Hormone105407119
enanthate    I-Hormone105407119
have    O
2    O
,    O
5    O
,    O
and    O
7    O
carbon    O
atoms    O
,    O
respectively    O
.    O

Estradiol    O
undecylate    O
was    O
developed    O
,    O
along    O
with    O
estradiol    B-Hormone105407119
valerate    I-Hormone105407119
,    O
in    O
1954    O
.    O

Prior    O
to    O
the    O
development    O
and    O
introduction    O
of    O
estradiol    B-Hormone105407119
valerate    I-Hormone105407119
and    O
estradiol    B-Hormone105407119
cypionate    I-Hormone105407119
in    O
the    O
1950s    O
,    O
estradiol    O
dipropionate    O
and    O
estradiol    O
benzoate    O
were    O
the    O
most    O
widely    O
used    O
estradiol    O
esters    O
.    O

Estradiol    B-Hormone105407119
valerate    I-Hormone105407119

difluprednate    B-Hormone105407119
(    O
INN    O
)    O

Because    O
the    O
device    O
still    O
requires    O
nutrients    O
to    O
be    O
supplied    O
by    O
the    O
mother    O
,    O
he    O
must    O
drastically    O
shorten    O
the    O
gestation    O
period    O
:    O
to    O
this    O
end    O
,    O
he    O
uses    O
an    O
experimental    O
growth    O
hormone    O
made    O
from    O
human    B-Hormone105407119
placental    I-Hormone105407119
lactogen    I-Hormone105407119
,    O
which    O
speeds    O
up    O
the    O
embryo    O
's    O
growth    O
.    O

Human    B-Hormone105407119
placental    I-Hormone105407119
lactogen    I-Hormone105407119
(    O
hPL    O
)    O
,    O
a    O
hormone    O

then    O
reaching    O
full    O
differentiation    O
as    O
type    O
4    O
lobules    O
requires    O
an    O
increase    O
of    O
human    B-Hormone105407119
placental    I-Hormone105407119
lactogen    I-Hormone105407119
(    O
hPL    O
)    O
which    O
occurs    O
in    O
the    O
last    O
few    O
months    O
of    O
pregnancy    O
.    O

List    O
of    O
estrogen    O
esters    O
–    O
estrogen    B-Hormone105407119
ester    I-Hormone105407119

Estradiol    O
diundecylenate    O
(    O
brand    O
name    O
Etrosteron    O
)    O
,    O
or    O
estradiol    O
diundecenoate    O
,    O
also    O
known    O
as    O
17β-estradiol    O
3,17β-diundec-10-enoate    O
,    O
is    O
a    O
semisynthetic    O
,    O
steroidal    O
estrogen    O
and    O
an    O
estrogen    B-Hormone105407119
ester    I-Hormone105407119
–    O
specifically    O
,    O
the    O
3,17β-diundecylenate    O
ester    O
of    O
estradiol    O
–    O
which    O
is    O
marketed    O
in    O
Argentina    O
.    O

Estrone    O
cyanate    O
,    O
or    O
estrone    O
3-O    O
-    O
cyanate    O
,    O
is    O
a    O
semisynthetic    O
,    O
steroidal    O
estrogen    O
and    O
an    O
estrogen    B-Hormone105407119
ester    I-Hormone105407119
–    O
specifically    O
,    O
the    O
3-O    O
-    O
cyanate    O
ester    O
of    O
estrone    O
–    O
that    O
was    O
investigated    O
for    O
use    O
in    O
oral    O
contraceptives    O
but    O
was    O
found    O
to    O
be    O
of    O
relatively    O
low    O
potency    O
and    O
ultimately    O
was    O
never    O
marketed    O
.    O

Estriol    O
triacetate    O
,    O
also    O
known    O
as    O
estra-1,3,5(10)-triene-3,16α,17β-triol    O
3,16α,17β-triacetate    O
,    O
is    O
a    O
semisynthetic    O
,    O
steroidal    O
estrogen    O
and    O
an    O
estrogen    B-Hormone105407119
ester    I-Hormone105407119
–    O
specifically    O
,    O
the    O
triacetate    O
ester    O
of    O
estriol    O
–    O
which    O
was    O
never    O
marketed    O
.    O

Estradiol    O
mustard    O
(    O
developmental    O
code    O
name    O
NSC-112259    O
)    O
,    O
also    O
known    O
as    O
chlorphenacyl    O
estradiol    O
diester    O
,    O
as    O
well    O
as    O
estradiol    O
3,17β-bis(4-(bis(2-chloroethyl)amino)phenyl)acetate    O
,    O
is    O
a    O
synthetic    O
,    O
steroidal    O
estrogen    O
and    O
alkylating    O
antineoplastic    O
agent    O
and    O
a    O
chlorphenacyl    O
nitrogen    O
mustard    O
-    O
coupled    O
estrogen    B-Hormone105407119
ester    I-Hormone105407119
that    O
was    O
never    O
marketed    O
.    O

Estradiol    O
butyrate    O
benzoate    O
,    O
or    O
estradiol    O
3-benzoate    O
17β-n    O
-    O
butyrate    O
,    O
also    O
known    O
as    O
estra-1,3,5(10)-triene-3,17β-diol    O
3-benzoate    O
17β-n    O
-    O
butyrate    O
,    O
is    O
a    O
semisynthetic    O
,    O
steroidal    O
estrogen    O
and    O
an    O
estrogen    B-Hormone105407119
ester    I-Hormone105407119
–    O
specifically    O
,    O
the    O
3-benzoate    O
17β-n    O
-    O
butyrate    O
diester    O
of    O
estradiol    O
–    O
which    O
was    O
never    O
marketed    O
.    O

:    O
R03AC05    O
Rimiterol    B-Hormone105407119

After    O
an    O
insect    O
attack    O
tomato    O
plants    O
produce    O
systemin    B-Hormone105407119
,    O
a    O
plant    B-Hormone105407119
peptide    I-Hormone105407119
hormone    I-Hormone105407119
.    O

:    O
C01CA22    O
Arbutamine    B-Hormone105407119

Furazabol    B-Hormone105407119

Furazabol    B-Hormone105407119

Levels    O
of    O
progesterone    O
,    O
17α-hydroxyprogesterone    O
,    O
androstenedione    B-Hormone105407119
,    O
testosterone    O
,    O
and    O
dihydrotestosterone    B-Hormone105407119
(    O
DHT    O
)    O
were    O
elevated    O
in    O
the    O
sisters    O
,    O
while    O
concentrations    O
of    O
adrenal    O
steroids    O
including    O
cortisol    B-Hormone105407119
,    O
dehydroepiandrosterone    B-Hormone105407119
(    O
DHEA    O
)    O
,    O
11β-hydroxyandrostenedione    O
,    O
11-deoxycortisol    O
,    O
and    O
21-deoxycortisol    O
were    O
within    O
normal    O
ranges    O
.    O

Cortisol    B-Hormone105407119
decreases    O
amino    O
acid    O
uptake    O
by    O
muscle    O
tissue    O
,    O
and    O
inhibits    O
protein    O
synthesis    O
.    O

Some    O
common    O
naturally    O
occurring    O
steroid    O
hormones    O
are    O
cortisol    B-Hormone105407119
,    O
corticosterone    O
,    O
cortisone    O
and    O
aldosterone    O
.    O

Glucocorticoids    O
such    O
as    O
cortisol    B-Hormone105407119
affect    O
carbohydrate    O
,    O
fat    O
,    O
and    O
protein    O
metabolism    O
,    O
and    O
have    O
anti    O
-    O
inflammatory    O
,    O
immunosuppressive    O
,    O
anti    O
-    O
proliferative    O
,    O
and    O
vasoconstrictive    O
effects    O
.    O
Anti    O
-    O
inflammatory    O
effects    O
are    O
mediated    O
by    O
blocking    O
the    O
action    O
of    O
inflammatory    O
mediators    O
(    O
transrepression    O
)    O
and    O
inducing    O
anti    O
-    O
inflammatory    O
mediators    O
(    O
transactivation    O
)    O
.    O

Cortisol    B-Hormone105407119
.    O

Its    O
principal    O
effects    O
are    O
increased    O
production    O
and    O
release    O
of    O
cortisol    B-Hormone105407119
by    O
the    O
cortex    O
of    O
the    O
adrenal    O
gland    O
.    O

Conversely    O
,    O
chronically    O
elevated    O
ACTH    O
levels    O
occur    O
in    O
primary    O
adrenal    O
insufficiency    O
(    O
e.g.    O
Addison    O
's    O
disease    O
)    O
when    O
adrenal    O
gland    O
production    O
of    O
cortisol    B-Hormone105407119
is    O
chronically    O
deficient    O
.    O

Glucocorticoids    O
are    O
released    O
by    O
the    O
hypothalamic    O
pituitary    O
adrenal    O
(    O
HPA    O
)    O
axis    O
in    O
response    O
to    O
stress    O
,    O
of    O
which    O
cortisol    B-Hormone105407119
is    O
the    O
most    O
prominent    O
in    O
humans    O
.    O

This    O
tumor    O
causes    O
excessive    O
production    O
of    O
cortisol    B-Hormone105407119
from    O
the    O
adrenal    O
cortex    O
which    O
leads    O
to    O
the    O
classic    O
signs    O
of    O
alopecia    O
(    O
hair    O
loss    O
)    O
,    O
polyuria    O
(    O
excessive    O
urination    O
)    O
,    O
polydipsia    O
(    O
excessive    O
water    O
drinking    O
)    O
,    O
and    O
a    O
pot    O
-    O
bellied    O
appearance    O
of    O
the    O
abdomen    O
due    O
to    O
muscle    O
break    O
down    O
.    O

Cases    O
of    O
mild    O
impairment    O
of    O
cortisol    B-Hormone105407119
and    O
androgen    O
synthesis    O
have    O
been    O
noted    O
,    O
however    O
,    O
despite    O
the    O
fact    O
that    O
deficient    O
POR    O
impairs    O
androgen    O
synthesis    O
,    O
patients    O
with    O
Williams    O
syndrome    O
often    O
show    O
increased    O
androgen    O
levels    O
.    O

The    O
HPA    O
axis    O
appears    O
to    O
be    O
dysregulated    O
in    O
psychotic    O
depression    O
,    O
with    O
dexamethasone    B-Hormone105407119
suppression    I-Hormone105407119
test    I-Hormone105407119
demonstrating    O
higher    O
levels    O
of    O
cortisol    B-Hormone105407119
following    O
dexamethasone    O
administration    O
(    O
i.e.    O
lower    O
cortisol    O
suppression    O
)    O
.    O

In    O
patients    O
,    O
flesinoxan    O
enhances    O
REM    O
sleep    O
latency    O
,    O
decreases    O
body    O
temperature    O
,    O
and    O
increases    O
ACTH    O
,    O
cortisol    B-Hormone105407119
,    O
prolactin    O
,    O
and    O
growth    O
hormone    O
secretion    O
.    O

Increased    O
levels    O
of    O
catecholamines    O
and    O
cortisol    B-Hormone105407119
can    O
cause    O
a    O
hypermetabolic    O
state    O
that    O
can    O
last    O
for    O
years    O
.    O

It    O
has    O
been    O
shown    O
to    O
lead    O
to    O
reductions    O
in    O
stress    O
hormones    O
such    O
as    O
cortisol    B-Hormone105407119
and    O
epinephrine    O
.    O

Mice    O
fed    O
"    O
L.    O
rhamnosus    O
"    O
JB-1    O
had    O
less    O
anxiety    O
and    O
different    O
levels    O
of    O
a    O
brain    O
-    O
chemical    O
sensor    O
and    O
stress    B-Hormone105407119
hormones    I-Hormone105407119
.    O

Evidence    O
points    O
to    O
abnormalities    O
in    O
the    O
hypothalamic    O
-    O
pituitary    O
-    O
adrenal    O
axis    O
(    O
HPA    O
axis    O
)    O
in    O
some    O
,    O
but    O
not    O
all    O
,    O
persons    O
with    O
CFS    O
,    O
which    O
may    O
include    O
slightly    O
low    O
cortisol    O
levels    O
,    O
a    O
decrease    O
in    O
the    O
variation    O
of    O
cortisol    B-Hormone105407119
levels    O
throughout    O
the    O
day    O
,    O
decreased    O
responsiveness    O
of    O
the    O
HPA    O
axis    O
,    O
and    O
a    O
high    O
serotonergic    O
state    O
,    O
which    O
can    O
be    O
considered    O
to    O
be    O
a    O
"    O
HPA    O
axis    O
phenotype    O
"    O
that    O
is    O
also    O
present    O
in    O
some    O
other    O
conditions    O
,    O
including    O
PTSD    O
and    O
some    O
autoimmune    O
conditions    O
.    O

Examples    O
of    O
endogenous    O
compounds    O
that    O
have    O
been    O
implicated    O
in    O
stress    O
and    O
depression    O
include    O
corticotropin-releasing    B-Hormone105407119
hormone    I-Hormone105407119
(    O
CRH    O
)    O
,    O
cytokines    O
(    O
e.g.    O
,    O
interferon-α    O
,    O
interleukin-2    O
)    O
,    O
tachykinins    O
(    O
e.g.    O
,    O
substance    O
P    O
)    O
,    O
glucocorticoids    O
(    O
e.g.    O
,    O
cortisol    B-Hormone105407119
,    O
cortisone    O
)    O
,    O
and    O
dynorphin    O
.    O

Dexamethasone    O
is    O
a    O
synthetic    O
pregnane    B-Hormone105407119
corticosteroid    O
and    O
derivative    O
of    O
cortisol    B-Hormone105407119
(    O
hydrocortisone    O
)    O
and    O
is    O
also    O
known    O
as    O
1-dehydro-9α-fluoro-16α-methylhydrocortisone    O
or    O
as    O
9α-fluoro-11β,17α,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione    O
.    O

In    O
cases    O
of    O
acute    O
,    O
persistent    O
pain    O
,    O
the    O
metabolism    O
becomes    O
predominantly    O
catabolic    O
,    O
causing    O
reduced    O
efficiency    O
of    O
the    O
immune    O
system    O
and    O
a    O
breakdown    O
of    O
proteins    O
caused    O
by    O
the    O
action    O
of    O
the    O
stress    B-Hormone105407119
hormone    I-Hormone105407119
.    O

The    O
former    O
are    O
simple    O
direct    O
observation    O
,    O
while    O
the    O
latter    O
requires    O
specific    O
equipment    O
to    O
monitor    O
blood    O
pressure    O
and    O
stress    B-Hormone105407119
hormone    I-Hormone105407119
levels    O
.    O

First    O
,    O
during    O
the    O
early    O
slow    O
-    O
wave    O
-    O
sleep    O
stage    O
,    O
a    O
sudden    O
drop    O
in    O
blood    O
levels    O
of    O
cortisol    B-Hormone105407119
,    O
epinephrine    O
,    O
and    O
norepinephrine    O
induce    O
increased    O
blood    O
levels    O
of    O
the    O
hormones    O
leptin    O
,    O
pituitary    O
growth    O
hormone    O
,    O
and    O
prolactin    O
.    O

Research    O
confirms    O
high    O
levels    O
of    O
cortisol    B-Hormone105407119
-    O
a    O
hormone    O
associated    O
with    O
stress    O
-    O
affects    O
dogs    O
during    O
and    O
after    O
thunderstorms    O
.    O

The    O
HPA    O
axis    O
responds    O
to    O
physical    O
and    O
mental    O
challenge    O
to    O
maintain    O
homeostasis    O
in    O
part    O
by    O
controlling    O
the    O
body    O
's    O
cortisol    B-Hormone105407119
level    O
.    O

Therefore    O
,    O
affected    O
patients    O
might    O
also    O
have    O
hyperprolactinemia    O
and    O
elevated    O
levels    O
of    O
corticosteroids    O
(    O
especially    O
cortisol    B-Hormone105407119
)    O
and    O
growth    O
hormone    O
.    O

Measures    O
of    O
lunar    O
influence    O
on    O
sleep    O
structure    O
,    O
electroencephalographic    O
activity    O
during    O
non    O
-    O
rapid    O
eye    O
movement    O
sleep    O
(    O
NREM    O
)    O
,    O
and    O
secretion    O
of    O
the    O
hormones    O
melatonin    O
and    O
cortisol    B-Hormone105407119
,    O
were    O
retrospectively    O
analyzed    O
.    O

|rowspan=4|    O
Cortisol    B-Hormone105407119

High    O
levels    O
of    O
testosterone    O
combined    O
with    O
low    O
levels    O
of    O
cortisol    B-Hormone105407119
and/or    O
serotonin    O
have    O
been    O
theorized    O
as    O
contributing    O
factors    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl    O
-    O
CoA    O
and    O
cortisol    B-Hormone105407119
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
cortisol    O
21-acetate    O
.    O

CSR    O
has    O
also    O
been    O
associated    O
with    O
cortisol    B-Hormone105407119
and    O
corticosteroids    O
.    O

Isolated    O
hypoaldosteronism    O
is    O
the    O
condition    O
of    O
having    O
lowered    O
aldosterone    O
without    O
corresponding    O
changes    O
in    O
cortisol    B-Hormone105407119
.    O

Aldosterone    O
deficiency    O
should    O
be    O
treated    O
with    O
a    O
mineralocorticoid    O
(    O
such    O
as    O
fludrocortisone    O
)    O
,    O
as    O
well    O
as    O
possibly    O
a    O
glucocorticoid    O
for    O
cortisol    B-Hormone105407119
deficiency    O
,    O
if    O
present    O
.    O

Despite    O
the    O
high    O
levels    O
of    O
ACTH    O
,    O
cortisol    B-Hormone105407119
levels    O
vary    O
,    O
and    O
are    O
sometimes    O
lower    O
than    O
normal    O
.    O

This    O
signals    O
the    O
release    O
of    O
cortisol    B-Hormone105407119
,    O
the    O
stress    O
hormone    O
,    O
initiating    O
a    O
multitude    O
of    O
physical    O
effects    O
on    O
the    O
body    O
to    O
aid    O
in    O
survival    O
.    O

One    O
manifestation    O
of    O
depression    O
is    O
an    O
altered    O
hypothalamic    O
-    O
pituitary    O
-    O
adrenal    O
axis    O
(    O
HPA    O
axis    O
)    O
that    O
resembles    O
the    O
neuro    O
-    O
endocrine    O
(    O
cortisol    B-Hormone105407119
)    O
response    O
to    O
stress    O
,    O
that    O
of    O
increased    O
cortisol    O
production    O
and    O
a    O
subsequent    O
impaired    O
negative    O
feedback    O
mechanism    O
.    O

Hydrocortisone    O
,    O
sold    O
under    O
a    O
number    O
of    O
brand    O
names    O
,    O
is    O
the    O
name    O
for    O
the    O
hormone    O
cortisol    B-Hormone105407119
when    O
supplied    O
as    O
a    O
medication    O
.    O

Cortisol    B-Hormone105407119
(    O
or    O
hydrocortisone    O
)    O
is    O
the    O
most    O
important    O
human    O
glucocorticoid    O
.    O

In    O
the    O
fasted    O
state    O
,    O
cortisol    B-Hormone105407119
stimulates    O
several    O
processes    O
that    O
collectively    O
serve    O
to    O
increase    O
and    O
maintain    O
normal    O
concentrations    O
of    O
glucose    O
in    O
blood    O
.    O

Cortisol    B-Hormone105407119
is    O
the    O
standard    O
of    O
comparison    O
for    O
glucocorticoid    O
potency    O
.    O

Aldosterone    O
and    O
cortisol    B-Hormone105407119
(    O
a    O
glucosteroid    O
)    O
have    O
similar    O
affinity    O
for    O
the    O
mineralocorticoid    O
receptor    O
;    O
however    O
,    O
glucocorticoids    O
circulate    O
at    O
roughly    O
100    O
times    O
the    O
level    O
of    O
mineralocorticoids    O
.    O

Police    O
considered    O
few    O
of    O
the    O
findings    O
to    O
be    O
of    O
note    O
,    O
except    O
multiple    O
tubes    O
of    O
hydrocortisone    B-Hormone105407119
cream    O
and    O
a    O
fairly    O
extensive    O
collection    O
of    O
the    O
fiction    O
of    O
C.    O
S.    O
Lewis    O
.    O

The    O
so    O
-    O
called    O
classic    O
catabolic    O
hormones    O
known    O
since    O
the    O
early    O
20th    O
century    O
are    O
cortisol    B-Hormone105407119
,    O
glucagon    O
,    O
and    O
adrenaline    O
(    O
and    O
other    O
catecholamines    O
)    O
.    O

11β-Hydroxysteroid    O
dehydrogenase    O
(    O
HSD-11β    O
or    O
11β-HSD    O
)    O
is    O
a    O
family    O
of    O
enzymes    O
that    O
catalyze    O
the    O
conversion    O
of    O
inert    O
11    O
keto    O
-    O
products    O
(    O
cortisone    O
)    O
to    O
active    O
cortisol    B-Hormone105407119
,    O
or    O
vice    O
versa    O
,    O
thus    O
regulating    O
the    O
access    O
of    O
glucocorticoids    O
to    O
the    O
steroid    O
receptors    O
:    O

Cortisol    B-Hormone105407119
,    O
a    O
glucocorticoid    O
,    O
binds    O
the    O
glucocorticoid    O
receptor    O
.    O

Cortisol    B-Hormone105407119
.    O

In    O
chemical    O
structure    O
,    O
it    O
is    O
a    O
corticosteroid    O
closely    O
related    O
to    O
cortisol    B-Hormone105407119
.    O

One    O
end    O
-    O
product    O
of    O
this    O
pathway    O
is    O
cortisol    B-Hormone105407119
.    O

Corticosterol    B-Hormone105407119

It    O
has    O
been    O
theorized    O
that    O
CrossFit    O
's    O
implementation    O
of    O
resistance    O
coupled    O
with    O
anaerobic    O
and    O
aerobic    O
exercise    O
across    O
varying    O
training    O
time    O
domains    O
may    O
benefit    O
muscle    O
size    O
,    O
cortisol    B-Hormone105407119
levels    O
,    O
and    O
improved    O
endurance    O
performance    O
but    O
this    O
has    O
not    O
been    O
substantiated    O
by    O
a    O
body    O
of    O
good    O
medical    O
evidence    O
.    O

The    O
adrenal    O
glands    O
(    O
also    O
known    O
as    O
suprarenal    O
glands    O
)    O
are    O
endocrine    O
glands    O
that    O
produce    O
a    O
variety    O
of    O
hormones    O
including    O
adrenaline    O
and    O
the    O
steroids    O
aldosterone    O
and    O
cortisol    B-Hormone105407119
.    O

The    O
glucocorticoids    O
cortisol    B-Hormone105407119
and    O
corticosterone    O
are    O
synthesized    O
in    O
the    O
zona    O
fasciculata    O
;    O
their    O
functions    O
include    O
the    O
regulation    O
of    O
metabolism    O
and    O
immune    O
system    O
suppression    O
.    O

The    O
adrenal    O
cortex    O
is    O
devoted    O
to    O
production    O
of    O
hormones    O
,    O
namely    O
aldosterone    O
,    O
cortisol    B-Hormone105407119
,    O
and    O
androgens    O
.    O

Cells    O
in    O
this    O
layer    O
are    O
responsible    O
for    O
producing    O
glucocorticoids    O
such    O
as    O
cortisol    B-Hormone105407119
.    O

Glucocorticoids    O
such    O
as    O
cortisol    B-Hormone105407119
influence    O
metabolism    O
rates    O
of    O
proteins    O
,    O
fats    O
and    O
sugars    O
(    O
"    O
glucose    O
"    O
)    O
.    O

Cortisol    B-Hormone105407119
is    O
the    O
main    O
glucocorticoid    O
in    O
humans    O
.    O

Cortical    O
development    O
of    O
the    O
adrenal    O
gland    O
is    O
regulated    O
mostly    O
by    O
ACTH    O
,    O
a    O
hormone    O
produced    O
by    O
the    O
pituitary    O
gland    O
that    O
stimulates    O
cortisol    B-Hormone105407119
synthesis    O
.    O

Cholesterol    O
and    O
its    O
derivatives    O
(    O
such    O
as    O
progesterone    O
,    O
aldosterone    O
,    O
cortisol    B-Hormone105407119
,    O
and    O
testosterone    O
)    O
,    O
are    O
common    O
examples    O
of    O
compounds    O
with    O
the    O
cyclopentanoperhydrophenanthrene    O
nucleus    O
.    O

For    O
example    O
,    O
insufficient    O
adrenocorticotropic    O
hormone    O
means    O
that    O
the    O
adrenal    O
glands    O
will    O
not    O
produce    O
sufficient    O
cortisol    B-Hormone105407119
,    O
resulting    O
in    O
slow    O
recovery    O
from    O
illness    O
,    O
inflammation    O
and    O
chronic    O
fatigue    O
;    O
insufficient    O
growth    O
hormone    O
in    O
children    O
and    O
adolescents    O
leads    O
to    O
diminished    O
stature    O
but    O
which    O
can    O
have    O
many    O
other    O
explanations    O
.    O

Cushing    O
's    O
syndrome    O
is    O
a    O
hormonal    O
disorder    O
that    O
causes    O
hypercortisolism    O
,    O
which    O
is    O
elevated    O
levels    O
of    O
cortisol    B-Hormone105407119
in    O
the    O
blood    O
.    O

CD    O
results    O
when    O
a    O
pituitary    O
adenoma    O
causes    O
excessive    O
secretion    O
of    O
adrenocorticotropic    O
hormone    O
(    O
ACTH    O
)    O
that    O
stimulates    O
the    O
adrenal    O
glands    O
to    O
produce    O
excessive    O
amounts    O
of    O
cortisol    B-Hormone105407119
.    O

When    O
the    O
blood    O
glucose    O
level    O
falls    O
below    O
normal    O
,    O
the    O
body    O
responds    O
by    O
releasing    O
the    O
endocrine    O
hormone    O
glucagon    O
as    O
well    O
as    O
the    O
stress    O
hormones    O
epinephrine    O
,    O
cortisol    B-Hormone105407119
and    O
growth    O
hormone    O
.    O

Cortisol    B-Hormone105407119
,    O
a    O
stress    O
hormone    O
,    O
was    O
found    O
to    O
be    O
elevated    O
in    O
males    O
during    O
stressful    O
situations    O
.    O

The    O
fetal    O
adrenal    O
cortex    O
lacks    O
expression    O
of    O
the    O
enzyme    O
early    O
on    O
,    O
thus    O
mineralocorticoids    O
(    O
e.g.    O
aldosterone    O
)    O
and    O
glucocorticoids    O
(    O
e.g.    O
cortisol    B-Hormone105407119
)    O
can    O
not    O
be    O
synthesized    O
.    O

Consequences    O
of    O
the    O
alcohol    O
induced    O
redox    O
changes    O
in    O
the    O
human    O
body    O
include    O
increased    O
triglyceride    O
production    O
,    O
increased    O
amino    O
acid    O
catabolism    O
,    O
inhibition    O
of    O
the    O
citric    O
acid    O
cycle    O
,    O
lactic    O
acidosis    O
,    O
ketoacidosis    O
,    O
hyperuricemia    O
,    O
disturbance    O
in    O
cortisol    B-Hormone105407119
and    O
androgen    O
metabolism    O
and    O
increased    O
fibrogenesis    O
.    O

There    O
is    O
strong    O
evidence    O
that    O
individuals    O
with    O
depression    O
experience    O
irregular    O
biological    O
rhythms    O
,    O
including    O
disrupted    O
sleep    O
-    O
wake    O
cycles    O
,    O
temperature    O
,    O
and    O
cortisol    B-Hormone105407119
rhythms    O
.    O

Dobutamine    B-Hormone105407119
.    O

Dextrose    O
and    O
Dobutamine    B-Hormone105407119
are    O
both    O
used    O
to    O
increase    O
blood    O
flow    O
to    O
the    O
kidney    O
and    O
act    O
within    O
30    O
to    O
60    O
minutes    O
.    O

For    O
cases    O
in    O
which    O
the    O
LVOT    O
is    O
not    O
obstructed    O
,    O
inotropic    O
therapy    O
(    O
e.g.    O
dobutamine    B-Hormone105407119
and    O
dopamine    O
)    O
may    O
be    O
used    O
,    O
but    O
with    O
the    O
consideration    O
that    O
takotsubo    O
is    O
caused    O
by    O
excess    O
catecholamines    O
.    O

Following    O
this    O
,    O
myocardial    O
stress    O
is    O
induced    O
,    O
either    O
by    O
exercise    O
or    O
pharmacologically    O
with    O
adenosine    O
,    O
dobutamine    B-Hormone105407119
or    O
dipyridamole(Persantine    O
)    O
,    O
which    O
increase    O
the    O
heart    O
rate    O
or    O
by    O
regadenoson(Lexiscan    O
)    O
,    O
a    O
vasodilator    O
.    O

There    O
are    O
numerous    O
other    O
drugs    O
(    O
e.g.    O
,    O
dobutamine    B-Hormone105407119
,    O
ephedrine    O
,    O
isoproterenol    O
)    O
that    O
manipulate    O
the    O
adrenergic    O
receptors    O
and    O
have    O
variable    O
specificity    O
for    O
the    O
receptors    O
and    O
are    O
,    O
thus    O
,    O
used    O
for    O
various    O
reasons    O
.    O

Metalloestrogen    B-Hormone105407119
:    O
cadmium    O
,    O
others    O

methallenestril    B-Hormone105407119
(    O
INN    O
)    O

Methallenestril    B-Hormone105407119

Zearalanone    B-Hormone105407119

Zearalanone    B-Hormone105407119

Fluocortin    B-Hormone105407119
=    O
6α-fluoro-11β,21-dihydroxy-16α-methylpregna-1,4-diene-3,20,21-trione    O

Glucagon    O
is    O
produced    O
,    O
like    O
other    O
peptide    O
hormones    O
,    O
as    O
part    O
of    O
a    O
larger    O
precursor    O
(    O
preproglucagon    B-Hormone105407119
)    O
,    O
which    O
is    O
cleaved    O
to    O
produce    O
glucagon    O
,    O
glucagon-like    B-Hormone105407119
protein    I-Hormone105407119
I    I-Hormone105407119
,    O
glucagon    O
-    O
like    O
protein    O
II    O
,    O
and    O
glicentin    O
.    O

Enteroglucagon    B-Hormone105407119
is    O
a    O
peptide    O
hormone    O
derived    O
from    O
preproglucagon    B-Hormone105407119
.    O

Proglucagon    B-Hormone105407119

Micronor    B-Hormone105407119

:    O
norethisterone    B-Hormone105407119
(    O
contraceptive    O
)    O

In    O
contrast    O
,    O
the    O
non    O
-    O
halogenated    O
19-nortestosterone    O
derivatives    O
norgestrel    O
,    O
norethisterone    B-Hormone105407119
,    O
noretynodrel    O
,    O
and    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
were    O
not    O
found    O
to    O
produce    O
such    O
nodules    O
.    O

It    O
is    O
a    O
chloroethynylated    O
derivative    O
of    O
norethisterone    B-Hormone105407119
.    O

In    O
contrast    O
,    O
the    O
non    O
-    O
halogenated    O
19-nortestosterone    O
derivatives    O
norgestrel    O
,    O
norethisterone    B-Hormone105407119
,    O
noretynodrel    O
,    O
and    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
which    O
are    O
much    O
less    O
potent    O
as    O
progestogens    O
,    O
did    O
not    O
produce    O
such    O
effects    O
at    O
the    O
dosages    O
tested    O
.    O

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-Hormone105407119
)    O
,    O
desogestrel    B-Hormone105407119
,    O
ethylestrenol    B-Hormone105407119
,    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
ethinylestradiol    O
,    O
gestrinone    B-Hormone105407119
,    O
levonorgestrel    B-Hormone105407119
,    O
norethisterone    B-Hormone105407119
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    B-Hormone105407119
)    O
,    O
quinestrol    B-Hormone105407119
,    O
19-norprogesterone    B-Hormone105407119
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-Hormone105407119
acetate    I-Hormone105407119
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
.    O

Nandrolone    O
,    O
together    O
with    O
ethisterone    B-Hormone105407119
(    O
17α-ethynyltestosterone    O
)    O
,    O
is    O
also    O
the    O
parent    O
compound    O
of    O
a    O
large    O
group    O
of    O
progestins    O
,    O
the    O
norethisterone    B-Hormone105407119
(    O
17α-ethynyl-19-nortestosterone    O
)    O
derivatives    O
.    O

The    O
estranes    O
include    O
norethisterone    B-Hormone105407119
(    O
norethindrone    O
)    O
,    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
norethisterone    O
enanthate    O
,    O
lynestrenol    B-Hormone105407119
,    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-Hormone105407119
,    O
desogestrel    B-Hormone105407119
,    O
etonogestrel    B-Hormone105407119
,    O
gestodene    B-Hormone105407119
,    O
norgestimate    B-Hormone105407119
,    O
dienogest    B-Hormone105407119
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    B-Hormone105407119
.    O

In    O
1978    O
the    O
company    O
brought    O
to    O
market    O
the    O
first    O
once    O
-    O
a    O
-    O
week    O
oral    O
contraceptive    O
"    O
Deposiston    O
"    O
,    O
a    O
combination    O
of    O
ethinylestradiol    O
sulfonate    O
and    O
norethisterone    B-Hormone105407119
acetate    O
.    O

Treatment    O
with    O
a    O
progestin    O
,    O
norethisterone    B-Hormone105407119
,    O
reduced    O
her    O
estradiol    O
concentrations    O
to    O
normal    O
levels    O
and    O
decreased    O
the    O
size    O
of    O
her    O
ovaries    O
and    O
the    O
number    O
of    O
ovarian    O
cysts    O
,    O
alleviating    O
her    O
hypothalamic    O
-    O
pituitary    O
-    O
gonadal    O
axis    O
hyperactivity    O
and    O
ovarian    O
pathology    O
.    O

Examples    O
include    O
drugs    O
such    O
as    O
Norethisterone    B-Hormone105407119
,    O
Ethisterone    B-Hormone105407119
,    O
and    O
Lynestrenol    B-Hormone105407119
.    O

A    O
2001    O
comparative    O
study    O
of    O
the    O
IMS    O
LifeLink    O
Health    O
Plan    O
Claims    O
Database    O
interpreted    O
that    O
in    O
a    O
large    O
cohort    O
of    O
women    O
using    O
oral    O
contraceptives    O
,    O
there    O
was    O
found    O
a    O
small    O
,    O
statistically    O
significant    O
increase    O
in    O
the    O
risk    O
of    O
gallbladder    O
disease    O
associated    O
with    O
desogestrel    B-Hormone105407119
,    O
drospirenone    O
and    O
norethisterone    B-Hormone105407119
compared    O
with    O
levonorgestrel    B-Hormone105407119
.    O

Conversely    O
,    O
replacement    O
of    O
the    O
C17α    O
alkyl    O
group    O
with    O
an    O
ethynyl    O
group    O
greatly    O
reduces    O
but    O
does    O
not    O
abolish    O
androgenic    O
activity    O
,    O
as    O
in    O
ethisterone    B-Hormone105407119
(    O
17α-ethynyltestosterone    O
)    O
and    O
norethisterone    B-Hormone105407119
(    O
17α-ethynyl-19-nortestosterone    O
)    O
.    O

Camila    O
,    O
brand    O
name    O
of    O
a    O
progestogen    O
-    O
only    O
pill    O
containing    O
norethisterone    B-Hormone105407119
(    O
norethindrone    O
)    O

Gestodene    B-Hormone105407119
is    O
a    O
19-nortestosterone    O
derivative    O
with    O
antimineralocorticoid    O
properties    O
.    O

gestodene    B-Hormone105407119
(    O
INN    O
)    O

The    O
estranes    O
include    O
norethisterone    B-Hormone105407119
(    O
norethindrone    O
)    O
,    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
,    O
norethisterone    O
enanthate    O
,    O
lynestrenol    B-Hormone105407119
,    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-Hormone105407119
,    O
desogestrel    B-Hormone105407119
,    O
etonogestrel    B-Hormone105407119
,    O
gestodene    B-Hormone105407119
,    O
norgestimate    B-Hormone105407119
,    O
dienogest    B-Hormone105407119
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    B-Hormone105407119
.    O

Peptide    B-Hormone105407119
YY    I-Hormone105407119

This    O
appetite    O
inhibition    O
is    O
long    O
-    O
term    O
,    O
in    O
contrast    O
to    O
the    O
rapid    O
inhibition    O
of    O
hunger    O
by    O
cholecystokinin    O
(    O
CCK    O
)    O
and    O
the    O
slower    O
suppression    O
of    O
hunger    O
between    O
meals    O
mediated    O
by    O
PYY3-36    B-Hormone105407119
.    O

Another    O
satiety    O
signal    O
produced    O
by    O
cells    O
is    O
peptide    B-Hormone105407119
YY3-36    I-Hormone105407119
(    O
PYY    O
)    O
,    O
which    O
is    O
released    O
after    O
a    O
meal    O
in    O
amounts    O
proportional    O
to    O
the    O
calories    O
ingested    O
.    O

α-Zearalenol    O
is    O
a    O
nonsteroidal    O
estrogen    O
of    O
the    O
resorcylic    O
acid    O
lactone    O
group    O
related    O
to    O
mycoestrogen    B-Hormone105407119
found    O
in    O
"    O
Fusarium    O
spp    O
"    O
.    O

Zeranol    O
(    O
INN    O
,    O
USAN    O
,    O
BAN    O
)    O
(    O
brand    O
names    O
Frideron    O
,    O
Ralabol    O
,    O
Ralgro    O
,    O
Ralone    O
,    O
Zerano    O
;    O
developmental    O
code    O
names    O
MK-188    O
,    O
P-1496    O
)    O
,    O
or    O
zearanol    O
,    O
also    O
known    O
as    O
α-zearalanol    O
or    O
simply    O
zearalanol    O
,    O
is    O
a    O
synthetic    O
nonsteroidal    O
estrogen    O
of    O
the    O
resorcylic    O
acid    O
lactone    O
group    O
related    O
to    O
mycoestrogen    B-Hormone105407119
found    O
in    O
fungi    O
in    O
the    O
"    O
Fusarium    O
"    O
genus    O
and    O
is    O
used    O
mainly    O
as    O
an    O
anabolic    O
agent    O
in    O
veterinary    O
medicine    O
.    O

Some    O
other    O
examples    O
of    O
putative    O
EDCs    O
are    O
polychlorinated    O
dibenzo    O
-    O
dioxins    O
(    O
PCDDs    O
)    O
and    O
-furans    O
(    O
PCDFs    O
)    O
,    O
polycyclic    O
aromatic    O
hydrocarbons    O
(    O
PAHs    O
)    O
,    O
phenol    O
derivatives    O
and    O
a    O
number    O
of    O
pesticides    O
(    O
most    O
prominent    O
being    O
organochlorine    O
insecticides    O
like    O
endosulfan    O
,    O
kepone    O
(    O
chlordecone    O
)    O
and    O
DDT    O
and    O
its    O
derivatives    O
,    O
the    O
herbicide    O
atrazine    O
,    O
and    O
the    O
fungicide    O
vinclozolin    O
)    O
,    O
the    O
contraceptive    O
17-alpha    O
ethinylestradiol    O
,    O
as    O
well    O
as    O
naturally    O
occurring    O
phytoestrogens    B-Hormone105407119
such    O
as    O
genistein    B-Hormone105407119
and    O
mycoestrogens    B-Hormone105407119
such    O
as    O
zearalenone    O
.    O

Under    O
the    O
developmental    O
code    O
name    O
MK-665    O
,    O
it    O
was    O
studied    O
in    O
combination    O
with    O
mestranol    O
as    O
an    O
oral    B-Hormone105407119
contraceptive    I-Hormone105407119
.    O

In    O
the    O
1999    O
ratings    O
for    O
88    O
countries    O
,    O
73%    O
of    O
countries    O
offered    O
condoms    O
to    O
at    O
least    O
half    O
their    O
population    O
,    O
65%    O
of    O
countries    O
offered    O
the    B-Hormone105407119
pill    I-Hormone105407119
,    O
54%    O
offered    O
IUDs    O
,    O
42%    O
offered    O
female    O
sterilization    O
,    O
and    O
26%    O
offered    O
male    O
sterilization    O
.    O

In    O
1970    O
,    O
Nelson    O
called    O
for    O
Congressional    O
hearings    O
on    O
the    O
safety    O
of    O
combined    B-Hormone105407119
oral    I-Hormone105407119
contraceptive    I-Hormone105407119
pill    I-Hormone105407119
,    O
which    O
were    O
famously    O
called    O
"    O
The    O
Nelson    O
Pill    O
Hearings    O
.    O
"    O

Terry    O
Prone    O
demonstrated    O
her    O
view    O
that    O
soaps    O
,    O
rather    O
than    O
"    O
dusty    O
old    O
current    O
affairs    O
programmes    O
"    O
,    O
had    O
been    O
central    O
to    O
social    O
change    O
.    O
"    O
The    O
Riordans    O
"    O
caused    O
scandal    O
when    O
one    O
of    O
the    O
characters    O
,    O
named    O
Maggie    O
,    O
went    O
on    O
the    B-Hormone105407119
pill    I-Hormone105407119
.    O

Oftentimes    O
,    O
for    O
women    O
treating    O
acne    O
,    O
spironolactone    O
is    O
prescribed    O
and    O
paired    O
with    O
a    O
birth    B-Hormone105407119
control    I-Hormone105407119
pill    I-Hormone105407119
.    O

The    O
DU    O
spectrophotometer    O
was    O
also    O
used    O
in    O
the    O
study    O
of    O
steroids    O
by    O
researchers    O
like    O
Alejandro    O
Zaffaroni    O
,    O
who    O
helped    O
to    O
develop    O
the    O
birth    B-Hormone105407119
control    I-Hormone105407119
pill    I-Hormone105407119
,    O
the    O
nicotine    O
patch    O
,    O
and    O
corticosteroids    O
.    O

She    O
is    O
currently    O
working    O
on    O
her    O
third    O
film    O
,    O
"    O
Sweetening    O
the    O
Pill    O
,    O
"    O
a    O
film    O
that    O
aims    O
to    O
address    O
the    O
side    O
effects    O
of    O
taking    O
the    O
birth    B-Hormone105407119
control    I-Hormone105407119
pill    I-Hormone105407119
.    O

The    O
first    O
highly    O
successful    O
instance    O
being    O
the    O
discovery    O
in    O
1947    O
of    O
the    O
tuber    O
"    O
Barbasco    O
"    O
(    O
"    O
Dioscorea    O
composita    O
"    O
)    O
which    O
has    O
a    O
high    O
content    O
of    O
diosgenin    O
,    O
revolutionizing    O
the    O
production    O
of    O
synthetic    O
hormones    O
in    O
the    O
1950s    O
and    O
1960s    O
and    O
eventually    O
leading    O
to    O
the    O
invention    O
of    O
combined    B-Hormone105407119
oral    I-Hormone105407119
contraceptive    I-Hormone105407119
pill    I-Hormone105407119
.    O

There    O
is    O
currently    O
contention    O
over    O
whether    O
hormonal    O
contraception    O
methods    O
have    O
post    O
-    O
fertilization    O
methods    O
,    O
specifically    O
the    O
most    O
popular    O
hormonal    O
method    O
-    O
the    O
combined    B-Hormone105407119
oral    I-Hormone105407119
contraceptive    I-Hormone105407119
pill    I-Hormone105407119
(    O
COCP    O
)    O
.    O

The    O
advent    O
of    O
the    B-Hormone105407119
pill    I-Hormone105407119
and    O
other    O
forms    O
of    O
birth    O
control    O
,    O
the    O
Women    O
's    O
Liberation    O
movement    O
,    O
and    O
the    O
legalization    O
of    O
abortion    O
in    O
many    O
countries    O
are    O
believed    O
to    O
have    O
led    O
to    O
a    O
wider    O
practice    O
of    O
casual    O
sex    O
.    O

Many    O
common    O
combined    B-Hormone105407119
oral    I-Hormone105407119
contraceptive    I-Hormone105407119
pill    I-Hormone105407119
could    O
be    O
used    O
for    O
the    O
Yuzpe    O
regimen    O
,    O
although    O
their    O
manufacturers    O
did    O
not    O
label    O
the    O
pills    O
for    O
this    O
use    O
.    O

The    O
Food    O
and    O
Drug    O
Administration    O
announces    O
it    O
will    O
approve    O
birth    O
control    O
as    O
an    O
additional    O
indication    O
for    O
Searle    O
's    O
Enovid    O
,    O
making    O
Enovid    O
the    O
world    O
's    O
first    O
approved    O
oral    B-Hormone105407119
contraceptive    I-Hormone105407119
pill    I-Hormone105407119
.    O

In    O
1966    O
,    O
the    O
band    O
was    O
suspended    O
for    O
several    O
games    O
for    O
the    O
infamous    O
"    O
birth    O
control    O
"    O
show    O
where    O
they    O
formed    O
a    O
birth    B-Hormone105407119
control    I-Hormone105407119
pill    I-Hormone105407119
,    O
a    O
calendar    O
(    O
for    O
the    O
rhythm    O
method    O
)    O
,    O
and    O
a    O
chastity    O
belt    O
.    O

4    O
December    O
–    O
birth    B-Hormone105407119
control    I-Hormone105407119
pills    I-Hormone105407119
become    O
available    O
on    O
the    O
National    O
Health    O
Service    O
after    O
their    O
availability    O
is    O
backed    O
by    O
Health    O
Minister    O
Enoch    O
Powell    O
.    O

The    O
PDA    O
discovered    O
that    O
birth    B-Hormone105407119
control    I-Hormone105407119
pills    I-Hormone105407119
were    O
used    O
by    O
only    O
20%    O
of    O
the    O
population    O
because    O
getting    O
them    O
required    O
access    O
to    O
medical    O
personnel    O
.    O

On    O
her    O
break    O
,    O
Peggy    O
goes    O
to    O
the    O
office    O
of    O
a    O
doctor    O
recommended    O
by    O
the    O
all    O
-    O
knowing    O
Joan    O
,    O
where    O
she    O
gets    O
a    O
prescription    O
for    O
the    O
recently    O
introduced    O
birth    B-Hormone105407119
control    I-Hormone105407119
pill    I-Hormone105407119
,    O
which    O
at    O
the    O
time    O
was    O
not    O
supposed    O
to    O
be    O
prescribed    O
to    O
unmarried    O
women    O
or    O
married    O
women    O
without    O
their    O
husband    O
's    O
consent    O
.    O

The    O
first    O
large    O
-    O
scale    O
human    O
trial    O
of    O
the    O
birth    B-Hormone105407119
control    I-Hormone105407119
pill    I-Hormone105407119
was    O
carried    O
out    O
in    O
Puerto    O
Rico    O
in    O
the    O
1950s    O
.    O

Carl    O
Djerassi    O
-    O
chemist    O
,    O
developed    O
the    O
first    B-Hormone105407119
oral    I-Hormone105407119
contraceptive    I-Hormone105407119
pill    I-Hormone105407119
,    O
nominated    O
as    O
one    O
of    O
the    O
greatest    O
medical    O
discoveries    O
in    O
the    O
last    O
166    O
years    O

Such    O
preparations    O
were    O
used    O
in    O
early    O
combined    B-Hormone105407119
oral    I-Hormone105407119
contraceptive    I-Hormone105407119
pill    I-Hormone105407119
.    O

Tanaka    O
's    O
views    O
on    O
abortion    O
became    O
well    O
publicized    O
and    O
controversial    O
:    O
Other    O
Japanese    O
feminists    O
protested    O
in    O
favour    O
of    O
legalization    O
of    O
the    O
birth    B-Hormone105407119
control    I-Hormone105407119
pill    I-Hormone105407119
during    O
the    O
same    O
era    O
.    O

If    O
they    O
took    O
contraceptive    B-Hormone105407119
pills    I-Hormone105407119
,    O
he    O
told    O
them    O
to    O
stop    O
it    O
and    O
they    O
felt    O
they    O
had    O
to    O
obey    O
.    O

It    O
is    O
also    O
used    O
as    O
an    O
oral    B-Hormone105407119
contraceptive    I-Hormone105407119
with    O
estradiol    O
(    O
as    O
Zoely    O
)    O
.    O

She    O
funded    O
most    O
of    O
the    O
research    O
necessary    O
to    O
develop    O
the    O
first    B-Hormone105407119
birth    I-Hormone105407119
control    I-Hormone105407119
pill    I-Hormone105407119
.    O

Estradiol    O
and    O
progesterone    O
,    O
taken    O
in    O
various    O
forms    O
including    O
combined    B-Hormone105407119
oral    I-Hormone105407119
contraceptive    I-Hormone105407119
pill    I-Hormone105407119
,    O
mimics    O
the    O
hormonal    O
levels    O
of    O
the    O
menstrual    O
cycle    O
and    O
engage    O
in    O
negative    O
feedback    O
of    O
folliculogenesis    O
and    O
ovulation    O
.    O

In    O
those    O
with    O
more    O
significant    O
symptoms    O
birth    B-Hormone105407119
control    I-Hormone105407119
pill    I-Hormone105407119
or    O
the    O
diuretic    O
spironolactone    O
may    O
be    O
useful    O
.    O

In    O
those    O
with    O
more    O
significant    O
symptoms    O
birth    B-Hormone105407119
control    I-Hormone105407119
pill    I-Hormone105407119
may    O
be    O
useful    O
.    O

Hormonal    O
contraception    O
is    O
commonly    O
used    O
;    O
common    O
forms    O
include    O
the    O
combined    B-Hormone105407119
oral    I-Hormone105407119
contraceptive    I-Hormone105407119
pill    I-Hormone105407119
and    O
the    O
contraceptive    O
patch    O
.    O

Before    O
the    O
highly    O
effective    O
birth    B-Hormone105407119
control    I-Hormone105407119
pill    I-Hormone105407119
was    O
available    O
,    O
women    O
planning    O
professional    O
careers    O
,    O
which    O
required    O
a    O
long    O
-    O
term    O
,    O
expensive    O
commitment    O
,    O
had    O
to    O
"    O
pay    O
the    O
penalty    O
of    O
abstinence    O
or    O
cope    O
with    O
considerable    O
uncertainty    O
regarding    O
pregnancy    O
.    O
"    O
This    O
control    O
over    O
their    O
reproductive    O
decisions    O
allowed    O
women    O
to    O
more    O
easily    O
make    O
long    O
-    O
term    O
decisions    O
about    O
their    O
education    O
and    O
professional    O
opportunities    O
.    O

Given    O
that    O
older    O
studies    O
show    O
no    O
difference    O
in    O
incidence    O
between    O
men    O
and    O
women    O
,    O
it    O
has    O
been    O
suggested    O
that    O
the    O
use    O
of    O
oral    B-Hormone105407119
contraceptives    I-Hormone105407119
in    O
women    O
is    O
behind    O
the    O
disparity    O
between    O
the    O
sexes    O
.    O

The    O
decline    O
in    O
the    O
fertility    O
rate    O
is    O
associated    O
with    O
the    O
introduction    O
of    O
the    B-Hormone105407119
pill    I-Hormone105407119
in    O
1960    O
,    O
the    O
completion    O
of    O
legalization    O
of    O
artificial    O
birth    O
control    O
methods    O
,    O
the    O
introduction    O
of    O
federal    O
funding    O
to    O
make    O
family    O
planning    O
services    O
more    O
available    O
to    O
the    O
young    O
and    O
low    O
income    O
,    O
and    O
the    O
legalization    O
of    O
abortion    O
.    O

The    O
Editor    O
of    O
"    O
The    O
Irish    O
Times    O
"    O
,    O
Douglas    O
Gageby    O
,    O
is    O
in    O
favour    O
of    O
open    O
debate    O
over    O
the    O
contraceptive    B-Hormone105407119
pill    I-Hormone105407119
in    O
the    O
correspondence    O
columns    O
of    O
his    O
newspaper    O
,    O
and    O
reflects    O
on    O
the    O
emerging    O
difficulties    O
of    O
censorship    O
.    O

Other    O
elements    O
of    O
the    O
sexual    O
revolution    O
included    O
the    O
development    O
of    O
The    B-Hormone105407119
Pill    I-Hormone105407119
,    O
Mary    O
Quant    O
's    O
miniskirt    O
and    O
the    O
1967    O
legalisation    O
of    O
homosexuality    O
.    O

Min    O
Chueh    O
Chang    O
(    O
張明覺    O
)    O
-    O
co    O
-    O
inventor    O
of    O
the    O
first    B-Hormone105407119
birth    I-Hormone105407119
control    I-Hormone105407119
pill    I-Hormone105407119
;    O
made    O
significant    O
contributions    O
to    O
the    O
development    O
of    O
in    O
vitro    O
fertilisation    O

With    O
the    O
appearance    O
of    O
the    O
first    B-Hormone105407119
oral    I-Hormone105407119
contraceptives    I-Hormone105407119
in    O
1960    O
,    O
dissenters    O
in    O
the    O
Church    O
argued    O
for    O
a    O
reconsideration    O
of    O
the    O
Church    O
positions    O
.    O

Gregory    O
Goodwin    O
Pincus    O
,    O
one    O
of    O
the    O
three    O
"    O
fathers    O
"    O
of    O
the    O
birth    B-Hormone105407119
control    I-Hormone105407119
pill    I-Hormone105407119

Behaviors    O
surrounding    O
the    O
testing    O
period    O
have    O
been    O
extreme    O
under    O
some    O
reports    O
,    O
with    O
doctors    O
in    O
Tianjin    O
purportedly    O
prescribing    O
birth    B-Hormone105407119
control    I-Hormone105407119
pill    I-Hormone105407119
to    O
female    O
students    O
whose    O
parents    O
wanted    O
to    O
ensure    O
the    O
girls    O
were    O
not    O
menstruating    O
at    O
the    O
time    O
of    O
examination    O
.    O

With    O
the    O
discovery    O
of    O
the    O
chemical    O
properties    O
of    O
the    O
barbasco    O
root    O
,    O
world    O
market    O
prices    O
for    O
steroids    O
and    O
other    O
synthetic    O
hormones    O
plummeted    O
-    O
making    O
them    O
feasible    O
for    O
large    O
scale    O
production    O
of    O
medicines    O
for    O
common    O
ailments    O
such    O
as    O
arthritis    O
or    O
Addison    O
's    O
disease    O
,    O
and    O
eventually    O
as    O
the    O
basis    O
for    O
the    O
combined    B-Hormone105407119
oral    I-Hormone105407119
contraceptive    I-Hormone105407119
pill    I-Hormone105407119
.    O

Carl    O
Djerassi    O
-    O
the    O
inventor    O
of    O
the    O
first    B-Hormone105407119
contraceptive    I-Hormone105407119
pill    I-Hormone105407119
.    O

Ethinylestradiol    O
/    O
levonorgestrel    O
(    O
also    O
ethinyl    O
estradiol    O
/    O
levonorgestrel    O
)    O
is    O
a    O
combined    B-Hormone105407119
birth    I-Hormone105407119
control    I-Hormone105407119
pill    I-Hormone105407119
made    O
up    O
of    O
ethinylestradiol    O
,    O
an    O
estrogen    O
and    O
levonorgestrel    B-Hormone105407119
a    O
progestin    O
.    O

The    O
1960s    O
introduced    O
the    O
birth    B-Hormone105407119
control    I-Hormone105407119
pill    I-Hormone105407119
—    O
and    O
the    O
potential    O
for    O
women    O
to    O
gain    O
greater    O
control    O
over    O
their    O
reproductive    O
lives    O
.    O

The    O
majority    O
of    O
studies    O
indicate    O
antibiotics    O
do    O
not    O
interfere    O
with    O
birth    B-Hormone105407119
control    I-Hormone105407119
pill    I-Hormone105407119
,    O
such    O
as    O
clinical    O
studies    O
that    O
suggest    O
the    O
failure    O
rate    O
of    O
contraceptive    O
pills    O
caused    O
by    O
antibiotics    O
is    O
very    O
low    O
(    O
about    O
1%    O
)    O
.    O

During    O
the    O
Francisco    O
Franco    O
years    O
,    O
the    O
ban    O
on    O
the    O
sale    O
of    O
contraceptives    O
was    O
complete    O
and    O
rigid    O
at    O
least    O
in    O
theory    O
,    O
even    O
though    O
the    O
introduction    O
of    O
the    O
combined    B-Hormone105407119
oral    I-Hormone105407119
contraceptive    I-Hormone105407119
pill    I-Hormone105407119
had    O
brought    O
contraception    O
to    O
at    O
least    O
half    O
a    O
million    O
Spanish    O
women    O
by    O
1975    O
.    O

The    O
song    O
tells    O
a    O
story    O
of    O
a    O
wife    O
who    O
is    O
upset    O
about    O
her    O
husband    O
getting    O
her    O
pregnant    O
year    O
after    O
year    O
,    O
but    O
is    O
now    O
happy    O
because    O
she    O
can    O
control    O
her    O
own    O
reproductive    O
choices    O
because    O
she    O
has    O
"    O
the    B-Hormone105407119
Pill    I-Hormone105407119
"    O
(    O
which    O
had    O
been    O
introduced    O
in    O
1960    O
)    O
.    O

Mestranol    O
/    O
norethynodrel    O
was    O
the    O
first    O
combined    B-Hormone105407119
oral    I-Hormone105407119
contraceptive    I-Hormone105407119
pill    I-Hormone105407119
(    O
COCP    O
)    O
being    O
mestranol    O
and    O
norethynodrel    O
.    O

He    O
is    O
best    O
known    O
for    O
the    O
major    O
role    O
he    O
played    O
in    O
the    O
development    O
of    O
the    O
first    O
birth    B-Hormone105407119
control    I-Hormone105407119
pill    I-Hormone105407119
,    O
colloquially    O
called    O
"    O
the    O
pill    O
"    O
.    O

Older    O
high    O
-    O
dose    O
estrogen    O
oral    B-Hormone105407119
contraceptive    I-Hormone105407119
pills    I-Hormone105407119
could    O
cause    O
features    O
of    O
ICP    O
.    O

Mauldin    O
,    O
a    O
divorced    O
mother    O
of    O
two    O
,    O
was    O
working    O
for    O
32    O
hours    O
per    O
week    O
at    O
a    O
rate    O
of    O
US$    O
12.14    O
per    O
hour    O
and    O
spending    O
$    O
30    O
a    O
month    O
on    O
birth-control    B-Hormone105407119
pills    I-Hormone105407119
.    O

Trenbolone    B-Hormone105407119
(    O
δ9,11    O
-    O
19-NT    O
)    O

Trenbolone    B-Hormone105407119

Other    O
steroids    O
stacked    O
with    O
metandienone    O
are    O
primarily    O
,    O
if    O
not    O
always    O
,    O
injectable    O
compounds    O
such    O
as    O
testosterone    O
,    O
trenbolone    B-Hormone105407119
and    O
nandrolone    O
.    O

Trenbolone    B-Hormone105407119
(    O
trienolone    O
)    O

The    O
infamous    O
"    O
duchess    O
"    O
cocktail    O
administered    O
to    O
Russian    O
athletes    O
at    O
the    O
Sochi    O
Winter    O
Olympics    O
consisted    O
of    O
oxandrolone    B-Hormone105407119
,    O
metenolone    O
,    O
and    O
trenbolone    B-Hormone105407119
.    O

Magnacort    B-Hormone105407119

Amir    O
Aliakbari    O
of    O
Iran    O
originally    O
won    O
the    O
gold    O
medal    O
,    O
but    O
was    O
disqualified    O
after    O
he    O
tested    O
positive    O
for    O
Anabolic    B-Hormone105407119
steroid    I-Hormone105407119
.    O

In    O
the    O
episode    O
,    O
Marge    O
develops    O
agoraphobia    O
in    O
response    O
to    O
a    O
traumatic    O
mugging    O
and    O
overcomes    O
the    O
fear    O
through    O
exercise    O
and    O
bodybuilding    O
,    O
which    O
ultimately    O
leads    O
to    O
her    O
taking    O
anabolic    B-Hormone105407119
steroids    I-Hormone105407119
and    O
experiencing    O
a    O
change    O
in    O
personality    O
.    O

That    O
medal    O
was    O
lost    O
a    O
couple    O
of    O
days    O
later    O
when    O
it    O
was    O
found    O
that    O
he    O
had    O
used    O
anabolic    B-Hormone105407119
steroids    I-Hormone105407119
.    O

In    O
1990    O
,    O
the    O
US    O
Congress    O
passed    O
an    O
omnibus    O
crime    O
bill    O
,    O
the    O
Crime    O
Control    O
Act    O
of    O
1990    O
,    O
that    O
amended    O
the    O
Federal    O
Food    O
,    O
Drug    O
,    O
and    O
Cosmetic    O
Act    O
,    O
that    O
classified    O
anabolic    B-Hormone105407119
steroids    I-Hormone105407119
as    O
controlled    O
substances    O
and    O
added    O
a    O
new    O
section    O
which    O
reads    O
:    O

Clostebol    B-Hormone105407119
(    O
INN    O
)    O
,    O
also    O
known    O
as    O
4-chlorotestosterone    B-Hormone105407119
,    O
usually    O
as    O
the    O
ester    O
clostebol    O
acetate    O
,    O
is    O
a    O
synthetic    O
anabolic    B-Hormone105407119
androgenic    I-Hormone105407119
steroid    I-Hormone105407119
(    O
AAS    O
)    O
.    O

However    O
,    O
the    O
MLB    O
has    O
received    O
some    O
criticism    O
because    O
the    O
consequences    O
for    O
amphetamine    O
use    O
are    O
dramatically    O
less    O
severe    O
than    O
for    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
use    O
,    O
with    O
the    O
first    O
offense    O
bringing    O
only    O
a    O
warning    O
and    O
further    O
testing    O
.    O

Trenbolone    O
enanthate    O
(    O
nickname    O
Trenabol    O
)    O
,    O
or    O
trenbolone    O
heptanoate    O
,    O
also    O
known    O
as    O
19-nor-δ9,11-testosterone    O
17β-enanthate    O
or    O
as    O
19-norandrost-4,9,11-trien-17β-ol-3-one    O
17β-enanthate    O
,    O
is    O
a    O
synthetic    O
,    O
injected    O
anabolic-androgenic    B-Hormone105407119
steroid    I-Hormone105407119
(    O
AAS    O
)    O
and    O
derivative    O
of    O
19-nortestosterone    O
(    O
nandrolone    O
)    O
that    O
was    O
never    O
marketed    O
.    O

Howard    O
Bryant    O
in    O
the    O
Acknowledgments    O
section    O
of    O
"    O
Juicing    O
the    O
Game    O
"    O
,    O
his    O
2005    O
book    O
about    O
steroids    B-Hormone105407119
in    O
baseball    O
,    O
said    O
of    O
Halberstam    O
's    O
assistance    O
:    O
"    O
He    O
provided    O
me    O
with    O
a    O
succinct    O
road    O
map    O
and    O
the    O
proper    O
mind    O
-    O
set    O
.    O
"    O

The    O
various    O
factory    O
team    O
sponsors    O
were    O
taking    O
a    O
vigorous    O
zero    O
tolerance    O
policies    O
particularly    O
ever    O
since    O
the    O
revelations    O
of    O
Ronnie    O
Anderson    O
's    O
admitted    O
10    O
year    O
drug    O
habit    O
as    O
he    O
revealed    O
in    O
quotes    O
in    O
the    O
December    O
8    O
,    O
1986    O
issue    O
of    O
"    O
Sports    O
Illustrated    O
"    O
and    O
rumors    O
and    O
accusations    O
of    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
use    O
by    O
top    O
pro    O
racer    O
Pete    O
Loncarevich    O
which    O
were    O
never    O
substantiated    O
.    O

These    O
caused    O
health    O
problems    O
for    O
her    O
in    O
later    O
life    O
,    O
including    O
a    O
liver    O
tumor    O
she    O
attributed    O
to    O
the    O
use    O
of    O
anabolic    B-Hormone105407119
steroids    I-Hormone105407119
and    O
birth    O
control    O
pills    O
.    O

They    O
know    O
each    O
other    O
from    O
university    O
and    O
he    O
is    O
studying    O
for    O
a    O
PhD.    O
Is    O
apparently    O
extremely    O
well    O
endowed    O
,    O
having    O
compared    O
his    O
penis    O
to    O
a    O
can    O
of    O
Red    O
Bull    O
and    O
his    O
testicles    O
to    O
Ribena    O
berries    O
on    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
.    O

Nandrolone    O
is    O
an    O
injected    O
anabolic–androgenic    B-Hormone105407119
steroid    I-Hormone105407119
(    O
AAS    O
)    O
which    O
is    O
used    O
medically    O
in    O
the    O
form    O
of    O
esters    O
such    O
as    O
nandrolone    O
decanoate    O
(    O
brand    O
name    O
Deca    O
-    O
Durabolin    O
)    O
and    O
nandrolone    O
phenylpropionate    O
(    O
brand    O
name    O
Durabolin    O
)    O
.    O

On    O
February    O
12    O
,    O
2013    O
the    O
International    O
Olympic    O
Committee    O
stripped    O
Perepetchenov    O
of    O
his    O
2004    O
Olympic    O
medal    O
after    O
both    O
probes    O
were    O
retested    O
and    O
showed    O
traces    O
of    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
.    O

Selective    O
androgen    O
receptor    O
modulators    O
may    O
also    O
be    O
used    O
by    O
athletes    O
to    O
assist    O
in    O
training    O
and    O
increase    O
physical    O
stamina    O
and    O
fitness    O
,    O
potentially    O
producing    O
effects    O
similar    O
to    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
but    O
with    O
significantly    O
fewer    O
side    O
effects    O
.    O

SARMs    O
are    O
a    O
new    O
class    O
of    O
drugs    O
which    O
produce    O
tissue    O
-    O
specific    O
anabolic    O
effects    O
in    O
some    O
tissues    O
such    O
as    O
muscle    O
and    O
bone    O
,    O
but    O
without    O
stimulating    O
androgen    O
receptors    O
in    O
other    O
tissues    O
such    O
as    O
in    O
the    O
prostate    O
gland    O
,    O
thus    O
avoiding    O
side    O
effects    O
such    O
as    O
benign    O
prostatic    O
hypertrophy    O
which    O
can    O
occur    O
following    O
treatment    O
with    O
unselective    O
androgens    O
like    O
testosterone    O
or    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
.    O

Rhesus    O
growth    O
hormone    O
was    O
never    O
used    O
by    O
physicians    O
to    O
treat    O
human    O
patients    O
,    O
but    O
rhesus    O
GH    O
was    O
part    O
of    O
the    O
lore    O
of    O
the    O
underground    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
community    O
in    O
those    O
years    O
,    O
and    O
fraudulent    O
versions    O
may    O
have    O
been    O
bought    O
and    O
sold    O
in    O
gyms    O
.    O

In    O
the    O
book    O
,    O
he    O
freely    O
admits    O
that    O
his    O
athletes    O
were    O
taking    O
anabolic    B-Hormone105407119
steroids    I-Hormone105407119
,    O
as    O
he    O
claims    O
all    O
top    O
athletes    O
at    O
the    O
time    O
were    O
,    O
and    O
also    O
claims    O
that    O
Johnson    O
could    O
not    O
possibly    O
have    O
tested    O
positive    O
for    O
that    O
particular    O
steroid    O
since    O
Johnson    O
actually    O
preferred    O
furazabol    B-Hormone105407119
.    O

The    O
subsequent    O
release    O
of    O
state    O
documents    O
showed    O
Madetzky    O
was    O
given    O
an    O
annual    O
amount    O
of    O
2390    O
mg    O
of    O
Oral    O
-    O
Turinabol    O
(    O
a    O
banned    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
)    O
during    O
her    O
career    O
under    O
coach    O
Gerhard    O
Böttcher    O
.    O

In    O
addition    O
to    O
the    O
sports    O
storylines    O
,    O
the    O
strip    O
also    O
deals    O
with    O
issues    O
facing    O
teenagers    O
such    O
as    O
teen    O
pregnancy    O
,    O
steroids    B-Hormone105407119
,    O
and    O
drug    O
abuse    O
.    O

Cloxotestosterone    B-Hormone105407119
(    O
INN    O
)    O
,    O
also    O
known    O
as    O
17β-chloral    B-Hormone105407119
hemiacetal    I-Hormone105407119
testosterone    I-Hormone105407119
,    O
is    O
a    O
synthetic    O
anabolic-androgenic    B-Hormone105407119
steroid    I-Hormone105407119
(    O
AAS    O
)    O
and    O
an    O
androgen    O
ether    O
–    O
specifically    O
,    O
the    O
17β-chloro    O
hemiacetal    O
ether    O
of    O
testosterone    O
–    O
which    O
was    O
never    O
marketed    O
.    O

Penmesterol    O
(    O
INN    O
)    O
(    O
brand    O
names    O
Pandrocine    O
,    O
Testopan    O
;    O
former    O
developmental    O
code    O
name    O
RP-12222    O
)    O
,    O
or    O
penmestrol    O
,    O
also    O
known    O
as    O
17α-methyltestosterone    O
3-cyclopentyl    O
enol    O
ether    O
,    O
is    O
a    O
synthetic    O
,    O
orally    O
active    O
anabolic-androgenic    B-Hormone105407119
steroid    I-Hormone105407119
(    O
AAS    O
)    O
that    O
was    O
developed    O
in    O
the    O
early    O
1960s    O
.    O

Rosterolone    O
is    O
a    O
derivative    O
of    O
mesterolone    B-Hormone105407119
,    O
which    O
,    O
in    O
contrast    O
,    O
is    O
an    O
androgen    O
and    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
.    O

Metenolone    B-Hormone105407119
enanthate    I-Hormone105407119
(    O
brand    O
names    O
Nibal    B-Hormone105407119
Injection    I-Hormone105407119
,    O
Primobolan    B-Hormone105407119
Depot    I-Hormone105407119
)    O
,    O
or    O
methenolone    B-Hormone105407119
enanthate    I-Hormone105407119
,    O
is    O
an    O
injected    O
anabolic–androgenic    B-Hormone105407119
steroid    I-Hormone105407119
(    O
AAS    O
)    O
of    O
the    O
dihydrotestosterone    B-Hormone105407119
(    O
DHT    O
)    O
group    O
.    O

In    O
February    O
2009    O
,    O
"    O
Sports    O
Illustrated    O
"    O
reported    O
that    O
Alex    O
Rodriguez    O
tested    O
positive    O
for    O
two    O
anabolic    B-Hormone105407119
steroids    I-Hormone105407119
,    O
testosterone    O
and    O
metenolone    O
enanthate    O
,    O
while    O
playing    O
for    O
the    O
Texas    O
Rangers    O
in    O
2003    O
.    O

Boldenone    B-Hormone105407119
,    O
also    O
known    O
as    O
Δ1-testosterone    B-Hormone105407119
,    O
is    O
a    O
synthetic    O
anabolic-androgenic    B-Hormone105407119
steroid    I-Hormone105407119
(    O
AAS    O
)    O
and    O
the    O
1(2)-dehydrogenated    O
analogue    O
of    O
testosterone    O
.    O

Uzbekistan    O
's    O
Elmira    O
Ramileva    O
,    O
the    O
69    O
kilogram    O
weightlifter    O
,    O
tested    O
positive    O
for    O
an    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
.    O

Sammartino    O
took    O
steroids    B-Hormone105407119
during    O
the    O
mid-1980s    O
.    O

The    O
main    O
event    O
was    O
originally    O
scheduled    O
as    O
an    O
interim    O
lightweight    O
championship    O
fight    O
;    O
however    O
,    O
then    O
-    O
lightweight    O
champion    O
Sean    O
Sherk    O
was    O
stripped    O
of    O
his    O
title    O
after    O
the    O
California    O
State    O
Athletic    O
Commission    O
upheld    O
his    O
suspension    O
for    O
testing    O
positive    O
for    O
the    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
Nandrolone    O
.    O

Initially    O
the    O
company    O
produced    O
a    O
wide    O
range    O
of    O
generic    O
steroids    O
,    O
including    O
corticosteroids    O
,    O
but    O
later    O
on    O
it    O
focused    O
on    O
anabolic    B-Hormone105407119
steroids    I-Hormone105407119
,    O
estrogens    O
and    O
progestins    O
.    O

East    O
Germany    O
had    O
been    O
running    O
a    O
state    O
-    O
sponsored    O
mass    O
doping    O
program    O
for    O
its    O
athletes    O
with    O
anabolic    B-Hormone105407119
steroids    I-Hormone105407119
,    O
mostly    O
with    O
Oral    O
Turinabol    O
,    O
a    O
product    O
that    O
Jenapharm    O
had    O
developed    O
.    O

The    O
first    O
original    O
product    O
developed    O
at    O
Jenapharm    O
was    O
4-chlorodehydromethyltestosterone    O
,    O
an    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
which    O
was    O
marketed    O
under    O
the    O
name    O
Oral    O
Turinabol    O
.    O

Taking    O
additional    O
testosterone    O
,    O
as    O
in    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
,    O
will    O
increase    O
results    O
.    O

A    O
humorous    O
,    O
yet    O
fairly    O
accurate    O
shorthand    O
description    O
of    O
a    O
Harrier    O
is    O
that    O
of    O
"    O
a    O
Beagle    O
on    O
steroids    B-Hormone105407119
.    O
"    O

Neuropsychiatric    O
:    O
steroid    B-Hormone105407119
psychosis    I-Hormone105407119
,    O
and    O
anxiety    O
,    O
depression    O
.    O

The    O
possible    O
correlation    O
between    O
testosterone    O
and    O
aggression    O
could    O
explain    O
the    O
"    O
roid    O
rage    O
"    O
that    O
can    O
result    O
from    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
use    O
,    O
although    O
an    O
effect    O
of    O
abnormally    O
high    O
levels    O
of    O
steroids    O
does    O
not    O
prove    O
an    O
effect    O
at    O
physiological    O
levels    O
.    O

A    O
2006    O
Cochrane    O
review    O
did    O
not    O
find    O
evidence    O
sufficient    O
for    O
the    O
use    O
of    O
androgenic    B-Hormone105407119
anabolic    I-Hormone105407119
steroids    I-Hormone105407119
.    O

Hydrogenation    O
of    O
these    O
compounds    O
produces    O
anabolic    B-Hormone105407119
steroids    I-Hormone105407119
with    O
oral    O
bioavailability    O
,    O
such    O
as    O
Norethandrolone    O
.    O

On    O
13    O
August    O
2012    O
,    O
the    O
International    O
Olympic    O
Committee    O
stripped    O
shot    O
putter    O
Nadzeya    O
Astapchuk    O
of    O
her    O
gold    O
medal    O
after    O
testing    O
positive    O
for    O
the    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
metenolone    B-Hormone105407119
,    O
and    O
the    O
gold    O
medal    O
was    O
subsequently    O
awarded    O
to    O
silver    O
medalist    O
Valerie    O
Adams    O
from    O
New    O
Zealand    O
.    O

On    O
August    O
13    O
,    O
International    O
Olympic    O
Committee    O
decided    O
the    O
shot    O
putter    O
Nadzeya    O
Astapchuk    O
,    O
the    O
nation    O
's    O
only    O
track    O
and    O
field    O
medalist    O
,    O
to    O
strip    O
off    O
her    O
gold    O
medal    O
at    O
the    O
London    O
games    O
after    O
she    O
was    O
tested    O
positive    O
for    O
the    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
metenolone    B-Hormone105407119
.    O

He    O
was    O
later    O
convicted    O
for    O
distribution    O
of    O
anabolic    B-Hormone105407119
steroids    I-Hormone105407119
.    O

This    O
saves    O
the    O
United    O
States    O
Olympic    O
Committee    O
from    O
a    O
potentially    O
embarrassing    O
situation    O
,    O
as    O
Montgomery    O
has    O
been    O
officially    O
charged    O
with    O
steroids    B-Hormone105407119
use    O
.    O

The    O
results    O
came    O
in    O
on    O
the    O
day    O
of    O
the    O
announcement    O
and    O
revealed    O
Silva    O
tested    O
positive    O
for    O
drostanolone    B-Hormone105407119
metabolites    O
,    O
which    O
is    O
an    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
.    O

Six    O
days    O
later    O
,    O
Japanese    O
news    O
agency    O
Kyodo    O
News    O
reported    O
that    O
Indian    O
middle    O
distance    O
runner    O
Sunita    O
Rani    O
had    O
tested    O
positive    O
for    O
a    O
banned    O
substance    O
,    O
which    O
was    O
later    O
confirmed    O
by    O
Lee    O
Choon    O
-    O
Sup    O
,    O
Deputy    O
Secretary    O
General    O
of    O
the    O
Busan    O
Asian    O
Games    O
Organizing    O
Committee    O
;    O
an    O
unofficial    O
report    O
stated    O
that    O
the    O
substance    O
was    O
the    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
nandrolone    O
.    O

Anabolic-androgenic    B-Hormone105407119
steroid    I-Hormone105407119
like    O
oxandrolone    B-Hormone105407119
may    O
be    O
beneficial    O
in    O
cancer    O
cachexia    O
but    O
their    O
use    O
is    O
recommended    O
for    O
maximal    O
2    O
weeks    O
since    O
a    O
longer    O
duration    O
of    O
treatment    O
increases    O
the    O
burden    O
from    O
side    O
effects    O
.    O

These    O
included    O
the    O
promotion    O
of    O
appetite    O
stimulants    O
,    O
tonics    O
and    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
to    O
parents    O
of    O
malnourished    O
children    O
.    O

This    O
categorically    O
excludes    O
the    O
use    O
of    O
substances    O
like    O
anabolic    B-Hormone105407119
steroids    I-Hormone105407119
,    O
insulin    O
,    O
diuretics    O
and    O
human    O
growth    O
hormone    O
.    O

It    O
was    O
announced    O
in    O
1997    O
that    O
Truyol    O
had    O
tested    O
positive    O
for    O
an    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
and    O
stimulant    O
during    O
a    O
Challenger    O
tournament    O
the    O
previous    O
year    O
in    O
Ostend    O
,    O
Belgium    O
.    O

Under    O
his    O
aegis    O
,    O
central    O
and    O
local    O
government    O
funding    O
of    O
sports    O
centres    O
and    O
other    O
sports    O
facilities    O
was    O
rapidly    O
increased    O
,    O
and    O
he    O
also    O
initiated    O
the    O
first    O
testing    O
for    O
use    O
of    O
anabolic    B-Hormone105407119
steroids    I-Hormone105407119
in    O
sport    O
.    O

Use    O
of    O
certain    O
medications    O
such    O
as    O
androgens    O
/    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
,    O
phenytoin    O
,    O
and    O
minoxidil    O
.    O

He    O
was    O
named    O
in    O
the    O
Mitchell    O
Report    O
,    O
which    O
detailed    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
use    O
in    O
MLB    O
,    O
on    O
December    O
13    O
,    O
2007    O
.    O

According    O
to    O
the    O
report    O
,    O
Donnels    O
purchased    O
both    O
human    O
growth    O
hormone    O
and    O
anabolic    B-Hormone105407119
steroids    I-Hormone105407119
from    O
Kirk    O
Radomski    O
between    O
2000    O
-    O
2004    O
.    O

McLeod    O
only    O
finished    O
third    O
but    O
second    O
placed    O
Martti    O
Vainio    O
had    O
been    O
disqualified    O
for    O
taking    O
anabolic    B-Hormone105407119
steroids    I-Hormone105407119
.    O

In    O
September    O
1994    O
while    O
playing    O
for    O
FC    O
Dinamo    O
Minsk    O
,    O
Byalkevich    O
was    O
banned    O
from    O
European    O
competitions    O
for    O
one    O
year    O
by    O
UEFA    O
after    O
testing    O
positive    O
for    O
anabolic    B-Hormone105407119
steroids    I-Hormone105407119
following    O
a    O
UEFA    O
Cup    O
match    O
.    O

Gherasim    O
tested    O
positive    O
for    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
at    O
the    O
Amsterdam    O
Marathon    O
in    O
2002    O
and    O
received    O
a    O
two    O
-    O
year    O
doping    O
ban    O
.    O

The    O
2014    O
-    O
15    O
list    O
of    O
NCAA    O
banned    O
drugs    O
includes    O
the    O
following    O
classes    O
:    O
stimulants    O
(    O
except    O
for    O
phenylephrine    O
and    O
pseudoephedrine    O
,    O
which    O
are    O
permitted    O
)    O
;    O
anabolic    B-Hormone105407119
agent    I-Hormone105407119
;    O
diuretics    O
and    O
other    O
masking    O
agents    O
;    O
"    O
street    O
drugs    O
"    O
(    O
the    O
NCAA    O
gives    O
as    O
examples    O
heroin    O
,    O
marijuana    O
,    O
tetrahydrocannabinol    O
(    O
THC    O
)    O
,    O
and    O
synthetic    O
cannabinoids    O
)    O
;    O
peptide    B-Hormone105407119
hormone    I-Hormone105407119
and    O
analogues    O
;    O
anti    O
-    O
estrogens    O
,    O
and    O
beta-2    O
agonists    O
.    O

After    O
the    O
fight    O
,    O
the    O
California    O
State    O
Athletic    O
Commission    O
(    O
CSAC    O
)    O
announced    O
that    O
Sherk    O
had    O
tested    O
positive    O
for    O
Nandrolone    O
,    O
a    O
banned    O
steroid    B-Hormone105407119
,    O
in    O
a    O
urine    O
test    O
the    O
day    O
prior    O
to    O
the    O
fight    O
.    O

anabolic    B-Hormone105407119
steroid    I-Hormone105407119
–    O
hormones    O
that    O
build    O
muscle    O
tissue    O

:    O
"    O
N.B.    O
Sub    O
-    O
paragraphs    O
(    O
b    O
)    O
,    O
(    O
c    O
)    O
,    O
(    O
d    O
)    O
and    O
(    O
e    O
)    O
all    O
refer    O
to    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
that    O
were    O
banned    O
in    O
1996    O
(    O
unless    O
referenced    O
otherwise    O
)    O
"    O
:    O

The    O
classic    O
anabolic    O
hormones    O
are    O
the    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
,    O
which    O
stimulate    O
protein    O
synthesis    O
,    O
muscle    O
growth    O
,    O
and    O
insulin    O
.    O

Metandienone    B-Hormone105407119
(    O
INN    O
)    O
(    O
brand    O
names    O
Averbol    B-Hormone105407119
,    O
Dianabol    B-Hormone105407119
,    O
Danabol    B-Hormone105407119
,    O
Metanabol    B-Hormone105407119
,    O
Naposim    B-Hormone105407119
,    O
Vetanabol    B-Hormone105407119
)    O
,    O
or    O
methandienone    B-Hormone105407119
(    O
BAN    O
)    O
,    O
also    O
commonly    O
known    O
as    O
methandrostenolone    B-Hormone105407119
,    O
is    O
a    O
synthetic    O
,    O
orally    O
active    O
anabolic-androgenic    B-Hormone105407119
steroid    I-Hormone105407119
(    O
AAS    O
)    O
and    O
a    O
17α-methylated    O
derivative    O
of    O
testosterone    O
which    O
was    O
formerly    O
used    O
medically    O
but    O
has    O
since    O
been    O
discontinued    O
in    O
most    O
countries    O
.    O

Letrozole    O
is    O
sometimes    O
used    O
as    O
a    O
treatment    O
for    O
gynecomastia    O
,    O
although    O
it    O
is    O
probably    O
most    O
effective    O
at    O
this    O
if    O
caught    O
in    O
an    O
early    O
stage    O
(    O
such    O
as    O
in    O
users    O
of    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
)    O
.    O

In    O
July    O
1997    O
,    O
Titus    O
was    O
sentenced    O
to    O
21    O
months    O
in    O
prison    O
for    O
violating    O
his    O
probation    O
by    O
using    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
.    O

Since    O
adolescence    O
,    O
Breivik    O
had    O
spent    O
much    O
time    O
on    O
weight    O
training    O
,    O
and    O
started    O
using    O
anabolic    B-Hormone105407119
steroids    I-Hormone105407119
.    O

His    O
appearance    O
at    O
the    O
Olympics    O
proved    O
to    O
be    O
his    O
last    O
official    O
competition    O
in    O
Olympic    O
weightlifting    O
,    O
as    O
he    O
retired    O
from    O
weightlifting    O
,    O
vowing    O
never    O
to    O
return    O
unless    O
the    O
sport    O
is    O
"    O
cleaned    O
up    O
"    O
of    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
use    O
.    O

In    O
a    O
November    O
2005    O
interview    O
with    O
"    O
ESPN    O
The    O
Magazine    O
"    O
,    O
Joyner    O
revealed    O
that    O
he    O
had    O
briefly    O
used    O
steroids    B-Hormone105407119
.    O

After    O
six    O
years    O
out    O
of    O
the    O
Western    O
Australian    O
side    O
,    O
he    O
returned    O
to    O
play    O
six    O
one    O
-    O
day    O
matches    O
for    O
WA    O
in    O
the    O
2000/01    O
season    O
and    O
after    O
the    O
last    O
of    O
these    O
matches    O
,    O
he    O
returned    O
a    O
positive    O
drug    O
test    O
to    O
the    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
nandrolone    O
.    O

One    O
modern    O
day    O
method    O
of    O
achieving    O
above    O
average    O
abilities    O
include    O
performance    O
-    O
enhancing    O
drugs    O
;    O
these    O
include    O
substances    O
such    O
as    O
painkillers    O
,    O
blood    O
boosters    O
,    O
stimulants    O
,    O
and    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
,    O
but    O
can    O
also    O
encompass    O
substances    O
that    O
are    O
n't    O
fully    O
recognized    O
as    O
enhancers    O
such    O
as    O
caffeine    O
,    O
protein    O
supplements    O
,    O
and    O
vitamins    O
.    O

A    O
17α-alkylated    O
anabolic    O
steroid    O
is    O
a    O
synthetic    O
anabolic-androgenic    B-Hormone105407119
steroid    I-Hormone105407119
(    O
AAS    O
)    O
that    O
features    O
an    O
alkyl    O
group    O
,    O
specifically    O
a    O
methyl    O
or    O
ethyl    O
group    O
,    O
at    O
the    O
C17α    O
position    O
.    O

Dienolone    O
(    O
developmental    O
code    O
name    O
RU-3118    O
;    O
online    O
product    O
names    O
Trenazone    O
,    O
Dienazone    O
)    O
,    O
or    O
nordienolone    O
,    O
also    O
known    O
as    O
19-nor-δ9(10)-testosterone    O
,    O
δ9(10)-nandrolone    O
,    O
or    O
estra-4,9(10)-dien-17β-ol-3-one    O
,    O
is    O
a    O
synthetic    O
anabolic-androgenic    B-Hormone105407119
steroid    I-Hormone105407119
(    O
AAS    O
)    O
of    O
the    O
19-nortestosterone    O
group    O
that    O
was    O
never    O
marketed    O
.    O

Ethyltestosterone    O
,    O
or    O
17α-ethyltestosterone    O
,    O
also    O
known    O
as    O
17α-ethylandrost-4-en-17β-ol-3-one    O
or    O
17α-pregn-4-en-17-ol-3-one    O
,    O
is    O
a    O
synthetic    O
,    O
orally    O
active    O
anabolic-androgenic    B-Hormone105407119
steroid    I-Hormone105407119
(    O
AAS    O
)    O
of    O
the    O
17α-alkylated    O
group    O
related    O
to    O
methyltestosterone    O
which    O
was    O
never    O
marketed    O
.    O

List    O
of    O
androgens    O
/    O
anabolic    O
steroids    O
–    O
steroidal    O
androgens    O
/    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119

However    O
,    O
on    O
July    O
13    O
,    O
1981    O
,    O
the    O
International    O
Association    O
of    O
Athletics    O
Federations    O
banned    O
Plucknett    O
from    O
further    O
competition    O
after    O
he    O
had    O
tested    O
positive    O
for    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
use    O
,    O
and    O
the    O
records    O
were    O
removed    O
.    O

Šilhavá    O
tested    O
positive    O
for    O
anabolic    B-Hormone105407119
steroids    I-Hormone105407119
at    O
the    O
European    O
Cup    O
in    O
Moscow    O
in    O
August    O
1985    O
and    O
was    O
subsequently    O
banned    O
for    O
life    O
by    O
the    O
European    O
Athletics    O
Federation    O
.    O

Schwarzenegger    O
has    O
admitted    O
to    O
using    O
performance    O
-    O
enhancing    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
while    O
they    O
were    O
legal    O
,    O
writing    O
in    O
1977    O
that    O
"    O
steroids    O
were    O
helpful    O
to    O
me    O
in    O
maintaining    O
muscle    O
size    O
while    O
on    O
a    O
strict    O
diet    O
in    O
preparation    O
for    O
a    O
contest    O
.    O

In    O
Giambi    O
suffered    O
several    O
ailments    O
,    O
and    O
was    O
also    O
dogged    O
by    O
the    O
BALCO    O
steroids    B-Hormone105407119
scandal    O
.    O

Metenolone    B-Hormone105407119
,    O
or    O
methenolone    B-Hormone105407119
,    O
also    O
known    O
as    O
methylandrostenolone    B-Hormone105407119
,    O
is    O
a    O
synthetic    O
,    O
orally    O
active    O
anabolic-androgenic    B-Hormone105407119
steroid    I-Hormone105407119
(    O
AAS    O
)    O
and    O
a    O
derivative    O
of    O
dihydrotestosterone    B-Hormone105407119
(    O
DHT    O
)    O
.    O

He    O
left    O
WWE    O
on    O
September    O
15    O
,    O
2004    O
when    O
his    O
steroid    B-Hormone105407119
usage    O
came    O
to    O
light    O
following    O
a    O
staph    O
infection    O
.    O

Former    O
U.S.    O
Senator    O
George    O
J.    O
Mitchell    O
publicly    O
releases    O
a    O
report    O
,    O
accusing    O
89    O
retired    O
and    O
active    O
Major    O
League    O
Baseball    O
players    O
of    O
anabolic    B-Hormone105407119
steroid    I-Hormone105407119
use    O
.    O

AC    O
/    O
DC    O
singer    O
and    O
car    O
enthusiast    O
Brian    O
Johnson    O
cited    O
the    O
Maxi    O
as    O
the    O
worst    O
he    O
'd    O
driven    O
:    O
"    O
Like    O
a    O
matchbox    O
on    O
steroids    B-Hormone105407119
.    O

John    O
follows    O
Hector    O
deeper    O
into    O
circuit    O
scene    O
,    O
using    O
a    O
variety    O
of    O
drugs    O
including    O
Special    O
K    O
,    O
GHB    O
,    O
cocaine    O
,    O
crystal    O
meth    O
and    O
,    O
suffering    O
from    O
body    O
dysmorphia    O
despite    O
being    O
in    O
terrific    O
physical    O
shape    O
,    O
anabolic    B-Hormone105407119
steroids    I-Hormone105407119
.    O

4-Hydroxytestosterone    B-Hormone105407119
(    O
4-OHT    B-Hormone105407119
)    O
,    O
also    O
known    O
as    O
4,17β-dihydroxyandrost-4-en-3-one    B-Hormone105407119
,    O
is    O
a    O
synthetic    O
anabolic-androgenic    B-Hormone105407119
steroid    I-Hormone105407119
(    O
AAS    O
)    O
and    O
a    O
derivative    O
of    O
testosterone    O
that    O
was    O
never    O
marketed    O
.    O

Kirk    O
J.    O
Radomski    O
(    O
born    O
1969    O
)    O
(    O
colloquially    O
known    O
by    O
players    O
as    O
Murdock    O
)    O
is    O
a    O
former    O
batboy    O
and    O
clubhouse    O
employee    O
for    O
the    O
New    O
York    O
Mets    O
Major    O
League    O
Baseball    O
team    O
from    O
1985–1995    O
,    O
who    O
on    O
April    O
27    O
,    O
2007    O
pleaded    O
guilty    O
in    O
United    O
States    O
district    O
court    O
to    O
money    O
laundering    O
and    O
illegal    O
distribution    O
of    O
anabolic    B-Hormone105407119
steroids    I-Hormone105407119
,    O
human    O
growth    O
hormone    O
,    O
Clenbuterol    O
,    O
amphetamines    O
and    O
other    O
drugs    O
to    O
"    O
dozens    O
of    O
current    O
and    O
former    O
Major    O
League    O
Baseball    O
players    O
,    O
and    O
associates    O
,    O
on    O
teams    O
throughout    O
Major    O
League    O
Baseball    O
.    O
"    O

Radomski    O
was    O
a    O
prominent    O
witness    O
in    O
former    O
United    O
States    O
Senate    O
Majority    O
Leader    O
George    O
J.    O
Mitchell    O
's    O
investigation    O
into    O
the    O
use    O
of    O
performance-enhancing    B-Hormone105407119
substances    I-Hormone105407119
in    O
Major    O
League    O
Baseball    O
.    O

HGH    B-Hormone105407119
controversies    I-Hormone105407119

Somatomedins    B-Hormone105407119
are    O
produced    O
,    O
predominantly    O
by    O
the    O
liver    O
,    O
when    O
growth    O
hormones    O
act    O
on    O
target    O
tissue    O
.    O

A    O
somatomedin    O
(    O
IGF    O
)    O
receptor    O
is    O
a    O
receptor    O
which    O
binds    O
the    O
somatomedin    B-Hormone105407119
(    O
IGFs    O
)    O
.    O

Isoetarine    B-Hormone105407119
is    O
a    O
selective    O
short    O
-    O
acting    O
β2    O
adrenoreceptor    O
agonist    O
.    O

Isoetharine    B-Hormone105407119

N-Acetylserotonin    B-Hormone105407119

Harmaline    O
forces    O
the    O
anabolic    O
metabolism    O
of    O
serotonin    O
into    O
normelatonin    B-Hormone105407119
or    O
n-acetylserotonin    B-Hormone105407119
,    O
and    O
then    O
to    O
melatonin    O
,    O
the    O
body    O
's    O
principle    O
sleep    O
-    O
regulating    O
hormone    O
and    O
a    O
powerful    O
antioxidant    O
.    O

SNAT    O
catalyzes    O
the    O
anabolic    O
metabolism    O
of    O
serotonin    O
into    O
"N"-acetylserotonin    B-Hormone105407119
,    O
another    O
neuromodulator    O
(    O
specifically    O
a    O
neurotrophic    O
factor    O
via    O
TrkB    O
agonism    O
)    O
and    O
the    O
immediate    O
precursor    O
for    O
melatonin    O
.    O

Hormones    O
secreted    O
include    O
somatostatin    B-Hormone105407119
,    O
motilin    O
,    O
cholecystokinin    O
,    O
neurotensin    O
,    O
vasoactive    B-Hormone105407119
intestinal    I-Hormone105407119
peptide    I-Hormone105407119
,    O
and    O
enteroglucagon    B-Hormone105407119
.    O

Tetracosactide    O
stimulates    O
the    O
release    O
of    O
corticosteroids    O
such    O
as    O
cortisol    B-Hormone105407119
from    O
the    O
adrenal    O
glands    O
,    O
and    O
is    O
used    O
for    O
the    O
ACTH    B-Hormone105407119
stimulation    I-Hormone105407119
test    I-Hormone105407119
to    O
assess    O
adrenal    O
gland    O
function    O
.    O

Both    O
versions    O
of    O
the    O
hormone    O
are    O
also    O
used    O
to    O
perform    O
the    O
ACTH    B-Hormone105407119
stimulation    I-Hormone105407119
test    I-Hormone105407119
to    O
diagnose    O
hypoadrenocorticism    O
in    O
dogs    O
and    O
sometimes    O
cats    O
.    O

ACTH    B-Hormone105407119
stimulation    I-Hormone105407119
test    I-Hormone105407119

Cortivazol    B-Hormone105407119
=    O
6,16α-dimethyl-11β,17α,21-trihydroxy-2'-phenyl[3,2-c]pyrazolopregna-4,6-dien-20-one    O
21-acetate    O

FSH    O
is    O
available    O
mixed    O
with    O
LH    O
activity    O
in    O
various    O
menotropins    B-Hormone105407119
including    O
more    O
purified    O
forms    O
of    O
urinary    O
gonadotropins    O
such    O
as    O
Menopur    B-Hormone105407119
,    O
as    O
well    O
as    O
without    O
LH    O
activity    O
as    O
recombinant    O
FSH    O
(    O
Gonapure    O
,    O
Gonal    O
F    O
,    O
Follistim    O
,    O
Follitropin    O
alpha    O
)    O
.    O

When    O
he    O
replies    O
with    O
a    O
no    O
,    O
she    O
tells    O
him    O
"    O
in    O
vitro    O
"    O
needs    O
twice    O
-    O
a    O
-    O
day    O
menotropin    B-Hormone105407119
injections    O
and    O
she    O
can    O
not    O
do    O
them    O
herself    O
so    O
she    O
asks    O
House    O
to    O
do    O
it    O
.    O

Follicle    O
-    O
stimulating    O
hormone    O
(    O
FSH    O
)    O
as    O
a    O
recombinant    O
gonadotropin    B-Hormone105407119
preparation    I-Hormone105407119
replaced    O
Serono    O
's    O
Pergonal    B-Hormone105407119
which    O
was    O
previously    O
isolated    O
from    O
post    O
-    O
menopausal    O
female    O
urine    O

Human    B-Hormone105407119
menopausal    I-Hormone105407119
gonadotrophin    I-Hormone105407119
(    O
hMG    O
)    O
is    O
used    O
to    O
stimulate    O
sperm    O
production    O
in    O
men    O
and    O
for    O
multiple    O
egg    O
production    O
and    O
ovulation    O
induction    O
in    O
women    O
.    O

Low    O
-    O
dosage    O
steroidal    O
eye    O
-    O
drops    O
,    O
such    O
as    O
prednisone    O
,    O
fluorometholone    B-Hormone105407119
,    O
loteprednol    B-Hormone105407119
(    O
Lotemax    O
0.5%    O
)    O
or    O
rimexolone    B-Hormone105407119
.    O

Most    O
studies    O
of    O
phytoestrogens    B-Hormone105407119
in    O
soy    O
have    O
identified    O
the    O
isoflavones    B-Hormone105407119
genistein    B-Hormone105407119
and    O
daidzein    O
as    O
its    O
principal    O
phytoestrogenic    O
substances    O
.    O

In    O
addition    O
to    O
pharmaceuticals    O
,    O
some    O
herbal    O
breast    O
enlargement    O
supplements    O
contain    O
phytoestrogen    B-Hormone105407119
such    O
as    O
8-prenylnaringenin    O
(    O
found    O
in    O
hops    O
)    O
and    O
miroestrol    O
(    O
a    O
constituent    O
of    O
"    O
Pueraria    O
mirifica    O
"    O
)    O
and    O
thus    O
may    O
be    O
regarded    O
as    O
a    O
form    O
of    O
hormonal    O
breast    O
enhancement    O
.    O

Isoflavonoids    O
are    O
a    O
class    O
of    O
flavonoid    O
phenolic    O
compounds    O
,    O
many    O
of    O
which    O
are    O
biologically    O
active    O
.    O
Isoflavonoids    O
and    O
their    O
derivatives    O
are    O
sometimes    O
referred    O
to    O
as    O
phytoestrogen    B-Hormone105407119
,    O
as    O
many    O
isoflavonoid    O
compounds    O
have    O
biological    O
effects    O
via    O
the    O
estrogen    O
receptor    O
.    O

Isoflavone    B-Hormone105407119
phytoestrogens    B-Hormone105407119
-    O
found    O
primarily    O
in    O
soy    O
,    O
peanuts    O
,    O
and    O
other    O
members    O
of    O
the    O
Fabaceae    O
family    O

Genistein    B-Hormone105407119
is    O
an    O
isoflavone    B-Hormone105407119
that    O
is    O
described    O
as    O
an    O
angiogenesis    O
inhibitor    O
and    O
a    O
phytoestrogen    B-Hormone105407119
.    O

although    O
,    O
timing    O
of    O
phytoestrogen    B-Hormone105407119
use    O
is    O
also    O
important    O
.    O

Other    O
forms    O
of    O
endocrine    O
disruptors    O
are    O
phytoestrogens    B-Hormone105407119
(    O
plant    O
hormones    O
)    O
.    O

Some    O
other    O
examples    O
of    O
putative    O
EDCs    O
are    O
polychlorinated    O
dibenzo    O
-    O
dioxins    O
(    O
PCDDs    O
)    O
and    O
-furans    O
(    O
PCDFs    O
)    O
,    O
polycyclic    O
aromatic    O
hydrocarbons    O
(    O
PAHs    O
)    O
,    O
phenol    O
derivatives    O
and    O
a    O
number    O
of    O
pesticides    O
(    O
most    O
prominent    O
being    O
organochlorine    O
insecticides    O
like    O
endosulfan    O
,    O
kepone    O
(    O
chlordecone    O
)    O
and    O
DDT    O
and    O
its    O
derivatives    O
,    O
the    O
herbicide    O
atrazine    O
,    O
and    O
the    O
fungicide    O
vinclozolin    O
)    O
,    O
the    O
contraceptive    O
17-alpha    O
ethinylestradiol    O
,    O
as    O
well    O
as    O
naturally    O
occurring    O
phytoestrogens    B-Hormone105407119
such    O
as    O
genistein    B-Hormone105407119
and    O
mycoestrogens    B-Hormone105407119
such    O
as    O
zearalenone    O
.    O

Phytoestrogen    B-Hormone105407119
,    O
plant    O
compounds    O
with    O
estrogen    O
-    O
like    O
biological    O
activity    O
,    O
such    O
as    O
genistein    B-Hormone105407119
,    O
formononetin    B-Hormone105407119
,    O
biochanin    O
A    O
and    O
daidzein    O
,    O
as    O
well    O
as    O
a    O
mixture    O
of    O
these    O
phytoestrogens    O
were    O
found    O
able    O
to    O
reduce    O
E    O
-    O
selectin    O
as    O
well    O
as    O
VCAM-1    O
and    O
ICAM-1    O
on    O
cell    O
surface    O
and    O
in    O
culture    O
supernatant    O
.    O

Although    O
there    O
is    O
only    O
preclinical    O
evidence    O
for    O
a    O
possible    O
mechanism    O
,    O
the    O
meta    O
-    O
analysis    O
report    O
stated    O
that    O
soy    O
phytoestrogens    B-Hormone105407119
–    O
the    O
isoflavones    B-Hormone105407119
,    O
genistein    B-Hormone105407119
and    O
daidzein    O
–    O
may    O
be    O
involved    O
in    O
reducing    O
serum    O
cholesterol    O
levels    O
.    O

To    O
reach    O
the    O
recommended    O
amount    O
of    O
fibre    O
,    O
consumption    O
of    O
dietary    O
fibre    O
from    O
foods    O
(    O
e.g.    O
plants    O
,    O
vegetables    O
,    O
legumes    O
,    O
and    O
grains    O
)    O
instead    O
of    O
supplements    O
is    O
preferred    O
because    O
they    O
contain    O
additional    O
beneficial    O
nutrients    O
and    O
non    O
-    O
nutritive    O
components    O
(    O
e.g.    O
antioxidants    O
and    O
phytoestrogens    B-Hormone105407119
)    O
.    O

Other    O
substances    O
known    O
to    O
stimulate    O
insulin    O
release    O
include    O
the    O
amino    O
acids    O
arginine    O
and    O
leucine    O
,    O
parasympathetic    O
release    O
of    O
acetylcholine    O
(    O
acting    O
via    O
the    O
phospholipase    O
C    O
pathway    O
)    O
,    O
sulfonylurea    O
,    O
cholecystokinin    O
(    O
CCK    O
,    O
also    O
via    O
phospholipase    O
C    O
)    O
,    O
and    O
the    O
gastrointestinally    O
derived    O
incretins    B-Hormone105407119
,    O
such    O
as    O
glucagon-like    B-Hormone105407119
peptide-1    I-Hormone105407119
(    O
GLP-1    O
)    O
and    O
glucose-dependent    B-Hormone105407119
insulinotropic    I-Hormone105407119
peptide    I-Hormone105407119
(    O
GIP    O
)    O
.    O

K    O
cells    O
secrete    O
gastric    B-Hormone105407119
inhibitory    I-Hormone105407119
peptide    I-Hormone105407119
,    O
an    O
incretin    B-Hormone105407119
,    O
which    O
also    O
promotes    O
triglyceride    O
storage    O
.    O

While    O
research    O
on    O
stem    O
cells    O
and    O
regulation    O
of    O
stemness    O
was    O
the    O
first    O
field    O
of    O
application    O
of    O
intestinal    O
organoids    O
,    O
they    O
are    O
now    O
also    O
used    O
to    O
study    O
e.g.    O
uptake    O
of    O
nutrients    O
,    O
drug    O
transport    O
and    O
secretion    O
of    O
incretin    B-Hormone105407119
hormones    O
.    O

Davide    O
Rebellin    O
won    O
the    O
silver    O
medal    O
in    O
the    O
men    O
's    O
road    O
race    O
,    O
but    O
was    O
stripped    O
of    O
that    O
medal    O
,    O
as    O
he    O
tested    O
positive    O
for    O
CERA    B-Hormone105407119
after    O
the    O
event    O
.    O

On    O
8    O
July    O
2010    O
Tysse    O
was    O
suspended    O
from    O
all    O
competitions    O
,    O
after    O
findings    O
of    O
CERA    B-Hormone105407119
(    O
EPO    O
)    O
in    O
his    O
blood    O
tests    O
from    O
Sesto    O
San    O
Giovanni    O
in    O
Italy    O
.    O

Di    O
Luca    O
–    O
who    O
had    O
previously    O
served    O
a    O
fifteen    O
-    O
month    O
suspension    O
after    O
testing    O
positive    O
for    O
continuous    B-Hormone105407119
erythropoietin    I-Hormone105407119
receptor    I-Hormone105407119
activator    I-Hormone105407119
(    O
CERA    O
)    O
at    O
the    O
2009    O
Giro    O
d'Italia    O
–    O
himself    O
expressed    O
his    O
"    O
surprise    O
"    O
at    O
the    O
positive    O
test    O
,    O
while    O
race    O
director    O
Michele    O
Acquarone    O
angrily    O
chastised    O
Di    O
Luca    O
at    O
a    O
press    O
conference    O
,    O
describing    O
him    O
as    O
"    O
stupid    O
"    O
.    O

However    O
,    O
later    O
it    O
was    O
found    O
that    O
Rebellin    O
had    O
tested    O
positive    O
for    O
Continuous    B-Hormone105407119
erythropoietin    I-Hormone105407119
receptor    I-Hormone105407119
activator    I-Hormone105407119
(    O
CERA    O
,    O
a    O
third    O
-    O
generation    O
form    O
of    O
erythropoietin    O
)    O
and    O
his    O
medal    O
was    O
removed    O
by    O
both    O
the    O
UCI    O
and    O
the    O
IOC    O
.    O

The    O
Italian    O
Olympic    O
committee    O
then    O
confirmed    O
that    O
a    O
male    O
Italian    O
cyclist    O
had    O
tested    O
positive    O
for    O
CERA    B-Hormone105407119
during    O
the    O
men    O
's    O
road    O
race    O
,    O
without    O
identifying    O
a    O
name    O
.    O

Bencik    O
's    O
official    O
result    O
was    O
later    O
elevated    O
to    O
seventy    O
-    O
fourth    O
position    O
,    O
when    O
Italy    O
's    O
Davide    O
Rebellin    O
had    O
tested    O
positive    O
for    O
CERA    B-Hormone105407119
that    O
consequently    O
stripped    O
off    O
his    O
Olympic    O
silver    O
medal    O
.    O

In    O
March    O
2017    O
,    O
results    O
from    O
the    O
MONARCH    O
2    O
study    O
indicated    O
Abemaciclib    O
demonstrated    O
superior    O
progression    O
-    O
free    O
survival    O
(    O
PFS    O
)    O
over    O
placebo    O
plus    O
fulvestrant    O
in    O
patients    O
with    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
positive    O
and    O
HER2    O
negative    O
advanced    O
or    O
metastatic    O
breast    O
cancer    O
.    O

Quercetin    O
has    O
also    O
been    O
reported    O
to    O
have    O
estrogenic    O
(    O
female    O
sex    O
hormone    O
like    O
)    O
activities    O
by    O
activating    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
.    O

Prinaberel    B-Hormone105407119
(    O
INN    O
,    O
USAN    O
)    O
(    O
developmental    O
code    O
names    O
ERB-041    B-Hormone105407119
,    O
WAY-202041    B-Hormone105407119
)    O
is    O
a    O
synthetic    O
,    O
nonsteroidal    O
,    O
and    O
highly    O
selective    O
agonist    O
of    O
the    O
ERβ    O
subtype    O
of    O
the    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
.    O

One    O
example    O
of    O
this    O
is    O
the    O
loss    O
of    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
ER    O
)    O
and    O
progesterone    B-Hormone105407119
receptor    I-Hormone105407119
(    O
PR    O
)    O
upon    O
anti    O
-    O
estrogen    O
treatment    O
of    O
breast    O
cancer    O

Estrogen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
ER    O
)    O
mixed    O
agonist    O
/    O
antagonist    O

Estrogen    B-Hormone105407119
receptors    I-Hormone105407119
are    O
important    O
in    O
both    O
maintaining    O
a    O
normal    O
mammary    O
gland    O
,    O
and    O
in    O
the    O
development    O
of    O
primary    O
and    O
secondary    O
breast    O
cancer    O
.    O

Estrogen    B-Hormone105407119
receptor    I-Hormone105407119
agonist    O
(    O
Ki    O
>    O
5    O
μM    O
;    O
EC50    O
>    O
5    O
μM    O
)    O

Estrogen    O
insensitivity    O
syndrome    O
(    O
EIS    O
)    O
,    O
or    O
estrogen    O
resistance    O
,    O
is    O
a    O
form    O
of    O
congenital    O
estrogen    O
deficiency    O
or    O
hypoestrogenism    B-Hormone105407119
which    O
is    O
caused    O
by    O
a    O
defective    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
ER    O
)    O
–    O
specifically    O
,    O
the    O
estrogen    O
receptor    O
alpha    O
(    O
ERα    O
)    O
–    O
that    O
results    O
in    O
an    O
inability    O
of    O
estrogen    O
to    O
mediate    O
its    O
biological    O
effects    O
in    O
the    O
body    O
.    O
Congenital    O
estrogen    O
deficiency    O
can    O
alternatively    O
be    O
caused    O
by    O
a    O
defect    O
in    O
aromatase    O
,    O
the    O
enzyme    O
responsible    O
for    O
the    O
biosynthesis    O
of    O
estrogens    O
,    O
a    O
condition    O
which    O
is    O
referred    O
to    O
as    O
aromatase    B-Hormone105407119
deficiency    I-Hormone105407119
and    O
is    O
similar    O
in    O
symptomatology    O
to    O
EIS    O
.    O

Estrogen    O
insensitivity    O
syndrome    O
,    O
a    O
condition    O
in    O
which    O
the    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
is    O
defective    O
and    O
unable    O
to    O
respond    O
to    O
estrogens    O
.    O

Kudzu    O
has    O
no    O
benefit    O
for    O
treating    O
cancer    O
and    O
is    O
specifically    O
contraindicated    O
in    O
people    O
with    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
-    O
positive    O
breast    O
cancer    O
.    O

Estrogen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
ER    O
)    O
has    O
been    O
shown    O
to    O
transactivate    O
other    O
transcription    O
factors    O
in    O
this    O
manner    O
,    O
despite    O
the    O
absence    O
of    O
an    O
estrogen    O
response    O
element    O
(    O
ERE    O
)    O
in    O
the    O
proximal    O
promoter    O
region    O
of    O
the    O
gene    O
.    O

Enclomifene    O
acts    O
by    O
antagonizing    O
the    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
ER    O
)    O
in    O
the    O
pituitary    O
gland    O
,    O
which    O
reduces    O
negative    O
feedback    O
by    O
estrogen    O
on    O
the    O
hypothalamic    O
-    O
pituitary    O
-    O
gonadal    O
axis    O
,    O
thereby    O
increasing    O
gonadotropin    O
secretion    O
and    O
hence    O
gonadal    O
production    O
of    O
testosterone    O
.    O

The    O
trial    O
suggested    O
that    O
anastrozole    O
is    O
the    O
preferred    O
medical    O
therapy    O
for    O
postmenopausal    O
women    O
with    O
localized    O
breast    O
cancer    O
,    O
which    O
is    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
ER    O
)    O
positive    O
.    O

Women    O
affected    O
with    O
triple    O
negative    O
breast    O
cancer    O
(    O
TNBC    O
)    O
(    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
negative    O
,    O
progesterone    B-Hormone105407119
receptor    I-Hormone105407119
negative    O
,    O
and    O
HER2/neu    O
negative    O
)    O
under    O
the    O
age    O
of    O
50    O

BPA    O
has    O
been    O
found    O
to    O
bind    O
to    O
both    O
of    O
the    O
nuclear    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
ERs    O
)    O
,    O
ERα    O
and    O
ERβ.    O
It    O
is    O
1000-    O
to    O
2000-fold    O
less    O
potent    O
than    O
estradiol    O
.    O

An    O
estrogen    O
receptor    O
test    O
is    O
a    O
laboratory    O
test    O
to    O
find    O
out    O
if    O
cancer    O
cells    O
have    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
proteins    O
to    O
which    O
estrogen    O
will    O
bind    O
)    O
.    O

p90rsk    O
also    O
regulates    O
transcription    O
factors    O
including    O
cAMP    O
response    O
element    O
-    O
binding    O
protein    O
(    O
CREB    O
)    O
;    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
ERα    O
)    O
;    O
IκBα/NF-κB    O
;    O
and    O
c    O
-    O
Fos    O
.    O

It    O
also    O
binds    O
to    O
the    O
glucocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
,    O
but    O
is    O
only    O
a    O
weak    O
antiglucocorticoid    O
relative    O
to    O
mifepristone    O
,    O
and    O
has    O
no    O
relevant    O
affinity    O
to    O
the    O
estrogen    B-Hormone105407119
,    O
androgen    B-Hormone105407119
and    O
mineralocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
.    O

Apo    O
-    O
VLDL    O
-    O
II    O
is    O
produced    O
in    O
the    O
liver    O
and    O
secreted    O
into    O
the    O
blood    O
stream    O
when    O
induced    O
by    O
estrogen    B-Hormone105407119
production    O
in    O
female    O
birds    O
.    O

Menerba    O
,    O
an    O
estrogen    O
receptor    O
beta    O
(    O
ERβ    O
)    O
agonist    O
(    O
ERBA    O
)    O
,    O
is    O
part    O
of    O
a    O
new    O
class    O
of    O
receptor    O
subtype    O
-    O
selective    O
estrogens    O
,    O
which    O
is    O
selective    O
in    O
transcriptional    O
regulation    O
to    O
one    O
of    O
the    O
two    O
known    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
ER    O
)    O
subtypes    O
.    O

Menerba    O
does    O
not    O
activate    O
the    O
ERα-regulated    O
proliferative    O
genes    O
,    O
c    O
-    O
myc    O
and    O
cyclin    O
D1    O
,    O
or    O
stimulate    O
MCF-7    O
breast    O
cancer    O
cell    O
proliferation    O
or    O
tumor    O
formation    O
,    O
demonstrating    O
that    O
it    O
may    O
be    O
a    O
viable    O
alternative    O
for    O
hormone    O
therapy    O
in    O
comparison    O
to    O
estrogens    O
that    O
non    O
-    O
selectively    O
activate    O
both    O
ER    B-Hormone105407119
subtypes    I-Hormone105407119
.    O

The    O
drug    O
possesses    O
relatively    O
low    O
affinity    O
for    O
the    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
and    O
must    O
be    O
given    O
at    O
high    O
dosages    O
to    O
achieve    O
significant    O
estrogenic    O
and    O
antigonadotropic    O
action    O
,    O
for    O
instance    O
,    O
0.8    O
to    O
1.6    O
g    O
/    O
day    O
.    O

Radiolabeled    O
[    O
16α-125I]iodo    O
-    O
E2    O
has    O
been    O
employed    O
in    O
imaging    O
to    O
study    O
the    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
.    O

The    O
steroid    O
is    O
only    O
very    O
weakly    O
estrogenic    O
,    O
and    O
is    O
able    O
to    O
antagonize    O
the    O
estrogenic    O
effects    O
of    O
estradiol    O
,    O
indicating    O
that    O
its    O
intrinsic    O
activity    O
at    O
the    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
is    O
less    O
than    O
that    O
of    O
estradiol    O
and    O
hence    O
that    O
it    O
possesses    O
the    O
profile    O
of    O
a    O
selective    B-Hormone105407119
estrogen    I-Hormone105407119
receptor    I-Hormone105407119
modulator    I-Hormone105407119
.    O

Upon    O
reassessment    O
many    O
decades    O
later    O
,    O
the    O
compound    O
was    O
found    O
to    O
bind    O
only    O
weakly    O
to    O
the    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
,    O
and    O
,    O
unexpectedly    O
,    O
did    O
not    O
actually    O
have    O
functional    O
activity    O
as    O
an    O
estrogen    O
or    O
antiestrogen    O
"    O
in    O
vitro    O
"    O
or    O
"    O
in    O
vivo    O
"    O
.    O

It    O
is    O
selectively    O
distributed    O
into    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
ER)-positive    O
tissues    O
such    O
as    O
ER    O
-    O
expressing    O
tumors    O
like    O
those    O
seen    O
in    O
breast    O
and    O
prostate    O
cancers    O
.    O

In    O
contrast    O
to    O
estradiol    O
,    O
the    O
binding    O
of    O
16α-hydroxyestrone    O
to    O
the    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
is    O
,    O
uniquely    O
,    O
covalent    O
and    O
irreversible    O
,    O
and    O
genotoxicity    O
and    O
aberrant    O
hyperproliferations    O
may    O
result    O
.    O

is    O
a    O
transcriptional    O
corepressor    O
for    O
nuclear    O
receptors    O
such    O
as    O
glucocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
and    O
a    O
coactivator    O
for    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
.    O

However    O
,    O
some    O
genes    O
become    O
hypermethylated    O
with    O
age    O
,    O
including    O
genes    O
for    O
the    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
,    O
p16    O
,    O
and    O
insulin-like    B-Hormone105407119
growth    I-Hormone105407119
factor    I-Hormone105407119
2    I-Hormone105407119
.    O

In    O
studies    O
of    O
breast    O
cancer    O
prevention    O
,    O
lasofoxifene    O
showed    O
a    O
79%    O
reduction    O
in    O
breast    O
cancer    O
incidence    O
and    O
an    O
83%    O
reduction    O
specific    O
incidence    O
of    O
estrogen    B-Hormone105407119
receptor    I-Hormone105407119
-    O
positive    O
breast    O
cancers    O
,    O
which    O
is    O
significantly    O
higher    O
than    O
reductions    O
found    O
with    O
the    O
related    O
SERMs    O
tamoxifen    O
and    O
raloxifene    O
.    O

Human    O
growth    O
hormone    O
(    O
rHGH    B-Hormone105407119
)    O
:    O
Humatrope    B-Hormone105407119
from    O
Lilly    O
and    O
Serostim    B-Hormone105407119
from    O
Serono    O
replaced    O
cadaver    O
harvested    O
human    O
growth    O
hormone    O

fosfestrol    B-Hormone105407119
(    O
INN    O
)    O

Fosfestrol    B-Hormone105407119

Conversely    O
,    O
hyperandrogenism    B-Hormone105407119
in    O
women    O
,    O
for    O
instance    O
due    O
to    O
polycystic    O
ovary    O
syndrome    O
(    O
PCOS    O
)    O
or    O
congenital    O
adrenal    O
hyperplasia    O
(    O
CAH    O
)    O
,    O
is    O
commonly    O
associated    O
with    O
acne    O
and    O
hirsutism    O
as    O
well    O
as    O
virilization    O
(    O
masculinization    O
)    O
in    O
general    O
.    O

The    O
International    O
Association    O
of    O
Athletics    O
Federations    O
(    O
IAAF    O
)    O
"    O
,    O
and    O
in    O
July    O
2015    O
the    O
CAS    O
issued    O
a    O
decision    O
to    O
suspend    O
its    O
sex    O
verification    O
policy    O
on    O
excluding    O
women    O
athletes    O
with    O
hyperandrogenism    B-Hormone105407119
(    O
high    O
levels    O
of    O
testosterone    O
)    O
due    O
to    O
insufficient    O
evidence    O
of    O
a    O
link    O
between    O
high    O
androgen    O
levels    O
and    O
improved    O
athletic    O
performance    O
.    O

The    O
older    O
sister    O
had    O
chest    O
acne    O
,    O
which    O
could    O
be    O
attributed    O
to    O
hyperandrogenism    B-Hormone105407119
(    O
see    O
below    O
)    O
.    O

Due    O
to    O
the    O
substantially    O
elevated    O
testosterone    O
levels    O
,    O
there    O
is    O
hyperandrogenism    B-Hormone105407119
,    O
including    O
masculinization    O
of    O
the    O
preputial    O
glands    O
.    O

Valproic    O
acid    O
has    O
been    O
found    O
to    O
directly    O
stimulate    O
androgen    O
biosynthesis    O
in    O
the    O
gonads    O
via    O
inhibition    O
of    O
histone    O
deacetylases    O
and    O
has    O
been    O
associated    O
with    O
hyperandrogenism    B-Hormone105407119
in    O
women    O
and    O
increased    O
4-androstenedione    B-Hormone105407119
levels    O
in    O
men    O
.    O

The    O
condition    O
is    O
called    O
hyperandrogenism    B-Hormone105407119
.    O

Hyperandrogenism    B-Hormone105407119
is    O
a    O
medical    O
condition    O
where    O
there    O
are    O
excessive    O
levels    O
of    O
androgens    O
in    O
the    O
body    O
.    O

Immunoassays    O
are    O
used    O
in    O
sports    O
anti    O
-    O
doping    O
laboratories    O
to    O
test    O
athletes    O
'    O
blood    O
samples    O
for    O
prohibited    O
recombinant    B-Hormone105407119
human    I-Hormone105407119
growth    I-Hormone105407119
hormone    I-Hormone105407119
(    O
rhGH    O
,    O
rGH    O
,    O
hGH    O
,    O
GH    O
)    O
.    O

Medullipin    B-Hormone105407119

Drostanolone    B-Hormone105407119
propionate    I-Hormone105407119
(    O
Masteron    O
,    O
Drolban    O
,    O
Masteril    O
,    O
Mastisol    O
,    O
Metormon    O
,    O
Permastril    O
)    O

Masterone    B-Hormone105407119
(    O
Syntex    O
)    O

Endothelin    B-Hormone105407119
is    O
a    O
potent    O
vasoactive    O
peptide    O
produced    O
by    O
endothelial    O
cells    O
that    O
has    O
both    O
vasoconstrictor    O
and    O
vasodilator    O
properties    O
.    O

They    O
also    O
contain    O
neurons    O
with    O
receptors    O
for    O
angiotensin    O
,    O
atrial    B-Hormone105407119
natriuretic    I-Hormone105407119
factor    I-Hormone105407119
,    O
endothelin    B-Hormone105407119
and    O
relaxin    O
,    O
each    O
of    O
which    O
important    O
in    O
the    O
regulation    O
of    O
fluid    O
and    O
electrolyte    O
balance    O
.    O

Inhibitors    O
have    O
been    O
designed    O
with    O
the    O
aim    O
of    O
developing    O
analgesic    O
and    O
antihypertensive    O
agents    O
that    O
act    O
by    O
preventing    O
neprilysin    O
's    O
activity    O
against    O
signaling    O
peptides    O
such    O
as    O
enkephalins    O
,    O
substance    O
P    O
,    O
endothelin    B-Hormone105407119
,    O
and    O
atrial    B-Hormone105407119
natriuretic    I-Hormone105407119
factor    I-Hormone105407119
.    O

Inhibitors    O
have    O
been    O
designed    O
with    O
the    O
aim    O
of    O
developing    O
analgesic    O
and    O
antihypertensive    O
agents    O
that    O
act    O
by    O
preventing    O
neprilysin    O
's    O
activity    O
against    O
signaling    O
peptides    O
such    O
as    O
enkephalins    O
,    O
substance    O
P    O
,    O
endothelin    B-Hormone105407119
,    O
and    O
atrial    B-Hormone105407119
natriuretic    I-Hormone105407119
factor    I-Hormone105407119
.    O

:    O
Hydrolysis    O
of    O
the    O
-Trp21-Val-    O
bond    O
in    O
big    O
endothelin    B-Hormone105407119
to    O
form    O
endothelin    O
1    O

Sitaxentan    O
is    O
a    O
small    O
molecule    O
that    O
blocks    O
the    O
action    O
of    O
endothelin    B-Hormone105407119
(    O
ET    O
)    O
on    O
the    O
endothelin    O
-    O
A    O
(    O
ETA    O
)    O
receptor    O
selectively    O
(    O
by    O
a    O
factor    O
of    O
6000    O
compared    O
with    O
the    O
ETB    O
)    O
.    O

Following    O
apoptosis    O
,    O
it    O
is    O
thought    O
there    O
is    O
a    O
massive    O
degranulation    O
of    O
vasoconstrictors    O
,    O
including    O
endothelin    B-Hormone105407119
and    O
free    O
radicals    O
,    O
that    O
cause    O
the    O
vasospasm    O
.    O

Specific    O
genes    O
have    O
also    O
had    O
reported    O
association    O
with    O
the    O
development    O
of    O
intracranial    O
aneurysms    O
,    O
including    O
perlecan    O
,    O
elastin    O
,    O
collagen    O
type    O
1    O
A2    O
,    O
endothelial    O
nitric    O
oxide    O
synthase    O
,    O
endothelin    B-Hormone105407119
receptor    O
A    O
and    O
cyclin    O
dependent    O
kinase    O
inhibitor    O
.    O

Altrenogest    B-Hormone105407119

altrenogest    B-Hormone105407119
-    O
used    O
to    O
synchronize    O
estrus    O

According    O
to    O
the    O
lactate-shuttle    B-Hormone105407119
hypothesis    I-Hormone105407119
,    O
glial    O
cells    O
are    O
responsible    O
for    O
transforming    O
glucose    O
into    O
lactate    O
,    O
and    O
for    O
providing    O
lactate    O
to    O
the    O
neurons    O
.    O

Ecdysteroids    B-Hormone105407119
are    O
insect    O
moulting    O
and    O
sex    O
hormones    O
;    O
examples    O
of    O
ecdysteroids    O
include    O
ecdysone    B-Hormone105407119
,    O
ecdysterone    B-Hormone105407119
,    O
turkesterone    O
and    O
20-hydroxyecdysone    B-Hormone105407119
.    O

The    O
skeleton    O
is    O
rich    O
in    O
histidine    O
and    O
contains    O
the    O
unusual    O
ecdysterone    B-Hormone105407119
,    O
ajugasterone    O
-    O
C.    O
The    O
growth    O
rate    O
of    O
the    O
colony    O
is    O
slow    O
and    O
carbon-14    O
dating    O
techniques    O
have    O
given    O
an    O
age    O
of    O
2,700    O
years    O
,    O
giving    O
this    O
zoanthid    O
one    O
of    O
the    O
longest    O
lifespans    O
of    O
any    O
organism    O
on    O
Earth    O
.    O

Oral    O
Turinabol    O
,    O
combining    O
the    O
chemical    O
structures    O
of    O
clostebol    O
and    O
metandienone    B-Hormone105407119
,    O
was    O
widely    O
used    O
in    O
the    O
East    O
German    O
state    O
-    O
sponsored    O
doping    O
program    O
.    O

She    O
was    O
handed    O
an    O
eight    O
-    O
year    O
doping    O
ban    O
for    O
the    O
use    O
of    O
Methandienone    B-Hormone105407119
and    O
Dehydrochloromathyltestosterone    O
.    O

Boldenone    O
was    O
synthesized    O
in    O
an    O
attempt    O
to    O
create    O
a    O
long    O
-    O
acting    O
injectable    O
methandrostenolone    B-Hormone105407119
(    O
Dianabol    O
)    O
,    O
for    O
androgen    O
deficiency    O
disorders    O
.    O

Pulsabsakul    O
served    O
a    O
two    O
-    O
year    O
doping    O
ban    O
from    O
6    O
July    O
2011    O
to    O
6    O
July    O
2013    O
after    O
testing    O
positive    O
for    O
Methandienone    B-Hormone105407119
.    O

In    O
March    O
2007    O
,    O
he    O
received    O
a    O
two    O
-    O
year    O
ban    O
after    O
testing    O
positive    O
for    O
17-epimethandienone    B-Hormone105407119
.    O

Methandienone    B-Hormone105407119

Metandienone    B-Hormone105407119
(    O
INN    O
)    O
(    O
brand    O
names    O
Averbol    B-Hormone105407119
,    O
Dianabol    B-Hormone105407119
,    O
Danabol    B-Hormone105407119
,    O
Metanabol    B-Hormone105407119
,    O
Naposim    B-Hormone105407119
,    O
Vetanabol    B-Hormone105407119
)    O
,    O
or    O
methandienone    B-Hormone105407119
(    O
BAN    O
)    O
,    O
also    O
commonly    O
known    O
as    O
methandrostenolone    B-Hormone105407119
,    O
is    O
a    O
synthetic    O
,    O
orally    O
active    O
anabolic-androgenic    B-Hormone105407119
steroid    I-Hormone105407119
(    O
AAS    O
)    O
and    O
a    O
17α-methylated    O
derivative    O
of    O
testosterone    O
which    O
was    O
formerly    O
used    O
medically    O
but    O
has    O
since    O
been    O
discontinued    O
in    O
most    O
countries    O
.    O

Metandienone    B-Hormone105407119
(methandrostenolone)    I-Hormone105407119

In    O
September    O
2005    O
Baggaley    O
tested    O
positive    O
for    O
banned    O
steroids    O
(    O
stanozolol    B-Hormone105407119
and    O
methandienone    B-Hormone105407119
)    O
.    O

Large    O
amounts    O
of    O
fertile    O
eggs    O
,    O
he    O
said    O
,    O
are    O
equal    O
to    O
the    O
anabolic    O
steroid    O
Dianabol    B-Hormone105407119
in    O
effectiveness    O
.    O

Gamma    B-Hormone105407119
Lipotropin    B-Hormone105407119
(    O
γ-LPH    O
)    O

Corticotropes    O
(    O
or    O
corticotrophs    O
)    O
are    O
basophilic    O
cells    O
in    O
the    O
anterior    O
pituitary    O
that    O
produce    O
melanocyte    O
-    O
stimulating    O
hormone    O
,    O
adrenocorticotropic    O
hormone    O
(    O
ACTH    O
)    O
and    O
lipotropin    B-Hormone105407119
.    O

Leukocyte-promoting    B-Hormone105407119
factor    I-Hormone105407119

Triamcinolone    B-Hormone105407119
acetonide    I-Hormone105407119
,    O
triamcinolone    O
alcohol    O
,    O
amcinonide    B-Hormone105407119
,    O
budesonide    B-Hormone105407119
,    O
desonide    B-Hormone105407119
,    O
fluocinonide    B-Hormone105407119
,    O
fluocinolone    B-Hormone105407119
acetonide    I-Hormone105407119
,    O
and    O
halcinonide    B-Hormone105407119

Amcinonide    B-Hormone105407119
,    O
budesonide    B-Hormone105407119
,    O
desonide    B-Hormone105407119
,    O
fluocinolone    B-Hormone105407119
acetonide    I-Hormone105407119
,    O
fluocinonide    B-Hormone105407119
,    O
halcinonide    B-Hormone105407119
,    O
and    O
triamcinolone    B-Hormone105407119
acetonide    I-Hormone105407119
.    O

gestrinone    B-Hormone105407119
(    O
INN    O
)    O

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-Hormone105407119
)    O
,    O
desogestrel    B-Hormone105407119
,    O
ethylestrenol    B-Hormone105407119
,    O
etynodiol    B-Hormone105407119
diacetate    I-Hormone105407119
,    O
ethinylestradiol    O
,    O
gestrinone    B-Hormone105407119
,    O
levonorgestrel    B-Hormone105407119
,    O
norethisterone    B-Hormone105407119
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    B-Hormone105407119
)    O
,    O
quinestrol    B-Hormone105407119
,    O
19-norprogesterone    B-Hormone105407119
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-Hormone105407119
acetate    I-Hormone105407119
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-Hormone105407119
acetate    I-Hormone105407119
.    O

This    O
can    O
also    O
be    O
accomplished    O
with    O
progestational    O
agents    O
(    O
i.e.    O
,    O
medroxyprogesterone    B-Hormone105407119
acetate    I-Hormone105407119
)    O
,    O
danazol    B-Hormone105407119
,    O
gestrinone    B-Hormone105407119
,    O
or    O
gonadotropin    O
-    O
releasing    O
hormone    O
agonists    O
(    O
GnRH    B-Hormone105407119
)    O
,    O
as    O
well    O
as    O
other    O
less    O
well    O
-    O
known    O
agents    O
.    O

Mineralocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
(    O
type    O
I    O
)    O
–    O
mineralocorticoids    O
like    O
aldosterone    O

Deactivation    O
of    O
enzymatic    O
activity    O
reduces    O
aldosterone    O
concentrations    O
in    O
plasma    O
and    O
tissues    O
which    O
decreases    O
mineralocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
-    O
dependent    O
and    O
independent    O
effects    O
in    O
cardiac    O
vascular    O
and    O
renal    O
target    O
organs    O
.    O

Mineralocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
(    O
MR    O
)    O
antagonist    O

In    O
addition    O
to    O
the    O
mineralocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
,    O
prorenone    O
also    O
binds    O
to    O
the    O
glucocorticoid    B-Hormone105407119
,    O
androgen    B-Hormone105407119
,    O
and    O
progesterone    B-Hormone105407119
receptor    I-Hormone105407119
.    O

In    O
addition    O
to    O
the    O
mineralocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
,    O
mexrenone    O
also    O
binds    O
to    O
the    O
glucocorticoid    B-Hormone105407119
,    O
androgen    B-Hormone105407119
,    O
and    O
progesterone    B-Hormone105407119
receptor    I-Hormone105407119
.    O

Mineralocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
antagonist    O
(    O
Ki    O
=    O
39    O
nM    O
)    O

This    O
is    O
a    O
critical    O
residue    O
that    O
is    O
completely    O
conserved    O
among    O
species    O
and    O
in    O
the    O
androgen    B-Hormone105407119
receptor    I-Hormone105407119
(    O
AR    O
)    O
and    O
mineralocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
(    O
MR    O
)    O
.    O

It    O
also    O
binds    O
to    O
the    O
glucocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
,    O
but    O
is    O
only    O
a    O
weak    O
antiglucocorticoid    O
relative    O
to    O
mifepristone    O
,    O
and    O
has    O
no    O
relevant    O
affinity    O
to    O
the    O
estrogen    B-Hormone105407119
,    O
androgen    B-Hormone105407119
and    O
mineralocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
.    O

Mineralocorticoids    O
bind    O
to    O
the    O
mineralocorticoid    B-Hormone105407119
receptor    I-Hormone105407119
in    O
the    O
cell    O
cytosol    O
,    O
and    O
are    O
able    O
to    O
freely    O
cross    O
the    O
lipid    O
bilayer    O
of    O
the    O
cell    O
.    O

Insulin    B-Hormone105407119
degludec    I-Hormone105407119
(    O
INN    O
/    O
USAN    O
)    O
is    O
an    O
ultralong    O
-    O
acting    O
basal    O
insulin    B-Hormone105407119
analogue    I-Hormone105407119
that    O
was    O
developed    O
by    O
Novo    O
Nordisk    O
under    O
the    O
brand    O
name    O
Tresiba    B-Hormone105407119
.    O

Notable    O
examples    O
include    O
the    O
non-17α-alkylated    O
trenbolone    B-Hormone105407119
and    O
the    O
17α-alkylated    O
ethylestrenol    B-Hormone105407119
(    O
ethylnandrol    O
)    O
and    O
metribolone    B-Hormone105407119
(    O
R-1881    O
)    O
,    O
as    O
well    O
as    O
the    O
17α-alkylated    O
designer    O
steroids    O
norboletone    B-Hormone105407119
and    O
tetrahydrogestrinone    B-Hormone105407119
(    O
THG    O
)    O
.    O

Tetrahydrogestrinone    B-Hormone105407119
(    O
THG    O
;    O
17α-ethyl-18-methyl-δ9,11    O
-    O
19-NT    O
)    O

The    O
IAAF    O
officially    O
annuls    O
all    O
of    O
Marion    O
Jones    O
'    O
competition    O
results    O
since    O
September    O
2000    O
,    O
including    O
her    O
medals    O
at    O
the    O
2001    O
World    O
Championships    O
,    O
in    O
the    O
wake    O
of    O
her    O
confession    O
to    O
having    O
used    O
steroids    B-Hormone105407119
in    O
2000    O
and    O
2001    O
.    O

Tetrahydrogestrinone    B-Hormone105407119
(THG)    I-Hormone105407119

Derivatives    O
of    O
ethyltestosterone    O
include    O
norethandrolone    O
(    O
ethylnandrolone    O
,    O
ethylestrenolone    O
)    O
,    O
ethylestrenol    B-Hormone105407119
(    O
ethylnandrol    O
)    O
,    O
norboletone    B-Hormone105407119
,    O
ethyldienolone    O
,    O
tetrahydrogestrinone    B-Hormone105407119
,    O
bolenol    B-Hormone105407119
(    O
ethylnorandrostenol    O
)    O
,    O
and    O
propetandrol    B-Hormone105407119
.    O

In    O
2003    O
,    O
it    O
was    O
reported    O
that    O
U.S.    O
authorities    O
found    O
e    O
-    O
mails    O
by    O
Victor    O
Conte    O
addressed    O
to    O
Tzekos    O
while    O
searching    O
BALCO    O
(    O
Bay    O
Area    O
Laboratory    O
Co    O
-    O
operative    O
)    O
,    O
the    O
California    O
company    O
secretly    O
dealing    O
Tetrahydrogestrinone    B-Hormone105407119
,    O
an    O
anabolic    O
steroid    O
specially    O
designed    O
so    O
as    O
to    O
make    O
it    O
undetectable    O
under    O
normal    O
drug    O
testing    O
.    O

In    O
addition    O
,    O
according    O
to    O
the    O
respected    O
French    O
paper    O
"    O
L'Equipe    O
,    O
"    O
Tzekos    O
was    O
directly    O
dealing    O
with    O
the    O
creator    O
of    O
norbolethone    B-Hormone105407119
and    O
THG    O
(    O
tetrahydrogestrinone    B-Hormone105407119
)    O
Patrick    O
Arnold    O
,    O
the    O
father    O
of    O
pro    O
-    O
hormone    O
craze    O
and    O
some    O
undetectable    O
designer    O
steroids    O
.    O

Corticosteroids    O
:    O
Inhaled    O
corticosteroids    O
(    O
i.e.    O
fluticasone    B-Hormone105407119
,    O
budesonide    B-Hormone105407119
)    O
are    O
typically    O
used    O
when    O
bronchoconstrictive    O
disease    O
has    O
advanced    O
to    O
a    O
persistent    O
inflammatory    O
state    O
,    O
more    O
specifically    O
in    O
persistent    O
or    O
severe    O
asthma    O
and    O
chronic    O
obstructive    O
pulmonary    O
disease    O
(    O
COPD    O
)    O
.    O

Fluticasone    B-Hormone105407119

In    O
this    O
case    O
,    O
the    O
main    O
compounds    O
used    O
are    O
beclometasone    O
,    O
budesonide    B-Hormone105407119
,    O
fluticasone    B-Hormone105407119
,    O
mometasone    O
and    O
ciclesonide    B-Hormone105407119
.    O

Also    O
,    O
the    O
N    O
-    O
terminal    O
25    O
amino    O
acids    O
of    O
alpha    O
-    O
COP    O
encode    O
the    O
bioactive    O
peptide    O
,    O
xenin    B-Hormone105407119
,    O
which    O
stimulates    O
exocrine    O
pancreatic    O
secretion    O
and    O
may    O
act    O
as    O
a    O
gastrointestinal    O
hormone    O
.    O

Klotho    B-Hormone105407119
(biology)    I-Hormone105407119
,    O
a    O
membrane    O
protein    O
that    O
may    O
be    O
involved    O
in    O
aging    O
.    O

Klotho    B-Hormone105407119
gene    I-Hormone105407119

inhibit    O
secretion    O
of    O
many    O
hormones    O
,    O
such    O
as    O
gastrin    O
,    O
cholecystokinin    O
,    O
glucagon    O
,    O
growth    O
hormone    O
,    O
insulin    O
,    O
secretin    B-Hormone105407119
,    O
pancreatic    B-Hormone105407119
polypeptide    I-Hormone105407119
,    O
TSH    O
,    O
and    O
vasoactive    B-Hormone105407119
intestinal    I-Hormone105407119
peptide    I-Hormone105407119
,    O

The    O
signalling    O
within    O
the    O
chemoreceptors    O
is    O
thought    O
to    O
be    O
mediated    O
by    O
the    O
release    O
of    O
neurotransmitters    O
by    O
the    O
glomus    O
cells    O
,    O
including    O
dopamine    O
,    O
noradrenaline    O
,    O
acetylcholine    O
,    O
substance    O
P    O
,    O
vasoactive    B-Hormone105407119
intestinal    I-Hormone105407119
peptide    I-Hormone105407119
and    O
enkephalins    O
.    O

In    O
gastrointestinal    O
smooth    O
muscle    O
,    O
the    O
slow    O
-    O
wave    O
threshold    O
can    O
be    O
altered    O
by    O
input    O
from    O
endogenous    O
and    O
exogenous    O
innervation    O
,    O
as    O
well    O
as    O
excitatory    O
(    O
acetylcholine    O
and    O
Substance    O
P    O
)    O
and    O
inhibitory    O
(    O
vasoactive    B-Hormone105407119
intestinal    I-Hormone105407119
peptide    I-Hormone105407119
and    O
nitric    O
oxide    O
)    O
compounds    O
.    O

Hormones    O
secreted    O
include    O
somatostatin    B-Hormone105407119
,    O
motilin    O
,    O
cholecystokinin    O
,    O
neurotensin    O
,    O
vasoactive    B-Hormone105407119
intestinal    I-Hormone105407119
peptide    I-Hormone105407119
,    O
and    O
enteroglucagon    B-Hormone105407119
.    O

Other    O
hormones    O
produced    O
include    O
cholecystokinin    O
,    O
somatostatin    B-Hormone105407119
,    O
vasoactive    B-Hormone105407119
intestinal    I-Hormone105407119
peptide    I-Hormone105407119
,    O
substance    O
P    O
,    O
alpha    O
and    O
gamma    O
-    O
endorphin    O
.    O

VPAC1    O
is    O
a    O
receptor    O
for    O
vasoactive    B-Hormone105407119
intestinal    I-Hormone105407119
peptide    I-Hormone105407119
(    O
VIP    O
)    O
,    O
a    O
small    O
neuropeptide    O
.    O

Vasoactive    B-Hormone105407119
intestinal    I-Hormone105407119
peptide    I-Hormone105407119
and    O
peptide    B-Hormone105407119
histidine    I-Hormone105407119
isoleucine    I-Hormone105407119
help    O
to    O
regulate    O
prolactin    O
secretion    O
in    O
humans    O
,    O
but    O
the    O
functions    O
of    O
these    O
hormones    O
in    O
birds    O
can    O
be    O
quite    O
different    O
.    O

A    O
number    O
of    O
brain    O
-    O
signalling    O
molecules    O
(    O
neuropeptides    O
and    O
neurotransmitters    O
)    O
have    O
been    O
found    O
in    O
bone    O
,    O
including    O
adrenaline    O
,    O
noradrenaline    O
,    O
serotonin    O
,    O
calcitonin    O
gene    O
-    O
related    O
peptide    O
,    O
vasoactive    B-Hormone105407119
intestinal    I-Hormone105407119
peptide    I-Hormone105407119
and    O
neuropeptide    B-Hormone105407119
Y    I-Hormone105407119
Leptin    O
binds    O
to    O
its    O
receptors    O
in    O
the    O
hypothalamus    O
,    O
where    O
it    O
acts    O
through    O
the    O
sympathetic    O
nervous    O
system    O
to    O
regulate    O
bone    O
metabolism    O
.    O

Budesonide    B-Hormone105407119
,    O
by    O
its    O
trade    O
name    O
"    O
Giona    O
"    O

Amcinonide    B-Hormone105407119
,    O
budesonide    B-Hormone105407119
,    O
desonide    B-Hormone105407119
,    O
fluocinolone    B-Hormone105407119
acetonide    I-Hormone105407119
,    O
fluocinonide    B-Hormone105407119
,    O
halcinonide    B-Hormone105407119
,    O
and    O
triamcinolone    B-Hormone105407119
acetonide    I-Hormone105407119
.    O

Budesonide    B-Hormone105407119

Corticosteroids    O
:    O
Inhaled    O
corticosteroids    O
(    O
i.e.    O
fluticasone    B-Hormone105407119
,    O
budesonide    B-Hormone105407119
)    O
are    O
typically    O
used    O
when    O
bronchoconstrictive    O
disease    O
has    O
advanced    O
to    O
a    O
persistent    O
inflammatory    O
state    O
,    O
more    O
specifically    O
in    O
persistent    O
or    O
severe    O
asthma    O
and    O
chronic    O
obstructive    O
pulmonary    O
disease    O
(    O
COPD    O
)    O
.    O

Budesonide    B-Hormone105407119

In    O
this    O
case    O
,    O
the    O
main    O
compounds    O
used    O
are    O
beclometasone    O
,    O
budesonide    B-Hormone105407119
,    O
fluticasone    B-Hormone105407119
,    O
mometasone    O
and    O
ciclesonide    B-Hormone105407119
.    O

Cholesterol    O
(    O
(    O
3β)-cholest-5-en-3-ol    O
)    O
is    O
hydroxylated    O
by    O
cholesterol    O
side    O
-    O
chain    O
cleavage    O
enzyme    O
(    O
P450scc    O
)    O
to    O
form    O
22"R    O
"-    O
hydroxycholesterol    O
,    O
which    O
is    O
subsequently    O
hydroxlated    O
again    O
by    O
P450scc    O
to    O
form    O
20α,22"R    O
"-    O
dihydroxycholesterol    O
,    O
and    O
finally    O
the    O
bond    O
between    O
carbons    O
20    O
and    O
22    O
is    O
cleaved    O
by    O
P450scc    O
to    O
form    O
pregnenolone    B-Hormone105407119
(    O
(    O
3β)-3-hydroxypregn-5-en-20-one    O
)    O
,    O
the    O
precursor    O
to    O
the    O
steroid    O
hormones    O
.    O

Cholesterol    O
(    O
(    O
3β)-cholest-5-en-3-ol    O
)    O
is    O
hydroxylated    O
by    O
cholesterol    O
side    O
-    O
chain    O
cleavage    O
enzyme    O
(    O
P450scc    O
)    O
to    O
form    O
22"R    O
"-    O
hydroxycholesterol    O
,    O
which    O
is    O
subsequently    O
hydroxlated    O
again    O
by    O
P450scc    O
to    O
form    O
20α,22"R    O
"-    O
dihydroxycholesterol    O
,    O
and    O
finally    O
the    O
bond    O
between    O
carbons    O
20    O
and    O
22    O
is    O
cleaved    O
by    O
P450scc    O
to    O
form    O
pregnenolone    B-Hormone105407119
(    O
(    O
3β)-3-hydroxypregn-5-en-20-one    O
)    O
,    O
the    O
precursor    O
to    O
the    O
steroid    O
hormones    O
.    O

The    O
development    O
of    O
the    O
corpus    O
luteum    O
is    O
accompanied    O
by    O
an    O
increase    O
in    O
the    O
level    O
of    O
the    O
steroidogenic    O
enzyme    O
P450scc    O
that    O
converts    O
cholesterol    O
to    O
pregnenolone    B-Hormone105407119
in    O
the    O
mitochondria    O
.    O

It    O
has    O
also    O
been    O
found    O
to    O
act    O
as    O
an    O
agonist    O
of    O
the    O
human    O
pregnane    O
X    O
receptor    O
,    O
albeit    O
with    O
an    O
EC50    O
that    O
is    O
more    O
than    O
an    O
order    O
of    O
magnitude    O
lower    O
than    O
that    O
of    O
other    O
endogenous    O
pregnane    B-Hormone105407119
like    O
pregnenolone    B-Hormone105407119
,    O
pregnanediol    O
,    O
allopregnanedione    O
,    O
and    O
allopregnanolone    O
.    O

The    O
first    O
enzymatic    O
step    O
in    O
the    O
production    O
of    O
all    O
steroid    O
hormones    O
is    O
cleavage    O
of    O
the    O
cholesterol    O
side    O
chain    O
,    O
a    O
reaction    O
that    O
forms    O
pregnenolone    B-Hormone105407119
as    O
a    O
product    O
and    O
is    O
catalyzed    O
by    O
the    O
enzyme    O
P450scc    O
,    O
also    O
known    O
as    O
"    O
cholesterol    O
desmolase    O
"    O
.    O

3β-Hydroxysteroid    O
dehydrogenase/Δ5    O
-    O
4    O
isomerase    O
(    O
3β-HSD    O
)    O
is    O
an    O
enzyme    O
that    O
catalyzes    O
the    O
biosynthesis    O
of    O
progesterone    O
from    O
pregnenolone    B-Hormone105407119
,    O
17α-hydroxyprogesterone    O
from    O
17α-hydroxypregnenolone    O
,    O
and    O
androstenedione    B-Hormone105407119
from    O
dehydroepiandrosterone    B-Hormone105407119
(    O
DHEA    O
)    O
in    O
the    O
adrenal    O
gland    O
.    O

Pregnenolone    B-Hormone105407119
to    O
progesterone    O

P450scc    O
is    O
a    O
mitochondrial    O
enzyme    O
that    O
catalyzes    O
conversion    O
of    O
cholesterol    O
to    O
pregnenolone    B-Hormone105407119
.    O

File    O
:    O
Pregnenolone    B-Hormone105407119

For    O
those    O
who    O
are    O
unresponsive    O
to    O
somatostatin    O
analogues    O
,    O
or    O
for    O
whom    O
they    O
are    O
otherwise    O
contraindicated    O
,    O
it    O
is    O
possible    O
to    O
treat    O
using    O
one    O
of    O
the    O
dopamine    O
agonists    O
,    O
bromocriptine    B-Hormone105407119
or    O
cabergoline    B-Hormone105407119
.    O

It    O
was    O
shown    O
through    O
various    O
testing    O
that    O
administration    O
of    O
Bromocriptine    B-Hormone105407119
can    O
improve    O
field    O
of    O
vision    O
defects    O
and    O
lower    O
prolactin    O
levels    O
.    O

Dopamine    O
agonists    O
include    O
bromocriptine    B-Hormone105407119
,    O
pergolide    O
,    O
pramipexole    B-Hormone105407119
,    O
ropinirole    O
,    O
piribedil    O
,    O
cabergoline    B-Hormone105407119
,    O
apomorphine    O
and    O
lisuride    O
.    O

Hypoprolactinemia    O
can    O
result    O
from    O
hypopituitarism    O
,    O
excessive    O
dopaminergic    O
action    O
in    O
the    O
tuberoinfundibular    O
pathway    O
and    O
ingestion    O
of    O
D2    O
receptor    O
agonists    O
such    O
as    O
bromocriptine    B-Hormone105407119
.    O

The    O
D2    O
receptor    O
is    O
involved    O
in    O
the    O
regulation    O
of    O
prolactin    O
secretion    O
,    O
and    O
agonists    O
of    O
the    O
receptor    O
such    O
as    O
bromocriptine    B-Hormone105407119
and    O
cabergoline    B-Hormone105407119
decrease    O
prolactin    O
levels    O
while    O
antagonists    O
of    O
the    O
receptor    O
such    O
as    O
domperidone    O
,    O
metoclopramide    O
,    O
haloperidol    O
,    O
risperidone    O
,    O
and    O
sulpiride    O
increase    O
prolactin    O
levels    O
.    O

Bromocriptine    B-Hormone105407119

Dihydroergocryptine    O
is    O
a    O
hydrogenated    O
ergot    O
derivative    O
that    O
is    O
also    O
structurally    O
very    O
similar    O
to    O
bromocriptine    B-Hormone105407119
,    O
another    O
drug    O
that    O
has    O
anti    O
-    O
Parkinson    O
effects    O
.    O

Bromocriptine    B-Hormone105407119

Preproinsulin    B-Hormone105407119
is    O
the    O
primary    O
translational    O
product    O
of    O
the    O
"    O
INS    O
"    O
gene    O
.    O

Bolazine    B-Hormone105407119


